Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 10-K
ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 20192021
OR 
¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from          to 

Commission File Number 1-7293 

________________________________________
TENET HEALTHCARE CORPORATIONCORPORATION
(Exact name of Registrant as specified in its charter) 
Nevada95-2557091
(State of Incorporation)(IRS Employer Identification No.)
14201 Dallas Parkway
Dallas,, TX75254
(Address of principal executive offices, including zip code)
 
(469(469) 893-2200
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common stock,$0.05 par valueTHCNew York Stock Exchange
6.875% Senior Notes due 2031THC31New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None


Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes Yesxý No ¨

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No Noxý

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes Yesxý No ¨

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Yes Yesxý No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company (each as defined in Exchange Act Rule 12b-2).
Large accelerated filerxýAccelerated filer¨Non-accelerated filer¨
Smaller reporting company¨Emerging growth company¨

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ý

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes ¨ No xý

As of June 30, 2019,2021, the aggregate market value of the shares of common stock held by non-affiliates of the Registrant (treating directors, executive officers who were SEC reporting persons, and holders of 10% or more of the common stock outstanding as of that date, for this purpose, as affiliates) was approximately $1.2$5.4 billion based on the closing price of the Registrant’s shares on the New York Stock Exchange on Friday, June 28, 2019.that day. As of January 31, 2020,2022, there were 104,288,796107,416,704 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE 
Portions of the Registrant’s definitive proxy statement for the 20202022 annual meeting of shareholders are incorporated by reference into Part III of this Form 10-K.




Table of Contents
TABLE OF CONTENTS
 
Page

i


PART I.
ITEM 1. BUSINESS

OVERVIEW

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” the “Company,” “we” or “us”) is a diversified healthcare services company headquartered in Dallas, Texas. Through our subsidiaries, partnerships and joint ventures, including USPI Holding Company, Inc. (“USPI”), at December 31, 2019,2021, we operated an expansive care network that included 6560 hospitals and over 500535 other healthcare facilities, including surgical hospitals, ambulatory surgery centers urgent care centers,(“ASCs”), imaging centers, surgical hospitals, off-campusoff‑campus emergency departments and micro-hospitals.micro‑hospitals. We also had over 20 ASCs in development at December 31, 2021. In addition, we operate Conifer Health Solutions, LLC through our Conifer Holdings, Inc. subsidiary (“Conifer”) subsidiary,, which provides revenue cycle management and value-basedvalue‑based care services to hospitals, healthcarehealth systems, physician practices, employers and other customers. Following exploration of strategic alternatives for Conifer, in July 2019, we announced our intention to pursue a tax-free spin-off of Conifer as a separate, independent, publicly traded company.clients. For financial reporting purposes, our business lines are classified into three separate reportable operating segments – Hospital Operations and other (“Hospital Operations”), Ambulatory Care and Conifer. Additional information about our businessoperating segments is provided below; statistical data for the segments can be found in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of Part II of this report.report (“MD&A”).

In 2021, the ongoing COVID‑19 pandemic significantly impacted, and it continues to affect, all three segments of our business, as well as our patients, communities and employees. As a provider of healthcare services, we are acutely affected by the public health and economic effects of the pandemic. Throughout MD&A, we have provided additional information on the impact of the COVID‑19 pandemic on our results of operations, disclosed certain of the steps we have taken, and are continuing to take, in response, and described various legislative actions that have mitigated some of the economic disruption caused by the pandemic on our business. The ultimate extent and scope of the pandemic and its future impact on our business remain unknown. For information about risks and uncertainties related to COVID‑19 that could affect our business, financial condition, results of operations and cash flows, we refer you to the Risk Factors section below.

OPERATIONS

HOSPITAL OPERATIONS AND OTHER SEGMENT

Hospitals, Ancillary Outpatient Facilities and Related Businesses—In 2021, we continued to make investments across our Hospital Operations segment to offer more convenient access to higher‑demand and higher‑acuity clinical service lines in the communities we serve. We also exited service lines, businesses and markets that we believe are no longer a core part of our long‑term growth strategy. In April 2021, we divested the majority of our urgent care centers and, in August 2021, we sold five Miami‑area hospitals and certain related operations.

At December 31, 2019,2021, our subsidiaries operated 6560 hospitals, serving primarily urban and suburban communities in nine states. Our subsidiaries had sole ownership of 5452 of thethese hospitals, we operated at December 31, 2019, ninesix were owned or leased by entities that are, in turn, jointlymajority owned by a Tenet subsidiary, and a healthcare system partner, and two were owned by third parties and leased by our wholly owned subsidiaries. Our Hospital Operations and other segment also included 159112 outpatient centers at December 31, 2019,2021, the majority of which are provider‑based and freestanding urgent care centers, provider-based diagnostic imaging centers, off-campusoff‑campus hospital emergency departments, provider-based ambulatory surgery centersprovider‑based ASCs and micro-hospitals.micro‑hospitals. In addition, at December 31, 2019,2021, our subsidiaries owned or leased and operated: a number of medical office buildings, all of which were located on, or nearby, our hospital campuses; 730over 750 physician practices; fourseveral accountable care organizations and 10 clinically integrated networks; and other ancillary healthcare businesses.

Each of our general hospitals offers acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories and pharmacies; in addition, most have: intensive care, critical care and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal and obstetrics services; and outpatient services, including physical therapy. Many of our hospitals provide tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care and neurosurgery, and some also offer quaternary care in areas such as heart and kidney transplants. Moreover, a number of our hospitals offer advanced treatment options for patients, including limb-salvaginglimb‑salvaging vascular procedures, acute level 1 trauma services, comprehensive intravascular stroke care, minimally invasive cardiac valve replacement, cutting-edgecutting‑edge imaging technology, and telemedicine access for selected medical specialties.

Each of our hospitals (other than our one critical access hospital) is accredited by The Joint Commission. With such accreditation, our hospitals are deemed to meet the Medicare Conditions of Participation and Conditions for Coverage and are eligible to participate in government-sponsoredgovernment‑sponsored provider programs, such as the Medicare and Medicaid programs. Although our critical access hospital has not sought to be accredited, it also participates in the Medicare and Medicaid programs by otherwise meeting the Medicare Conditions




Table of Participation.Contents


The following table lists, by state, the hospitals wholly owned, operated as part of a joint venture, or leased and operated by our wholly owned subsidiaries at December 31, 2019:
2021:
HospitalLocation
Licensed

Beds
Status
Alabama
Brookwood Baptist Medical Center(1)
 Homewood595
JV/Owned
Citizens Baptist Medical Center(1)(2)
 Talladega122
JV/Leased
Princeton Baptist Medical Center(1)(2)
 Birmingham505
JV/Leased
Shelby Baptist Medical Center(1)(2)
 Alabaster252
JV/Leased
Walker Baptist Medical Center(1)(2)
 Jasper267
JV/Leased

Arizona
Abrazo Arizona Heart Hospital(3)
Phoenix59
Owned
Abrazo Arrowhead CampusGlendale217
Owned
Abrazo Central CampusPhoenix206
Owned
Abrazo Scottsdale CampusPhoenix120
Owned
Abrazo West CampusGoodyear200
Owned
Holy Cross Hospital(4)(5)
Nogales25
JV/Owned
St. Joseph’s Hospital(4)
Tucson486
JV/Owned
St. Mary’s Hospital(4)
Tucson400
JV/Owned
California
Desert Regional Medical Center(6)(5)
 Palm Springs385
 Leased
Doctors Hospital of Manteca Manteca73
 Owned
Doctors Medical Center Modesto461
 Owned
Emanuel Medical Center Turlock209
 Owned
Fountain Valley Regional Hospital and Medical Center Fountain Valley400
 Owned
Hi-Desert Medical Center(7)(6)
 Joshua Tree179
 Leased
John F. Kennedy Memorial Hospital Indio145
 Owned
Lakewood Regional Medical Center Lakewood172
 Owned
Los Alamitos Medical Center Los Alamitos162172 
 Owned
Placentia Linda Hospital Placentia114
 Owned
San Ramon Regional Medical Center(8)(7)
 San Ramon123
JV/Owned
Tenet Health Central Coast Sierra Vista Regional Medical Center San Luis Obispo162
 Owned
Tenet Health Central Coast Twin Cities Community Hospital Templeton122
 Owned
Florida
Coral Gables Hospital Coral Gables245
 Owned
Delray Medical Center Delray Beach536
 Owned
Florida Medical Center – a campus of North Shore Lauderdale Lakes459
 Owned
Good Samaritan Medical Center West Palm Beach333
 Owned
Hialeah Hospital Hialeah366
 Owned
North Shore Medical Center Miami337
 Owned
Palm Beach Gardens Medical Center Palm Beach Gardens199
 Owned
Palmetto General Hospital Hialeah368
 Owned
St. Mary’s Medical Center West Palm Beach460
 Owned
West Boca Medical Center Boca Raton195
 Owned
Massachusetts
MetroWest Medical Center – Framingham Union CampusFramingham126 Owned
MetroWest Medical Center – Leonard Morse Campus(3)
Natick103 Owned
Saint Vincent HospitalWorcester290 Owned

2

HospitalLocation
Licensed

Beds
Status
Massachusetts
MetroWest Medical Center – Framingham Union Campus Framingham147
Owned
MetroWest Medical Center – Leonard Morse Campus Natick160
Owned
Saint Vincent Hospital Worcester283
Owned
Michigan
Children’s Hospital of Michigan Detroit228
Owned
Detroit Receiving Hospital Detroit273
Owned
Harper University Hospital Detroit470
Owned
Huron Valley-Sinai Hospital Commerce Township158
Owned
Hutzel Women’s Hospital Detroit114
Owned
Rehabilitation Institute of Michigan(3)
 Detroit69
Owned
Sinai-Grace Hospital Detroit404
Owned
South Carolina
Coastal Carolina Hospital Hardeeville41
Owned
East Cooper Medical Center Mount Pleasant140
Owned
Hilton Head Hospital Hilton Head109
Owned
Piedmont Medical Center Rock Hill288300 
Owned
Tennessee
Saint Francis Hospital(9)
Memphis479
Owned
Saint Francis Hospital – Bartlett(9)
Bartlett196
Owned
Texas
Baptist Medical Center San Antonio623607 
 Owned
The Hospitals of Providence East Campus El Paso182
 Owned
The Hospitals of Providence Memorial Campus El Paso480
 Owned
The Hospitals of Providence Sierra Campus El Paso283306 
 Owned
The Hospitals of Providence Transmountain Campus El Paso106108 
 Owned
Mission Trail Baptist Hospital San Antonio102110 
 Owned
Nacogdoches Medical Center Nacogdoches161
 Owned
North Central Baptist Hospital San Antonio443
 Owned
Northeast Baptist Hospital San Antonio371347 
 Owned
Resolute Health Hospital New Braunfels128
 Owned
St. Luke’s Baptist Hospital San Antonio287
 Owned
Valley Baptist Medical Center Harlingen586
 Owned
Valley Baptist Medical Center – Brownsville Brownsville240
 Owned
Total Licensed Beds17,21015,379
(1)Operated by a limited liability company formed as part of a joint venture with Baptist Health System, Inc. (“BHS”), a not-for-profit healthcare system in Alabama; a Tenet subsidiary owned a 60% interest in the entity at December 31, 2019, and BHS owned a 40% interest.
(2)In order to receive certain tax benefits for these hospitals, which were operated as nonprofit hospitals prior to our joint venture with BHS, we have entered into arrangements with the City of Talladega, the City of Birmingham, the City of Alabaster and the City of Jasper such that a Medical Clinic Board owns each of these hospitals, and the hospitals are leased to our joint venture entity. These capital leases expire between November 2025 and September 2036, but contain two optional renewal terms of 10 years each.
(3)Specialty hospital.
(4)Owned by a limited liability company formed as part of a joint venture with Dignity Health (which, following a 2019 merger with Catholic Health Initiatives, is now a part of CommonSpirit Health) and Ascension Arizona, each of which is a not-for-profit healthcare system; a Tenet subsidiary owned a 60% interest in the entity at December 31, 2019, Dignity Health owned a 22.5% interest and Ascension Arizona owned a 17.5% interest.
(5)Designated by the Centers for Medicare and Medicaid Services (“CMS”) as a critical access hospital.
(6)Lease expires in May 2027.
(7)Lease expires in July 2045.
(8)Owned by a limited liability company formed as part of a joint venture with John Muir Health (“JMH”), a not-for-profit healthcare system in the San Francisco Bay area; a Tenet subsidiary owned a 51% interest in the entity at December 31, 2019, and JMH owned a 49% interest.
(9)In December 2019, we reached a definitive agreement to sell these hospitals to an unaffiliated third party. The transaction is currently expected to be completed in 2020, subject to regulatory approvals and customary closing conditions.


(1)Operated by a limited liability company formed as part of a joint venture with Baptist Health System, Inc. (“BHS”), a not‑for‑profit health system in Alabama; a Tenet subsidiary owned a 70% interest in the entity at December 31, 2021, and BHS owned a 30% interest.
(2)In order to receive certain tax benefits for these hospitals, which were operated as nonprofit hospitals prior to our joint venture with BHS, we have entered into arrangements with the City of Talladega, the City of Birmingham, the City of Alabaster and the City of Jasper such that a Medical Clinic Board owns each of these hospitals, and the hospitals are leased to our joint venture entity. These capital leases expire between November 2025 and September 2036, but contain two optional renewal terms of 10 years each.
(3)Specialty hospital.
(4)Designated by the Centers for Medicare and Medicaid Services (“CMS”) as a critical access hospital.
(5)Lease expires in May 2027.
(6)Lease expires in July 2045.
(7)Owned by a limited liability company formed as part of a joint venture with John Muir Health (“JMH”), a not‑for‑profit health system in the San Francisco Bay area; a Tenet subsidiary owned a 51% interest in the entity at December 31, 2021, and JMH owned a 49% interest.

Information regarding the utilization of licensed beds and other operating statistics at December 31, 20192021 and 20182020 can be found in Item 7, Management’s Discussion and AnalysisMD&A.

3

Table of Financial Condition and Results of Operations, of Part II of this report.Contents

At December 31, 2019,2021, our Hospital Operations and other segment also included 48 diagnostic43 imaging centers, 13 off-campus14 off‑campus emergency departments and 11 ambulatory surgery centers10 ASCs operated as departments of our hospitals and under the same license, as well as 8745 separately licensed, freestanding outpatient centers – typically at locations complementary to our hospitals – consisting of six diagnostic26 imaging centers, 1015 emergency facilities (9(14 of which are licensed as micro-hospitals)micro‑hospitals), two ambulatory surgery centersASCs and 69two urgent care centers. Nearly all of our freestanding urgent care centers are managed by USPI and operated under our national MedPost brand. OverApproximately half of the outpatient centers in our Hospital Operations and other segment at December 31, 20192021 were in California, FloridaTexas and Texas,California, the same states where we had the largest concentrations of licensed hospital beds. Strong concentrations of hospital beds and outpatient centers within market areas may help us contract more successfully with managed care payers, reduce management, marketing and other expenses, and more efficiently utilize resources. However, these concentrations increase the risk that, should any adverse economic, regulatory, environmental, competitive or other condition (including COVID‑19 surges) occur in these areas, our overall business, financial condition, results of operations or cash flows could be materially adversely affected.

Accountable Care Organizations and Clinically Integrated Networks—We own, control or operate fourthree accountable care organizations (“ACOs”) and 10four clinically integrated networks (“CINs”) – in Alabama, Arizona, California, Florida, Massachusetts Michigan, Missouri, Tennessee and Texas – and participate in an additional ACO and an additional CIN with other healthcare providers for select markets in Arizona. An ACO is a group of providers and suppliers that work together to redesign delivery processes in an effort to achieve high-qualityhigh‑quality and efficient provision of services under contract with CMS. ACOs that achieve quality performance standards established by the U.S. Department of Health and Human Services (“HHS”) are eligible to share in a portion of the amounts saved by the Medicare program. A CIN coordinates the healthcare needs of the communities served by its network of providers with the purpose of improving the quality and efficiency of healthcare services through collaborative programs, including contracts with managed care payers that create a high degree of interdependence and cooperation among the network providers. Because they promote accountability and coordination of care, ACOs and CINs are intended to produce savings as a result of improved quality and operational efficiencies.

Health Plans—We previously announced our intention to sell or otherwise dispose of our health plan businesses because they are not a core part of our long-term growth strategy. To that end, we sold, divested the membership of or discontinued four health plans in 2017 and, in 2018, we divested our Chicago-based preferred provider network and our Southern California Medicare Advantage plan. Health plans we have not sold outright are being wound-down; however, during this time, they continue to be subject to numerous federal and state statutes and regulations related to their business operations, and certain of these health plans continue to be licensed by one or more agencies in the states in which they conduct business. In addition, insurance regulations in the states in which we currently operate have required us to maintain cash reserves in connection with certain health plans throughout the wind-down process.

AMBULATORY CARE SEGMENT

Our Ambulatory Care segment is comprised of the operations of USPI, which, at December 31, 2019, had interests in 260USPI’s ambulatory surgery centers 39 urgent care centers (nearly all of which are operated under the CareSpot brand), 23 imaging centers and 24 surgical hospitals in 27 states.hospitals. At December 31, 2019,2021, we owned approximately 95% of USPI, and Baylor University Medical Center (“Baylor”) owned approximately 5%. We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. In December 2021, in connection with the closing of a previously announced transaction with Surgical Center Development #3, LLC and Surgical Center Development #4, LLC (“SCD”), subsidiaries of USPI acquired SCD’s ownership interests in 86 musculoskeletal‑focused ASCs, along with other related ambulatory support services. In an effort to attain a majority ownership position in certain of the ASCs to consolidate their financial results, USPI has separately made offers, and continues to make offers in an ongoing process, to acquire a portion of the equity interests from the physician owners; USPI acquired such equity interests in 10 centers prior to the end of 2021. At December 31, 2021, USPI had interests in a total of 399 ASCs and 24 surgical hospitals in 34 states.

Also as previously announced, USPI and SCD’s principals have entered into a joint venture and development agreement under which USPI will have the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50 de novo ASCs over a period of five years. We believe that these transactions will enable us to continue to sharpen our focus on the growth and expansion of ambulatory surgical services.

Operations of USPI—USPI acquires and develops its facilities primarily through the formation of joint ventures with physicians and healthcarehealth systems. USPI’s subsidiaries hold ownership interests in the facilities directly or indirectly and operate the facilities on a day-to-dayday‑to‑day basis through management services contracts. USPI does not currently have management services contracts for the SCD facilities acquired in December 2021 in which it owns only a minority interest.

USPI’s surgical facilities primarily specialize in non-emergency cases. We believe surgery centersUSPI’s ASCs and surgical hospitals offer many advantages to patients and physicians, including greaterincreased affordability, predictability and convenience. Medical emergencies at acute care hospitals often demand the unplanned use of operating rooms and result in the postponement or delay of scheduled surgeries, disrupting physicians’ practices and inconveniencing patients. OutpatientUSPI’s facilities generally provide physicians with greater scheduling flexibility, more consistent nurse staffing and faster turnaround timetimes between cases.cases than they could expect in an acute care hospital setting. In addition, we believe many physicians choose to perform surgery in outpatientUSPI’s facilities because their patients prefer the comfort of a less institutional atmosphere and the convenienceexpediency of simplified registration and discharge procedures. USPI’s facilities also serve as an alternative point‑of‑service as acute care hospitals manage their capacity during the COVID‑19 pandemic and otherwise.

4

New surgical techniques and technology, as well as advances in anesthesia, have significantly expanded the types of surgical procedures that are being performed in surgery centers and have helped drive the growth in outpatient surgery.

Improved anesthesia has shortened recovery time by minimizing post-operativepost‑operative side effects, such as nausea and drowsiness, thereby avoidingpreventing the need for overnight hospitalization in many cases. Furthermore, some states permit surgery centers to keep a patient for up to 23 hours, which allows for moreIn addition, certain complex surgeries, previously performed only in an inpatient setting, to beare now capable of being performed in a surgery center.

In addition to these technological and other clinical advancements, a changing payer environment has contributed to the growth of outpatient surgery relative to all surgery performed. Government programs, private insurance companies, managed care organizations and self-insuredself‑insured employers have implemented cost-containmentcost‑containment measures to limit increases in healthcare expenditures, including procedure reimbursement. Furthermore, as self-fundedself‑funded employers are looking to curb annual increases in their employee health benefits costs, they continue to shift additional financial responsibility to patients through higher co-pays,co‑pays, deductibles and premium contributions.contributions to curb annual increases in their employee health benefits costs. These cost-containmentcost‑containment measures have contributed to the shift in the delivery of certain healthcare services away from traditional inpatientacute care hospitals to more cost-effectivecost‑effective alternate sites, including surgery centers and surgical facilities.hospitals. We believe that surgeries performed at surgery centers and surgical facilitieshospitals are generally less expensive than hospital-basedacute care hospital‑based outpatient surgeries because of lower facility development costs, more efficient staffing and space utilization, and a specialized operating environment focused on quality of care and cost containment. In general, we believe that our focus on quality of care has a positive impact on, among other things, physician and patient satisfaction, as well as our revenues as governmental and private payers continue to move to pay‑for‑performance models.

We operate USPI’s facilities, structure our joint ventures, and adopt staffing, scheduling, and clinical systems and protocols with the goal of increasing physician productivity. We believe that this focus on physician satisfaction, combined with providing high-qualityhigh‑quality healthcare in a friendly and convenient environment for patients, will continue to increase the number of procedures performed at our facilities each year.over time. Our joint ventures also enable healthcarehealth systems to offer patients, physicians and payers the cost advantages, convenience and other benefits of ambulatory care in a freestanding facility and, in certain markets, establish networks needed to manage the full continuum of care for a defined population. Further, these relationships allow the healthcarehealth systems to focus their attention and resources on their core business without the challenge of acquiring, developing and operating these facilities.

CONIFER SEGMENT

Nearly all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC or one of its direct or indirect wholly owned subsidiaries. At December 31, 2019,2021, we owned 76.2% of Conifer Health Solutions, LLC, and Catholic Health Initiatives (“CHI”) had a 23.8% ownership position. (As a result of its 2019 merger with Dignity Health, CHI is now a part of CommonSpirit Health.) Following exploration of strategic alternatives for Conifer, in July 2019, we announced our intention to pursue a tax-free spin-offtax‑free spin‑off of Conifer as a separate, independent, publicly traded company. Completion of the proposed spin-offpotential spin‑off is subject to a number of conditions, including, among others, assurance that the separation will be tax-freetax‑free for U.S. federal income tax purposes, execution of a restructuredcomprehensive amendment to and restatement of the master services agreement between Conifer and Tenet, finalization of Conifer’s capital structure, the effectiveness of appropriate filings with the U.S. Securities and Exchange Commission (“SEC”), and final approval from our board of directors. We are targetingIf consummated, the spin-off is expected to completepotentially enhance shareholder value and, to a lesser degree, reduce the separation by the endlevel of the second quarter of 2021; however, thereour debt through a tax-free debt-for-debt exchange. There can be no assurance regarding the timeframe for completingcompletion of the spin-off,Conifer spin‑off, the allocation of assets and liabilities between Tenet and Conifer, that the other conditions of the spin-offspin‑off will be met, or that the spin-offit will be completed at all.

Services—Conifer provides healthcarecomprehensive end‑to‑end and focused‑point business process services, in the areas ofincluding hospital and physician revenue cycle management, patient communications and value-basedengagement support, and value‑based care solutions, to healthcarehospitals, health systems, as well as individual hospitals, physician practices, self-insured organizations, health plansemployers and other entities.clients.

Conifer’s revenue cycle management solutions consist of: (1) patient services, including: centralized insurance and benefit verification; financial clearance, pre-certification,pre‑certification, registration and check-incheck‑in services; and financial counseling services, including reviews of eligibility for government healthcare or financial assistance programs, for both insured and uninsured patients, as well as qualified health plan coverage; (2) clinical revenue integrity solutions, including: clinical admission reviews; coding; clinical documentation improvement; coding compliance audits; charge description master management; and health information services; and (3) accounts receivable management solutions, including: third-partythird‑party billing and collections; denials management; and patient collections. All of these solutions include ongoing measurement and monitoring of key revenue cycle metrics, as well as productivity and quality improvement programs. These revenue cycle management solutions assist hospitals, physician practices and other healthcare organizations in improving cash flow, revenue, and physician and patient satisfaction.

5

In addition, Conifer offers customized communications and engagement solutions to optimize the relationship between providers and patients. Conifer’s trained customer service representatives provide direct, 24-hour,24‑hour, multilingual support for (1) physician referral requests, calls regarding maternity services and other patient inquiries, (2) community education and

outreach, and (3) scheduling and appointment reminders. Additionally, Conifer coordinates and implements marketing outreach programs to keep patients informed of screenings, seminars, and other events and services.

Conifer also offers value-basedvalue‑based care solutions, including clinical integration, financial risk management and population health management, all of which assist hospitals, physicians, ACOs, health plans, self-insuredself‑insured employers and government agencies in improving the cost and quality of healthcare delivery, as well as patient outcomes. Conifer helps clients build clinically integrated networksCINs that provide predictive analytics and quality measures across the care continuum. In addition, Conifer helps clients align and manage financial incentives among healthcare stakeholders through risk modeling and administration of various payment models. Furthermore, Conifer offers clients tools and analytics to improve quality of care and provide care management services for patients with chronic diseases by identifying high-riskhigh‑risk patients, coordinating with patients and clinicians in managing care, and monitoring clinical outcomes.

Clients—At December 31, 2019,2021, Conifer provided one or more of the business process services described above to approximately 660650 Tenet and non-Tenetnon‑Tenet hospital and other clients nationwide. Tenet and CHI facilities represented over 300approximately 45% of these clients, and the remainder were unaffiliated healthcarehealth systems, hospitals, physician practices, self-insuredself‑insured organizations, health plans and other entities. Contractual agreements have been in place for many yearsIn 2012, we entered into an agreement documenting the terms and conditions of various services Conifer provides to Tenet hospitals (“RCM Agreement”), as well as an agreement documenting certain administrative services our Hospital Operations and other segment provides to Conifer. WhileIn March 2021, we entered into a month‑to‑month agreement amending the RCM Agreement effective January 1, 2021 (“Amended RCM Agreement”) to update certain terms and conditions related to the revenue cycle management services Conifer preparesprovides to Tenet hospitals. We believe the pricing terms for the spin-off, these contracts have been renewed on a short-term basisservices provided under the Amended RCM Agreement are commercially reasonable and consistent with certain scope of services modifications; however,estimated third-party terms. As noted above, execution of restructured long-termlong‑term services agreements between Conifer and Tenet is a condition to completion of the proposed spin-off.spin‑off. Conifer’s agreement with CHI to provide patient access, revenue integrity, accounts receivable management and patient financial services to CHI’s facilities expires inon December 31, 2032. For the year ended December 31, 2019,2021, approximately 42%38% of Conifer’s net operating revenues were attributable to its relationship with Tenet and approximately 41%45% were attributable to its relationship with CHI. As we pursue a tax-free spin-off of Conifer, weWe are continuing to market Conifer’s revenue cycle management, patient communications and engagement services, and value-basedvalue‑based care solutions businesses. The timing and uncertainty associated with our spin‑off plans for Conifer may have an adverse impact on our ability to secure new clients for Conifer. Additional information about our Conifer operating segment can be found in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of Part II of this report.    

REAL PROPERTY

The locations of our hospitals and the number of licensed beds at each hospital at December 31, 20192021 are set forth in the table beginning on page 2. We lease the majority of our outpatient facilities in both our Hospital Operations and other segment and our Ambulatory Care segment. These leases typically have initial terms ranging from five to 20 years, and most of the leases contain options to extend the lease periods. Our subsidiaries also operate a number of medical office buildings, all of which are located on, or nearby, our hospital campuses. We own many of these medical office buildings; the remainder are owned by third parties and leased by our subsidiaries.

Our corporate headquarters are located in Dallas, Texas, where we recently consolidated several office locations.Texas. In addition, we maintain administrative offices in marketsregions where we operate hospitals and other businesses.businesses, as well as our Global Business Center in the Philippines. We typically lease our office space under operating lease agreements. We believe that all of our properties are suitable for their respective uses and are, in general, adequate for our present needs.

INTELLECTUAL PROPERTY

We rely on a combination of trademark, copyright and trade secret laws, as well as contractual terms and conditions, to protect our rights in our intellectual property assets. However, third parties may develop intellectual property that is similar or superior to ours. We also license third-party software, other technology and certain trademarks through agreements that impose certain restrictions on our ability to use the licensed items. We control access to and use of our software and other technology through a combination of internal and external controls. Although we do not believe the intellectual property we utilize infringes any intellectual property right held by a third party, we could be prevented from utilizing such property and could be subject to significant damage awards if our use is found to do so.


HUMAN CAPITAL RESOURCES
PHYSICIANS AND EMPLOYEES

Physicians—Our operations depend in significantlarge part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who have been admitted toare members of the medical staffs of our hospitals and other facilities, as well as physicians who affiliate with us and use our facilities as an extension of their practices. Under state laws and other licensing standards, medical staffs are generally self-governingself‑governing organizations subject to ultimate oversight by the facility’s local governing board. Members of the medical staffs of our facilities also often serve on the medical staffs of facilities we do not operate, and they are free to terminate their association with our facilities or admit their patients to competing facilities at any time. At December 31, 2019,2021, we owned 730over 750 physician practices, and weour subsidiaries employed (where permitted by state law) or otherwise affiliated with over 1,7001,500 physicians; however, we have no contractual relationship with the overwhelming majority of the physicians who practice at our hospitals and outpatient centers.
6


It is essential to our ongoing business and clinical program development that we attract an appropriate number of quality physicians in the specialties required to support our services and that we maintain good relations with those physicians. In 2021, we continued to experience challenges in recruiting and retaining physicians as a result of the prioritization of COVID‑19 care and the challenges associated with relocating physicians during the pandemic. In some of our markets, physician recruitment and retention are affected by a shortage of qualified physicians in certain specialtieshigher-demand clinical service lines and the difficulties that physicians can experience in obtaining affordable malpractice insurance or finding insurers willing to provide such insurance.specialties. Moreover, our ability to recruit and employ physicians is closely regulated.


EMPLOYEES
We believe each employee across our network has a role integral to our mission, which is to provide quality, compassionate care in the communities we serve. At December 31, 2021, our subsidiaries and affiliates employed approximately 101,100 people (of which approximately 24% were part‑time employees) in our three operating segments, as follows:
Hospital Operations70,000 
Ambulatory Care20,200 
Conifer10,900 
Total101,100
Employees
At December 31, 2021, our employee headcount had decreased by nearly 9,000 employees as compared to December 31, 2020, primarily due to the divestiture of five hospitals in Florida and our urgent care business in 2021. At December 31, 2021, we had employees in all 50 U.S. states and the District of Columbia, as well as over 2,000 employees providing support across our entire network at our Global Business Center in the Philippines. Approximately 31% of our employees are nurses.

Board OversightOur Healthcare Facilities—board of directors and its committees oversee human capital matters through regular reports from management and advisors. The board’s human resources committee (“HR Committee”) is responsible for establishing general compensation policies that (1) support our overall business strategies and objectives, (2) enhance our efforts to attract and retain skilled employees, (3) link compensation with our business objectives and organizational performance, and (4) provide competitive compensation opportunities for key executives. The HR Committee also provides, among other things, its perspectives regarding performance management, succession planning, leadership development, diversity, recruiting, retention and employee training. The board’s environmental, social and governance (“ESG”) committee, which was formed in 2021, provides oversight with respect to our ESG strategy and guidance on ESG matters, including human rights, diversity and inclusion, and other ESG issues that are relevant to our business.

Human Resources Practices—We have established – and continue to enhance and refine – a comprehensive set of practices for recruiting, managing and optimizing the human resources of our organization. In many cases, we utilize objective benchmarking and other tools in our efforts, including a commercial product that is widely used in the healthcare industry and provides metrics in such areas as organizational effectiveness, voluntary turnover and staffing efficiencies.

Compensation and Benefits; Culture—In general, we seek to attract, develop and retain an engaged workforce, cultivate a high‑performance culture that embraces data‑driven decision‑making, and improve talent management processes to promote diversity and inclusion. To that end, we offer:

a competitive range of compensation and benefit programs designed to reward performance and promote well‑being;

opportunities for continuing education and advancement through a broad range of clinical training and leadership development experiences, including in‑person and online courses and mentoring opportunities;

a supportive, inclusive and patient‑centered culture based on respect for others;

company‑sponsored efforts encouraging and recognizing volunteerism and community service; and

a code of conduct that promotes integrity, accountability and transparency, among other high ethical standards.

Employee Safety and Welfare—We believe our employees comprise a community built on care, and we place a high priority on maintaining a secure and healthy workplace for them. We promote a culture of safety and reporting by connecting
7

employee safety policies with patient safety policies, and we review and refine the policies regularly. At our hospitals, outpatient facilities, and other care sites and clinics, we align staffing to need in our nursing units, and we invest in appropriate training to improve the competency of our caregivers. With the onset of the pandemic, we instituted COVID-safe infrastructure and heightened our infection-prevention protocols. We maintain consistent availability of personal protective equipment and disinfection supplies, and we regularly provide concise and current infection prevention guidance.

We also offer resources to help employees manage challenging circumstances, including a comprehensive employee assistance program comprised of counseling services, financial guidance and legal aid. The Tenet Care Fund (the “Care Fund”) is a 501(c)(3) public charity that provides financial assistance to our employees who have experienced hardship due to, among other things, natural disasters, extended illness or injury, and the impact of the COVID-19 pandemic. The Care Fund is funded primarily by our employees for our employees.

Diversity and Inclusion—We continue to focus on the hiring, advancement and retention of underrepresented populations to further our objective of fostering an engaging culture with a workforce and leadership teams that represent the markets we serve. As of December 31, 2021, our total workforce was greater than 75% female, and nearly 50% of our employees self‑identified as racially or ethnically diverse. Over 55% of new employees (i.e., those we hired in 2021) self‑identified as racially or ethnically diverse.

We have a Diversity Council, which consists of leaders representing different facets of our enterprise, to support our overall diversity and inclusion efforts, including in the areas of recruiting, talent development, new‑hire mentoring, community partnerships, and educational opportunities. The Diversity Council works to provide tools, guidelines and training with respect to best practices in these areas. In 2021, the Diversity Council provided oversight to our human resources department in the development and implementation of an enterprise-wide inclusive culture training session. In addition, the Diversity Council is in the process of setting up employee resource groups to physicians, the operations of our facilities are dependent on the efforts, abilitiessupport team members with similar backgrounds or shared interests. Each employee resource group has an executive sponsor to help in setting a unique mission and experience of our facilities management and medical support employees, including nurses, therapists, pharmacists and lab technicians. operating model.

Competition; Staffing Ratio RequirementsWe compete with other healthcare providers in recruiting and retaining qualified personnel responsible for the day-to-day operationsoperation of our facilities. In some markets, thereThere is a limited availability of experienced medical support personnel nationwide, which drives up the local wages and benefits required to recruit and retain employees. In particular, like others in the healthcare industry, we continue to experience a shortage of critical-carecritical‑care nurses in certain disciplines and geographic areas. Moreover,This shortage has been exacerbated by the COVID‑19 pandemic as more nurses choose to retire early, leave the workforce or take travel assignments. In some areas, the increased demand for care of COVID‑19 patients in our hospitals, as well as the direct impact of COVID‑19 on physicians, employees and their families, have put a strain on our resources and staff. Over the past two years, we hire many newly licensed nurses in additionhave had to experienced nurses,rely on higher-cost temporary and contract labor, which requires uswe compete with other healthcare providers to invest in their training.secure, and pay premiums above standard compensation for essential workers.

California is the only state in which we operate that requires minimum nurse-to-patientnurse‑to‑patient staffing ratios to be maintained at all times in acute care hospitals. If other states in which we operate adopt mandatory nurse-staffingnurse‑staffing ratios, it could have a significant effect on our labor costs and have an adverse impact on our net operating revenues if we are required to limit patient volumes in order to meet the required ratios.

Union Activity and Labor Relations—At December 31, 2019,2021, approximately 28%27% of the employees in our Hospital Operations and other segment were represented by labor unions. Less than 1% of the total employees in both our Ambulatory Care and Conifer segments belong to a union. Unionized employees – primarily registered nurses and service, technical and maintenance workers – are located at 3533 of our hospitals, the majority of which are in California, Florida and Michigan. When negotiating collective bargaining agreements with unions, whether such agreements are renewals or first contracts, there is a possibility that strikes could occur, and our continued operation during any strikes could increase our labor costs and have an adverse effect on our patient volumes and net operating revenues. Organizing activities by labor unions could increase our level of union representation in future periods, which could resultimpact our labor costs.

When we are negotiating collective bargaining agreements with unions (whether such agreements are renewals or first contracts), work stoppages and strikes may occur, as they did at one of our hospitals in increases2021. Although relatively uncommon, extended strikes have had, and could in salaries, wagesthe future have, an adverse effect on our patient volumes, net operating revenues and benefits expense.

labor costs at individual hospitals or in local markets.
Headcount—At December 31, 2019, we employed approximately 113,600 people (of which approximately 22% were part-time employees) in our three business segments, as follows:
8

Hospital Operations and other83,300
Ambulatory Care19,500
Conifer10,800
Total113,600

COMPETITION

HEALTHCARE SERVICES

Generally, otherWe believe our hospitals and outpatient centers in thefacilities compete within local communities we serve provide services similar to those we offer,on the basis of many factors, including: quality of care; location and in some cases, competing facilities are more established or newer than ours. Furthermore, our competitors (1) may offer a broader arrayease of access; the scope and breadth of services or more desirableoffered; reputation; and the caliber of the facilities, to patientsequipment and employees. In addition, the competitive positions of hospitals and outpatient facilities depend in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians than ours, (2) may have larger or more specializedwho are members of the medical staffs to admit and refer patients, (3) may have a better reputation for access or overall services in the community, or (4) may be able to negotiate more favorable reimbursement rates that they may use to strengthen their competitive position. In the future, we expect to encounter increased competition from system-affiliated hospitals and

healthcare companies,of those facilities, as well as health insurersphysicians who affiliate with and private equity companies seeking to acquire providers, in specific geographic markets.

We also face competition from specialty hospitals (some of which are physician-owned) and unaffiliated freestandinguse outpatient centers for market share in diagnosticas an extension of their practices. Physicians often serve on the medical staffs of more than one facility, and specialty services and for quality physicians and personnel. In recent years, the number of freestanding specialty hospitals, surgery centers, emergency departments and diagnostic imaging centers in the geographic areas in which we operate has increased significantly. Furthermore, somethey are typically free to terminate their association with such facilities or admit their patients to competing facilities at any time.

Some of the hospitals that compete with our hospitals are owned by tax‑supported government agencies, or not-for-profit organizations. These tax-exempt competitorsand many others are owned by not‑for‑profit organizations that may have certain financial advantages not available to our facilities, such asincluding (1) support through endowments, charitable contributions tax-exemptand tax revenues, (2) access to tax‑exempt financing, and (3) exemptions from sales, property and income taxes. In addition, in certain markets in which we operate, large teaching hospitals provide highly specialized facilities, equipment and services that may not be available at most of our hospitals. Trends toward clinical and pricing transparency may also impact a healthcare facility’s competitive position in ways that are difficult to predict.

The existence or absence of state laws that require findings of need for construction and expansion of healthcare facilities or services (as described in “Healthcare Regulation and Licensing – Certificate of Need Requirements” below) may also impact competition. In recent years, the number of freestanding specialty hospitals, surgery centers, emergency departments and imaging centers in the geographic areas in which we operate has increased significantly. Some of these facilities are physician‑owned. Moreover, we expect to encounter additional competition from system‑affiliated hospitals and healthcare companies, as well as health insurers and private equity companies seeking to acquire providers, in specific geographic markets in the future.

Another major factor in the competitive position of a hospital or outpatient facility is the ability to negotiate contractsscope of its relationships with managed care plans. Health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), third-partythird‑party administrators, and other third-partythird‑party payers use managed care contracts to encourage patients to use certain hospitals in exchange for discounts from the hospitals’ established charges. These negotiated discounts generally limit our ability to increase reimbursement rates to offset increasing costs. Nevertheless, our future success depends, in part, on our ability to retain and renew our managed care contracts and enter into newGenerally, we compete for managed care contracts on competitive terms.the basis of price, market reputation, geographic location, quality and range of services, caliber of the medical staff and convenience. Other healthcare providers may affect our ability to enter into acceptable managed care contractual arrangements or negotiate increases in our reimbursement. For example, some of our competitors may negotiate exclusivity provisions with managed care plans or otherwise restrict the ability of managed care companies to contract with us. Furthermore, the ongoing trend toward consolidationVertical integration efforts involving third‑party payers and healthcare providers, among non-government payers tends toother factors, may increase their bargaining power over fee structures.competitive challenges.

In addition, the competitive positions of hospitals and outpatient facilities depend in significant part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who have been admitted to the medical staffs of those facilities, as well as physicians who affiliate with and use outpatient centers as an extension of their practices. Members of the medical staffs of our facilities also often serve on the medical staffs of facilities we do not operate, and they are free to terminate their association with our facilities or admit their patients to competing facilities at any time. State laws that require findings of need for construction and expansion of healthcare facilities or services (as described in “Healthcare Regulation and Licensing – Certificate of Need Requirements” below) may also impact competition.

Our strategies are designed to help our hospitals and outpatient facilities remain competitive. We believe emphasis on higher-demandcompetitive, to attract and higher-acuityretain an appropriate number of physicians of distinction in various specialties, as well as skilled clinical service lines (including outpatient lines), focus on patient and physician access, investments in medical technology, improved quality metrics and contracting strategies that create shared value with payers should help us grow our patient volumes over time. We have also sought to include all of our hospitalspersonnel and other healthcare businesses in the related geographic area or nationally when negotiating new managed care contracts, which may result in additional volumes at facilitiesprofessionals, and to increase patient volumes. To that were not previously a part of such managed care networks.

We have significantly increased our focus on operating our outpatient centers with improved accessibility and more convenient service for patients, increased predictability and efficiency for physicians, and (for most services) lower costs for payers than would be incurred with a hospital visit. In addition,end, we have made significant investments in equipment, technology, education and operational strategies designed to improve clinical quality at all of our facilities. We believe physicians refer patients to a hospital on the basis of the quality, access and scope of services it renders to patients and physicians, the quality of other physicians on the medical staff, the location of the hospital, and the quality of the hospital’s facilities, equipment and employees. In addition, we continually collaborate with physicians to implement the most current evidence-basedevidence‑based medicine techniques to improve the way we provide care, while using labor management tools and supply supply‑chain initiatives to reduce variable costs. Moreover, we participate in various value‑based programs to improve quality and cost of care. We believe the use of these practices will promote the most effective and efficient utilization of resources and result in more appropriate lengths of stay, as well as reductions in readmissions for hospitalized patients. In general, we believe that quality of care improvements may have the effects of: (1) reducing costs; (2) increasing payments from Medicare and certain managed care payers for our services as governmental and private payers continue to move to pay-for-performancepay‑for‑performance models, and the commercial market movescontinues to move to more narrow networks and other methods designed to encourage covered individuals to use certain facilities over others; and (3) increasing physician and patient satisfaction, which may improve our volumes.

Moreover, in many of our markets, we have formed clinically integrated networks, which are collaborations with independent physicians and hospitals to develop ongoing clinical initiatives designed to control costs and improve the quality of care delivered to patients. Arrangements like these provide a foundation for negotiating with plans under an ACO structure or other risk-sharing model. However, It should be noted, however, that we do face competition from other healthcarehealth systems that are implementing similar strategies.


physician alignmentIn addition, we have significantly increased our focus on operating our outpatient centers with improved accessibility and more convenient service for patients, increased predictability and efficiency for physicians, and (for most services) lower costs for payers than would be incurred with a hospital visit. We believe that emphasis on higher‑demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service and participation in Medicare Advantage health plans that have been experiencing higher growth rates than traditional Medicare, among other strategies, will also help us address competitive challenges in our markets.

9

We also recognize that our future success depends, in part, on our ability to maintain and renew our existing managed care contracts and enter into new managed care contracts on competitive terms. To bolster our competitive position, we have sought to include all of our hospitals and other healthcare businesses in the related geographic area or nationally when negotiating new managed care contracts, which may result in additional volumes at facilities that were not previously a part of such as employing physicians, acquiring physician practice groups, and participatingmanaged care networks. We also continue to engage in ACOs or other clinical integration models.contracting strategies that create shared value with payers.

REVENUE CYCLE MANAGEMENT SOLUTIONS

Conifer faces competition from existing participants and new entrants to the revenue cycle management market,business, some of which may have significantly greater capital resources than Conifer. In addition, the internal revenue cycle management staff of hospitals and other healthcare providers, who have historically performedperform many of the functions addressed by our services, in effect compete with us. Moreover, providers who have previously made investments in internally developed solutions may choose to continue to rely on their own resources. We also currently compete with several categories of external participants in thewho offer revenue cycle market,services, including:

software vendors and other technology-supportedtechnology‑supported revenue cycle management business process outsourcing companies; 

traditional consultants, either specialized healthcare consulting firms or healthcare divisions of large accounting firms; and

large, non-healthcarenon‑healthcare focused business process and information technology outsourcing firms.

We believe that competition for the revenue cycle management and other services Conifer provides is based primarily on: (1) knowledge and understanding of the complex public and private healthcare payment and reimbursement systems; (2) a track record of delivering revenue improvements and efficiency gains for hospitals and other healthcare providers; (3) the ability to deliver solutions that are fully integrated along each step of the revenue cycle; (4) cost-effectiveness,cost‑effectiveness, including the breakdown between up-frontup‑front costs and pay-for-performancepay‑for‑performance incentive compensation; (5) reliability, simplicity and flexibility of the technology platform; (6) understanding of the healthcare industry’s regulatory environment, as well as laws and regulations relating to consumer protection; and (7) financial resources to maintain current technology and other infrastructure.

To be successful, Conifer must respond more quickly and effectively than its competitors to new or changing opportunities, technologies, standards, regulations and client requirements. Existing or new competitors may introduce technologies or services that render Conifer’s technologies or services obsolete or less marketable. Even if Conifer’s technologies and services are more effective than the offerings of its competitors, current or potential clients might prefer competitive technologies or services to Conifer’s technologies and services. Furthermore, increased competition has resulted and may continue to result in pricing pressures, which could negatively impact Conifer’s margins, growth rate or market share. In addition, the timing and uncertainty regarding our potential spin-offspin‑off of Conifer may have an adverse impact on Conifer’s ability to secure new clients.

HEALTHCARE REGULATION AND LICENSING

HEALTHCARE REFORM

THE AFFORDABLE CARE ACT
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”) extended health coverage to millions of uninsured legal U.S. residents through a combination of private sector health insurance reforms and public program expansion. To fund the expansion of insurance coverage, the ACA includes measures designed to promote quality and cost efficiency in healthcare delivery and to generate budgetary savings in the Medicare and Medicaid programs. In addition, the ACA contains provisions intended to strengthen fraud and abuse enforcement.

The initial expansion of health insurance coverage under the ACA resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions. Although a substantial portion of both our patient volumes and, as a result, our revenues has historically been derived from government healthcare programs, reductions to our reimbursement under the Medicare and Medicaid programs as a result of the ACA have been partially offset by increased revenues from providing care to previously uninsured individuals.

In recent years, theThe healthcare industry, in general, and the acute care hospital business, in particular, have been experiencingexperienced significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to significantly modifylimit, alter or repeal and potentially replace the ACA. Effective January 2019, Congress eliminated the financial penalty for noncompliance under the ACA’s individual mandate provision, which requires most U.S. citizensSince 2010, various states, private entities and noncitizens who lawfully reside in the country toindividuals have health insurance meeting specified standards. The Congressional Budget Office and

the Joint Committee on Taxation have estimated that eliminationchallenged parts or all of the individual mandate penalty will resultACA numerous times in seven million more uninsured by 2021state and put upward pressure on health insurance premiums. Members of Congressfederal courts, and other politiciansthe U.S. Supreme Court has issued decisions in three such cases, most recently in June 2021. Various state legislatures have also proposed measures that would expand government-sponsored coverage, including single-payer plans, such as Medicare for All.challenged parts or all of the ACA through legislation, while other states have acted to safeguard the ACA by codifying certain provisions into state law. We cannot predict if or when further modification of the ACA will occur or what future action, if any, Congress might take with respect to eventually repealing and possibly replacing the law. Furthermore, in December 2019, a federal appeals court panel agreed with a December 2018 ruling by the U.S. District Court for the Northern District of Texas in the matter of Texas v. United States that the ACA’s individual mandate is unconstitutional now that Congress has eliminated the tax penalty that was intended to enforce it. The appeals court sent the case back to the lower court to determine how much of the rest of the ACA, if any, can stand in light of its ruling. On January 3, 2020, the U.S. House of Representatives, 20 states and the District of Columbia filed a petition asking the U.S. Supreme Court to review the case on an expedited basis, but their petition was denied on January 21, 2020. Pending a final decision on the matter, the current administration has continued to enforce the ACA.

WeFurthermore, we are unable to predict the impact on our future revenues and operations of (1) the final decision in Texas v. United States and other court challenges to the
10

ACA, (2) administrative, regulatory and legislative changes, including the possibility of expansion of government-sponsoredgovernment‑sponsored coverage, or (3) market reactions to those changes. However, if the ultimate impact is that significantly fewer individuals have private or public health coverage, we likely will experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect our results of operations and cash flows. This negative effect will be exacerbated if the ACA’s reductions in Medicare reimbursement and reductions in Medicare disproportionate share hospital (“DSH”) payments that have already taken effect are not reversed if the law is repealed or if further reductions (including Medicaid DSH reductions scheduled to take effect in federal fiscal years 2020 through 2025) are made.

ANTI-KICKBACK AND SELF-REFERRAL REGULATIONS

Anti-KickbackAntiKickback Statute—Medicare and Medicaid anti-kickbackanti‑kickback and anti-fraudanti‑fraud and abuse amendments codified under Section 1128B(b) of the Social Security Act (the “Anti-kickback“Anti‑kickback Statute”) prohibitproscribe certain business practices and relationships that might affect the provision and cost of healthcare services payable under the Medicare and Medicaid programs and other government programs, including the payment or receipt of remuneration for the referral of patients whose care will be paid for by such programs. Specifically, the law prohibits any person or entity from offering, paying, soliciting or receiving anything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid and other federal healthcare programs or the leasing, purchasing, ordering or arranging for or recommending the lease, purchase or order of any item, good, facility or service covered by these programs. In addition to addressing other matters, as discussed below, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) also amended Title XI (42 U.S.C. Section 1301 et seq.) to broaden the scope of fraud and abuse laws to include all health plans, whether or not payments under such health plans are made pursuant to a federal program. Moreover, the Affordable Care Act amended the Anti-kickbackAnti‑kickback Statute to provide that intent to violate the Anti-kickback Statute is not required; rather, intent to violate the law generally is all that is required.

Sanctions for violating the Anti-kickbackAnti‑kickback Statute include criminal and civil penalties, as well as fines and mandatory exclusion from government programs, such as Medicare and Medicaid. In addition, submission of a claim for services or items generated in violation of the Anti-kickbackAnti‑kickback Statute constitutes a false or fraudulent claim and may be subject to additional penalties under the federal False Claims Act (“FCA”). Furthermore, it is a violation of the federal Civil Monetary Penalties Law (“CMPL”) to offer or transfer anything of value to Medicare or Medicaid beneficiaries that is likely to influence their decision to obtain covered goods or services from one provider or service over another. Many states have statutes similar to the federal Anti-kickbackAnti‑kickback Statute, except that the state statutes usually apply to referrals for services reimbursed by all third-partythird‑party payers, not just federal programs.

The federal government has also issued regulations – referred to as the “Safe Harbor” regulations – that describe some of the conduct and business relationships that are permissible under the Anti-kickbackAnti‑kickback Statute. These regulations are often referred to as the “Safe Harbor” regulations. Currently, there are safe harborsHistorically, Safe Harbors for various activities includinghave included the following: investment interests; space rental; equipment rental; practitioner recruitment; personal services and management contracts; sales of practices; referral services; warranties; discounts; employees; group purchasing organizations; waivers of beneficiary coinsurance and deductible amounts; managed care arrangements; obstetrical malpractice insurance subsidies; investments in group practices; ambulatory surgery centers;ASCs; referral agreements for specialty services; cost-sharingcost‑sharing waivers for pharmacies and emergency ambulance services; and local transportation. In December 2020, the HHS Office of Inspector General (“OIG”) published new rules (the “2020 AKS and CMPL Update”) that updated the Safe Harbor regulations and the CMPL. The 2020 AKS and CMPL Update modified existing Safe Harbors and added new Safe Harbors, as well as a new CMPL exception to remove barriers to more effective coordination and management of patient care and delivery of value‑based care. The 2020 AKS and CMPL Update includes: three new Safe Harbors to protect certain payments among individuals and entities in a value‑based arrangement; a Safe Harbor to protect certain remuneration provided in connection with CMS‑sponsored models; a Safe Harbor to protect donations of cybersecurity technology; and a Safe Harbor to protect the furnishing of certain tools and support to patients in order to improve quality, health outcomes and efficiency. The fact that certain conduct or a given business arrangement does not meet a Safe Harbor does not necessarily render the conduct or business arrangement illegal under the Anti-kickbackAnti‑kickback Statute. Rather, such conduct and business arrangements may be subject to increased scrutiny by government enforcement authorities and should be reviewed on a case-by-case basis.authorities.


Stark Law—The Stark law generally restricts physician referrals by physicians of Medicare or Medicaid patients to entities with which the physician or an immediate family member has a financial relationship, unless one of several exceptions applies. The referral prohibition applies to a number of statutorily defined “designated health services,” such as clinical laboratory, physical therapy, radiology, and inpatient and outpatient hospital services; the prohibition does not apply to health services provided by an ambulatory surgery centerASC if those services are included in the surgery center’sASC’s composite Medicare payment rate. However, if the ambulatory surgery centerASC is separately billing Medicare for designated health services that are not covered under the ambulatory surgery center’sits composite Medicare payment rate, or if either the ambulatory surgery centerASC or an affiliated physician is performing (and billing Medicare) for procedures that involve designated health services that Medicare has not designated as an ambulatory surgery centerASC service, the Stark law’s self-referralself‑referral prohibition would apply and such services could implicate the Stark law. Exceptions to the Stark law’s referral prohibition cover a broad range of common financial relationships. These statutory and the subsequent regulatory exceptions are available to protect certain permitted employment relationships, relocation arrangements, leases, group practice arrangements, medical directorships, and other commonordinary relationships between physicians and providers of designated health services, such as hospitals. In December 2020, CMS published new rules (the “2020 Stark Law Update”) that include new exceptions for: certain value‑based compensation
11

arrangements between or among physicians, providers and suppliers; limited remuneration to a physician for the provision of items and services without the need for a signed writing and compensation that is set in advance if certain conditions are met; and the protection of arrangements involving the donation of certain cybersecurity technology and related services, including certain cybersecurity hardware donations. The 2020 Stark Law Update also includes several new rules and clarifications to existing Stark Law regulations and key definitions intended to clarify some of the more challenging aspects of Stark Law compliance. CMS explained that the purpose of the 2020 Stark Law Update is to modernize and clarify the regulations to support the innovation necessary for a healthcare delivery and payment system that pays for value and to reduce unnecessary regulatory burdens on physicians and other healthcare providers and suppliers, while reinforcing the physician self‑referral law’s goal of protecting against program and patient abuse.

A violation of the Stark law may result in a denial of payment, required refunds to patients and the Medicare program, civil monetary penalties of up to $15,000 for each violation, civil monetary penalties of up to $100,000 for “sham” arrangements, civil monetary penalties of up to $10,000 for each day that an entity fails to report required information, and exclusion from participation in the Medicare and Medicaid programs and other federal programs. In addition, the submission of a claim for services or items generated in violation of the Stark law may constitute a false or fraudulent claim, and thus be subject to additional penalties under the FCA. Many states have adopted self-referralself‑referral statutes similar to the Stark law, some of which extend beyond the related state Medicaid program to prohibit the payment or receipt of remuneration for the referral of patients and physician self-referralsself‑referrals regardless of the source of the payment for the care. Our participation in and development of joint ventures and other financial relationships with physicians could be adversely affected by the Stark law and similar state enactments.

The Affordable Care Act also made changes to the “whole hospital” exception in the Stark law, effectively preventing new physician-ownedphysician‑owned hospitals after March 23, 2010 and limiting the capacity and amount of physician ownership in then-existing physician-ownedthen‑existing physician‑owned hospitals. As revised, the Stark law prohibits physicians from referring Medicare patients to a hospital in which they have an ownership or investment interest unless the hospital had physician ownership and a Medicare provider agreement as of March 23, 2010 (or, for those hospitals under development at the time of the ACA’s enactment, as of December 31, 2010). A physician-ownedphysician‑owned hospital that meets these requirements is still subject to restrictions that limit the hospital’s aggregate physician ownership percentage and, with certain narrow exceptions for hospitals with a high percentage of Medicaid patients, prohibit expansion of the number of operating rooms, procedure rooms or beds. Physician-ownedPhysician‑owned hospitals are also currently subject to reporting requirements and extensive disclosure requirements on the hospital’s website and in any public advertisements.

Implications of Fraud and Abuse Laws—At December 31, 2019,2021, the majority of the facilities that operate as surgical hospitals in our Ambulatory Care segment are owned by joint ventures that include some physician owners and are subject to the limitations and requirements in the Affordable Care Act on physician-ownedphysician‑owned hospitals. Furthermore, the majority of ambulatory surgery centersASCs in our Ambulatory Care segment, which are owned by joint ventures with physicians and/or healthcarehealth systems, are subject to the Anti-kickbackAnti‑kickback Statute and, in certain circumstances, may be subject to the Stark law. In addition, we have contracts with physicians and non-physiciannon‑physician referral services providing for a variety of financial arrangements, including employment contracts, leases and professional service agreements, such as medical director agreements. We have also provided financial incentives to recruit physicians to relocate to communities served by our hospitals, including income and collection guarantees and reimbursement of relocation costs, and willintend to continue to provide recruitment packages in the future. Furthermore, there can be no assurance that the government will not challenge new payment structures, such as ACOs and other arrangements involving combinations of hospitals, physicians and other providers who share payment savings, could potentially be seenunder anti‑kickback and self‑referral provisions, although this risk has been reduced as implicating anti-kickbacka result of the 2020 AKS and self-referral provisions.CMPL Update and the 2020 Stark Law Update, which updates are intended to remove potential federal regulatory barriers to care coordination and value‑based care.

Our operations could be adversely affected by the failure ofshould our arrangements fail to comply with the Anti-kickbackAnti‑kickback Statute, the Stark law, billing requirements, current state laws, or other legislation or regulations in these areas adopted in the future. We are unable to predict whether other legislation or regulations at the federal or state level in any of these areas will be adopted, what form such legislation or regulations may take or how they may impact our operations. For example, we cannot predict whether physicians may ultimately be restricted from holding ownership interests in hospitals or whether the exception relating to services provided by ambulatory surgery centersASCs could be eliminated. We are continuing to enter into new financial arrangements with physicians and other providers in a manner we believe complies with applicable anti-kickbackanti‑kickback and anti-fraudanti‑fraud and abuse laws. However, governmental officials responsible for enforcing these laws may nevertheless assert that we are in violation of these provisions. In addition, these statutes or regulations may be interpreted and enforced by the courts in a manner that is not consistent with our interpretation. An adverse determination could subject us to liabilities under the Social Security Act, including criminal penalties, civil monetary penalties and exclusion from participation in Medicare, Medicaid or other federal healthcare programs, any of which could have a material adverse effect on our business, financial

condition or results of operations. In addition, any
12

determination by a federal or state agency or court that USPI or its subsidiaries has violated any of these laws could give certain of our healthcare systemjoint venture partners a right to terminate their relationships with us; and any similar determination with respect to Conifer or any of its subsidiaries could give Conifer’s clients the right to terminate their services agreements with us. Moreover, any violations by and resulting penalties or exclusions imposed upon USPI’s healthcare systemjoint venture partners or Conifer’s clients could adversely affect their financial condition and, in turn, have a material adverse effect on our business and results of operations.

Retention of Independent Compliance Monitor—In September 2016, the Company and certain of its subsidiaries, including Tenet HealthSystem Medical, Inc. (“THSMI”), Atlanta Medical Center, Inc. (“AMCI”) and North Fulton Medical Center, Inc. (“NFMCI”), executed agreements with the U.S. Department of Justice (“DOJ”) and others to resolve a civil qui tam action and criminal investigation. In accordance with the terms of the resolution agreements, THSMI entered into a Non-Prosecution Agreement (as amended, the “NPA”) with the Criminal Division, Fraud Section, of the DOJ and the U.S. Attorney’s Office for the Northern District of Georgia (together, the “Offices”). The NPA requires, among other things, (1) THSMI and the Company to fully cooperate with the Offices in any matters relating to the conduct described in the NPA and other conduct under investigation by the Offices at any time during the term of the NPA, and (2) the Company to retain an independent compliance monitor to assess, oversee and monitor its compliance with the obligations under the NPA. The powers, duties and responsibilities of the independent compliance monitor are broadly defined. On February 1, 2017, the Company retained two independent co-monitors (the “Monitor”), who are partners in a national law firm.

The Monitor’s primary responsibility is to assess, oversee and monitor the Company’s compliance with its obligations under the NPA to specifically address and reduce the risk of any recurrence of violations of the Anti-kickback Statute and Stark law by any entity the Company owns, in whole or in part. In doing so, the Monitor reviews and monitors the effectiveness of the Company’s compliance with the Anti-kickback Statute and the Stark law, as well as respective implementing regulations, advisories and advisory opinions promulgated thereunder, and makes such recommendations as the Monitor believes are necessary to comply with the NPA. With respect to all entities in which the Company or one of its affiliates owns a direct or indirect equity interest of 50% or less and does not manage or control the day-to-day operations, the Monitor’s access to such entities is co-extensive with the Company’s access or control and for the purpose of reviewing the conduct. During its term, the Monitor will review and provide recommendations for improving compliance with the Anti-kickback Statute and Stark law, as well as the design, implementation and enforcement of the Company’s compliance and ethics programs for the purpose of preventing future criminal and ethical violations by the Company and its subsidiaries, including, but not limited to, violations related to the conduct giving rise to the NPA and the Criminal Information filed in connection with the NPA. If we are alleged or found to have violated the terms of the NPA described above or federal healthcare laws, rules or regulations in the future, our business, financial condition, results of operations or cash flows could be materially adversely affected. For additional information regarding the duties and authorities of the Monitor, reference is made to our Current Report on Form 8-K filed with the SEC on October 3, 2016.

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT

Title II, Subtitle F of the Health Insurance Portability and Accountability Act mandates the adoption of specific standards for electronic transactions and code sets that are used to transmit certain types of health information. HIPAA’s objective is to encourage efficiency and reduce the cost of operations within the healthcare industry. To protect the information transmitted using the mandated standards and the patient information used in the daily operations of a covered entity, HIPAA also sets forth federal rules protecting the privacy and security of protected health information (“PHI”). The privacy and security regulations address the use and disclosure of individually identifiable health information and the rights of patients to understand and control how their information is used and disclosed. The law provides both criminal and civil fines and penalties for covered entities that fail to comply with HIPAA.

To receive reimbursement from CMS for electronic claims, healthcare providers and health plans must use HIPAA’s electronic data transmission (transaction and code set) standards when transmitting certain healthcare information electronically. Our electronic data transmissions are compliant with current HHS standards for additional electronic transactions and with HHS’ operating rules to promote uniformity in the implementation of each standardized electronic transaction.

Under HIPAA, covered entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic PHI maintained or transmitted by them or by others on their behalf. The covered entities we operate are in material compliance with the privacy, security and National Provider Identifier requirements of HIPAA. In addition, most of Conifer’s clients are covered entities, and Conifer is a business associate to many of those clients under HIPAA as a result of its contractual obligations to perform certain functions on behalf of and provide certain

services to those clients. As a business associate, Conifer’s use and disclosure of PHI is restricted by HIPAA and the business associate agreements Conifer is required to enter into with its covered entity clients.

The Health Information Technology for Economic and Clinical Health (“HITECH”) Act imposed certain of the HIPAA privacy and security requirements directly upon business associates of covered entities and significantly increased the monetary penalties for violations of HIPAA. Regulations also require business associates such as Conifer to notify covered entities, who in turn must notify affected individuals and government authorities, of data security breaches involving unsecured PHI. Since the passage of the HITECH Act, enforcement of HIPAA violations has increased. If Conifer knowingly breaches the HIPAA privacy and security requirements made applicable to business associates by the HITECH Act, it could expose Conifer to criminal liability (as well as contractual liability to the associated covered entity); a breach of safeguards and processes that is not due to a reasonable cause or involves willful neglect could expose Conifer to significant civil penalties and the possibility of civil litigation under HIPAA and applicable state law.

We have developed a comprehensive set of policies and procedures in our efforts to comply with HIPAA, and similar state privacy laws, under the guidance of our ethics and compliance department. Our compliance officers and information security officers are responsible for implementing and monitoring enterprise-wide compliance with our HIPAA privacy and security policies and procedures throughout our company.procedures. We have also created an internal web-basedweb‑based HIPAA training program, which is mandatory for all employees. Based on existing regulations and our experience with HIPAA to this point, we continue to believe that the ongoing costs of complying with HIPAA will not have a material adverse effect on our business, financial condition, results of operations or cash flows.

THE NO SURPRISES ACT
The No Surprises Act was signed into law in December 2020 as part of the Consolidated Appropriations Act, 2021. The No Surprises Act is intended to address unexpected gaps in insurance coverage that result in “surprise medical bills” when patients unknowingly obtain medical services from physicians and other providers outside their health insurance network, including certain emergency services, anesthesiology services and air ambulance transportation. The protections of the No Surprises Act went into effect on January 1, 2022. As a result, patients will be liable only for their in‑network cost‑sharing amount, and insurers and providers will be given the opportunity to resolve disputed out‑of‑network reimbursement through negotiation and an independent dispute resolution process unless state law specifies a different approach. The No Surprises Act does not set a benchmark reimbursement amount.

13

In July 2021, HHS, along with the U.S. Department of Labor, the U.S. Department of Treasury and the Office of Personnel Management (collectively, the “Agencies”) issued “Requirements Related to Surprise Billing; Part I” (“Part I”), an interim final rule implementing several provisions of the No Surprises Act. Part I addresses (1) the ban on balance billing for certain out‑of‑network services, (2) the notice and consent process that some providers may use to bill patients for out‑of‑network services, (3) patient cost‑sharing calculations, and (4) a complaint process for any potential violations of the provisions in the law. Part I also clarifies that a health plan that provides emergency coverage must provide that coverage without prior authorization, without regard to whether a facility is in-network or out-of-network, and regardless of other terms of the plan, except for exclusions or coordination of benefits. Health plans also cannot deny claims for emergency coverage based on an after-the-fact assessment of the care provided, any purported delay between when symptoms began and when the patient sought care, or based on how long the symptoms were present.

In September 2021, the Agencies released the interim final rule “Requirements Related to Surprise Billing; Part II” (“Part II”), which addresses (1) the independent dispute resolution process that providers and plans may use to adjudicate any outstanding reimbursement disputes, (2) the good-faith cost estimates providers must share with uninsured or self‑pay patients for scheduled services, (3) a process to resolve any disputes between uninsured/self‑pay patients and providers about the cost estimates, and (4) an external review process as part of the oversight of health plan/issuer compliance with the law and regulations. The Agencies also established a website where an interested party may go to apply to serve as an independent dispute resolution entity and where providers and plans may initiate the process. The provisions in Part I and Part II also went into effect on January 1, 2022.

Many of the provisions of the No Surprises Act impact processes Conifer utilizes to collect accounts receivable, and Conifer has been working with its clients to develop policies and procedures to facilitate compliance. At this time, we are unable to assess the effect that the No Surprises Act or regulations relating to the No Surprises Act might have on our business, financial condition, results of operations or cash flows.

HOSPITAL PRICE TRANSPARENCY RULE
In November 2019, CMS issued a final rule (the “Hospital Price Transparency Rule”) requiring that hospitals share payer-specific negotiated prices for certain health care services with the goal of making it easier for consumers to shop and compare prices across hospitals and estimate the cost of care before going to the hospital. The Hospital Price Transparency Rule, which became effective on January 1, 2021, requires each hospital operating in the United States to provide clear, accessible pricing information online about the items and services it provides in two ways: (1) as a comprehensive machine-readable file with all items and services; and (2) in a display of shoppable services in a consumer-friendly format. These requirements apply to hospitals regardless of Medicare enrollment status. In a final rule issued in November 2021, CMS affirmed its commitment to enforcement and public access to pricing information by modifying the Hospital Price Transparency Rule to increase the civil monetary penalties for noncompliance, setting a minimum penalty of $300 per day for smaller hospitals with a bed count of 30 or fewer and a penalty of $10 per bed per day for hospitals with a bed count greater than 30, not to exceed a maximum daily dollar amount of $5,500. Under this approach, the minimum total annual penalty amount would be $109,500 per hospital, and the maximum total annual penalty amount would be $2,007,500 per hospital. CMS began auditing a sample of hospitals for compliance in January 2022, and it will also investigate complaints. We have developed processes to comply with the requirements of the Hospital Price Transparency Rule, and we believe we are in material compliance with those requirements.

GOVERNMENT ENFORCEMENT EFFORTS AND QUI TAM LAWSUITS

Both federal and state government agencies continueThe healthcare industry is subject to heightened and coordinated civil and criminal enforcement efforts against the healthcare industry.from both federal and state government agencies. The Office of Inspector General (“OIG”)OIG was established as an independent and objective oversight unit of HHS to carry out the mission of preventing fraud and abuse and promoting economy, efficiency and effectiveness of HHS programs and operations. In furtherance of this mission, the OIG, among other things, conducts audits, evaluations and investigations relating to HHS programs and operations and, when appropriate, imposes civil monetary penalties, assessments and administrative sanctions. Although weWe have extensive policies and procedures in place to facilitate compliance with the laws, rules and regulations affecting the healthcare industry, however, these policies and procedures may not be effective.cannot ensure compliance in every case.

Healthcare providers are also subject to qui tam or “whistleblower” lawsuits under the FCA, which allows private individuals to bring actions on behalf of the government, alleging that a hospital or healthcare provider has defrauded a government program, such as Medicare or Medicaid. If the government intervenes in the action and prevails, the defendant may be required to pay three times the damages sustained by the government, plus mandatory civil penalties for each false claim submitted to the government. As part of the resolution of a qui tam case, the qui tam plaintiff may share in a portion of any settlement or judgment. If the government does not intervene in the action, the qui tam plaintiff may continue to pursue the action independently. There are many potential bases for liability under the FCA. Liability often arises when an entity
14

knowingly submits a false claim for reimbursement to the federal government. The FCA defines the term “knowingly” broadly. Though simple negligence will not give rise to liability under the FCA, submitting a claim with reckless disregard to its truth or falsity constitutes a “knowing” submission under the FCA and, therefore, will qualify for liability. The Fraud Enforcement and Recovery Act of 2009 expanded the scope of the FCA by, among other things, creating liability for knowingly and improperly avoiding repayment of an overpayment received from the government and broadening protections for whistleblowers. It is a violation of the FCA to knowingly fail to report and return an overpayment within 60 days of identifying the overpayment or by the date a corresponding cost report is due, whichever is later. Qui tam actions can also be filed under certain state false claims laws if the fraud involves Medicaid funds or funding from state and local agencies. We have paid significant amounts to resolve qui tam matters brought against us in the past, and we are unable to predict the impact of future qui tam actions on our business, financial condition, results of operations or cash flows.

HEALTHCARE FACILITY LICENSING REQUIREMENTS

The operation of healthcare facilities is subject to federal, state and local regulations relating to personnel, operating policies and procedures, fire prevention, rate-setting,rate‑setting, the adequacy of medical care, and compliance with building codes and environmental protection laws. Various licenses and permits also are required in order to dispense narcotics, operate pharmacies, handle radioactive materials and operate certain equipment. Our facilities are subject to periodic inspection by governmental and other authorities to assure continued compliance with the various standards necessary for licensing and accreditation. We believe that all of our healthcare facilities hold all required governmental approvals, licenses and permits material to the operation of their business.


UTILIZATION REVIEW COMPLIANCE AND HOSPITAL GOVERNANCE

In addition to certain statutory coverage limitsThe Social Security Act and exclusions, federalMedicare regulations specifically the Medicare Conditions of Participation, generally require healthcare providers, including hospitals that furnish or order healthcare services that may be paid for under the Medicare program or state healthcare programs to ensure that claims for reimbursement are for services or items that are (1) provided economically and only when, and to the extent, they are medically reasonable and necessary, (2) of a quality that meets professionally recognized standards of healthcare, and (3) supported by appropriate evidence of medical necessity and quality. The Quality Improvement Organization program established under the Social Security Act established the Utilization and Quality Control Peer Review Organization program, now known as the Quality Improvement Organization (“QIO”) program,seeks to promoteimprove the effectiveness, efficiency, economy and quality of services delivered to Medicare beneficiaries andbeneficiaries; to ensurepreserve the Medicare Trust Fund by ensuring that thoseMedicare pays only for services that are reasonable and necessary. CMS administersnecessary and that are provided in the program through a network of QIOs that work with consumers, physicians, hospitalsmost appropriate setting; and to protect Medicare beneficiaries by expeditiously addressing complaints, violations under the Emergency Medical Treatment and Active Labor Act, and other caregivers to refine care delivery systems to ensure patients receive the appropriate care at the appropriate time, particularly among underserved populations. The QIO program also safeguards the integrity of the Medicare trust fund by reviewing Medicare patient admissions, treatments and discharges, and ensuring payment is made only for medically necessary services, and investigates beneficiary complaints about quality of care. The QIOs have the authority to deny payment for services provided and recommend to HHS that a provider that is in substantial noncompliance with certain standards be excluded from participating in the Medicare program.quality-related issues.

There has been increased scrutiny from outside auditors, government enforcement agencies and others, as well as an increased risk of government investigations and qui tam lawsuits, related to hospitals’ Medicare observation rates and inpatient admission decisions. The term “Medicare observation rate” is defined as total unique observation claims divided by the sum of total unique observation claims and total inpatient short-stayshort‑stay acute care hospital claims. A low rate may raise suspicions that a hospital is inappropriately admitting patients that could be cared for in an observation setting. In addition, CMS has established a concept referred to as the “two-midnight“two‑midnight rule” to guide practitioners admitting patients and contractors on when it is appropriate to admit individuals as hospital inpatients. Under the two-midnighttwo‑midnight rule, a Medicare patient should generally be admitted on an inpatient basis only when there is a reasonable expectation that the patient’s care will cross two midnights; if not, the patient generally should be treated as an outpatient, unless an exception applies. In our affiliated hospitals, we conduct reviews of Medicare inpatient stays of less than two midnights to determine whether a patient qualifies for inpatient admission. Enforcement of the two-midnighttwo‑midnight rule has not had, and is not expected to have, a material impact on inpatient admission rates at our hospitals.

Medical and surgical services and practices are extensively supervised by committees of staff doctorsphysicians at each of our healthcare facilities, are overseen by each facility’s local governing board, the members of which primarily are community members and physicians, and are reviewed by our clinical quality personnel. The local governing board also helps maintain standards for quality care, develop short-termshort‑term and long-rangelong‑range plans, and establish, review and enforce practices and procedures, as well as approves the credentials, disciplining and, if necessary, the termination of privileges of medical staff members.

CERTIFICATE OF NEED REQUIREMENTS

Some states require state approval for construction, acquisition and closure of healthcare facilities, including findings of need for additional or expanded healthcare facilities or services. Certificates or determinations of need, which are issued by governmental agencies with jurisdiction over healthcare facilities, are at times required for capital expenditures exceeding a prescribed amount, changes in bed capacity or services, and certain other matters. Our subsidiaries operate acute care hospitals in five states that require a form of state approval under certificate of need programs applicable to those hospitals. Approximately 31%34% of our licensed hospital beds are located in these states (namely, Alabama, Massachusetts, Michigan,
15

South Carolina and Tennessee). The certificate of need programs in most of these states, along with several others, also apply to ambulatory surgery centers.ASCs.

Failure to obtain necessary state approval can result in the inability to expand facilities, add services, acquire a facility or change ownership. Further, violation of such laws may result in the imposition of civil sanctions or the revocation of a facility’s license. We are unable to predict whether we will be required or able to obtain any additional certificates of need in any jurisdiction where they are required, or if any jurisdiction will eliminate or alter its certificate of need requirements in a manner that will increase competition and, thereby, affect our competitive position. In those states that do not have certificate of need requirements or that do not require review of healthcare capital expenditure amounts below a relatively high threshold, competition in the form of new services, facilities and capital spending is more prevalent.


ENVIRONMENTAL MATTERS

Our healthcare operations are subject to a number of federal, state and local environmental laws, rules and regulations that govern, among other things, our disposal of solid waste, as well as our use, storage, transportation and disposal of hazardous and toxic materials (including radiological materials). Our operations also generate medical waste that must be disposed of in compliance with statutes and regulations that vary from state to state. In addition, although we are not engaged in manufacturing or other activities that produce meaningful levels of greenhouse gas emissions, our operating expenses could be adversely affected if legal and regulatory developments related to climate change or other initiatives result in increased energy or other costs. We could also be affected by climate change and other environmental issues to the extent such issues adversely affect the general economy or result in severe weather affecting the communities in which our facilities are located. At this time, based on current climate conditions and our assessment of existing and pending environmental rules and regulations, as well as treaties and international accords relating to climate change, we do not believe that the costs of complying with environmental laws, including regulations relating to climate change issues, will have a material adverse effect on our future capital expenditures, results of operations or cash flows. There were no material capital expenditures for environmental matters in the year ended December 31, 2019.2021.

ANTITRUST LAWS

The federal government and most states have enacted antitrust laws that prohibit specific types of anti-competitiveanti‑competitive conduct, including price fixing, wage fixing, anticompetitive hiring practices, restrictive covenants, concerted refusals to deal, price discrimination and tying arrangements, as well as monopolization and acquisitions of competitors that have, or may have, a substantial adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties.

Antitrust enforcement in the healthcare industry is currently a priority of the U.S. Federal Trade Commission (“FTC”). In recent years, the FTC has filed multiple administrative complaints and public comments challenging hospital transactions in several states. The FTC has focused its enforcement efforts on preventing hospital mergers that may, in the government’s view, leave insufficient local options for patient services.services, which could result in increased costs to consumers. In addition, to hospital merger enforcement, the FTC has given increased attention to the effect of combinations involving other healthcare providers, including physician practices.practices, as well as to the use of restrictive covenants that limit the ability of employees and others to engage in certain competitive activities. The FTC has also entered into numerous consent decrees in the past several years settling allegations of price-fixingprice‑fixing among providers.

REGULATIONS AFFECTING CONIFER’S OPERATIONS

Conifer and its subsidiaries are subject to civil and criminal statutes and regulations governing consumer finance, medical billing, coding, collections and other operations. In connection with these laws and regulations, Conifer and its subsidiaries have been and expect to continue to be party to various lawsuits, claims, and federal and state regulatory investigations from time to time. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against Conifer and its subsidiaries or the effect thatthat judgments, penalties or settlements in such matters may have on Conifer.

BILLING AND COLLECTION ACTIVITIES

The federal Fair Debt Collection Practices Act (“FDCPA”) regulates persons who regularly collect or attempt to collect, directly or indirectly, consumer debts owed or asserted to be owed to another person. Certain of the accounts receivable handled by Conifer’s third-partythird‑party debt collection vendors are subject to the FDCPA, which establishes specific guidelines and procedures that debt collectors must follow in communicating with consumer debtors, including the time, place and manner of such communications. Conifer audits and monitors its vendors for compliance, but there can be no assurance that such audits and monitoring will detect all instances of potential non-compliance.non‑compliance.

16

Many states also regulate the billing and collection practices of creditors who collect their own debt, as well as the companies a creditor engages to bill and collect from consumers on the creditor’s behalf. These state regulations may be more stringent than the FDCPA. In addition, state regulations may be specific to medical billing and collections or the same or similar to state regulations applicable to third-partythird‑party collectors. Certain of the accounts receivable Conifer or its billing, servicing and collections subsidiary, PSS Patient Solution Services, LLC, manages for its clients are subject to these state regulations.

Conifer and its subsidiaries are also subject to both federal and state regulatory agencies who have the authority to investigate consumer complaints relating to a variety of consumer protection laws, including but not limited to the Telephone Consumer Protection Act and its state equivalent. These agencies may initiate enforcement actions, including actions to seek

restitution and monetary penalties from, or to require changes in business practices of, regulated entities. In addition, affected consumers may bring suits, including class action suits, to seek monetary remedies (including statutory damages) for violations of the federal and state provisions discussed above.

COMPLIANCE AND ETHICS

General—Our ethics and compliance department maintains our values-basedvalues‑based ethics and compliance program, which is designed to (1) help staff in our corporate, USPI and Conifer offices, hospitals, outpatient centers and physician practices meet or exceed applicable standards established by federal and state statutes and regulations, as well as industry practice, (2) monitor and raise awareness of ethical issues among employees and others, and stress the importance of understanding and complying with our StandardsCode of Conduct, and (3) provide a channel for employees to make confidential ethics and compliance-relatedcompliance‑related reports anonymously if they choose. The ethics and compliance department operates independently – it has its own operating budget; it has the authority to hire outside counsel, access any company document and interview any of our personnel; and our chief compliance officer reports directly to the quality, compliance and ethics committee of our board of directors.

Program Charter—Our Quality, Compliance and Ethics Program Charter is the governing document for our ethics and compliance program. Our adherence to the charter is intended to:

support and maintain our present and future responsibilities with regard to participation in federal healthcare programs; and

further our goals of operating an organization that (1) fosters and maintains the highest ethical standards among all employees, officers and directors, physicians practicing at our facilities and contractors that furnish healthcare items or services, (2) values compliance with all state and federal statutes and regulations as a foundation of its corporate philosophy, and (3) aligns its behaviors and decisions with Tenet’s core values.

The primary focus of our quality, compliance and ethics program is compliance with the requirements of Medicare, Medicaid and other federally funded healthcare programs. Pursuant to the terms of the charter, our ethics and compliance department is responsible for, among other things, the following activities: (1) ensuring, in collaboration with in-house counsel, facilitation of the Monitor’s activities and compliance with the provisions of the NPA and related company policies; (2) assessing, critiquing, and (as appropriate) drafting and distributing company policies and procedures; (3)(2) developing, providing, and tracking ethics and compliance training and other training programs, including job-specificjob‑specific training to those who work in clinical quality, coding, billing, cost reporting and referral source arrangements, in collaboration with the respective department responsible for oversight of each of these areas; (4)(3) creating and disseminating the Company’sour StandardsCode of Conduct and obtaining certifications of adherence to the StandardsCode of Conduct as a condition of employment; (5)(4) maintaining and promoting the Company’sour Ethics Action Line, a 24-hour, toll-free24‑hour, toll‑free hotline that allows for confidential reporting of issues on an anonymous basis and emphasizes the Company’s no-retaliationour no‑retaliation policy; and (6)(5) responding to and ensuring resolution of all compliance-relatedcompliance‑related issues that arise from the Ethics Action Line and compliance reports received from facilities and compliance officers (utilizing any compliance reporting software that the Companywe may employ for this purpose) or any other source that results in a report to the ethics and compliance department.

StandardsCode of Conduct—All of our employees and officers, including our chief executive officer, chief financial officer and principal accounting officer, are required to abide by our StandardsCode of Conduct to advance our mission that our business be conducted in a legal and ethical manner. The members of our board of directors and all of our contractors having functional roles similar to our employees are also required to abide by our StandardsCode of Conduct. The standards therein reflect our basic values and form the foundation of a comprehensive process that includes compliance with all corporate policies, procedures and practices. Our standards coverCode of Conduct covers such areas as quality patient care, compliance with all applicable statutes and regulations, appropriate use of our assets, protection of patient information and avoidance of conflicts of interest.

17

As part of the program, we provide compliance training sessions at least annually to every employee and officer, as well as our board of directors and certain physicians and contractors. All such persons are required to report incidents that they believe in good faith may be in violation of the StandardsCode of Conduct or our policies, and all are encouraged to contact our Ethics Action Line when they have questions about the standards or any ethics concerns. All reports to the Ethics Action Line are kept confidential to the extent allowed by law, and any individual who makes a report has the option to remain anonymous. Incidents of alleged financial improprieties reported to the Ethics Action Line or the ethics and compliance department are communicated to the audit committee of our board of directors. Reported cases that involve a possible violation of the law or regulatory policies and procedures are referred to the ethics and compliance department for investigation, although certain matters may be referred out to the law or human resources department. Retaliation against anyone in connection with reporting

ethical concerns is considered a serious violation of our StandardsCode of Conduct, and, if it occurs, it will result in discipline, up to and including termination of employment.

Non-Prosecution Agreement—In September 2016, our THSMI subsidiary entered into a Non-Prosecution Agreement with the DOJ’s Criminal Division, Fraud Section, and the U.S. Attorney’s Office for the Northern District of Georgia. The NPA requires, among other things, that we and THSMI (1) fully cooperate with the Offices in any matters relating to the conduct described in the NPA and other conduct under investigation by the Offices at any time during the term of the NPA, (2) retain an independent compliance monitor to assess, oversee and monitor our compliance with the obligations under the NPA, (3) promptly report any evidence or allegations of actual or potential violations of the Anti-kickback Statute, (4) maintain our compliance and ethics program throughout our operations, including those of our subsidiaries, affiliates, agents and joint ventures (to the extent that we manage or control or THSMI manages or controls such joint ventures), and (5) notify the DOJ and undertake certain other obligations specified in the NPA relative to, among other things, any sale, merger or transfer of all or substantially all of our and THSMI’s respective business operations or the business operations of our or its subsidiaries or affiliates, including an obligation to include in any contract for sale, merger, transfer or other change in corporate form a provision binding the purchaser to retain the commitment of us or THSMI, or any successor-in-interest thereto, to comply with the NPA obligations except as may otherwise be agreed by the parties to the NPA in connection with a particular transaction. Except as may otherwise be agreed by the parties in connection with a particular transaction, if, during the term of the NPA, THSMI undertakes or we undertake any change in corporate form that involves business operations that are material to our consolidated operations or to the operations of any subsidiaries or affiliates involved in the conduct described in the NPA, whether such transaction is structured as a sale, asset sale, merger, transfer or other change in corporate form, we are required to provide notice to the Offices at least 30 days prior to undertaking any such change in corporate form.

The NPA was originally scheduled to expire on February 1, 2020 (three years from the date on which the Monitor was retained); however, the DOJ subsequently extended the expiration date of the NPA by nine months to November 1, 2020 following its determination that we had breached certain reporting obligations under the terms of the NPA. In the event the Offices determine, in their sole discretion, that the Company, or any of its subsidiaries or affiliates, has knowingly violated any provision of the NPA, the NPA could be further extended by the Offices, in their sole discretion without prejudice to the Offices’ other rights under the NPA.

If, during the remaining term of the NPA, THSMI commits any felony under federal law, or if the Company commits any felony related to the Anti-kickback Statute, or if THSMI or the Company fails to cooperate or otherwise fails to fulfill the obligations set forth in the NPA, then THSMI, the Company and our affiliates could be subject to prosecution, exclusion from participation in federal healthcare programs, and other substantial costs and penalties, including further extensions of the NPA. The Offices retain sole discretion over determining whether there has been a breach of the NPA and whether to pursue prosecution. The NPA provides that, in the event the DOJ determines that the Company or THSMI has breached the NPA, the DOJ will provide written notice prior to instituting any prosecution of the Company or THSMI resulting from such breach. Following receipt of such notice, the Company and THSMI have the opportunity to respond to the DOJ to explain the nature and circumstances of the breach, as well as the actions taken to address and remediate the situation, which the DOJ shall consider in determining whether to pursue prosecution of the Company, THSMI or its affiliates. Any liability or consequences associated with a failure to comply with the NPA could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Availability of Documents—The full text of our Quality, Compliance and Ethics Program Charter, our StandardsCode of Conduct, and a number of our ethics and compliance policies and procedures are published on our website, at www.tenethealth.com, under the “Our Commitment To Compliance” caption in the “About Us” section. A copy of our StandardsCode of Conduct is also available upon written request to our corporate secretary. Information about how to contact our corporate secretary is set forth under “Company Information” below. Amendments to the StandardsCode of Conduct and any grant of a waiver from a provision of the StandardsCode of Conduct requiring disclosure under applicable SEC rules will be disclosed at the same location as the StandardsCode of Conduct on our website. A copy of the NPA is attached as an exhibit to our Current Report on Form 8-K filed with the SEC on October 3, 2016, and the letter agreement amending the term of the NPA, which was finalized on June 1, 2018, is attached as an exhibit to our Report on Form 10-Q for the quarter ended June 30, 2018.


INSURANCE

Property Insurance—We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy periods April 1, 2018 through March 31, 2019 and April 1, 2019 through March 31, 2020, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub-limits of $100 million for floods, $200 million for earthquakes and a per-occurrence sub-limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. For the 2018-2019 policy period, deductibles are 5% of insured values up to a maximum of $25 million for California earthquakes, floods and named windstorms, and 2% of insured values for New Madrid fault earthquakes, with a maximum per claim deductible of $25 million. For the 2019-2020 policy period, deductibles are 5% of insured values up to a maximum of $40 million for California earthquakes, $25 million for floods and named windstorms, and 2% of insured values for New Madrid fault earthquakes, with a maximum per claim deductible of $25 million. For both policy periods, floods and certain other covered losses, including fires and other perils, have a minimum deductible of $1 million.

Professional and General Liability Insurance—As is typical in the healthcare industry, we are subject to claims and lawsuits in the ordinary course of business. The healthcare industry has seen significant increases in the cost of professional and general liability insurance due to increased litigation. In response, weclaims and lawsuits in the ordinary course of business. We maintain captive insurance companies to self-insure a substantial portionself‑insure for the majority of our professional and general liability risk.

Claims in excess of our self-insurance retentions are insured withclaims, and we purchase insurance from third parties to cover catastrophic claims. All such commercial insurance companies.we purchase is subject to per-claim and policy period aggregate limits. If the policy period aggregate limit of any of our professional and general liabilitythese policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period. Any losses not covered by or in excess of the amounts maintained under our professional and general liability insurance policies will be funded from our working capital.

In addition to the reserves recorded by our captive insurance subsidiaries, we maintain reserves, including reserves for incurred but not reported claims, for our self-insuredself‑insured professional liability retentions and claims in excess of the policies’ aggregate limits, based on modeled estimates of losses and related expenses. Also, we provide standby letters of credit to certain of our insurers, which can be drawn upon under certain circumstances, to collateralize the deductible and self-insuredself‑insured retentions under a selected number of our professional and general liability insurance programs.

We also purchase property, cybersecurity and other insurance coverage from third parties in amounts we believe are adequate and subject to terms of coverage that we believe are reasonable. Our commercial insurance does not cover all claims against us and may not offset the financial impact of a material loss event. Moreover, commercial insurance may not continue to be available at a reasonable cost for us to maintain at adequate levels. The rise in the number and severity of hurricanes, wildfires, tornadoes and other weather events, whether or not precipitated by climate change, has created increased risk for insurance companies; it is expected that this increased risk will lead to a rise in insurance premiums and reductions in coverage for property owners in the future. In addition, the risk of ransomware attacks, breaches or other disruptions to information technology systems is elevated in the current environment, which has caused an increase in cyber premiums, lower coverage limits and implementation of cyber-specific policies. For further information regarding our insurance coverage, see Note 16 to our Consolidated Financial Statements.

COMPANY INFORMATION

Tenet Healthcare Corporation was incorporated in the State of Nevada in 1975. We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our reports, proxy statements and other documents filed electronically with the SEC are available at the website maintained by the SEC at www.sec.gov.

Our website, www.tenethealth.com, also offers, free of charge, access to our annual, quarterly and current reports (and amendments to such reports), and other filings made with, or furnished to, the SEC as soon as reasonably practicable after such documents are submitted to the SEC. The information found on our website is not part of this or any other report we file with or furnish to the SEC.

Inquiries directed to our corporate secretary may be sent to Corporate Secretary, Tenet Healthcare Corporation, P.O. Box 139003, Dallas, Texas 75313-900375313‑9003 or by e-maile‑mail at CorporateSecretary@tenethealth.com.
18


FORWARD-LOOKING STATEMENTS

This report includes “forward-looking“forward‑looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-lookingforward‑looking statements, including (but not limited to) disclosure regarding (1) the impact of the COVID‑19 pandemic, (2) our future earnings, financial position, and operational and strategic initiatives, and (3) developments in the healthcare industry. Forward-lookingForward‑looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be

materially different from those expressed or implied by forward-lookingforward‑looking statements. Such factors include, but are not limited to, the following:

The impact of the COVID‑19 pandemic on our future operations, financial condition and liquidity, particularly if the U.S. economy remains volatile for a significant period of time;
The impact on our business of any future modifications to or court decisions affecting the viability of the Affordable Care Act and the enactment of, or changes in, other statutes and regulations affecting the healthcare industry generally, as well as reductions to Medicare and Medicaid payment rates or changes in reimbursement practices or to Medicaid supplemental payment programs;
Adverse regulatory developments, government investigations or litigation, as well as the timing and impact of additional changes in federal tax laws, regulations and policies, and the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions;
Our ability to enter into or renew managed care provider arrangements on acceptable terms; changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under managed care agreements; and the impact of the industry trends toward value‑based purchasing and alternative payment models;
The impact of competition, and clinical and price transparency regulations, on our business;
Our success in recruiting and retaining physicians, nurses and other healthcare professionals as impacted by the COVID‑19 pandemic, vaccine mandates and other factors;
Our ability to achieve operating and financial targets, attain expected levels of patient volumes, and identify and execute on measures designed to save or control costs or streamline operations,operations;
Potential security threats, catastrophic events and other disruptions affecting our information technology and related systems;

Operational and other risks associated with acquisitions, divestitures and joint venture arrangements, including our ability to realize savings under our cost-reduction initiatives;the integration of newly acquired businesses;

The outcome of the process we have undertaken to pursue a tax-free spin-offtax‑free spin‑off of Conifer as a separate, independent, publicly traded company;

Potentialcompany, including the potential that the spin‑off may not be completed at all, as well as possible disruptions to our business or diverted management attention as a result of the Conifer spin-off process or our cost-reduction efforts, including our plans to outsource certain functions unrelated to direct patient care;spin‑off process;

The impact onof our businesssignificant indebtedness; the availability and terms of recentcapital to refinance existing debt, fund our operations and future modifications of or court challenges to the Affordable Care Actexpand our business; and the enactment of, or changes in, other statutes and regulations affecting the healthcare industry generally;

Cuts to Medicare and Medicaid payment rates or changes in reimbursement practices or to Medicaid supplemental payment programs;

Our success in recruiting and retaining physicians and other healthcare professionals;

Adverse regulatory developments, government investigations or litigation;

Adverse developments with respect to our ability to comply with the terms of the Non-Prosecution Agreement, including any breach of the agreement;our debt covenants and, over time, reduce leverage;

Our ability to enter into or renew managed care provider arrangements on acceptable terms; and changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under managed care agreements;

The effect that general adverse economic conditions (including inflation), consumer behavior and other factors have on our volumes and our ability to collect outstanding receivables on a timely basis, among other things; and increases in the amount of uninsured accounts and deductibles and copays for insured accounts; and

Our success in completing acquisitions, divestitures and other corporate development transactions; and our success in entering into, and managing the relationships and risks associated with, joint ventures;

The impact of competition on all aspects of our business;

The impact of our significant indebtedness; the availability and terms of capital to refinance existing debt, fund our operations and expand our business; and our ability to comply with our debt covenants and, over time, reduce leverage;

Potential security threats, catastrophic events and other disruptions affecting our information technology and related systems;

The timing and impact of additional changes in federal tax laws, regulations and policies, and the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions;

The impact that local, national and worldwide infectious disease outbreaks have on our operations; and

Other factors and risks referenced in this report and our other public filings.
19


When considering forward-lookingforward‑looking statements, you should keep in mind the risk factors and other cautionary statements in this report. Should one or more of the risks and uncertainties described in this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-lookingforward‑looking statement. We specifically disclaim any obligation to update any information contained in a forward-lookingforward‑looking statement or any forward-lookingforward‑looking statement in its entirety, except as required by law.


All forward-lookingforward‑looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.information.
    
ITEM 1A. RISK FACTORS

Our business is subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual operating results or financial performance to be materially different from our expectations and make an investment in our securities risky. If one or more of the events discussed in this report were to occur, actual outcomes could differ materially from those expressed in or implied by any forward-lookingforward‑looking statements we make in this report or our other filings with the SEC, and our business, financial condition, results of operations or liquidity could be materially adversely affected; furthermore, the trading price of our common stock could decline and our shareholders could lose all or part of their investment. Additional risks and uncertainties not presently known, or currently deemed immaterial, may also constrain our business and operations.

Risks Related to Our Overall Operations
The COVID-19 pandemic has significantly affected our operations and financial condition, and it continues to do so; moreover, our liquidity could be negatively impacted, particularly if the U.S. economy remains volatile for a significant period of time.
In 2021, the ongoing COVID‑19 pandemic significantly affected, and it continues to impact, all three segments of our business, as well as our patients, communities and employees. As a provider of healthcare services, we are acutely affected by the public health and economic effects of the pandemic. Over the course of the last two years, federal, state and local governmental authorities have imposed a variety of restrictions on people and businesses, and public health authorities have offered regular guidance on health and safety, all of which has impacted general economic activity and consumer behavior. More recently, new variants of the virus have caused additional outbreaks, and there is substantial uncertainty about the nature and degree of the continued effects of COVID-19 over time. Known and unknown risks and uncertainties caused by the COVID‑19 pandemic, including those described below, have had, and are continuing to have, a material impact on our business, financial condition, results of operations and cash flows; such risks and uncertainties may heighten other risks to our business as described herein.

Given the geographic diversity of our operations and the impact of COVID‑19 surges, we have been and may in the future be forced to reduce services at individual locations. Restrictive measures, including travel bans, social distancing, quarantines and shelter‑in‑place orders, have had, and may in the future have, the effect of reducing the number of procedures performed at our facilities more generally, as well as the volume of emergency room and physician office visits. In general, federal, state or local laws, regulations, orders or other actions imposing direct or indirect restrictions on our business due to the COVID‑19 pandemic or otherwise may have an adverse impact on our financial condition, results of operations and cash flows.

In some areas, the increased demand for care of COVID‑19 patients in our hospitals, as well as the direct impact of COVID‑19 on physicians, employees and their families, have put a strain on our resources and staff. Over the past two years, we have had to rely on higher‑cost temporary and contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers. Increased demand could also cause some of our hospitals to temporarily reduce their overall operating capacity or suspend certain services. We have incurred and continue to incur additional costs to protect the health and well-being of patients and staff. Even with appropriate protective measures, however, exposure to COVID‑19 increases the risk that physicians, nurses and others in our facilities may contract the virus, which could further limit our ability to treat all patients who seek care. If current conditions persist or worsen in some of our markets, certain of our hospitals may experience workforce disruptions from illness, absenteeism or protests. Furthermore, we may be subject to lawsuits from patients, employees and others exposed to COVID‑19 at our facilities. Such actions may involve large demands, as well as substantial defense costs. Our professional and general liability insurance may not cover all claims against us.

20

We have experienced supply‑chain disruptions, including shortages and delays, as well as significant price increases in medical supplies, particularly for personal protective equipment. COVID‑19 surges and outbreaks of new variants could further impact the cost of medical supplies, and supply shortages and delays may impact our ability to see, admit and treat patients.

Broad economic factors resulting from the COVID-19 pandemic, including higher inflation, increased unemployment rates in certain areas in which we operate and reduced consumer spending, have impacted, and are continuing to impact, our service mix, revenue mix and patient volumes. Business closings and layoffs in the areas we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients to pay for services as rendered. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted, and there can be no assurance that we will be able to raise additional funds on terms acceptable to us, if at all.

In general, the extent of the impact of the COVID-19 pandemic on our future operational and financial performance is currently uncertain and will depend on many factors outside of our control, including, among others: the duration, severity and trajectory of the pandemic, including the possible spread of potentially more contagious and/or virulent forms of the virus; future economic conditions, as well as the impact of government actions and administrative regulations on the hospital industry and broader economy, including through existing and any future stimulus efforts; the development, availability and widespread use of effective medical treatments and vaccines; the imposition of public safety measures; the volume of canceled or rescheduled procedures at our facilities; and the volume of COVID-19 patients across our care network. Moreover, at such time as COVID-19 cases do abate, we cannot provide any assurances that our volumes and case mix will return to pre-pandemic levels. COVID-19 developments continue to evolve quickly, and additional developments may occur that we are unable to predict.

Changes to existing COVID-19-related relief measures may have an adverse impact on our business, financial condition, results of operations or cash flows, and we cannot predict whether we will qualify for, apply for, receive or benefit from additional financial assistance in the future, if any, or how any future laws and regulations related to or in response to the COVID-19 pandemic will impact our operations.
As described in detail in MD&A, the Coronavirus Aid, Relief, and Economic Security Act and other legislative and regulatory actions have provided relief measures intended to mitigate some of the economic disruption caused by the COVID‑19 pandemic on our business. We are unable to predict whether changes, if any, to existing COVID‑19 relief measures will have an adverse impact on our business, financial condition, results of operations or cash flows. Moreover, some of the measures allowing for flexibility in delivery of care and financial support for healthcare providers are available only for the duration of the public health emergency as declared by the Secretary of HHS, and it is unclear whether or for how long the HHS declaration will be extended past its current expiration date.

The federal government and state and local governments may consider additional stimulus and relief efforts, but we are unable to predict whether any such measures will be enacted. There can also be no assurance that we will be eligible or apply for, or receive or benefit from, additional COVID‑19‑related stimulus assistance in the future, nor can there be any assurance as to the amount and type of assistance we may receive or seek or whether we will be able to comply with the applicable terms and conditions to retain such assistance. To the extent we do receive amounts or benefits under future relief measures related to or in response to the COVID‑19 pandemic, we cannot predict how such assistance will affect our operations or whether it will offset the negative impacts on our operations arising from the pandemic.

We cannot predict the impact that future modifications of the Affordable Care Act may have on our business, financial condition, results of operations or cash flows.

The initial expansion of health insurance coverage underhealthcare industry, in general, and the Affordable Care Act resultedacute care hospital business, in an increaseparticular, have experienced significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to limit, alter or repeal the number of patients using our facilities with eitherACA. Since 2010, various states, private entities and individuals have challenged parts or public program coverage and a decrease in uninsured and charity care admissions. Although a substantial portion of both our patient volumes and, as result, our revenues has historically been derived from government healthcare programs, reductions to our reimbursement under the Medicare and Medicaid programs as a resultall of the ACA have been partially offset by increased revenues from providing care to previously uninsured individuals.

Effective January 2019, Congress eliminated the financial penalty for noncompliance under the ACA’s individual mandate provision. The Congressional Budget Officenumerous times in state and federal courts, and the Joint Committee on Taxation have estimated that elimination of that penalty will resultU.S. Supreme Court has issued decisions in seven million more uninsured by 2021 and put upward pressure on health insurance premiums. Members of Congress and other politiciansthree such cases, most recently in June 2021. Various state legislatures have also proposed measures that would expand government-sponsored coverage, including single-payer plans, such as Medicare for All.challenged parts or all of the ACA through legislation, while other states have acted to safeguard the ACA by codifying certain provisions into state law. We cannot predict if or when further modification of the ACA will occur or what future action, if any, Congress might take with respect to eventually repealing and possibly replacing the law.

Furthermore, in December 2019, a federal appeals court panel agreed with a December 2018 ruling by the U.S. District Court for the Northern District of Texas in the matter of Texas v. United States that the ACA’s individual mandate is unconstitutional now that Congress has eliminated the tax penalty that was intended to enforce it. The appeals court sent the case back to the lower court to determine how much of the rest of the ACA, if any, can stand in light of its ruling. On January 3, 2020, the U.S. House of Representatives, 20 states and the District of Columbia filed a petition asking the U.S. Supreme Court to review the case on an expedited basis, but their petition was denied on January 21, 2020. Pending a final decision on the matter, the current administration has continued to enforce the ACA.

We Furthermore, we are unable to predict the impact on our future revenues and operations of (1) the final decision in Texas v. United States and other court challenges to the ACA, (2) administrative, regulatory and legislative changes, including the possibility of expansion of government-sponsoredgovernment‑sponsored coverage, or (3) market reactions to those changes. However, if the ultimate impact is that significantly fewer individuals have private or public health coverage, we likely will experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect our results of operations and cash flows. This negative effect will be exacerbated if the ACA’s reductions in Medicare reimbursement and reductions in Medicare DSH payments that have already taken effect are not reversed if the law is repealed or if further reductions (including Medicaid DSH reductions scheduled to take effect in federal fiscal years 2020 through 2025) are made.


21

FurtherFuture changes in the Medicare and Medicaid programs or other government healthcare programs, including reductions in scale and scope, could have an adverse effect on our business.

We are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid by governmental payers are reduced, if the scope of services covered by governmental payers is limited, or if we or one or more of our subsidiaries’ hospitals are excluded from participation in the Medicare or Medicaid program or any other government healthcare program, there could be a material adverse effect on our business, financial condition, results of operations or cash flows.

For the year ended December 31, 2019,2021, approximately 20% 18% and 8% of our net patient service revenues from ourfor the hospitals and related outpatient facilities in our Hospital Operations segment were from the Medicare program and various state Medicaid programs, respectively, in each case excluding Medicare and Medicaid managed care programs. The Medicare and Medicaid programs are subject to: statutory and regulatory changes, administrative and judicial rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating payments or reimbursements, among other things; requirements for utilization review; and federal and state funding restrictions, all of which could materially increase or decrease payments from these government programs in the future, as well as affect the cost of providing services to our patients and the timing of payments to our facilities, which could in turn adversely affect our overall business, financial condition, results of operations or cash flows.


SeveralEven prior to the COVID‑19 pandemic, several states in which we operate continue to facefaced budgetary challenges that have resulted and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs or have received federal government waivers allowing them to test new approaches and demonstration projects to improve care. Federal government denials or delayed approvals of waiver applications or extension requests by the states in which we operate could materially impact our Medicaid funding levels. Continuing pressure on state budgets and other factors, including legislative and/orand regulatory changes, could result in future reductions to Medicaid payments, payment delays or changes to Medicaid supplemental payment programs or additional taxes on hospitals.programs.

In general, we are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid by governmental payers are reduced, if the scope of services covered by governmental payers is limited, or if we or one or more of our subsidiaries’ hospitals are excluded from participation in the Medicare or Medicaid program or any other government healthcare program, there could be a material adverse effect on our business, financial condition, results of operations or cash flows.

Violations of existing regulations or failure to comply with new or changed regulations could harm our business and financial results.

Our hospitals, outpatient centers and related healthcare businesses are subject to extensive federal, state and local regulation relating to, among other things, licensure, contractual arrangements, conduct of operations, privacy of patient information, ownership of facilities, physician relationships, addition of facilities and services, and reimbursement rates for services. The laws, rules and regulations governing the healthcare industry are extremely complex and, in certain areas, the industry has little or no regulatory or judicial interpretation for guidance. Moreover, under the ACA, the government and its contractors may suspend Medicare and Medicaid payments to providers of services “pending an investigation of a credible allegation of fraud.” The potential consequences for violating such laws, rules or regulations include reimbursement of government program payments, the assessment of civil monetary penalties, including treble damages, fines, which could be significant, exclusion from participation in federal healthcare programs, or criminal sanctions against current or former employees, any of which could have a material adverse effect on our business, financial condition or cash flows. Even a public announcement that we are being investigated for possible violations of law could have a material adverse effect on the value of our common stock and our business reputation could suffer.

Furthermore, the healthcare as one of the largest industries in the United States,industry continues to attract much legislative interest and public attention. We are unable to predict the future course of federal, state and local healthcare legislation, regulation or legislation, including Medicare and Medicaid statutes and regulations.enforcement efforts, particularly in light of the partisan divide in Congress. Further changes in the regulatory framework negatively affecting healthcare providers could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Moreover, now that weIn addition, our operations at our Global Business Center in the Philippines are outsourcing and offshoringsubject to certain functions unrelated to direct patient care to enhance efficiency, we must ensure that those operations are compliant with U.S. healthcare industry-specific requirements. In addition, we are requiredindustry‑specific requirements, as well as U.S. and foreign laws applicable to businesses generally, including anti‑corruption laws. One such law, the Foreign Corrupt Practices Act (“FCPA”), regulates U.S. companies in their dealings with foreign officials, prohibiting bribes and similar practices, and requires that they maintain records that fairly and accurately reflect transactions and appropriate internal accounting controls. FCPA enforcement actions continue to be a high priority for the SEC and the U.S. Department of Justice. Our failure to comply with various federalthe FCPA could result in the imposition of fines and state labor laws, rulesother civil and regulations governingcriminal penalties, which could be significant.

22

We could be subject to substantial uninsured liabilities or increased insurance costs as a varietyresult of workplace wagesignificant legal actions.
We are subject to medical malpractice lawsuits, antitrust claims and hour issues. Fromother legal actions in the ordinary course of business. In addition, from time to time, we have been and expect to continue to be subject to regulatory proceedings and private litigation (including employee class action lawsuits) concerning our application of suchvarious federal and state labor laws, rules and regulations.regulations governing a variety of workplace wage and hour issues. Some of these actions involve large demands, as well as substantial defense costs. Even in states that have imposed caps on damages, litigants are seeking recoveries under new theories of liability that might not be subject to such caps. Our commercial insurance does not cover all claims against us. Moreover, commercial insurance may not continue to be available at a reasonable cost for us to maintain at adequate levels. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us or on our insurance costs. Additionally, all professional and general liability insurance we purchase is subject to per-claim and policy period aggregate limits. If the policy period aggregate limit of any of these policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period. Any losses not covered by or in excess of the amounts maintained under insurance policies will be funded from our working capital. Furthermore, one or more of our insurance carriers could become insolvent and unable to fulfill its or their obligations to defend, pay or reimburse us when those obligations become due. In that case or if payments of claims exceed our estimates or are not covered by insurance, it could have a material adverse effect on our business, financial condition, results of operations or cash flows.

If we are unable to enter into, maintain and renew managed care contractual arrangements on competitive terms, if we experience material reductions in the contracted rates we receive from managed care payers or if we have difficulty collecting from managed care payers, our results of operations could be adversely affected.
Our future success depends, in part, on our ability to maintain and renew our existing managed care contracts and enter into new managed care contracts on competitive terms. For the year ended December 31, 2021, approximately 68%, or $9.985 billion, of our net patient service revenues for the hospitals and related outpatient facilities in our Hospital Operations segment was attributable to managed care payers, including Medicare and Medicaid managed care programs. In 2021, our commercial managed care net inpatient revenue per admission from the hospitals in our Hospital Operations segment was approximately 82% higher than our aggregate yield on a per‑admission basis from government payers, including managed Medicare and Medicaid insurance plans. Our ability to negotiate favorable contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans, as well as add new facilities to our existing agreements at contracted rates, significantly affects our revenues and operating results. We currently have thousands of managed care contracts with various HMOs and PPOs; however, our top 10 managed care payers generated 61% of our managed care net patient service revenues for the year ended December 31, 2021. Because of this concentration, we may experience a short or long‑term adverse effect on our net operating revenues if we cannot renew, replace or otherwise mitigate the impact of expired contracts with significant payers. Furthermore, any disputes between us and significant managed care payers could have a material adverse effect on our financial condition, results of operations or cash flows. At December 31, 2021, 67% of our net accounts receivable for our Hospital Operations segment was due from managed care payers.

Private payers are increasingly attempting to control healthcare costs through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment in managed care programs, such as HMOs and PPOs. Any negotiated discount programs we agree to generally limit our ability to increase reimbursement rates to offset increasing costs. Furthermore, the ongoing trend toward consolidation among non‑government payers tends to increase their bargaining power over contract terms. Generally, we compete for these contracts on the basis of price, market reputation, geographic location, quality and range of services, caliber of the medical staff and convenience. Our relationships with payers, and reimbursement for the care we provide, may be further impacted by clinical and price transparency initiatives and out‑of‑network billing restrictions, including those in the No Surprises Act, which took effect January 1, 2022. In general, any material reductions in the contracted or out-of-network rates we receive for our services or any significant difficulties in collecting receivables from managed care payers could have a material adverse effect on our financial condition, results of operations or cash flows.

The industry trends toward value-based purchasing and alternative payment models may negatively impact our revenues.
Value‑based purchasing and alternative payment model initiatives of both governmental and private payers tying financial incentives to quality and efficiency of care will increasingly affect the results of operations of our hospitals and other healthcare facilities, and may negatively impact our revenues if we are unable to meet expected quality standards. Medicare requires providers to report certain quality measures in order to receive full reimbursement increases for inpatient and outpatient procedures that were previously awarded automatically, and the number of quality measures hospitals are required to report
23

publicly has increased in recent years. In addition, hospitals that meet or exceed certain quality performance standards will receive increased reimbursement payments, and hospitals that have “excess readmissions” for specified conditions will receive reduced reimbursement. Furthermore, Medicare no longer pays hospitals additional amounts for the treatment of certain hospital‑acquired conditions (“HACs”), unless the conditions were present at admission. Hospitals that rank in the worst 25% of all hospitals nationally for HACs in the previous year receive reduced Medicare reimbursements. Moreover, the Affordable Care Act prohibits the use of federal funds under the Medicaid program to reimburse providers for treating certain provider‑preventable conditions.

The ACA also created the CMS Innovation Center to develop and test innovative payment and service delivery models that have the potential to reduce Medicare, Medicaid or Children’s Health Insurance Program expenditures while preserving or enhancing the quality of care for beneficiaries. Congress has defined – both through the ACA and previous legislation – a number of specific demonstrations for CMS to conduct, including bundled payment models. Generally, the bundled payment models hold hospitals financially accountable for the quality and costs for an entire episode of care for a specific diagnosis or procedure from the date of the hospital admission or inpatient procedure through 90 days post‑discharge, including services not provided by the hospital, such as physician, inpatient rehabilitation, skilled nursing and home health care. Provider participation in some of these models is voluntary; however, participation in certain other bundled payment arrangements is mandatory for providers located in randomly selected geographic locations. Under the mandatory models, hospitals are eligible to receive incentive payments or will be subject to payment reductions within certain corridors based on their performance against quality and spending criteria. We cannot predict what impact, if any, these demonstration programs will have on our inpatient volumes, net revenues or cash flows.

There are also trends among private payers toward value‑based purchasing and alternative payment models for healthcare services. Many large commercial payers expect hospitals to report quality data, and several of these payers will not reimburse hospitals for certain preventable adverse events. We expect value‑based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts.

We are unable at this time to predict how the industry trends toward value‑based purchasing and alternative payment models will affect our results of operations, but they could negatively impact our revenues, particularly if we are unable to meet the quality and cost standards established by both governmental and private payers.

Our hospitals, outpatient centers and other healthcare businesses operate in competitive environments, and competition in our markets can adversely affect patient volumes and other aspects of our operations.
We believe our hospitals and outpatient facilities compete within local communities on the basis of many factors, including: quality of care; location and ease of access; the scope and breadth of services offered; reputation; and the caliber of the facilities, equipment and employees. In addition, the competitive positions of hospitals and outpatient facilities depend in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who are members of the medical staffs of those facilities, as well as physicians who affiliate with and use outpatient centers as an extension of their practices.

Some of the hospitals that compete with our hospitals are owned by tax‑supported government agencies, and many others are owned by not‑for‑profit organizations that may have financial advantages not available to our facilities, including (1) support through endowments, charitable contributions and tax revenues, (2) access to tax‑exempt financing, and (3) exemptions from sales, property and income taxes. In addition, in certain markets in which we operate, large teaching hospitals provide highly specialized facilities, equipment and services that may not be available at most of our hospitals. The existence or absence of state laws that require findings of need for construction and expansion of healthcare facilities or services may also impact competition. In recent years, the number of freestanding specialty hospitals, surgery centers, emergency departments and imaging centers in the geographic areas in which we operate has increased significantly. Some of these facilities are physician‑owned. Moreover, we expect to encounter additional competition from system‑affiliated hospitals and healthcare companies, as well as health insurers and private equity companies seeking to acquire providers, in specific geographic markets in the future.

Another major factor in the competitive position of a hospital or outpatient facility is the scope of its relationships with managed care plans given that HMOs, PPOs, third‑party administrators and other third‑party payers use managed care contracts to encourage patients to use certain hospitals in exchange for discounts from the hospitals’ established charges. Generally, we compete for managed care contracts on the basis of price, market reputation, geographic location, quality and range of services, caliber of the medical staff and convenience. Other healthcare providers may affect our ability to enter into acceptable managed care contractual arrangements or negotiate increases in our reimbursement. For example, some of our competitors may
24

negotiate exclusivity provisions with managed care plans or otherwise restrict the ability of managed care companies to contract with us. Vertical integration efforts involving third‑party payers and healthcare providers, among other factors, may increase competitive challenges.

If our competitors are better able to attract patients, recruit physicians, expand services or obtain favorable managed care contracts at their facilities than we are, we may experience an overall decline in patient volumes. Furthermore, healthcare consumers are now able to access hospital performance data on quality measures and patient satisfaction, as well as standard charges for services, to compare competing providers. The No Surprises Act created additional price transparency requirements beginning January 1, 2022, including requiring providers to send to health plans of insured patients and to uninsured patients good faith estimates of the expected charges and diagnostic codes prior to the scheduled dates of services. If any of our hospitals achieve poor results (or results that are lower than our competitors) on quality measures or patient satisfaction surveys, or if our standard charges are or are perceived to be higher than our competitors, we may attract fewer patients.

It is essential to our ongoing business that we attract an appropriate number of quality physicians in the specialties required to support our services and that we maintain good relations with those physicians.
The success of our business and clinical program development depends in large part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who are members of the medical staffs of our hospitals and other facilities, as well as physicians who affiliate with us and use our facilities as an extension of their practices. Physicians are often not employees of the hospitals or surgery centers at which they practice. Members of the medical staffs of our facilities also often serve on the medical staffs of facilities we do not operate, and they are free to terminate their association with our facilities or admit their patients to competing facilities at any time. In addition, although physicians who own interests in our facilities are generally subject to agreements restricting them from owning an interest in competitive facilities, we may not learn of, or be unsuccessful in preventing, our physician partners from acquiring interests in competitive facilities.

We expect to encounter increased competition from health insurers and private equity companies seeking to acquire providers in the areas where we operate physician practices and, where permitted by law, employ physicians. In 2021, we continued to experience challenges in recruiting and retaining physicians as a result of the prioritization of COVID-19 care and the challenges associated with relocating physicians during the pandemic. In some of our markets, physician recruitment and retention are affected by a shortage of qualified physicians in certain higher-demand clinical service lines and specialties. Furthermore, our ability to recruit and employ physicians is closely regulated. For example, the types, amount and duration of compensation and assistance we can provide to recruited physicians are limited by the Stark law, the Anti‑kickback Statute, state anti‑kickback statutes and related regulations. All arrangements with physicians must also be fair market value and commercially reasonable. If we are unable to attract and retain sufficient numbers of quality physicians by providing adequate support personnel, technologically advanced equipment, and facilities that meet the needs of those physicians and their patients, physicians may choose not to refer patients to our facilities, admissions and outpatient visits may decrease, and our operating performance may decline.

Our labor costs have been, and we expect will continue to be, adversely affected by competition for staffing, the shortage of experienced nurses and labor union activity.
The operations of our facilities depend on the efforts, abilities and experience of our management and medical support personnel, including nurses, therapists, pharmacists and lab technicians, as well as our employed physicians. There is a limited availability of experienced medical support personnel nationwide, and we compete with other healthcare providers in recruiting and retaining employees. Like others in the healthcare industry, we continue to experience a shortage of critical‑care nurses in certain disciplines and geographic areas. This shortage has been exacerbated by the COVID‑19 pandemic as more nurses choose to retire early, leave the workforce or take travel assignments. As a result of the aforementioned challenges, we have been and we may continue to be required to enhance wages and benefits to recruit and retain experienced employees, pay premiums above standard compensation for essential workers, make greater investments in education and training for newly licensed medical support personnel, or hire more expensive temporary or contract employees, which we compete with other healthcare providers to secure. Furthermore, state‑mandated nurse‑staffing ratios in California affect not only our labor costs, but, if we are unable to hire the necessary number of experienced nurses to meet the required ratios, they may also cause us to limit volumes, which would have a corresponding adverse effect on our net operating revenues. In general, our failure to recruit and retain qualified management, experienced nurses and other medical support personnel, or to control labor costs, could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Increased labor union activity is another factor that can adversely affect our labor costs. At December 31, 2021, approximately 27% of the employees in our Hospital Operations segment were represented by labor unions. Less than 1% of the total employees in both our Ambulatory Care and Conifer segments belong to a union. Unionized employees – primarily registered nurses and service, technical and maintenance workers – are located at 33 of our hospitals, the majority of which are
25

in California, Florida and Michigan. Organizing activities by labor unions could increase our level of union representation in future periods, which could impact our labor costs.

When we are negotiating collective bargaining agreements with unions (whether such agreements are renewals or first contracts), work stoppages and strikes may occur, as they did at one of our hospitals in 2021. Extended strikes have had, and could in the future have, an adverse effect on our patient volumes, net operating revenues and labor costs at individual hospitals or in local markets.

Employee vaccine mandates may adversely impact our business.
In November 2021, CMS published an interim final rule that requires all staff at healthcare facilities subject to the regulation, except for those with approved medical or religious exemptions, to be vaccinated against COVID-19. On January 13, 2022, the U.S. Supreme Court ruled that CMS had proper legislative authority to issue the mandate, and – although it is still being challenged in the lower courts – the mandate is enforceable while the challenges continue. Following the Supreme Court’s decision, CMS released new guidance that will require healthcare workers in 25 states to get their first vaccination in February and their second dose before the end of March 2022. (The CMS guidance did not change the compliance dates for healthcare workers in 25 states where the mandate was already in effect; those workers were required to get their first vaccination by January 27 and be fully vaccinated or exempt from the requirement by February 28.)

We are taking steps to develop policies and procedures to enforce the mandate in all of our hospitals and other healthcare facilities that have not already adopted such a standard. It is currently not possible to predict with certainty the impact the CMS mandate will have on our workforce; however, we recognize that enforcement of the mandate could result in labor disruptions, attrition, including the loss of nurses and other skilled employees, and challenges in meeting future labor needs, which could have a material adverse effect on our ability to treat patients, as well as our financial condition, results of operations or cash flows.

Our business could be significantly and negatively impacted by security threats, catastrophic events and other disruptions affecting our information technology and related systems.
Our information technology systems are critical to the day‑to‑day operation of our business. We rely on our information technology to process, transmit and store clinical, financial and operational data that includes PHI, personally identifiable information, and proprietary and confidential business performance data. We utilize electronic health records and other information technology in connection with all of our operations, including our billing and other financial systems, supply chain and labor management tools. Our systems, in turn, interface with and rely on third‑party systems that we do not control, including medical devices and other processes supporting the interoperability of healthcare infrastructures. We monitor and routinely test our security systems and processes and have a diversified data network that provides redundancies as well as other measures designed to protect the integrity, security and availability of the data we process, transmit and store. However, the information technology and infrastructure we use, and the third‑party systems we interact with, have been, and will likely continue to be, subject to computer viruses, attacks by hackers, or breaches due to employee error or malfeasance. The COVID‑19 pandemic has placed additional stress on our information technology systems, and the risk of attack, breach or other disruption to these systems is elevated in the current environment. In particular, we face a heightened risk of cybersecurity threats targeting healthcare providers, including ransomware attacks.

In general, attacks on, or breaches or other disruptions to, our information technology assets or those of third parties that we rely upon could impact the integrity, security or availability of data we process, transmit or store. While we are not aware of having experienced a material breach of our systems, the preventive actions we take to reduce the risk of such incidents and protect our information technology may not be sufficient in the future. As cybersecurity threats continue to evolve, we may not be able to anticipate certain attack methods in order to implement effective protective measures, and we continue to be required to expend significant additional resources to modify and strengthen our security measures, investigate and remediate any vulnerabilities in our information systems and infrastructure, and invest in new technology designed to mitigate security risks. Our insurance against cyber‑risks and attacks may not offset the financial impact of a material loss event.

Third parties to whom we outsource certain of our functions, or with whom our systems interface and who may, in some instances, store our sensitive and confidential data, are also subject to the risks outlined above and may not have or use controls effective to protect such information. An attack, breach or other system disruption affecting any of these third parties could similarly harm our business. Further, successful cyber‑attacks at other healthcare services companies, whether or not we are impacted, could lead to a general loss of consumer confidence in our industry that could negatively affect us, including harming the market perception of the effectiveness of our security measures or of the healthcare industry in general, which could result in reduced use of our services.
26


Our networks and technology systems have experienced disruption due to events such as system implementations, upgrades, and other maintenance and improvements, and they are subject to disruption in the future for similar events, as well as catastrophic events, including a major earthquake, fire, hurricane, telecommunications failure, ransomware attack, terrorist attack or the like. Any breach, system interruption or unavailability of our information systems or of third-party systems with access to our data could result in: the unauthorized disclosure, misuse, loss or corruption of such data; interruptions and delays in our normal business operations (including the collection of revenues); patient harm; potential liability under privacy, security, consumer protection or other applicable laws; regulatory penalties; and negative publicity and damage to our reputation. Any of these could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Any future cost-reduction initiatives may not deliver the benefits we expect, and actions taken may adversely affect our business.
Our future financial performance and level of profitability may depend, in part, on various cost‑reduction initiatives, including our outsourcing certain functions unrelated to direct patient care. We may encounter challenges in executing cost‑reduction initiatives and not achieve the intended cost savings. In addition, we may face wrongful termination, discrimination or other legal claims from employees affected by any workforce reductions, and we may incur substantial costs defending against such claims, regardless of their merits. The threat of such claims may also significantly increase our severance costs. Workforce reductions, whether as a result of internal restructuring or in connection with outsourcing efforts, may result in the loss of numerous long‑term employees, the loss of institutional knowledge and expertise, the reallocation of certain job responsibilities and the disruption of business continuity, all of which could negatively affect operational efficiencies and increase our operating expenses in the short term. Moreover, outsourcing and offshoring expose us to additional risks, such as reduced control over operational quality and timing, foreign political and economic instability, compliance and regulatory challenges, and natural disasters not typically experienced in the United States, such as volcanic activity and tsunamis.

Trends affecting our actual or anticipated results may require us to record charges that may negatively impact our results of operations.
As a result of factors that have negatively affected our industry generally and our business specifically, we have been, and in the future expect to be, required to record various charges in our results of operations. Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility’s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long‑lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material. We believe significant factors that contribute to adverse financial trends include reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. Future restructuring of our operating structure that changes our goodwill reporting units could also result in future impairments of our goodwill. Any such charges could negatively impact our results of operations.

The utilization of our tax losses could be substantially limited if we experience an ownership change as defined in the Internal Revenue Code.
At December 31, 2021, we had federal net operating loss (“NOL”) carryforwards of approximately $194 million pre‑tax available to offset future taxable income. Of these NOL carryforwards, $13 million will expire in the years 2026 to 2036, and $181 million has no expiration date. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of a company’s taxable income that may be offset by the NOL carryforwards if it experiences an “ownership change” as defined in Section 382 of the Code. An ownership change occurs when a company’s “five‑percent shareholders” (as defined in Section 382 of the Code) collectively increase their ownership in the company by more than 50 percentage points (by value) over a rolling three‑year period. (This is different from a change in beneficial ownership under applicable securities laws.) These ownership changes include purchases of common stock under share repurchase programs, a company’s offering of its stock, the purchase or sale of company stock by five‑percent shareholders, or the issuance or exercise of rights to acquire company stock. While we expect to be able to realize our total NOL carryforwards prior to their expiration, if an ownership change occurs, our ability to use the NOL carryforwards to offset future taxable income will be subject to an annual limitation and will depend on the amount of taxable income we generate in future periods. There is no assurance that we will be able to fully utilize the NOL carryforwards. Furthermore, we could be required to record a valuation allowance related to the amount of the NOL carryforwards that may not be realized, which could adversely impact our results of operations.

27

Risks Related to Acquisitions, Divestitures and Joint Ventures
When we acquire new assets or businesses, we become subject to various risks and uncertainties that could adversely affect our results of operations and financial condition.
We have completed a number of acquisitions in recent years, and we expect to pursue similar transactions in the future. A key business strategy for USPI, in particular, is the acquisition and development of facilities, primarily through the formation of joint ventures with physicians and health system partners. With respect to planned or future transactions, we cannot provide any assurances that we will be able to identify suitable candidates, consummate transactions on terms that are favorable to us, or achieve synergies or other benefits in a timely manner or at all. Furthermore, companies or operations we acquire may not be profitable or may not achieve the profitability that justifies the investments made. Businesses we acquire may also have pre‑existing unknown or contingent liabilities, including liabilities for failure to comply with applicable healthcare regulations. These liabilities could be significant, and, if we are unable to exclude them from the acquisition transaction or successfully obtain and pursue indemnification from a third party, they could harm our business and financial condition. In addition, we may face significant challenges in integrating personnel and financial and other systems. Future acquisitions could result in the incurrence of additional debt and contingent liabilities, potentially dilutive issuances of equity securities, and increased operating expenses, any of which could adversely affect our results of operations and financial condition.

We cannot provide any assurances that we will be successful in divesting assets we wish to sell.
We continue to exit service lines, businesses and markets that we believe are no longer strategic to our long‑term growth. In April 2021, we divested the majority of our urgent care centers and, in August 2021, we sold five Miami-area hospitals and certain related operations. We cannot provide any assurances that completed, planned or future divestitures or other strategic transactions will achieve their business goals or the benefits we expect.

We have in the past, and may in the future, fail to obtain applicable regulatory approvals, including FTC approvals, with respect to planned divestitures of assets or businesses. Moreover, we may encounter difficulties in finding acquirers or alternative exit strategies on terms that are favorable to us, which could delay the receipt of anticipated proceeds necessary for us to complete our planned strategic objectives. In addition, our divestiture activities have required, and may in the future require, us to retain significant pre-closing liabilities, recognize impairment charges (as discussed above) or agree to contractual restrictions that limit our ability to reenter a particular market, which may be material. Many of our acute care hospital divestitures also necessitate us entering into a transition services agreement with the buyer for information technology and other related services. As a consequence, we may be exposed to the financial status of the buyer for any payments under such transition services agreements or for transferred contractual liabilities, which could be significant.

Furthermore, our divestiture and other corporate development activities, including the potential spin‑off of Conifer, may present financial and operational risks, including (1) the diversion of management attention from existing core businesses, (2) adverse effects (including a deterioration in the related asset or business and, in Conifer’s case, the loss of existing clients and the difficulties associated with securing new clients) from the announcement of the planned or potential activity, and (3) the challenges associated with separating personnel and financial and other systems.

USPI and our hospital-based joint ventures depend on existing relationships with key health system partners. If we are unable to maintain historical relationships with these systems, or enter into new relationships, we may be unable to implement our business strategies successfully.
USPI and our hospital‑based joint ventures depend in part on the efforts, reputations and success of health system partners and the strength of our relationships with those systems. Our joint ventures could be adversely affected by any damage to those health systems’ reputations or to our relationships with them. In addition, damage to our business reputation could negatively impact the willingness of health systems to enter into relationships with us or USPI. If we are unable to maintain existing arrangements on favorable terms or enter into relationships with additional health system partners, we may be unable to implement our business strategies for our joint ventures successfully.

The remaining put/call arrangements associated with USPI, if settled in cash, will require us to utilize our cash flow or incur additional indebtedness to satisfy the payment obligations in respect of such arrangements.
We have a put/call agreement (the “Baylor Put/Call Agreement”) with Baylor that contains put and call options with respect to the 5% ownership interest Baylor holds in USPI. Each year starting in 2021, Baylor may put up to one-third of its total shares in USPI held as of April 1, 2017 (the “Baylor Shares”) by delivering notice by the end of January of such year. In each year that Baylor does not put the full 33.3% of USPI’s shares allowable, we may call the difference between the number of shares Baylor put and the maximum number of shares it could have put that year. In addition, the Baylor Put/Call Agreement contains a call option pursuant to which we have the ability to acquire all of Baylor’s ownership interest by 2024. We have the
28

ability to choose whether to settle the purchase price for the Baylor put/call, which is mutually agreed-upon fair market value, in cash or shares of our common stock. Baylor did not deliver a put notice to us in January 2021 or January 2022. In February 2021, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares. We are continuing to negotiate the terms of that purchase. In February 2022, we notified Baylor of our intention to again exercise our call option to purchase an additional 33.3% of the Baylor Shares. The amount and timing of the payments related to the exercise of our call options in 2021 and 2022, as well as payments related to future put or call decisions under the Baylor Put/Call Agreement, are currently uncertain.

Put and call arrangements, to the extent settled in cash, may require us to dedicate a substantial portion of our cash flow to satisfy our payment obligations in respect of such arrangements, which may reduce the amount of funds available for our operations, capital expenditures and corporate development activities. Similarly, we may be required to incur additional indebtedness to satisfy our payment obligations in respect of such arrangements, which could have important consequences to our business and operations, as described more fully below.

Our joint venture arrangements are subject to a number of operational risks that could have a material adverse effect on our business, results of operations and financial condition.
We have invested in a number of joint ventures with other entities when circumstances warranted the use of these structures, and we may form additional joint ventures in the future. These joint ventures may not be profitable or may not achieve the profitability that justifies the investments made. Furthermore, the nature of a joint venture requires us to consult with and share certain decision‑making powers with unaffiliated third parties, some of which may be not‑for‑profit health systems. If our joint venture partners do not fulfill their obligations, the affected joint venture may not be able to operate according to its business or strategic plans. In that case, our results of operations could be adversely affected or we may be required to increase our level of financial commitment to the joint venture. Moreover, differences in economic or business interests or goals among joint venture participants could result in delayed decisions, failures to agree on major issues and even litigation. If these differences cause the joint ventures to deviate from their business or strategic plans, or if our joint venture partners take actions contrary to our policies, objectives or the best interests of the joint venture, our results of operations could be adversely affected. In addition, our relationships with not‑for‑profit health systems and the joint venture agreements that govern these relationships are intended to be structured to comply with current revenue rulings published by the Internal Revenue Service, as well as case law relevant to joint ventures between for‑profit and not‑for‑profit healthcare entities. Material changes in these authorities could adversely affect our relationships with not‑for‑profit health systems and related joint venture arrangements.

Our participation in joint ventures is also subject to the risks that:

We could experience an impasse on certain decisions because we do not have sole decision‑making authority, which could require us to expend additional resources on resolving such impasses or potential disputes.

We may not be able to maintain good relationships with our joint venture partners (including health systems), which could limit our future growth potential and could have an adverse effect on our business strategies.

Our joint venture partners could have investment or operational goals that are not consistent with our corporate‑wide objectives, including the timing, terms and strategies for investments or future growth opportunities.

Our joint venture partners might become bankrupt, fail to fund their share of required capital contributions or fail to fulfill their other obligations as joint venture partners, which may require us to infuse our own capital into any such venture on behalf of the related joint venture partner or partners despite other competing uses for such capital.

Many of our existing joint ventures require that one of our wholly owned affiliates provide a working capital line of credit to the joint venture, which could require us to allocate substantial financial resources to the joint venture potentially impacting our ability to fund our other short‑term obligations.

Some of our existing joint ventures require mandatory capital expenditures for the benefit of the applicable joint venture, which could limit our ability to expend funds on other corporate opportunities.

29

Our joint venture partners may have exit rights that would require us to purchase their interests upon the occurrence of certain events or the passage of certain time periods, which could impact our financial condition by requiring us to incur additional indebtedness in order to complete such transactions or, alternatively, in some cases we may have the option to issue shares of our common stock to our joint venture partners to satisfy such obligations, which would dilute the ownership of our existing shareholders. When our joint venture partners seek to exercise their exit rights, we may be unable to agree on the value of their interests, which could harm our relationship with our joint venture partners or potentially result in litigation.

Our joint venture partners may have competing interests in our markets that could create conflict of interest issues.

Any sale or other disposition of our interest in a joint venture or underlying assets of the joint venture may require consents from our joint venture partners, which we may not be able to obtain.

Certain corporate‑wide or strategic transactions may also trigger other contractual rights held by a joint venture partner (including termination or liquidation rights) depending on how the transaction is structured, which could impact our ability to complete such transactions.

Our joint venture arrangements that involve financial and ownership relationships with physicians and others who either refer or influence the referral of patients to our hospitals or other healthcare facilities are subject to greater regulatory scrutiny from government enforcement agencies. While we endeavor to comply with the applicable safe harbors under the Anti‑kickback Statute, certain of our current arrangements, including joint venture arrangements, do not qualify for safe harbor protection.

Risks Related to Conifer
We cannot provide any assurances that we will be successful in completing the proposed spin-off of Conifer.
We cannot predict the outcome of the process we are undertaking to pursue a tax‑free spin‑off of Conifer. We cannot provide any assurances regarding the timeframe for completing the spin‑off, the allocation of assets and liabilities between Tenet and Conifer, that the other conditions of the spin‑off will be met, or that the spin‑off will be completed at all. We also cannot provide any assurances that the proposed spin‑off of Conifer, if consummated, will achieve the business goals or the benefits we expect. Additional risks regarding our divestiture and other corporate development activities, including the potential spin‑off of Conifer are described above under “We cannot provide any assurances that we will be successful in divesting assets in non‑core markets.”

A spin-off of Conifer could adversely affect our earnings and cash flows.
Conifer contributes a significant portion of our earnings and cash flows. Although there can be no assurance that the Conifer spin‑off process will result in a consummated transaction, any separation of all or a portion of Conifer’s business could adversely affect our earnings and cash flows.

Conifer operates in a highly competitive industry, and its current or future competitors may be able to compete more effectively than Conifer does, which could have a material adverse effect on Conifer’s margins, growth rate and market share.
We are continuing to market Conifer’s revenue cycle management, patient communications and engagement services, and value‑based care solutions businesses. The timing and uncertainty associated with our spin‑off plans for Conifer may have an adverse impact on Conifer’s ability to secure new clients. There can be no assurance that Conifer will be successful in generating new client relationships, including with respect to hospitals we or Conifer’s other clients sell, as the respective buyers of such hospitals may not continue to use Conifer’s services or, if they do, they may not do so under the same contractual terms. The market for Conifer’s solutions is highly competitive, and we expect competition may intensify in the future. Conifer faces competition from existing participants and new entrants to the revenue cycle management market, as well as from the staffs of hospitals and other healthcare providers who handle these processes internally. In addition, electronic medical record software vendors may expand into services offerings that compete with Conifer. To be successful, Conifer must respond more quickly and effectively than its competitors to new or changing opportunities, technologies, standards, regulations and client requirements. Moreover, existing or new competitors may introduce technologies or services that render Conifer’s technologies or services obsolete or less marketable. Even if Conifer’s technologies and services are more effective than the offerings of its competitors, current or potential clients might prefer competitive technologies or services to Conifer’s technologies and services. Furthermore, increased competition has resulted and may continue to result in pricing pressures, which could negatively impact Conifer’s margins, growth rate or market share.

30

Violations of existing regulations or failure to comply with new or changed regulations could harm Conifer’s business and financial results.
Conifer and its subsidiaries are subject to numerous federal, state and local consumer protection and other laws governing such topics as privacy, financial services, and billing and collections activities. Regulations governing Conifer’s operations are subject to changing interpretations that may be inconsistent among different jurisdictions. In addition, a regulatory determination made by, or a settlement or consent decree entered into with, one regulatory agency may not be binding upon, or preclude, investigations or regulatory actions by other agencies. Conifer’s failure to comply with applicable consumer protection and other laws could result in, among other things, the issuance of cease and desist orders (which can include orders for restitution or rescission of contracts, as well as other kinds of affirmative relief), the imposition of fines or refunds, and other civil and criminal penalties, some of which could be significant in the case of knowing or reckless violations. In addition, Conifer’s failure to comply with the statutes and regulations applicable to it could result in reduced demand for its services, invalidate all or portions of some of Conifer’s services agreements with its clients, give clients the right to terminate Conifer’s services agreements with them or give rise to contractual liabilities, among other things, any of which could have a material adverse effect on Conifer’s business. Furthermore, if Conifer or its subsidiaries become subject to fines or other penalties, it could harm Conifer’s reputation, thereby making it more difficult for Conifer to retain existing clients or attract new clients.


A breach or any other failure to comply with our Non-Prosecution Agreement could subject us to criminal prosecution, substantial penalties and exclusion from participation in federal healthcare programs, any of which could adversely impact our business, financial condition, results of operations or cash flows.

In September 2016, one of our subsidiaries, Tenet HealthSystem Medical, Inc., entered into a Non-Prosecution Agreement with the DOJ’s Criminal Division, Fraud Section, and the U.S. Attorney’s Office for the Northern District of Georgia, as described in “Compliance and Ethics – Non-Prosecution Agreement” above. The NPA was originally scheduled to expire on February 1, 2020; however, the DOJ subsequently extended the expiration date of the NPA by nine months to November 1, 2020 following its determination that we had breached certain reporting obligations under the terms of the NPA. If, during the remaining term of the NPA, THSMI commits any felony under federal law, or if the Company commits any felony related to the Anti-kickback Statute, or if THSMI or the Company fails to cooperate or otherwise fails to fulfill the obligations set forth in the NPA, then THSMI, the Company and our affiliates could be subject to prosecution, exclusion from participation in federal healthcare programs, and other substantial costs and penalties, including further extensions of the NPA. The Offices retain sole discretion over determining whether there has been a breach of the NPA and whether to pursue prosecution. Any liability or consequences associated with a failure to comply with the NPA could have a material adverse effect on our business, financial condition, results of operations or cash flows.

We could be subject to substantial uninsured liabilities or increased insurance costs as a result of significant legal actions.

We are subject to medical malpractice lawsuits, antitrust and employment class action lawsuits, and other legal actions in the ordinary course of business. Some of these actions involve large demands, as well as substantial defense costs. Even in states that have imposed caps on damages, litigants are seeking recoveries under new theories of liability that might not be subject to such caps. Our professional and general liability insurance does not cover all claims against us, and it may not continue to be available at a reasonable cost for us to maintain at adequate levels, as the healthcare industry has seen significant increases in the cost of such insurance due to increased litigation. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us or on our insurance costs. Additionally, all professional and general liability insurance we purchase is subject to policy limitations. If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period. Any losses not covered by or in excess of the amounts maintained under insurance policies will be funded from our working capital. Furthermore, one or more of our insurance carriers could become insolvent and unable to fulfill its or their obligations to defend, pay or reimburse us when those obligations become due. In that case or if payments of claims exceed our estimates or are not covered by our insurance, it could have a material adverse effect on our business, financial condition, results of operations or cash flows.

If we are unable to enter into, maintain and renew managed care contractual arrangements on acceptable terms, if we experience material reductions in the contracted rates we receive from managed care payers or if we have difficulty collecting from managed care payers, our results of operations could be adversely affected.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the year ended December 31, 2019 was approximately $9.5 billion, which represented approximately 66% of our total net patient service revenues. In addition, in the year ended December 31, 2019, our commercial managed care net inpatient revenue per admission from the hospitals and related outpatient facilities in our Hospital Operations and other segment was approximately 101% higher than our aggregate yield on a per admission basis from government payers, including managed Medicare and Medicaid insurance plans. Our ability to negotiate favorable contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans, as well as add new facilities to our existing agreements at contracted rates, significantly affects our revenues and operating results. We currently have thousands of managed care contracts with various HMOs and PPOs; however, our top ten managed care payers generated 62% of our managed care net patient service revenues for the year ended December 31, 2019. Because of this concentration, we may experience a short or long-term adverse effect on our net operating revenues if we cannot renew, replace or otherwise mitigate the impact of expired contracts with significant payers. Furthermore, any disputes between us and significant managed care payers could have a material adverse effect on our financial condition, results of operations or cash flows. At December 31, 2019, 65% of our net accounts receivable for our Hospital Operations and other segment was due from managed care payers.

Private payers are increasingly attempting to control healthcare costs through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment in managed care programs, such as HMOs and PPOs. Any negotiated discount programs we agree to generally limit our ability to increase reimbursement rates to offset increasing costs. Furthermore, the ongoing trend toward consolidation among private managed care payers tends to

increase their bargaining power over prices and fee structures. Our future success will depend, in part, on our ability to renew existing managed care contracts and enter into new managed care contracts on competitive terms. Other healthcare companies, including some with greater financial resources, greater geographic coverage or a wider range of services, may compete with us for these opportunities. For example, some of our competitors may negotiate exclusivity provisions with managed care plans or otherwise restrict the ability of managed care companies to contract with us. Any material reductions in the contracted rates we receive for our services or any significant difficulties in collecting receivables from managed care payers could have a material adverse effect on our financial condition, results of operations or cash flows.

Our cost-reduction initiatives do not always deliver the benefits we expect, and actions taken may adversely affect our business, financial condition and results of operations.

Our future financial performance and level of profitability is dependent, in part, on various cost-reduction initiatives, including our efforts to outsource certain functions unrelated to direct patient care. We may encounter challenges in executing our cost-reduction initiatives and not achieve the intended cost savings. In addition, we may face wrongful termination, discrimination or other legal claims from employees affected by any workforce reductions, and we may incur substantial costs defending against such claims, regardless of their merits. Such claims may also significantly increase our severance costs. Workforce reductions, whether as a result of internal restructuring or in connection with outsourcing efforts, may result in the loss of numerous long-term employees, the loss of institutional knowledge and expertise, the reallocation of certain job responsibilities and the disruption of business continuity, all of which could negatively affect operational efficiencies and increase our operating expenses in the short term. Moreover, outsourcing and offshoring may expose us to additional risks, such as reduced control over operational quality and timing, foreign political and economic instability, compliance and regulatory challenges, and natural disasters not typically experienced in the United States, such as volcanic activity and tsunamis. Our failure to effectively execute our cost-reduction initiatives may lead to significant volatility, and a decline, in the price of our common stock. We cannot guarantee that our cost-reduction initiatives will be successful, and we may need to take additional steps in the future to achieve our profitability goals.

We cannot provide any assurances that we will be successful in completing the proposed spin-off of Conifer or in divesting assets in non-core markets.

We cannot predict the outcome of the process we have begun to pursue a tax-free spin-off of Conifer. We cannot provide any assurances regarding the timeframe for completing the spin-off, the allocation of assets and liabilities between Tenet and Conifer, that the other conditions of the spin-off will be met, or that the spin-off will be completed at all. We also continue to exit service lines, businesses and markets that we believe are no longer strategic to our long-term growth. To that end, since January 1, 2018, we have divested 11 hospitals in the United States, as well as all of our operations in the United Kingdom. In addition, in December 2019, we entered into a definitive agreement to divest our two hospitals and other operations in the Memphis, Tennessee area. We cannot provide any assurances that completed, planned or future divestitures or other strategic transactions will achieve their business goals or the benefits we expect.

With respect to all proposed divestitures of assets or businesses, we may fail to obtain applicable regulatory approvals for such divestitures, including any approval that may be required under our NPA. Moreover, we may encounter difficulties in finding acquirers or alternative exit strategies on terms that are favorable to us, which could delay the receipt of anticipated proceeds necessary for us to complete our planned strategic objectives. In addition, our divestiture activities have required, and may in the future require, us to retain significant pre-closing liabilities, recognize impairment charges (as discussed below) or agree to contractual restrictions that limit our ability to reenter the applicable market, which may be material. Furthermore, our divestiture or other corporate development activities, including the planned spin-off of Conifer, may present financial and operational risks, including (1) the diversion of management attention from existing core businesses, (2) adverse effects (including a deterioration in the related asset or business and, in Conifer’s case, the loss of existing clients and the difficulties associated with securing new clients) from the announcement of the planned or potential activity, and (3) the challenges associated with separating personnel and financial and other systems.

A spin-off of Conifer could adversely affect our earnings and cash flows.

Conifer contributes a significant portion of the Company’s earnings and cash flows. We have begun to pursue a tax-free spin-off of Conifer. Although there can be no assurance that this process will result in a consummated transaction, any separation of all or a portion of Conifer’s business could adversely affect our earnings and cash flows.

Economic factors, consumer behavior and other dynamics have affected, and may continue to impact, our business, financial condition and results of operations.

We believe broad economic factors (including high unemployment rates in some of the markets our facilities serve), instability in consumer spending, uncertainty regarding the future of the Affordable Care Act, and the continued shift of additional financial responsibility to insured patients through higher co-pays, deductibles and premium contributions, among other dynamics, have affected our service mix, revenue mix and patient volumes, as well as our ability to collect outstanding receivables. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations. The U.S. economy remains unpredictable. If industry trends, such as reductions in commercial managed care enrollment and patient decisions to postpone or cancel elective and non-emergency healthcare procedures, worsen or if general economic conditions deteriorate, we may not be able to sustain future profitability, and our liquidity and ability to repay our outstanding debt may be harmed.

In addition, a significant number of our hospitals and other healthcare facilities are located in California, Florida and Texas. These concentrations increase the risk that, should any adverse economic, regulatory, environmental or other condition occur in these areas, our overall business, financial condition, results of operations or cash flows could be materially adversely affected.

Trends affecting our actual or anticipated results may require us to record charges that may negatively impact our results of operations.

As a result of factors that have negatively affected our industry generally and our business specifically, we have been required to record various charges in our results of operations. During the years ended December 31, 2019 and 2018, we recorded impairment charges of $42 million and $77 million, respectively. Our impairment tests presume stable, improving or, in some cases, declining operating results in our hospitals, which are based on programs and initiatives being implemented that are designed to achieve the hospitals’ most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material. Future restructuring of our operating structure that changes our goodwill reporting units could also result in future impairments of our goodwill. Any such charges could negatively impact our results of operations.

When we acquire new assets or businesses, we become subject to various risks and uncertainties that could adversely affect our results of operations and financial condition.

We have completed a number of acquisitions in recent years, and we expect to pursue similar transactions in the future. A key business strategy for USPI, in particular, is the acquisition and development of facilities, primarily through the formation of joint ventures with physicians and healthcare systems. With respect to planned or future transactions, we cannot provide any assurances that we will be able to identify suitable candidates, consummate transactions on terms that are favorable to us, or achieve synergies or other benefits in a timely manner or at all. Furthermore, companies or operations we acquire may not be profitable or may not achieve the profitability that justifies the investments made. Businesses we acquire may also have pre-existing unknown or contingent liabilities, including liabilities for failure to comply with applicable healthcare regulations. These liabilities could be significant, and, if we are unable to exclude them from the acquisition transaction or successfully obtain indemnification from a third party, they could harm our business and financial condition. In addition, we may face significant challenges in integrating personnel and financial and other systems. Future acquisitions could result in potentially dilutive issuances of equity securities, the incurrence of additional debt and contingent liabilities, and increased operating expenses, any of which could adversely affect our results of operations and financial condition.

USPI and our hospital-based joint ventures depend on existing relationships with key healthcare system partners. If we are unable to maintain historical relationships with these healthcare systems, or enter into new relationships, we may be unable to implement our business strategies successfully.

USPI and our hospital-based joint ventures depend in part on the efforts, reputations and success of healthcare system partners and the strength of our relationships with those healthcare systems. Our joint ventures could be adversely affected by any damage to those healthcare systems’ reputations or to our relationships with them. In addition, damage to our business reputation could negatively impact the willingness of healthcare systems to enter into relationships with us or USPI. If we are unable to maintain existing arrangements on favorable terms or enter into relationships with additional healthcare system partners, we may be unable to implement our business strategies for our joint ventures successfully.


The remaining put/call arrangements associated with USPI, if settled in cash, will require us to utilize our cash flow or incur additional indebtedness to satisfy the payment obligations in respect of such arrangements.

As part of the formation of USPI in 2015, we entered into a put/call agreement with respect to the equity interests in USPI held by our joint venture partners at that time. During 2016, 2017 and 2018, we paid a total of $1.473 billion to purchase additional shares of USPI to increase our ownership interest in USPI from 50.1% to 95%.

We have also entered into a separate put/call agreement (the “Baylor Put/Call Agreement”) with respect to the remaining 5% outside ownership interest in USPI held by Baylor University Medical Center. Each year starting in 2021, Baylor may require us to purchase, or “put” to us, up to 33.3% of their total shares in USPI held as of April 1, 2017. In each year that Baylor does not put the full 33.3% of USPI’s shares allowable, we may call the difference between the number of shares Baylor put and the maximum number of shares they could have put that year. In addition, the Baylor Put/Call Agreement contains a call option pursuant to which we have the ability to acquire all of Baylor’s ownership interest by 2024. In each case, we have the ability to choose whether to settle the purchase price for the Baylor put/call in cash or shares of our common stock.

The put and call arrangements described above, to the extent settled in cash, may require us to dedicate a substantial portion of our cash flow to satisfy our payment obligations in respect of such arrangements, which may reduce the amount of funds available for our operations, capital expenditures and corporate development activities. Similarly, we may be required to incur additional indebtedness to satisfy our payment obligations in respect of such arrangements, which could have important consequences to our business and operations, as described more fully below under “Our level of indebtedness could, among other things, adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, and prevent us from meeting our obligations under the agreements relating to our indebtedness.”

Risks Related to Our joint venture arrangements are subject to a number of operational risks that could have a material adverse effect on our business, results of operations and financial condition.

We have invested in a number of joint ventures with other entities when circumstances warranted the use of these structures, and we may form additional joint ventures in the future. These joint ventures may not be profitable or may not achieve the profitability that justifies the investments made. Furthermore, the nature of a joint venture requires us to consult with and share certain decision-making powers with unaffiliated third parties, some of which may be not-for-profit healthcare systems. If our joint venture partners do not fulfill their obligations, the affected joint venture may not be able to operate according to its business or strategic plans. In that case, our results could be adversely affected or we may be required to increase our level of financial commitment to the joint venture. Moreover, differences in economic or business interests or goals among joint venture participants could result in delayed decisions, failures to agree on major issues and even litigation. If these differences cause the joint ventures to deviate from their business or strategic plans, or if our joint venture partners take actions contrary to our policies, objectives or the best interests of the joint venture, our results could be adversely affected. In addition, our relationships with not-for-profit healthcare systems and the joint venture agreements that govern these relationships are intended to be structured to comply with current revenue rulings published by the Internal Revenue Service, as well as case law relevant to joint ventures between for-profit and not-for-profit healthcare entities. Material changes in these authorities could adversely affect our relationships with not-for-profit healthcare systems and related joint venture arrangements.

Our participation in joint ventures is also subject to the risks that:

We could experience an impasse on certain decisions because we do not have sole decision-making authority, which could require us to expend additional resources on resolving such impasses or potential disputes.

We may not be able to maintain good relationships with our joint venture partners (including healthcare systems), which could limit our future growth potential and could have an adverse effect on our business strategies.

Our joint venture partners could have investment or operational goals that are not consistent with our corporate-wide objectives, including the timing, terms and strategies for investments or future growth opportunities.

Our joint venture partners might become bankrupt, fail to fund their share of required capital contributions or fail to fulfill their other obligations as joint venture partners, which may require us to infuse our own capital into any such venture on behalf of the related joint venture partner or partners despite other competing uses for such capital.


Many of our existing joint ventures require that one of our wholly owned affiliates provide a working capital line of credit to the joint venture, which could require us to allocate substantial financial resources to the joint venture potentially impacting our ability to fund our other short-term obligations.

Some of our existing joint ventures require mandatory capital expenditures for the benefit of the applicable joint venture, which could limit our ability to expend funds on other corporate opportunities.

Our joint venture partners may have exit rights that would require us to purchase their interests upon the occurrence of certain events or the passage of certain time periods, which could impact our financial condition by requiring us to incur additional indebtedness in order to complete such transactions or, alternatively, in some cases we may have the option to issue shares of our common stock to our joint venture partners to satisfy such obligations, which would dilute the ownership of our existing shareholders. When our joint venture partners seek to exercise their exit rights, we may be unable to agree on the value of their interests, which could harm our relationship with our joint venture partners or potentially result in litigation.

Our joint venture partners may have competing interests in our markets that could create conflict of interest issues.

Any sale or other disposition of our interest in a joint venture or underlying assets of the joint venture may require consents from our joint venture partners, which we may not be able to obtain.

Certain corporate-wide or strategic transactions may also trigger other contractual rights held by a joint venture partner (including termination or liquidation rights) depending on how the transaction is structured, which could impact our ability to complete such transactions.

Our joint venture arrangements that involve financial and ownership relationships with physicians and others who either refer or influence the referral of patients to our hospitals or other healthcare facilities are subject to greater regulatory scrutiny from government enforcement agencies. While we endeavor to comply with the applicable safe harbors under the Anti-kickback Statute, certain of our current arrangements, including joint venture arrangements, do not qualify for safe harbor protection.

It is essential to our ongoing business that we attract an appropriate number of quality physicians in the specialties required to support our services and that we maintain good relations with those physicians.

The success of our business and clinical program development depends in significant part on the number, quality, specialties, and admitting and scheduling practices of the licensed physicians who have been admitted to the medical staffs of our hospitals and other facilities, as well as physicians who affiliate with us and use our facilities as an extension of their practices. Physicians are often not employees of the hospitals or surgery centers at which they practice. Members of the medical staffs of our facilities also often serve on the medical staffs of facilities we do not operate, and they are free to terminate their association with our facilities or admit their patients to competing facilities at any time. In addition, although physicians who own interests in our facilities are generally subject to agreements restricting them from owning an interest in competitive facilities, we may not learn of, or be unsuccessful in preventing, our physician partners from acquiring interests in competitive facilities.

We expect to encounter increased competition from health insurers and private equity companies seeking to acquire providers in the markets where we operate physician practices and, where permitted by law, employ physicians. In some of our markets, physician recruitment and retention are affected by a shortage of physicians in certain specialties and the difficulties that physicians can experience in obtaining affordable malpractice insurance or finding insurers willing to provide such insurance. Furthermore, our ability to recruit and employ physicians is closely regulated. For example, the types, amount and duration of compensation and assistance we can provide to recruited physicians are limited by the Stark law, the Anti-kickback Statute, state anti-kickback statutes and related regulations. All arrangements with physicians must also be fair market value and commercially reasonable. If we are unable to attract and retain sufficient numbers of quality physicians by providing adequate support personnel, technologically advanced equipment, and facilities that meet the needs of those physicians and their patients, physicians may choose not to refer patients to our facilities, admissions and outpatient visits may decrease and our operating performance may decline.


Our labor costs can be adversely affected by competition for staffing, the shortage of experienced nurses and labor union activity.

The operations of our facilities depend on the efforts, abilities and experience of our management and medical support personnel, including nurses, therapists, pharmacists and lab technicians, as well as our employed physicians. We compete with other healthcare providers in recruiting and retaining employees, and, like others in the healthcare industry, we continue to experience a shortage of critical-care nurses in certain disciplines and geographic areas. As a result, from time to time, we may be required to enhance wages and benefits to recruit and retain experienced employees, make greater investments in education and training for newly licensed medical support personnel, or hire more expensive temporary or contract employees. Furthermore, state-mandated nurse-staffing ratios in California affect not only our labor costs, but, if we are unable to hire the necessary number of experienced nurses to meet the required ratios, they may also cause us to limit volumes, which would have a corresponding adverse effect on our net operating revenues. In general, our failure to recruit and retain qualified management, experienced nurses and other medical support personnel, or to control labor costs, could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Increased labor union activity is another factor that can adversely affect our labor costs. At December 31, 2019, approximately 28% of the employees in our Hospital Operations and other segment were represented by labor unions. Less than 1% of the total employees in both our Ambulatory Care and Conifer segments belong to a union. Unionized employees – primarily registered nurses and service, technical and maintenance workers – are located at 35 of our hospitals, the majority of which are in California, Florida and Michigan. When negotiating collective bargaining agreements with unions, whether such agreements are renewals or first contracts, there is a possibility that strikes could occur, and our continued operation during any strikes could increase our labor costs and have an adverse effect on our patient volumes and net operating revenues. Organizing activities by labor unions could increase our level of union representation in future periods, which could result in increases in salaries, wages and benefits expense.

Our hospitals, outpatient centers and other healthcare businesses operate in competitive environments, and competition in our markets can adversely affect patient volumes.

The healthcare business is highly competitive, and competition among hospitals and other healthcare providers for patients has intensified in recent years. Generally, other hospitals and outpatient centers in the local communities we serve provide services similar to those we offer, and, in some cases, our competitors (1) are more established or newer than ours, (2) may offer a broader array of services or more desirable facilities to patients and physicians than ours, and (3) may have larger or more specialized medical staffs to admit and refer patients, among other things. Furthermore, healthcare consumers are now able to access hospital performance data on quality measures and patient satisfaction, as well as standard charges for services, to compare competing providers; if any of our hospitals achieve poor results (or results that are lower than our competitors) on quality measures or patient satisfaction surveys, or if our standard charges are or are perceived to be higher than our competitors, we may attract fewer patients. Additional quality measures and trends toward clinical or billing transparency may have an unanticipated impact on our competitive position and patient volumes.

In the future, we expect to encounter increased competition from system-affiliated hospitals and healthcare companies, as well as health insurers and private equity companies seeking to acquire providers, in specific geographic markets. We also face competition from specialty hospitals (some of which are physician-owned) and unaffiliated freestanding outpatient centers for market share in diagnostic and specialty services and for quality physicians and personnel. In recent years, the number of freestanding specialty hospitals, surgery centers, emergency departments and diagnostic imaging centers in the geographic areas in which we operate has increased significantly. Furthermore, some of the hospitals that compete with our hospitals are owned by government agencies or not-for-profit organizations supported by endowments and charitable contributions and can finance capital expenditures and operations on a tax-exempt basis. If our competitors are better able to attract patients, recruit physicians, expand services or obtain favorable managed care contracts at their facilities than we are, we may experience an overall decline in patient volumes.

Conifer operates in a highly competitive industry, and its current or future competitors may be able to compete more effectively than Conifer does, which could have a material adverse effect on Conifer’s margins, growth rate and market share.

As we pursue a spin-off of Conifer, we are continuing to market Conifer’s revenue cycle management, patient communications and engagement services, and value-based care solutions businesses. The timing and uncertainty associated with our plans for Conifer may have an adverse impact on Conifer’s ability to secure new clients. There can be no assurance that Conifer will be successful in generating new client relationships, including with respect to hospitals we or Conifer’s other clients sell, as the respective buyers of such hospitals may not continue to use Conifer’s services or, if they do, they may not do

so under the same contractual terms. The market for Conifer’s solutions is highly competitive, and we expect competition may intensify in the future. Conifer faces competition from existing participants and new entrants to the revenue cycle management market, as well as from the staffs of hospitals and other healthcare providers who handle these processes internally. In addition, electronic medical record software vendors may expand into services offerings that compete with Conifer. To be successful, Conifer must respond more quickly and effectively than its competitors to new or changing opportunities, technologies, standards, regulations and client requirements. Moreover, existing or new competitors may introduce technologies or services that render Conifer’s technologies or services obsolete or less marketable. Even if Conifer’s technologies and services are more effective than the offerings of its competitors, current or potential clients might prefer competitive technologies or services to Conifer’s technologies and services. Furthermore, increased competition has resulted and may continue to result in pricing pressures, which could negatively impact Conifer’s margins, growth rate or market share.

Indebtedness
Our level of indebtedness could, among other things, adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, and prevent us from meeting our obligations under the agreements relating to our indebtedness.

At December 31, 2019,2021, we had approximately $14.8$15.646 billion of total long-termlong‑term debt, as well as $93$139 million in standby letters of credit outstanding in the aggregate under our senior secured revolving credit facility (as amended, “Credit Agreement”) and our letter of credit facility agreement (as amended, “LC Facility”). Our Credit Agreement is collateralized by eligible inventory and patient accounts receivable, including receivables for Medicaid supplemental payments, of substantially all of our domestic wholly owned acute care and specialty hospitals, and our LC Facility is guaranteed and secured by a first priority pledge of the capital stock and other ownership interests of certain of our hospital subsidiaries on an equal equal‑ranking basis with our existing senior secured notes. From time to time, we expect to engage in additional capital market, bank credit and other financing activities, depending on our needs and financing alternatives available at that time.

The interest expense associated with our indebtedness offsets a substantial portion of our operating income. During 2019,2021, our interest expense was $985$923 million and represented 65%32% of our $1.513$2.871 billion of operating income. As a result, relatively small percentage changes in our operating income can result in a relatively large percentage change in our net income and earnings per share, both positively and negatively. In addition:

Our substantial indebtedness may limit our ability to adjust to changing market conditions and place us at a competitive disadvantage compared to our competitors that have less debt.

We may be more vulnerable in the event of a deterioration in our business, in the healthcare industry or in the economy generally, or if federal or state governments substantially limit or reduce reimbursement under the Medicare or Medicaid programs.

Our debt service obligations reduce the amount of funds available for our operations, capital expenditures and corporate development activities, and may make it more difficult for us to satisfy our financial obligations.

Our operations are capital intensive and require significant investment to maintain buildings, equipment, software and other assets. Our substantial indebtedness could limit our ability to obtain additional financing to fund future capital expenditures, as well as working capital, acquisitions or other needs.

Our significant indebtedness may result in the market value of our stock being more volatile, potentially resulting in larger investment gains or losses for our shareholders, than the market value of the common stock of other companies that have a relatively smaller amount of indebtedness.

A significant portion of our outstanding debt is subject to early prepayment penalties, such as “make-whole premiums”;make‑whole premiums; as a result, it may be costly to pursue debt repayment as a deleveraging strategy.


31

Furthermore, our Credit Agreement, our LC Facility and the indentures governing our outstanding notes contain, and any future debt obligations may contain, covenants that, among other things, restrict our ability to pay dividends, incur additional debt and sell assets.See “Restrictive covenants in the agreements governing our indebtedness may adversely affect us.”

We may not be able to generate sufficient cash to service all of our indebtedness, and we may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.

Our ability to make scheduled payments on or to refinance our indebtedness depends on our financial and operating performance, which is subject to prevailing economic and competitive conditions and to financial, business and other factors

that may be beyond our control. We cannot assure you that we will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.

In addition, our ability to meet our debt service obligations is dependent upon the operating results of our subsidiaries and their ability to pay dividends or make other payments or advances to us. We hold most of our assets at, and conduct substantially all of our operations through, direct and indirect subsidiaries. Moreover, we are dependent on dividends or other intercompany transfers of funds from our subsidiaries to meet our debt service and other obligations, including payment on our outstanding debt. The ability of our subsidiaries to pay dividends or make other payments or advances to us will depend on their operating results and will be subject to applicable laws and restrictions contained in agreements governing the debt of such subsidiaries. Our less than wholly owned subsidiaries may also be subject to restrictions on their ability to distribute cash to us in their financing or other agreements and, as a result, we may not be able to access their cash flows to service their respective debt obligations.

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, including those required for operatingphysical plant maintenance or operation of our existing facilities, for integrating our historical acquisitions or for future corporate development activities, and such reduction or delay could continue for years. We also may be forced to sell assets or operations, seek additional capital, or restructure or refinance our indebtedness. We cannot assure you that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled debt service obligations, or that these actions would be permitted under the terms of our existing or future debt agreements, including our Credit Agreement, our LC Facility and the indentures governing our outstanding notes.

Restrictive covenants in the agreements governing our indebtedness may adversely affect us.

Our Credit Agreement, our LC Facility and the indentures governing our outstanding notes contain various covenants that, among other things, limit our ability and the ability of our subsidiaries to:

incur, assume or guarantee additional indebtedness;

incur liens;

make certain investments;

provide subsidiary guarantees;

consummate asset sales;

redeem debt that is subordinated in right of payment to outstanding indebtedness;

enter into sale and lease-backlease‑back transactions;

enter into transactions with affiliates; and

consolidate, merge or sell all or substantially all of our assets.

These restrictions are subject to a number of important exceptions and qualifications. In addition, under certain circumstances, the terms of our Credit Agreement require us to maintain a financial ratio relating to our ability to satisfy certain fixed expenses, including interest payments. Our ability to meet this financial ratio and the aforementioned restrictive covenants may be affected by events beyond our control, and we cannot assure you that we will meet those tests. These restrictions could limit our ability to obtain future financing, make acquisitions or needed capital expenditures, withstand economic downturns in our business or the economy in general, conduct operations or otherwise take advantage of business opportunities that may arise. In
32

addition, a breach of any of these covenants could cause an event of default, which, if not cured or waived, could require us to repay the indebtedness immediately. Under these conditions, we are not certain whether we would have, or be able to obtain, sufficient funds to make accelerated payments.

Despite current indebtedness levels, we have the ability and may be abledecide to incur substantially more debt or otherwise increase our leverage. This could further exacerbate the risks described above.

We have the ability to incur additional indebtedness in the future, subject to the restrictions contained in our Credit Agreement, our LC Facility and the indentures governing our outstanding notes. We may decide to incur additional

secured or unsecured debt in the future to finance our operations and any judgments or settlements or for other business purposes. Similarly, if we complete the proposed spin-offspin‑off of Conifer or continue to sell assets and do not use the proceeds to repay debt, this could further increase our financial leverage.

Our Credit Agreement provides for revolving loans in an aggregateaggregate principal amount of up to $1.5$1.9 billion, with a $200 million subfacility for standby letters of credit. Based on our eligible receivables, $1.499$1.797 billion was available for borrowing under the Credit Agreement at December 31, 2019.2021. Our LC Facility provides for the issuance of standby and documentarydocumentary letters of credit in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million).million. At December 31, 2019,2021, we had no cash borrowings outstanding under the Credit Agreement, and we had $93$139 million of standby letters of credit outstanding in the aggregate under the Credit Agreement and the LC Facility. If new indebtedness is added or our leverage increases, the related risks that we now face could intensify.

Our business could be negatively affected by security threats, catastrophic events and other disruptions affecting our information technology and related systems.

Information technology is a critical component of the day-to-day operation of our business. We rely on our information technology to process, transmit and store sensitive and confidential data, including protected health information, personally identifiable information, and our proprietary and confidential business performance data. We utilize electronic health records and other information technology in connection with all of our operations, including our billing and supply chain and labor management operations. Our systems, in turn, interface with and rely on third-party systems. Although we monitor and routinely test our security systems and processes and have a diversified data network that provides redundancies as well as other measures designed to protect the integrity, security and availability of the data we process, transmit and store, the information technology and infrastructure we use have been, and will likely continue to be, subject to computer viruses, attacks by hackers, or breaches due to employee error or malfeasance. Attacks or breaches could impact the integrity, security or availability of data we process, transmit or store, or they could disrupt our information technology systems, devices or businesses. While we are not aware of having experienced a material breach of our systems, the preventive actions we take to reduce the risk of such incidents and protect our information technology may not be sufficient in the future. As cybersecurity threats continue to evolve, we may not be able to anticipate certain attack methods in order to implement effective protective measures, and we will be required to expend significant additional resources to continue to modify and strengthen our security measures, investigate and remediate any vulnerabilities in our information systems and infrastructure, and invest in new technology designed to mitigate security risks. Furthermore, we have an increased risk of security breaches or compromised intellectual property rights as a result of outsourcing certain functions unrelated to direct patient care. Though we have insurance against some cyber-risks and attacks, it may not offset the impact of a material loss event.

Third parties to whom we outsource certain of our functions, or with whom our systems interface and who may, in some instances, store our sensitive and confidential data, are also subject to the risks outlined above and may not have or use controls effective to protect such information. A breach or attack affecting any of these third parties could similarly harm our business. Further, successful cyber-attacks at other healthcare services companies, whether or not we are impacted, could lead to a general loss of consumer confidence in our industry that could negatively affect us, including harming the market perception of the effectiveness of our security measures or of the healthcare industry in general, which could result in reduced use of our services.

Our networks and technology systems have experienced disruption due to events such as system implementations, upgrades, and other maintenance and improvements, and they are subject to disruption in the future for similar events, as well as catastrophic events, including a major earthquake, fire, hurricane, telecommunications failure, ransomware attack, terrorist attack or the like. Any breach or system interruption of our information systems or of third parties with access to our sensitive and confidential data could result in: the unauthorized disclosure, misuse, loss or alteration of such data; interruptions and delays in our normal business operations (including the collection of revenues); patient harm; potential liability under privacy, security, consumer protection or other applicable laws; regulatory penalties; and negative publicity and damage to our reputation. Any of these could have a material adverse effect on our business, financial position, results of operations or cash flows.

The utilization of our tax losses could be substantially limited if we experience an ownership change as defined in the Internal Revenue Code.

At December 31, 2019, we had federal net operating loss (“NOL”) carryforwards of approximately $600 million pre-tax available to offset future taxable income. These NOL carryforwards will expire in the years 2032 to 2034. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of a company’s taxable income that may be offset by the NOL carryforwards if it experiences an “ownership change” as defined in Section 382 of the Code. An ownership change

occurs when a company’s “five-percent shareholders” (as defined in Section 382 of the Code) collectively increase their ownership in the company by more than 50 percentage points (by value) over a rolling three-year period. (This is different from a change in beneficial ownership under applicable securities laws.) These ownership changes include purchases of common stock under share repurchase programs, a company’s offering of its stock, the purchase or sale of company stock by five-percent shareholders, or the issuance or exercise of rights to acquire company stock. While we expect to be able to realize our total NOL carryforwards prior to their expiration, if an ownership change occurs, our ability to use the NOL carryforwards to offset future taxable income will be subject to an annual limitation and will depend on the amount of taxable income we generate in future periods. There is no assurance that we will be able to fully utilize the NOL carryforwards. Furthermore, we could be required to record a valuation allowance related to the amount of the NOL carryforwards that may not be realized, which could adversely impact our results of operations.

The industry trend toward value-based purchasing and alternative payment models may negatively impact our revenues.

Value-based purchasing and alternative payment model initiatives of both governmental and private payers tying financial incentives to quality and efficiency of care will increasingly affect the results of operations of our hospitals and other healthcare facilities, and may negatively impact our revenues if we are unable to meet expected quality standards. Medicare now requires providers to report certain quality measures in order to receive full reimbursement increases for inpatient and outpatient procedures that were previously awarded automatically. In addition, hospitals that meet or exceed certain quality performance standards will receive increased reimbursement payments, and hospitals that have “excess readmissions” for specified conditions will receive reduced reimbursement. Furthermore, Medicare no longer pays hospitals additional amounts for the treatment of certain hospital-acquired conditions (“HACs”), unless the conditions were present at admission. Hospitals that rank in the worst 25% of all hospitals nationally for HACs in the previous year receive reduced Medicare reimbursements. Moreover, the ACA prohibits the use of federal funds under the Medicaid program to reimburse providers for treating certain provider-preventable conditions.

The ACA also created the CMS Innovation Center to test innovative payment and service delivery models that have the potential to reduce Medicare, Medicaid or Children’s Health Insurance Program expenditures while preserving or enhancing the quality of care for beneficiaries. Participation in some of these models is voluntary; however, participation in certain bundled payment arrangements is mandatory for providers located in randomly selected geographic locations. Generally, the bundled payment models hold hospitals financially accountable for the quality and costs for an entire episode of care for a specific diagnosis or procedure from the date of the hospital admission or inpatient procedure through 90 days post-discharge, including services not provided by the hospital, such as physician, inpatient rehabilitation, skilled nursing and home health services. Under the mandatory models, hospitals are eligible to receive incentive payments or will be subject to payment reductions within certain corridors based on their performance against quality and spending criteria. In 2015, CMS finalized a five-year bundled payment model, called the Comprehensive Care for Joint Replacement (“CJR”) model, which includes hip and knee replacements, as well as other major leg procedures. Seventeen hospitals in our Hospital Operations and other segment and four of USPI’s surgical hospitals currently participate in the CJR model. In addition, 61 hospitals in our Hospital Operations and other segment and six of USPI’s surgical hospitals participate in the CMS Bundled Payments for Care Improvement Advanced (“BPCIA”) program that became effective October 1, 2018. USPI also holds the CMS contract for two physician group practices participating in the BPCIA program. We cannot predict what impact, if any, these demonstration programs will have on our inpatient volumes, net revenues or cash flows.

There is also a trend among private payers toward value-based purchasing and alternative payment models for healthcare services. Many large commercial payers expect hospitals to report quality data, and several of these payers will not reimburse hospitals for certain preventable adverse events. We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts.

We are unable at this time to predict how the industry trend toward value-based purchasing and alternative payment models will affect our results of operations, but it could negatively impact our revenues, particularly if we are unable to meet the quality and cost standards established by both governmental and private payers.

Our operations and financial results could be harmed by a national or localized outbreak of a highly contagious disease, and a pandemic outside of the United States could also adversely impact our business.
If an epidemic or other public health crisis were to occur nationally or in an area in which we operate, our business and financial results could be adversely affected. If any of our facilities were involved, or perceived to be involved, in treating patients with a highly contagious disease, such asthe 2019 Novel Coronavirus (COVID-19) or the Ebola virus, our reputation

may be negatively impacted; as a result, other patients might cancel or defer elective procedures or otherwise avoid medical treatment, resulting in reduced patient volumes and operating revenues. Furthermore, the treatment of a highly contagious disease at one of our facilities may result in a temporary shutdown, the diversion of patients or staffing shortages. Moreover, we cannot predict the costs associated with the potential treatment of an infectious disease outbreak by our hospitals or preparation for such treatment. A pandemic outside of the United States could also adversely impact our business in ways that are difficult to predict. In the event that the current coronavirus outbreak, or any actions the Chinese government or other governmental authorities take in connection with COVID-19, disrupts the production or supply of pharmaceuticals and medical supplies from China, for example, our business could be adversely affected.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

The disclosure required under this Item is included in Item 1, Business, of Part I of this report.

ITEM 3. LEGAL PROCEEDINGS

Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material pending legal proceedings in which we are involved, see Note 17 to our Consolidated Financial Statements, which is incorporated by reference.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

33

PART II.

ITEM 5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Common Stock. Our common stock is listed on the New York Stock Exchange (“NYSE”) under the symbol “THC.” As of February 14, 2020,11, 2022, there were 3,7283,578 holders of record of our common stock. Our transfer agent and registrar is Computershare. Shareholders with questions regarding their stock certificates, including inquiries related to exchanging or replacing certificates or changing an address, should contact the transfer agent at (866) 229-8416.229‑8416.

Equity Compensation. Refer to Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, of Part III of this report, as well as Note 10 to our Consolidated Financial Statements, for information regarding securities authorized for issuance under our equity compensation plans.

Stock Performance Graph. The following graph shows the cumulative, five-yearfive‑year total return for our common stock compared to the following indices:

The S&P 500, a stock market index that measures the equity performance of 500 large companies listed on the stock exchanges in the United States (in which we are not included);

The S&P 500 Health Care, a stock market index comprised of those companies included in the S&P 500 that are classified as part of the healthcare sector (in which we are not included); and

A group made up of us and our hospital companyhealthcare provider peers (namely, Community Health Systems, Inc. (CYH), HCA Healthcare, Inc. (HCA), Tenet Healthcare Corporation (THC) and Universal Health Services, Inc. (UHS)), which we refer to as our “Peer Group”. herein.

Performance data assumes that $100.00 was invested on December 31, 20142016 in our common stock and each of the indices. The data assumes the reinvestment of all cash dividends and the cash value of other distributions. Moreover, in accordance with U.S. Securities and Exchange Commission (“SEC”) regulations, the returns of each company in our Peer Group have been weighted according to the respective company’s stock market capitalization at the beginning of each period for which a return is indicated. The stock price performance shown in the graph is not necessarily indicative of future stock price performance. The performance graph shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.






chart-1b1e157b5e7d5b7f8b9.jpg
34

Table of Contents
 12/14 12/15 12/16 12/17 12/18 12/19
Tenet Healthcare Corporation$100.00
 $59.80
 $29.29
 $29.92
 $33.83
 $75.05
S&P 500$100.00
 $101.38
 $113.51
 $138.29
 $132.23
 $173.86
S&P Health Care$100.00
 $106.89
 $104.01
 $126.98
 $135.19
 $163.34
Peer Group$100.00
 $86.95
 $82.39
 $94.36
 $124.69
 $154.63
thc-20211231_g1.jpg


At December 31,
 201620172018201920202021
Tenet Healthcare Corporation$100.00 $102.16 $115.50 $256.27 $269.07 $550.47 
S&P 500$100.00 $121.83 $116.49 $153.17 $181.35 $233.41 
S&P Health Care$100.00 $122.08 $129.97 $157.04 $178.15 $224.70 
Peer Group$100.00 $114.37 $150.52 $186.65 $203.55 $306.40 

ITEM 6. SELECTED FINANCIAL DATA

OPERATING RESULTS

RESERVED
The following tables present selected consolidated financial data for Tenet Healthcare Corporation and its wholly owned and majority-owned subsidiaries for the years ended December 31, 2015 through 2019. Effective January 1, 2019, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) using the modified retrospective transition approach as
35

Table of the period of adoption. Our financial statements for periods prior to January 1, 2019 were not modified for the application of the new lease accounting standard. The main difference between the guidance in ASU 2016-02 and previous accounting principles generally accepted in the United States of America (“GAAP”) is the recognition of lease assets and lease liabilities on the balance sheet by lessees for those leases classified as operating leases under previous GAAP. Upon adoption of ASU 2016-02, we recorded $822 million of right-of-use assets, net of deferred rent, associated with operating leases in investments and other assets in our consolidated balance sheet, $147 million of current liabilities associated with operating leases in other current liabilities in our consolidated balance sheet and $715 million of long-term liabilities associated with operating leases in other long-term liabilities in our consolidated balance sheet. Effective January 1, 2018, we adopted the FASB ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”) using a modified retrospective method of application to all contracts existing on January 1, 2018. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. For our Hospital Operations and other and Ambulatory Care segments, the adoption of ASU 2014-09 resulted in changes to our presentation and disclosure of revenue primarily related to uninsured or underinsured patients. Prior to the adoption of ASU 2014-09, a significant portion of our provision for doubtful accounts related to uninsured patients, as well as co-pays, co-insurance amounts and deductibles owed to us by patients with insurance. Under ASU 2014-09, the estimated uncollectable amounts due from these patients are generally considered implicit price concessions that are a direct reduction to net operating revenues, with a corresponding material reduction in the amounts presented separately as provision for doubtful accounts.Contents

Our portfolio of hospitals has changed during the periods presented below, primarily due to acquisition and divestiture activity. At December 31, 2019, 2018, 2017, 2016 and 2015, we consolidated the results of 65, 68, 72, 75 and 86 hospitals, respectively. Effective June 16, 2015, we completed a transaction that combined our freestanding ambulatory surgery and imaging center assets with the surgical facility assets of United Surgical Partners International, Inc. into a new joint venture called USPI Holding Company, Inc. (“USPI”). At December 31, 2019, we owned 95% of USPI. The following tables include USPI for the post-acquisition period only. Also, in the following tables, electronic health incentives have been reclassified to other operating expenses, net, as they are no longer significant enough to present separately. The following tables should be read in conjunction with Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and our Consolidated Financial Statements and notes thereto included in this report.

 Years Ended December 31,
 2019 2018 2017 2016 2015
 (In Millions, Except Per-Share Amounts)
Net operating revenues: 
  
  
  
  
Net operating revenues before provision for doubtful accounts    $20,613
 $21,070
 $20,111
Less: Provision for doubtful accounts    1,434
 1,449
 1,477
Net operating revenues$18,479
 $18,313
 19,179
 19,621
 18,634
Equity in earnings of unconsolidated affiliates175
 150
 144
 131
 99
Operating expenses: 
  
  
  
  
Salaries, wages and benefits8,704
 8,634
 9,274
 9,328
 8,990
Supplies3,057
 3,004
 3,085
 3,124
 2,963
Other operating expenses, net4,189
 4,256
 4,561
 4,859
 4,483
Depreciation and amortization850
 802
 870
 850
 797
Impairment and restructuring charges, and acquisition-related costs185
 209
 541
 202
 318
Litigation and investigation costs141
 38
 23
 293
 291
Net losses (gains) on sales, consolidation and deconsolidation of facilities15
 (127) (144) (151) (186)
Operating income1,513
 1,647
 1,113
 1,247
 1,077
Interest expense(985) (1,004) (1,028) (979) (912)
Other non-operating expense, net(5) (5) (22) (20) (20)
Gain (loss) from early extinguishment of debt(227) 1
 (164) 
 (1)
Income (loss) from continuing operations, before income taxes296
 639
 (101) 248
 144
Income tax expense(153) (176) (219) (67) (68)
Income (loss) from continuing operations, before discontinued operations143
 463
 (320) 181
 76
Less: Net income available to noncontrolling interests from continuing operations386
 355
 384
 368
 218
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders from continuing operations$(243) $108
 $(704) $(187) $(142)
Basic earnings available (loss attributable) per share to Tenet Healthcare Corporation common shareholders from continuing operations$(2.35) $1.06
 $(7.00) $(1.88) $(1.43)
Diluted earnings available (loss attributable) per share to Tenet Healthcare Corporation common shareholders from continuing operations$(2.35) $1.04
 $(7.00) $(1.88) $(1.43)

The operating results data presented above is not necessarily indicative of our future results of operations. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; trends in patient accounts receivable collectability and associated implicit price concessions; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains (losses) from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect service mix, revenue mix, patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: changes in federal and state healthcare regulations; the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; hospital performance data on quality measures and patient satisfaction, as well as standard charges for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures.


BALANCE SHEET DATA
 December 31,
 2019 2018 2017 2016 2015
 (In Millions)
Working capital (current assets minus current liabilities)$876
 $779
 $1,241
 $1,223
 $863
Total assets23,351
 22,409
 23,385
 24,701
 23,682
Long-term debt, net of current portion14,580
 14,644
 14,791
 15,064
 14,383
Redeemable noncontrolling interests in equity of consolidated subsidiaries1,506
 1,420
 1,866
 2,393
 2,266
Noncontrolling interests854
 806
 686
 665
 267
Total equity483
 687
 539
 1,082
 958

CASH FLOW DATA
 Years Ended December 31,
 2019 2018 2017 2016 2015
 (In Millions)
Net cash provided by operating activities$1,233
 $1,049
 $1,200
 $558
 $1,026
Net cash provided by (used in) investing activities(619) (115) 21
 (430) (1,317)
Net cash provided by (used in) financing activities(763) (1,134) (1,326) 232
 454


ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. Our Hospital Operations and other segment is comprised of our acute care and specialty hospitals, ancillary outpatient facilities, urgent care centers, micro-hospitals and physician practices. As described in Note 5 to the accompanying Consolidated Financial Statements, certain of our facilities were classified as held for sale at December 31, 2019. Our Ambulatory Care segment is comprised of the operations of USPI, in which we own a 95% interest, and included nine European Surgical Partners Limited (“Aspen”) facilities until their divestiture effective August 17, 2018. At December 31, 2019, USPI had interests in 260 ambulatory surgery centers, 39 urgent care centers, 23 imaging centers and 24 surgical hospitals in 27 states. Our Conifer segment provides revenue cycle management and value-based care services to hospitals, healthcare systems, physician practices, employers and other customers, through our Conifer Holdings, Inc. (“Conifer”) subsidiary. Nearly all of the services comprising the operations of our Conifer segment are provided directly by Conifer Health Solutions, LLC, in which we owned 76.2% as of December 31, 2019, or by one of its direct or indirect wholly owned subsidiaries. MD&A, which should be read in conjunction with the accompanying Consolidated Financial Statements, includes the following sections:

Management Overview
Sources of Revenue for Our Hospital Operations and Other Segment
Results of Operations
Liquidity and Capital Resources
Off-Balance Sheet Arrangements
Recently Issued Accounting Standards
Critical Accounting Estimates

Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices. At December 31, 2021, our subsidiaries operated 60 hospitals serving primarily urban and suburban communities in nine states. In April 2021, we completed the sale of the majority of the urgent care centers previously held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, we completed the sale of five Miami‑area hospitals and certain related operations (the “Miami Hospitals”) held by our Hospital Operations segment in August 2021.

Our Ambulatory Care segment is comprised of the operations of USPI Holding Company, Inc. (“USPI”), in which we hold an ownership interest of approximately 95%. At December 31, 2021, USPI had interests in 399 ambulatory surgery centers (“ASCs”) (249 consolidated) and 24 surgical hospitals (eight consolidated) in 34 states. At December 31, 2020, our Ambulatory Care segment also included 40 urgent care centers that were classified as held for sale and 24 imaging centers. In April 2021, we completed the divestiture of the 40 urgent care centers and transferred the 24 imaging centers to our Hospital Operations segment.

Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients, through our Conifer Holdings, Inc. subsidiary (“Conifer”). At December 31, 2021, Conifer provided services to approximately 650 Tenet and non‑Tenet hospitals and other clients nationwide. Nearly all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC, in which we owned an interest of approximately 76% at December 31, 2021, or by one of its direct or indirect wholly owned subsidiaries.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted patient per‑adjusted‑patient‑admission and per adjusted patient per‑adjusted‑patient‑day amounts). Continuing operations information includes the results of (i) our same 6560 hospitals operated throughout the years ended December 31, 20192021 and 2018, (ii) two Philadelphia-area hospitals, which2020, and the Miami Hospitals we divested effective January 11, 2018, (iii) MacNeal Hospital, which we divested effective March 1, 2018, (iv) Des Peres Hospital, which we divested effective May 1, 2018, (v) three Chicago-area hospitals, which we divested effective January 28, 2019, and (vi) Aspen’s nine facilities, which we divestedsold in August 17, 2018.2021. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses. We present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable. In addition, we present certain metrics on a per‑adjusted‑patient‑admission and per‑adjusted‑patient‑day basis to show trends other than volume.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same‑hospital basis, which includes the results of our same 60 hospitals operated throughout the years ended December 31, 2021 and 2020, and excludes the results of the Miami Hospitals we sold in August 2021 and the results of our discontinued operations. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our hospitals and other operations that are comparable for the periods presented.

36

MANAGEMENT OVERVIEW

RECENT DEVELOPMENTS

Redemption of Senior Secured First Lien Notes—On February 9, 2022, we called for the redemption of all $700 million aggregate principal amount outstanding of our 7.500% senior secured first lien notes due 2025 (“2025 Senior Secured First Lien Notes”). The 2025 Senior Secured First Lien Notes will be redeemed for an anticipated amount of approximately $730 million on February 23, 2022 using cash on hand. We expect this transaction will lower our future annual cash interest payments by approximately $53 million.
Termination
Exercise of Call Option to Purchase Additional Ownership Interest in USPI—We have a put/call agreement (the “Baylor Put/Call Agreement”) with Baylor University Medical Center (“Baylor”) with respect to Baylor’s 5% ownership in USPI. In February 2022, we notified Baylor of our intention to exercise our call option under the Baylor Put/Call Agreement to purchase 33.3% of the USPI Management Equity Planshares held by Baylor as of April 1, 2017. The amount andAdoption timing of USPI Restricted Stock Plan—As described inthe payment related to the exercise of our call option are currently uncertain. See Note 1018 to the accompanying Consolidated Financial Statements USPI previously maintainedfor additional information related to the Baylor Put/Call Agreement.

IMPACT OF THE COVID-19 PANDEMIC
The spread of COVID‑19 and the ensuing response of federal, state and local authorities beginning in March 2020 resulted in a management equity plan whereby it had granted non-qualified optionsmaterial reduction in our patient volumes and also adversely affected our net operating revenues in the years ended December 31, 2021 and 2020. Restrictive measures, including travel bans, social distancing, quarantines and shelter‑in‑place orders, reduced the number of procedures performed at our facilities, as well as the volume of emergency room and physician office visits. We began experiencing improvement in patient volumes in May 2020 as various states eased stay‑at‑home restrictions and our facilities were permitted to purchase nonvoting shares of USPI’s outstanding common stock to eligible plan participants. In February 2020,resume elective surgeries and other procedures; however, the planCOVID‑19 pandemic generally and, all unvested options granted undermost recently, the plan were terminated in accordance with the termsspread of the plan.Delta variant and emergence of the Omicron variant continue to impact all three segments of our business, as well as our patients, communities and employees. Broad economic factors resulting from the pandemic, including higher inflation, increased unemployment rates in certain areas in which we operate and reduced consumer spending, continued to impact our patient volumes, service mix and revenue mix in 2021. The pandemic also continued to have an adverse effect on our operating expenses to varying degrees in 2021. As further described below, we have been required to utilize higher‑cost temporary labor and pay premiums above standard compensation for essential workers. In addition, we have experienced significant price increases in medical supplies, particularly for personal protective equipment (“PPE”), and we have encountered supply‑chain disruptions, including shortages and delays.

As described under “Sources of Revenue for Our Hospital Operations Segment” below, various legislative actions have mitigated some of the economic disruption caused by the COVID‑19 pandemic on our business. Additional funding for the Public Health and Social Services Emergency Fund (“Provider Relief Fund” or “PRF”) was among the provisions of the COVID‑19 relief legislation. In the first quarteryears ended December 31, 2021 and 2020, we received cash payments of 2020, USPI will repurchase all vested options$215 million and all shares$974 million, respectively, due to grants from the Provider Relief Fund and other state and local grant programs. We recognized $191 million and $882 million, respectively, from these funds as grant income and $14 million and $17 million, respectively, in equity in earnings of USPI stock acquired upon exercise of an option. All participantsunconsolidated affiliates in the plan will receive fair market value for any such vested options or shares; all unvested options underaccompanying Consolidated Statements of Operations during the plan were canceled. USPI will pay approximately $35 million to eligible plan participants in connection with the repurchase of eligible securities.years ended December 31, 2021 and 2020.

Also in February 2020, USPI adopted a new restricted stock plan whereby USPI will grant shares of restricted non-voting common stock to eligible plan participants. Approximately 3% of USPI’s outstanding common stock (after giving effect to the repurchases described above) has been reserved for issuance under the new USPI restricted stock plan. The restricted stock will vest over a four-year period, with 60% vesting ratablyThroughout MD&A, we have provided additional information on the first three anniversariesimpact of the grant dateCOVID‑19 pandemic on our results of operations and the remaining 40% vestingsteps we have taken, and are continuing to take, in response. The ultimate extent and scope of the pandemic and its future impact on our business remain unknown. For information about risks and uncertainties related to COVID‑19 that could affect our results of operations, financial condition and cash flows, see the fourth anniversary. Upon each vesting, the participant must hold the underlying shares for at least six months plus one day and then is eligible to sell the underlying shares to USPI at their estimated fair market value, as determined by the USPI boardRisk Factors section in Part I of directors. Upon termination of service with USPI, a participant’s unvested restricted stock isthis report.

forfeited, and vested shares will be repurchased by USPI provided the shares have been held for the requisite holding period. Between August 2024 and February 2025, USPI will be required to purchase from each participant any of their outstanding shares of nonvoting common stock at their estimated fair market value, provided the shares have been held for the requisite holding period. Payment for USPI’s purchases of any eligible nonvoting common stock may be made in cash or in shares of Tenet’s common stock.

TRENDS AND STRATEGIES

As described above and throughout MD&A, we experienced a significant disruption to our business in 2020 and 2021 due to the COVID‑19 pandemic. Although we have seen improvement in our patient volumes, we continue to experience negative impacts of the pandemic on our business in varying degrees. Most recently, in the second half of 2021, we experienced significant acceleration in COVID‑19 cases associated with the Delta variant, with a peak in such cases in late August 2021, and the Omicron variant, which emerged in November 2021 to drive a new COVID‑19 surge. Throughout the COVID‑19 pandemic, we have taken, and we continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and operating revenues. We have issued new senior unsecured notes and senior secured first lien notes, redeemed existing senior unsecured notes and senior secured first lien notes, including those with the highest interest rate and nearest maturity date of all of our long‑term debt, and amended our revolving credit facility. We also decreased our employee headcount throughout the organization at the outset of the COVID‑19 pandemic, and we deferred certain operating
The
37

expenses that were not expected to impact our response to the pandemic. In addition, we reduced certain variable costs across the enterprise. Together with government relief packages, we believe these actions supported our continued operation during the initial uncertainty caused by the COVID‑19 pandemic and continue to do so. For further information on our liquidity, see “Liquidity and Capital Resources” below.

We have experienced, and continue to experience, increased competition with other healthcare providers in recruiting and retaining qualified personnel responsible for the operation of our facilities. There is a limited availability of experienced medical support personnel nationwide, which drives up the wages and benefits required to recruit and retain employees. In particular, like others in the healthcare industry, we continue to experience a shortage of critical‑care nurses in general,certain disciplines and the acute care hospital business, in particular, havegeographic areas. This shortage has been experiencing significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to significantly modify or repeal and potentially replace the Patient Protection and Affordable Care Act, as amendedexacerbated by the Health Care and Education Reconciliation ActCOVID‑19 pandemic as more nurses choose to retire early, leave the workforce or take travel assignments. In some areas, the increased demand for care of 2010 (“Affordable Care Act” or “ACA”). It is difficult to predictCOVID‑19 patients in our hospitals, as well as the fulldirect impact of regulatory uncertaintyCOVID‑19 on physicians, employees and their families, have put a strain on our future revenuesresources and operations. In addition,staff. Over the past two years, we have had to rely on higher-cost temporary and contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers. The length and extent of the disruptions caused by the COVID‑19 pandemic are currently unknown; however, we have thus far seen such disruptions continue into 2022, and we expect they may endure through the duration of the pandemic.

We believe that several key trends are shapingalso continuing to shape the demand for healthcare services: (1) consumers, employers and insurers are actively seeking lower-costlower‑cost solutions and better value as they focus more on healthcare spending; (2) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (3) the growing aging population requires greater chronic disease management and higher-acuityhigher‑acuity treatment; and (4) consolidation continues across the entire healthcare sector. In addition, the healthcare industry, in general, and the acute care hospital business, in particular, have experienced significant regulatory uncertainty based, in large part, on administrative, legislative and judicial efforts to limit, alter or repeal the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”). It is difficult to predict the full impact of regulatory uncertainty on our future revenues and operations.

Expansion of Our Ambulatory Care Segment—In response to these trends, we continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. During the years ended December 31, 2021 and 2020, we invested $1.315 billion and $1.200 billion, respectively, to acquire ownership interests in new, or increase our existing ownership in, ambulatory care facilities. This activity included the acquisition of ownership interests in 86 ASCs and related ambulatory support services (collectively, the “SCD Centers”) from Surgical Center Development #3, LLC and Surgical Center Development #4, LLC (“SCD”) in December 2021. The newly acquired facilities augmented our Ambulatory Care segment’s existing musculoskeletal service line and expanded the number of markets it serves. In addition, USPI and SCD’s principals entered into a joint venture and development agreement under which USPI will have the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50 de novo ASCs over a period of five years.

During the year ended December 31, 2021, we also acquired controlling interests in four ASCs in Maryland, two in each of Florida, Georgia and Texas and one in Arizona. We also opened four new ASCs – one each in Montana, Nevada, New Mexico and Tennessee. We believe USPI’s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

Driving Growth in Our Hospital Systems—We areremain committed to better positioning our hospital systems and competing more effectively in the ever-evolvingever‑evolving healthcare environment. We are focusedenvironment by focusing on driving performance through operational effectiveness, increasing capital efficiency and margins, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher-demandhigher‑demand and higher-acuityhigher‑acuity clinical service lines (including outpatient lines), expanding patient and physician access, and optimizing our portfolio of assets. WeOver the past several years, we have undertaken enterprise-wideenterprise‑wide cost reduction initiatives,measures, comprised primarily of workforce reductions in 2019 (including streamlining corporate overhead and centralized support functions), the consolidation of office locations, and the continuing renegotiation of contracts with suppliers and vendors, and the consolidation of office locations.vendors. Moreover, we have established offshore support operations at our Global Business Center (“GBC”) in the Republic of the Philippines. InWe incurred restructuring charges in conjunction with these initiatives we incurred restructuring charges relatedand our cost‑saving efforts in response to employee severance payments of $57 millionthe COVID‑19 pandemic in the yearyears ended December 31, 2021, 2020 and 2019, and we expect tocould incur additional such restructuring charges in 2020. We are continuing in 2020 to explore new opportunities to enhance efficiency, including further integration of enterprise-wide centralized support functions, outsourcing certain functions unrelated to direct patient care, and reducing clinical and vendor contract variation.if we identify other areas that can be transitioned offshore.

38

We also continue to exit service lines, businesses and markets that we believe are no longer a core part of our long-termlong‑term growth strategy. To that end, since January 1, 2018,In April 2021, we have divested 11 hospitals in the United States, as well as allmajority of our operations inurgent care centers operated under the United Kingdom.MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments. In addition, we sold our former Miami Hospitals in December 2019, we entered into a definitive agreement to divest our two hospitals and other operations in the Memphis, Tennessee area.August 2021. We intend to continue to further refine our portfolio of hospitals and other healthcare facilities when we believe such refinements will help us improve profitability, allocate capital more effectively in areas where we have a stronger presence, deploy proceeds on higher-returnhigher‑return investments across our business, enhance cash flow generation, reduce our debt and lower our ratio of debt-to-Adjusteddebt‑to‑Adjusted EBITDA.

Improving the Customer Care Experience—As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2) expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; (3) offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; (4) improving our culture of service; and (5) creating health and benefit programs, patient education and health literacy materials that are customized to the needs of the communities we serve. Through these efforts, we intend to improve the customer care experience in every part of our operations.

Expansion of Our Ambulatory Care Segment—We remain focused on opportunities to expand our Ambulatory Care segment through organic growth, building new outpatient centers, corporate development activities and strategic partnerships. We opened seven new outpatient centers in the year ended December 31, 2019, and we acquired 10 outpatient businesses. We believe USPI’s surgery centers and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.


Driving Conifer’s Growth While Pursuing a Tax-Free Spin-Off—We previously announced a number of actions to support our goals of improving financial performance and enhancing shareholder value, including the exploration of strategic alternatives for Conifer. In July 2019, we announced our intention to pursue a tax-free spin-offtax‑free spin‑off of Conifer as a separate, independent, publicly traded company. Completion of the proposed spin-offspin‑off is subject to a number of conditions, including, among others, assurance that the separation will be tax-freetax‑free for U.S. federal income tax purposes, execution of a restructured services agreement between Conifer and Tenet, finalization of Conifer’s capital structure, the effectiveness of appropriate filings with the SEC, and final approval from our board of directors. We are targetingAlthough in March 2021 we entered into a month‑to‑month agreement amending and updating certain terms and conditions related to complete the separation byrevenue cycle management services Conifer provides to Tenet hospitals (“Amended RCM Agreement”), the endexecution of a comprehensive amendment to and restatement of the second quartermaster services agreement between Conifer and Tenet remains an additional prerequisite to the spin‑off of 2021; however, thereConifer. If consummated, this transaction is expected to potentially enhance shareholder value and, to a lesser degree, the level of Tenet’s debt through a tax‑free debt‑for‑debt exchange. There can be no assurance regarding the timeframe for completingcompletion of the spin-off,Conifer spin‑off, the allocation of assets and liabilities between Tenet and Conifer, that the other conditions of the spin-offspin‑off will be met, or that the spin-offit will be completed at all.

Conifer serves approximately 660650 Tenet and non-Tenet hospitalnon‑Tenet hospitals and other clients nationwide. In addition to providing revenue cycle management services to healthcarehealth systems and physicians, Conifer provides support to both providers and self-insuredself‑insured employers seeking assistance with clinical integration, financial risk management and population health management. Conifer remains focused on driving growth by continuing to market and expand its revenue cycle management and value-basedvalue‑based care solutions businesses. We believe that our success in growing Conifer and increasing its profitability depends in part on our success in executing the following strategies: (1) attracting hospitals and other healthcare providers that currently handle their revenue cycle management processes internally as new clients; (2) generating new client relationships through opportunities from USPI and Tenet’s acute care hospital acquisition and divestiture activities; (3) expanding revenue cycle management and value-basedvalue‑based care service offerings through organic development and small acquisitions; and (4) leveraging data from tens of millions of patient interactions for continued enhancement of the value-basedvalue‑based care environment to drive competitive differentiation.

Improving Profitability—We are focusedAs we return to more normal operations, we will continue to focus on growing patient volumes and effective cost management as a means to improve profitability. We believe our inpatient admissions have been constrained in recent years (prior to the COVID‑19 pandemic) by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles, changing consumer behavior, and adverse economic conditions and demographic trends in certain of our markets. However, we also believe that emphasis on higher-demandhigher‑demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans that arehave been experiencing higher growth rates than traditional Medicare, plans, and contracting strategies that create shared value with payers should help us grow our patient volumes over time. In 2020, weWe are also continuing to explore new opportunities to enhance efficiency, including further integration of enterprise-wideenterprise‑wide centralized support functions, outsourcing certainadditional functions unrelated to direct patient care, and reducing clinical and vendor contract variation.

39

Reducing Our Leverage—Leverage Over Time—All of our outstanding long-termlong‑term debt has a fixed rate of interest, except for outstanding borrowings, if any, under our revolving credit facility, and the maturity dates of our notes are staggered from 20222023 through 2031. Although weWe believe that our capital structure minimizes the near-termnear‑term impact of increased interest rates, and the staggered maturities of our debt allow us to refinance our debt over time, it is nonethelesstime. During the year ended December 31, 2021, we retired approximately $2.988 billion aggregate principal amount of certain of our long-termsenior unsecured notes and senior secured first lien notes. These notes were retired using proceeds from the June 2021 sale of $1.400 billion aggregate principal amount of 4.250% senior secured first lien notes due 2029 (the “2029 Senior Secured First Lien Notes”), the proceeds from the sale of the Miami Hospitals in August 2021 and cash on hand. These transactions reduced future annual cash interest expense payments by approximately $96 million. Moreover, on February 9, 2022, we called for the redemption of all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes. We anticipate redeeming the notes using cash on hand. It remains our long‑term objective to reduce our debt and lower our ratio of debt-to-Adjusteddebt‑to‑Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk and increase the potential for us to continue to use lower rate secured debt to refinance portions of our higher rate unsecured debt.risk.

Our ability to execute on our strategies and respond to the aforementioned trends is subject to the extent and scope of the impact on our operations of the COVID‑19 pandemic, as well as a number of other risks and uncertainties, thatall of which may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward-LookingForward‑Looking Statements and Risk Factors sections in Part I of this report.

RECENT RESULTS OF OPERATIONS

We have provided below certain selected operating statistics for the three months ended December 31, 20192021 and 20182020 on a continuing operations basis, which includes the results of (i) our same 65 hospitals operated throughout the three months ended December 31, 2019 and 2018, (ii) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (iii) MacNeal Hospital, which we divested effective March 1, 2018, (iv) Des Peres Hospital, which we divested effective May 1, 2018, and (v) three Chicago-area hospitals, which we divested effective January 28, 2019.basis. The following tables also show information about facilities in our Ambulatory Care segment that we control and, therefore, consolidate. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses. We present certain metrics on a per-adjusted-patient-admission basis to show trends other than volume.

  Continuing Operations 
  Three Months Ended December 31, 
Selected Operating Statistics 2019 2018 
Increase
(Decrease)
 
Hospital Operations and other – hospitals and related outpatient facilities       
Number of hospitals (at end of period) 65
 68
 (3)(1)
Total admissions 170,815
 170,407
 0.2 % 
Adjusted patient admissions(2) 
 306,384
 308,113
 (0.6)% 
Paying admissions (excludes charity and uninsured) 160,244
 160,172
  % 
Charity and uninsured admissions 10,571
 10,235
 3.3 % 
Emergency department visits 645,791
 649,544
 (0.6)% 
Total surgeries 106,399
 108,535
 (2.0)% 
Patient days — total 796,239
 779,728
 2.1 % 
Adjusted patient days(2) 
 1,394,191
 1,383,372
 0.8 % 
Average length of stay (days) 4.66
 4.58
 1.7 % 
Average licensed beds 17,211
 17,935
 (4.0)% 
Utilization of licensed beds(3)
 50.3% 47.3% 3.0 %(1)
Total visits 1,700,696
 1,734,523
 (2.0)% 
Paying visits (excludes charity and uninsured) 1,586,704
 1,617,970
 (1.9)% 
Charity and uninsured visits 113,992
 116,553
 (2.2)% 
Ambulatory Care       
Total consolidated facilities (at end of period) 238
 227
 11
(1)
Total cases 549,319
 499,803
 9.9 % 
Continuing Operations
 Three Months Ended December 31,Increase
(Decrease)
Selected Operating Statistics20212020
Hospital Operations – hospitals and related outpatient facilities:   
Number of hospitals (at end of period)60 65 (5)(1)
Total admissions133,809 152,694 (12.4)%
Adjusted patient admissions(2) 
241,008 261,097 (7.7)%
Paying admissions (excludes charity and uninsured)127,092 143,195 (11.2)%
Charity and uninsured admissions6,717 9,499 (29.3)%
Admissions through emergency department99,772 114,887 (13.2)%
Emergency department visits, outpatient531,737 466,179 14.1 %
Total emergency department visits631,509 581,066 8.7 %
Total surgeries88,504 95,467 (7.3)%
Patient days — total713,947 790,522 (9.7)%
Adjusted patient days(2) 
1,253,882 1,322,063 (5.2)%
Average length of stay (days)5.34 5.18 3.1 %
Average licensed beds15,379 17,203 (10.6)%
Utilization of licensed beds(3)
50.5 %49.9 %0.6 %(1)
Total visits1,451,683 1,441,157 0.7 %
Paying visits (excludes charity and uninsured)1,364,789 1,350,576 1.1 %
Charity and uninsured visits86,894 90,581 (4.1)%
Ambulatory Care:
Total consolidated facilities (at end of period)257 290 (33)(1)
Total consolidated cases308,402 566,519 (45.6)%
(1)The change is the difference between the 20192021 and 20182020 amounts shown.
(2)Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3)Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

Total admissions increaseddecreased by 408,18,885, or 0.2%12.4%, in the three months ended December 31, 20192021 compared to the three months ended December 31, 2018,2020, and total surgeries decreased by 2,136,6,963, or 2.0%7.3%, in the 20192021 period compared to the 20182020 period. OurTotal emergency department visits decreased 0.6%increased 8.7% in the three months ended December 31, 20192021 compared to the same period in the prior year. OurThe decrease in our patient volumes from continuing operations in the three months ended
40

December 31, 20192021 compared to the three months ended December 31, 2018 were negatively affected by2020 is primarily attributable to the sale of three Chicago-area hospitals and affiliated operations effective January 28, 2019. Ourthe Miami Hospitals in August 2021. The decrease of Ambulatory Care total consolidated cases increased 9.9%of 45.6% in the three months ended December 31, 20192021 compared to the 2018.2020 period is primarily due to the divestiture of USPI’s urgent care centers and the realignment of its imaging centers under our Hospital Operations segment.

 Continuing Operations Continuing Operations
 Three Months Ended December 31,  Three Months Ended December 31,Increase
(Decrease)
Revenues 2019 2018 
Increase
(Decrease)
 Revenues20212020
Net operating revenues     

 
Hospital Operations and other prior to inter-segment eliminations $3,983
 $3,843
 3.6 % 
Net operating revenues:Net operating revenues:
Hospital Operations prior to inter-segment eliminationsHospital Operations prior to inter-segment eliminations$3,910 $4,065 (3.8)%
Ambulatory Care 632
 554
 14.1 % Ambulatory Care742 649 14.3 %
Conifer 332
 372
 (10.8)% Conifer324 344 (5.8)%
Inter-segment eliminations (141) (150) (6.0)% Inter-segment eliminations(120)(143)(16.1)%
Total $4,806
 $4,619
 4.0 % Total$4,856 $4,915 (1.2)%

Net operating revenues increaseddecreased by $187$59 million, or 4.0%1.2%, in the three months ended December 31, 20192021 compared to the same period in 2018,2020, primarily due to increased acuitythe sale of the Miami Hospitals and improved managedthe divestiture of the urgent care pricing.centers previously held by our Hospital Operations and Ambulatory Care segments. During the three months ended December 31, 2021 and 2020, we recognized net grant income of $138 million and $437 million, respectively, which amounts are not included in net operating revenues.

Our accounts receivable days outstanding (“AR Days”) from continuing operations were 58.457.0 days at December 31, 2019, 59.6 days at September 30, 20192021 and 56.555.6 days at December 31, 2018,2020, compared to our target of less than 55 days. AR Days are calculated as our accounts receivable from continuing operations on the last day ofdate in the quarter divided by our net operating revenues from continuing operations for the quarter ended on that date divided by the number of days in the quarter. This calculation includes our Hospital Operations and othersegment’s contract assets and the accounts receivable of our Memphis-area facilities that have been classified in assets held for sale on our Consolidated Balance Sheet at December 31, 2019, andassets. The AR Days calculation excludes (i) two Philadelphia-area hospitals,urgent care centers operated under the MedPost and CareSpot brands, which we divested effective January 11, 2018,in April 2021, (ii) MacNeal Hospital,the Miami Hospitals, which we divested effective March 1, 2018,sold in August 2021, and (iii) Des Peres Hospital, which we divested effective

May 1, 2018, (iv) three Chicago-area hospitals, which we divested effective January 28, 2019, and (v) our California provider fee revenues.
41

Table of Contents
  Continuing Operations
  Three Months Ended December 31,
Selected Operating Expenses 2019 2018 
Increase
(Decrease)
Hospital Operations and other  
  
  
Salaries, wages and benefits $1,886
 $1,785
 5.7 %
Supplies 670
 641
 4.5 %
Other operating expenses 882
 919
 (4.0)%
Total $3,438
 $3,345
 2.8 %
Ambulatory Care  
  
  
Salaries, wages and benefits $168
 $160
 5.0 %
Supplies 132
 114
 15.8 %
Other operating expenses 86
 84
 2.4 %
Total $386
 $358
 7.8 %
Conifer  
  
  
Salaries, wages and benefits $175
 $211
 (17.1)%
Supplies 1
 1
  %
Other operating expenses 62
 73
 (15.1)%
Total $238
 $285
 (16.5)%
Total  
  
  
Salaries, wages and benefits $2,229
 $2,156
 3.4 %
Supplies 803
 756
 6.2 %
Other operating expenses 1,030
 1,076
 (4.3)%
Total $4,062
 $3,988
 1.9 %
Rent/lease expense(1)
  
  
  
Hospital Operations and other $62
 $58
 6.9 %
Ambulatory Care 23
 20
 15.0 %
Conifer 2
 4
 (50.0)%
Total $87
 $82
 6.1 %
Continuing Operations
 Three Months Ended December 31,Increase
(Decrease)
Selected Operating Expenses20212020
Hospital Operations:   
Salaries, wages and benefits$1,841 $1,892 (2.7)%
Supplies649 674 (3.7)%
Other operating expenses875 910 (3.8)%
Total$3,365 $3,476 (3.2)%
Ambulatory Care:   
Salaries, wages and benefits$178 $171 4.1 %
Supplies188 149 26.2 %
Other operating expenses94 91 3.3 %
Total$460 $411 11.9 %
Conifer:   
Salaries, wages and benefits$169 $162 4.3 %
Supplies— %
Other operating expenses60 70 (14.3)%
Total$230 $233 (1.3)%
Total:   
Salaries, wages and benefits$2,188 $2,225 (1.7)%
Supplies838 824 1.7 %
Other operating expenses1,029 1,071 (3.9)%
Total$4,055 $4,120 (1.6)%
Rent/lease expense(1):
   
Hospital Operations$71 $74 (4.1)%
Ambulatory Care25 25 — %
Conifer(33.3)%
Total$98 $102 (3.9)%
(1)Included in other operating expenses.
  Continuing Operations
  Three Months Ended December 31,
Selected Operating Expenses per Adjusted Patient Admission 2019 2018 
Increase
(Decrease)
Hospital Operations and other      
Salaries, wages and benefits per adjusted patient admission(1)
 $6,153
 $5,791
 6.3 %
Supplies per adjusted patient admission(1)
 2,190
 2,079
 5.3 %
Other operating expenses per adjusted patient admission(1)
 2,869
 2,991
 (4.1)%
Total per adjusted patient admission $11,212
 $10,861
 3.2 %
Continuing Operations
 Three Months Ended December 31,Increase
(Decrease)
Selected Operating Expenses per Adjusted Patient Admission20212020
Hospital Operations:   
Salaries, wages and benefits per adjusted patient admission(1)
$7,634 $7,244 5.4 %
Supplies per adjusted patient admission(1)
2,692 2,583 4.2 %
Other operating expenses per adjusted patient admission(1)
3,632 3,480 4.4 %
Total per adjusted patient admission$13,958 $13,307 4.9 %
(1)
(1)Calculation excludes the expenses from our now-divested health plan businesses. Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

Salaries, wages and benefits per adjusted patient admission increased 6.3%for our Hospital Operations segment decreased $51 million, or 2.7%, in the three months ended December 31, 20192021 compared to the same period in 2018.2020. This change was primarily dueattributable to the sale of the Miami Hospitals in August 2021 and our continued focus on cost-reduction measures and corporate efficiencies, partially offset by increased contract labor costs, increased overtime expense and annual merit increases for certain of our employees,employees. On a greater number of employed physiciansper‑adjusted‑patient‑admission basis, salaries, wages and benefits increased incentive compensation expense, partially offset by the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives5.4% in the three months ended December 31, 20192021 compared to the three months ended December 31, 2018. 2020, primarily due to lower adjusted patient admissions and the expenses mentioned above.

Supplies expense per adjusted patient admission increased 5.3% infor our Hospital Operations segment decreased $25 million, or 3.7%, during the three months ended December 31, 20192021 compared to the three months ended December 31, 2018. The change in supplies expense2020. This decrease was primarily attributable to growththe sale of the Miami Hospitals, the decrease in patient volumes during the 2021 period and our higher acuity supply-intensive surgical services,cost-efficiency measures, partially offset by the impactincreased costs for certain supplies as a result of the group-purchasing strategiesCOVID-19 pandemic and supplies-management services we utilize to reduce costs.


Other operating expenses per adjustedhigher patient acuity. On a per‑adjusted‑patient‑admission decreased by 4.1%basis, supplies expense increased 4.2% in the three months ended December 31, 20192021 compared
42

Table of Contents
to the three months ended December 31, 2020, primarily due to higher patient acuity and increased costs of certain supplies as a result of the COVID-19 pandemic.

Other operating expenses for our Hospital Operations segment decreased $35 million, or 3.8%, in the three months ended December 31, 2021 compared to the prior-year period.same period in 2020. The decrease was primarily attributable to the sale of the Miami Hospitals and our cost-efficiency measures. On a per‑adjusted‑patient‑admission basis, other operating expenses in the three months ended December 31, 2021 increased 4.4% compared to the three months ended December 31, 2020. This decreaseincrease was primarily due to lower malpractice expense, which was $43 million lower in the 2019 period compared to the 2018 period, and decreased costs associated with funding indigent care services, which costs were substantially offset by decreased netadjusted patient revenues, partially offset by higher medical feesadmissions and the impactproportionally higher level of gains on asset salesfixed costs (e.g., rent expense) in the 2018 period primarily related to the sale of an equity method investment. The 2019 period included a favorable adjustment of approximately $5 million from a 21 basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities compared to an unfavorable adjustment of approximately $8 million from a 42 basis point decrease in the interest rate in the 2018 period.

other operating expenses.

LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $262 million$2.364 billion at December 31, 20192021 compared to $314 million$2.292 billion at September 30, 2019.2021.

Significant cash flow items in the three months ended December 31, 20192021 included:

Net cash provided by operating activities before interest, taxes, discontinued operations, impairment and restructuring charges, acquisition-relatedand acquisition‑related costs, and litigation costs and settlements of $812 million;$704 million, including $140 million received from federal, state and local grants, $186 million of Medicare advances recouped and repaid, and a $128 million payment of payroll taxes deferred during 2020;

PaymentsProceeds from the issuance of $1.450 billion aggregate principal amount of our 4.375% senior secured first lien notes due 2030 (the “2030 Senior Secured First Lien Notes”), which were primarily used to acquire the SCD Centers in December 2021;

$1.156 billion of payments for restructuring charges, acquisition-related costs, and litigation costs and settlementspurchases of $56 million;businesses or joint venture interests;

Capital expenditures of $178$304 million;

Proceeds from the sales of facilities and other assets of $19 million;

Proceeds from sale of marketable securities, long-term investments and other assets of $30 million;

Interest payments of $241$273 million;

$275 million of net repayments of cash borrowings under our credit facility; and

$84107 million of distributions paid to noncontrolling interests.interests;

Purchase of marketable securities and equity investments of $85 million; and

$78 million of Medicare advances recouped and repaid by our unconsolidated affiliates for which we provide cash management services.

Net cash provided by operating activities was $1.233$1.568 billion in the year ended December 31, 20192021 compared to $1.049$3.407 billion in the year ended December 31, 2018.2020. Key factors contributing to the change between the 20192021 and 2018 periods2020 include the following:

An increase in operating income of $29$1.031 billion before net losses on sales, consolidation and deconsolidation of facilities; litigation and investigation costs; impairment and restructuring charges and acquisition-related costs; depreciation and amortization; loss (income) from divested and closed businesses; and income recognized from government relief packages;

$512 million of Medicare advances recouped and repaid in the year ended December 31, 2021 compared to $1.393 billion of Medicare advances received in the year ended December 31, 2020;

$178 million of cash received from federal, state and local grants in 2021 compared to $900 million received in 2020;

A $128 million payment in 2021 of payroll taxes deferred pursuant to COVID-19 legislation compared to the deferral of $260 million of payroll taxes in 2020;

Lower interest payments of $25 million in 2021;

43

Table of Contents
Higher income tax payments of $80 million in 2021;

A decrease of $180 million in payments on reserves for restructuring charges, acquisition-relatedacquisition‑related costs, and litigation costs and settlements;settlements in 2021; and

Decreased cash receipts of $13 million related to supplemental Medicaid programs in California and Texas;

Lower interest payment of $30 million in the 2019 period;

Lower income tax payments of $13 million in the 2019 period;

A $146 million increase in income from continuing operations before income taxes, gain (loss) from early extinguishment of debt, other non-operating expense, net, interest expense, net gains (losses) on sales, consolidation and deconsolidation of facilities, litigation and investigation costs, impairment and restructuring charges, and acquisition-related costs, depreciation and amortization and income (loss) from divested operations and closed businesses (i.e., our health plan businesses) in the year ended December 31, 2019 compared to the year ended December 31, 2018; and

The timing of other working capital items.

SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS AND OTHER SEGMENT

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-basedindemnity‑based health insurance companies and uninsured patients (that is, patients who do not have health insurance and are not covered by some other form of third-partythird‑party arrangement).


The following table shows the sources of net patient service revenues less implicit price concessions and provision for doubtful accounts for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues less implicit price concessions and provision for doubtful accounts from all sources:
  Years Ended December 31,
Net Patient Service Revenues Less Implicit Price Concessions from: 2019 2018 2017
Medicare 20.1% 20.5% 21.9%
Medicaid 8.3% 9.2% 8.8%
Managed care(1)
 66.2% 65.4% 64.6%
Uninsured 0.7% 0.7% 0.6%
Indemnity and other 4.7% 4.2% 4.1%
 Years Ended December 31,
Net Patient Service Revenues Less Implicit Price Concessions from:202120202019
Medicare17.7 %19.8 %20.1 %
Medicaid8.5 %7.9 %8.3 %
Managed care(1)
67.7 %66.3 %66.2 %
Uninsured1.3 %1.2 %0.7 %
Indemnity and other4.8 %4.8 %4.7 %
(1)
(1)Includes Medicare and Medicaid managed care programs.

Our payer mix on an admissions basis for our hospitals and related outpatient facilities, expressed as a percentage of total admissions from all sources, is shown below:
  Years Ended December 31,
Admissions from: 2019 2018 2017
Medicare 24.8% 25.4% 26.0%
Medicaid 6.2% 6.3% 6.5%
Managed care(1)
 60.3% 59.7% 59.6%
Charity and uninsured 6.0% 6.0% 5.5%
Indemnity and other 2.7% 2.6% 2.4%
 Years Ended December 31,
Admissions from:202120202019
Medicare20.8 %22.8 %24.8 %
Medicaid5.8 %6.2 %6.2 %
Managed care(1)
64.4 %61.8 %60.3 %
Charity and uninsured5.8 %6.3 %6.0 %
Indemnity and other3.2 %2.9 %2.7 %
(1)
(1)Includes Medicare and Medicaid managed care programs.

GOVERNMENT PROGRAMS

The Centers for Medicare and Medicaid Services (“CMS”), an agency of the U.S. Department of Health and Human Services (“HHS”), is the single largest payer of healthcare services in the United States. Approximately 6063 millionindividuals rely on healthcare benefits through Medicare, and approximately 7283 millionindividuals are enrolled in Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and administered by CMS. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, as well as some younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is co-administeredco‑administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The CHIP, which is also co-administeredco‑administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. DuringFunding for the three months ended March 31, 2018, separate pieces of legislation were enacted extending CHIP funding for a total of 10 years fromhas been reauthorized through federal fiscal year (“FFY”) 2018 (which began on October 1, 2017) through FFY 2027.

44

Table of Contents
The Affordable Care Act

The Affordable Care Act extended health coverage to millions of uninsured legal U.S. residents through a combination of private sector health insurance reforms and public program expansion. The expansion of Medicaid in the 3638 states (including four of the nine states in which we currently operate acute care hospitals) and the District of Columbia that have taken action to do so is currently financed through:

negative adjustments to the annual market basket updates for the Medicare hospital inpatient and outpatient prospective payment systems, which began in 2010 and expired on September 30, 2019, as well as additional negative “productivity adjustments” to the annual market basket updates, which began in 2011 and do not expire under current law; and

reductions to Medicare and Medicaid disproportionate share hospital (“DSH”) payments, which began for Medicare payments in FFY 2014 and, under current law, are scheduled to commence for Medicaid payments in FFY 2020.


2024.
Effective January 2019, Congress eliminated the financial penalty for noncompliance
The ACA also includes measures designed to promote quality and cost efficiency in healthcare delivery and provisions intended to strengthen fraud and abuse enforcement.

The initial expansion of health insurance coverage under the ACA’s individual mandate provision, which requires most U.S. citizens and noncitizens who lawfully resideACA resulted in an increase in the countrynumber of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions. Although a substantial portion of our patient volumes and, as a result, our revenues has historically been derived from government healthcare programs, reductions to our reimbursement under the Medicare and Medicaid programs as a result of the ACA have health insurance meeting specified standards. been partially offset by increased revenues from providing care to previously uninsured individuals.

The Congressional Budget Officehealthcare industry, in general, and the Joint Committeeacute care hospital business, in particular, have experienced significant regulatory uncertainty based, in large part, on Taxationadministrative, legislative and judicial efforts to limit, alter or repeal the ACA. Since 2010, various states, private entities and individuals have estimated that eliminationchallenged parts or all of the individual mandate penalty will resultACA numerous times in seven million more uninsured by 2021state and put upward pressure on health insurance premiums. Members of Congressfederal courts, and other politiciansthe U.S. Supreme Court has issued decisions in three such cases, most recently in June 2021. Various state legislatures have also proposed measures that would expand government-sponsored coverage, including single-payer plans, such as Medicare for All.challenged parts or all of the ACA through legislation, while other states have acted to safeguard the ACA by codifying certain provisions into state law. We cannot predict if or when further modification of the ACA will occur or what future action, if any, Congress might take with respect to eventually repealing and possibly replacing the law. Furthermore, in December 2019, a federal appeals court panel agreed with a December 2018 ruling by the U.S. District Court for the Northern District of Texas in the matter of Texas v. United States that the ACA’s individual mandate is unconstitutional now that Congress has eliminated the tax penalty that was intended to enforce it. The appeals court sent the case back to the lower court to determine how much of the rest of the ACA, if any, can stand in light of its ruling. On January 3, 2020, the U.S. House of Representatives, 20 states and the District of Columbia filed a petition asking the U.S. Supreme Court to review the case on an expedited basis, but their petition was denied on January 21, 2020. Pending a final decision on the matter, the current administration has continued to enforce the ACA.

We Furthermore, we are unable to predict the impact on our future revenues and operations of (1) the final decision in Texas v. United States and other court challenges to the ACA, (2) administrative, regulatory and legislative changes, including the possibility of expansion of government-sponsoredgovernment‑sponsored coverage, or (3) market reactions to those changes. However, if the ultimate impact is that significantly fewer individuals have private or public health coverage, we likely will experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect our results of operations and cash flows. This negative effect will be exacerbated if the ACA’s reductions in Medicare reimbursement and reductions in Medicare
DSH payments that have already taken effect are not reversed if the law is repealed or if further reductions (including Medicaid DSH reductions scheduled to take effect in FFYs 2020 through 2025, as described below) are made.

Medicare

Medicare
Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee-for-servicefee‑for‑service (“FFS”) payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private fee-for-serviceFFS Medicare special needs plans and Medicare medical savings account plans. The major components of ourOur total net patient service revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital Operations and other segment for services provided to patients enrolled in the Original Medicare Plan were $2.615 billion, $2.695 billion, and $2.888 billion for the years ended December 31, 2021, 2020 and 2019, 2018 and 2017 are set forth in the following table:respectively.
  Years Ended December 31,
Revenue Descriptions 2019 2018 2017
Medicare severity-adjusted diagnosis-related group — operating $1,512
 $1,526
 $1,659
Medicare severity-adjusted diagnosis-related group — capital 133
 137
 162
Outliers 82
 83
 89
Outpatient 737
 748
 762
Disproportionate share 232
 228
 265
Other(1) 
 192
 160
 306
Total Medicare net patient service revenues 
 $2,888
 $2,882
 $3,243
(1)The other revenue category includes Medicare Direct Graduate Medical Education (“DGME”) and Indirect Medical Education (“IME”) revenues, IME revenues earned by our children’s hospitals (one of which we divested in 2018) under the Children’s Hospitals Graduate Medical Education Payment Program administered by the Health Resources and Services Administration of HHS, inpatient psychiatric units, inpatient rehabilitation units, one long-term acute care hospital (which was divested in 2017), other revenue adjustments, and adjustments to the estimates for current and prior-year cost reports and related valuation allowances.

A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided below. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.


Acute Care Hospital Inpatient Prospective Payment System

Medicare Severity-Adjusted Diagnosis-Related Group Payments—Sections 1886(d) and 1886(g) of the Social Security Act (the “Act”) set forth a system of payments for the operating and capital costs of inpatient acute care hospital admissions based on a prospective payment system (“PPS”). Under the inpatient prospective payment systems (“IPPS”), Medicare payments for hospital inpatient operating services are made at predetermined rates for each hospital discharge. Discharges are classified according to a system of Medicare severity-adjusted diagnosis-relatedseverity‑adjusted diagnosis‑related groups (“MS-DRGs”MS‑DRGs”), which categorize patients with similar clinical characteristics that are expected to require similar amounts of hospital resources. CMS assigns to each MS-DRGMS‑DRG a relative weight that represents the average resources required to treat cases in that particular MS-DRG,MS‑DRG, relative to the average resources used to treat cases in all MS-DRGs.MS‑DRGs.

45

Table of Contents
The base payment amount for the operating component of the MS-DRGMS‑DRG payment is comprised of an average standardized amount that is divided into a labor-relatedlabor‑related share and a nonlabor-related share. Both the labor-relatedlabor‑related share of operating base payments and the base payment amount for capital costs are adjusted for geographic variations in labor and capital costs, respectively. Using diagnosis and procedure information submitted by the hospital, CMS assigns to each discharge an MS-DRG,MS‑DRG, and the base payments are multiplied by the relative weight of the MS-DRGMS‑DRG assigned. The MS-DRGMS‑DRG operating and capital base rates, relative weights and geographic adjustment factors are updated annually, with consideration given to: the increased cost of goods and services purchased by hospitals,hospitals; the relative costs associated with each MS-DRG,MS‑DRG; changes in labor data by geographic area,area; and other policies. Although these payments are adjusted for area labor and capital cost differentials, the adjustments do not take into consideration an individual hospital’s operating and capital costs.

Outlier Payments—Outlier payments are additional payments made to hospitals on individual claims for treating Medicare patients whose medical conditions are costlier to treat than those of the average patient in the same MS-DRG.MS‑DRG. To qualify for a cost outlier payment, a hospital’s billed charges, adjusted to cost, must exceed the payment rate for the MS-DRGMS‑DRG by a fixed threshold establishedupdated annually by CMS. A Medicare Administrative Contractor (“MAC”) calculates the cost of a claim by multiplying the billed charges by an average cost-to-chargecost‑to‑charge ratio that is typically based on the hospital’s most recently filed cost report. Generally, if the computed cost exceeds the sum of the MS-DRGMS‑DRG payment plus the fixed threshold, the hospital receives 80% of the difference as an outlier payment.

Under the Social Security Act, CMS must project aggregate annual outlier payments to all PPS hospitals to be not less than 5% or more than 6% of total MS-DRGMS‑DRG payments (“Outlier Percentage”). The Outlier Percentage is determined by dividing total outlier payments by the sum of MS-DRGMS‑DRG and outlier payments. CMS annually adjusts the fixed threshold to bring projected outlier payments within the mandated limit. A change to the fixed threshold affects total outlier payments by changing: (1) the number of cases that qualify for outlier payments; and (2) the dollar amount hospitals receive for those cases that qualify for outlier payments. Under certain conditions, outlier payments are subject to reconciliation based on more recent data.

Disproportionate Share Hospital Payments—In addition to making payments for services provided directly to beneficiaries, Medicare makes additional payments to hospitals that treat a disproportionately high share of low-incomelow‑income patients. Prior to October 1, 2013, DSH payments were determined annually based on certain statistical information defined by CMS and calculated as a percentage add-on to the MS-DRG payments.each hospital’s low income utilization for each payment year (the “Pre‑ACA DSH Formula”). The ACA revised the Medicare DSH adjustment effective for discharges occurring on or after October 1, 2013. Under the revised methodology, hospitals receive 25% of the amount they previously would have received under the pre-ACA formula.Pre‑ACA DSH Formula. This amount is referred to as the “Empirically Justified Amount.”

Hospitals qualifying for the Empirically Justified Amount of DSH payments are also eligible to receive an additional payment for uncompensated care (the “UC “UC‑DSH Amount”). The UC UC‑DSH Amount is a hospital’s share of a pool of funds that the CMS Office of the Actuary estimates would equal 75% of Medicare DSH that otherwise would have been paid under the pre-ACA formula,Pre‑ACA DSH Formula, adjusted for changes in the percentage of individuals that are uninsured. Generally, the factors used to calculate and distribute UC UC‑DSH Amounts are set forth in the ACA and are not subject to administrative or judicial review. Although theThe statute requires that each hospital’s cost of uncompensated care (i.e., charity and bad debt) as a percentage of the total uncompensated care cost of all DSH hospitals be used to allocate the pool. As of December 31, 2019, 552021, 49 of our acute care hospitals in continuing operations qualified for Medicare DSH payments.

One of the variables used in the pre-ACA DSH formula is the number of Medicare inpatient days attributable to patients receiving Supplemental Security Income (“SSI”) who are also eligible for Medicare Part A benefits divided by total Medicare inpatient days (the “SSI Ratio”). In an earlier rulemaking, CMS established a policy of including not only days attributable to Original Medicare Plan patients, but also Medicare Advantage patients in the SSI ratio. The statutes and regulations that govern Medicare DSH payments have been the subject of various administrative appeals and lawsuits, and our hospitals have been participating in such appeals, including challenges to the inclusion of the Medicare Advantage days used in

the DSH calculation as set forth in the Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2005 Rates. We are unable to predict what action the Secretary of HHS might take with respect to the DSH calculation for prior periods in this regard or the outcome of the pending litigation; however, a favorable outcome of our DSH appeals could have a material impact on our future revenues and cash flows.

Direct Graduate and Indirect Medical Education Payments—The Medicare program provides additional reimbursement to approved teaching hospitals for additionalthe increased expenses incurred by such institutions. This additional reimbursement, which is subject to certain limits, including intern and resident full-time equivalent (“FTE”) limits, is made in the form of DGMEDirect Graduate Medical Education (“DGME”) and IMEIndirect Medical Education (“IME”) payments. As of December 31, 2019, 272021, 30 of our hospitals in continuing operations were affiliated with academic institutions and were eligible to receive such payments.

46

Table of Contents
IPPS Quality Adjustments—The ACA also authorizes the following quality adjustments to Medicare IPPS payments:

Value Value‑Based Purchasing (“VBP”) – Under the VBP program, IPPS operating payments to hospitals are reduced by 2% to fund value-basedvalue‑based incentive payments to eligible hospitals based on their overall performance on a set of quality measures;

Hospital Readmission Reduction Program (“HRRP”) – Under the HRRPthis program, IPPS operating payments to hospitals with excess readmissions are reduced up to a maximum of 3% of base MS-DRGMS‑DRG payments; and

Hospital-AcquiredHospital‑Acquired Conditions (“HAC”) Reduction Program (“HACRP”) – Under the HACRP,this program, overall inpatient payments are reduced by 1% for hospitals in the worst performing quartile of risk-adjustedrisk‑adjusted quality measures for reasonable preventable HACs.hospital‑acquired conditions.

These adjustments are generally based on a hospital’s performance from prior periods and are updated annually by CMS.

Hospital Outpatient Prospective Payment System

Under the outpatient prospective payment system, hospital outpatient services, except for certain services that are reimbursed on a separate fee schedule, are classified into groups called ambulatory payment classifications (“APCs”). Services in each APC are similar clinically and in terms of the resources they require, and a payment rate is established for each APC. Depending on the services provided, hospitals may be paid for more than one APC for an encounter. CMS annually updates the APCs and the rates paid for each APC.

Inpatient Psychiatric Facility Prospective Payment System

The inpatient psychiatric facility (“IPF”) prospective payment system (“IPF-PPS”) applies to psychiatric hospitals and psychiatric units located within acute care hospitals that have been designated as exempt from the hospital inpatient prospective payment system. The IPF-PPS is based on prospectively determined per-diemper‑diem rates and includes an outlier policy that authorizes additional payments for extraordinarily costly cases. As of December 31, 2019, 202021, 19 of our general hospitals in continuing operations operated IPF units.

Inpatient Rehabilitation Prospective Payment System

Rehabilitation hospitals and rehabilitation units in acute care hospitals meeting certain criteria established by CMS are eligible to be paid as an inpatient rehabilitation facility (“IRF”) under the IRF prospective payment system (“IRF-PPS”IRF‑PPS”). Payments under the IRF-PPSIRF‑PPS are made on a per-discharge basis. The IRF-PPSIRF‑PPS uses federal prospective payment rates across distinct case-mixcase‑mix groups established by a patient classification system. As of December 31, 2019,2021, we operated one freestanding IRF, and 1517 of our general hospitals in continuing operations operated IRF units.

Physician and Other Health Professional Services Payment System

Medicare uses a fee schedule to pay for physician and other health professional services based on a list of services and their payment rates referred to as the Medicare Physician Fee Schedule (“MPFS”). In determining payment rates for each service, CMS considers the amount of clinician work required to provide a service, expenses related to maintaining a practice, and professional liability insurance costs. These three factors are adjusted for variation in the input prices in different markets, and the sum is multiplied by the fee schedule’s conversion factor (average payment amount) to produce a total payment amount.


Cost Reports

The final determination of certain Medicare payments to our hospitals, such as DSH, DGME, IME and bad debt expense, are retrospectively determined based on our hospitals’ cost reports. The final determination of these payments often takes many years to resolve because of audits by the program representatives, providers’ rights of appeal, and the application of numerous technical reimbursement provisions.

For filed cost reports, we adjust the accrual for estimated cost report settlements based on those cost reports and subsequent activity, and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for estimated cost report settlements for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports and a corresponding valuation allowance is recorded as previously described. Cost reports must generally be filed within five months after the end of the annual cost report reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.
47

Table of Contents

Medicare Claims Reviews

HHS estimates that the overall FFY 20192021 Medicare fee-for-service (“FFS”)FFS improper payment rate for the program is approximately 7.3%6.3%. The FFY 20192021 error rate for Hospital IPPS payments is approximately 3.6%2.4%. CMS has identified the FFS program as a program at risk for significant erroneous payments. Onepayments, and one of CMS’the agency’s stated key goals is to pay claims properly the first time. This means paying the right amount, to legitimate providers, for covered, reasonable and necessary services provided to eligible beneficiaries. According to CMS, paying correctly the first time saves resources required to recover improper payments and ensures the proper expenditure of Medicare Trust Fund dollars. CMS has established several initiatives to prevent or identify improper payments before a claim is paid, and to identify and recover improper payments after paying a claim. The overall goal is to reduce improper payments by identifying and addressing coverage and coding billing errors for all provider types. Under the authority of the Social Security Act, CMS employs a variety of contractors (e.g., MACs, Recovery Audit Contractors and Unified Program Integrity Contractors) to process and review claims according to Medicare rules and regulations.

Claims selected for prepayment review are not subject to the normal Medicare FFS payment timeframe. Furthermore, prepayment and post-paymentpost‑payment claims denials are subject to administrative and judicial review, and we intend to pursue the reversal of adverse determinations where appropriate. We have established robust protocols to respond to claims reviews and payment denials. In addition to overpayments that are not reversed on appeal, we incur additional costs to respond to requests for records and pursue the reversal of payment denials. The degree to which our Medicare FFS claims are subjected to prepayment reviews, the extent to which payments are denied, and our success in overturning denials could have a material adverse effect on our cash flows and results of operations.

Meaningful Use of Health Information Technology
The Health Information Technology for Economic and Clinical Health (“HITECH”) Act, which is part of the American Recovery and Reinvestment Act of 2009, promotes the use of healthcare information technology by, among other things, providing financial incentives to hospitals and physicians to become “meaningful users” of electronic health record (“EHR”) systems and imposing penalties on those who do not. Under the HITECH Act and other laws and regulations, eligible hospitals that fail to demonstrate and maintain meaningful use of certified EHR technology and/or submit quality data every year (and have not applied and qualified for a hardship exception) are subject to a reduction of the Medicare market basket update. Eligible healthcare professionals are also subject to positive or negative payment adjustments based, in part, on their use of EHR technology. We have made significant investments in our information systems to bring our hospitals and employed physicians into EHR compliance, and we continue to invest in the maintenance and utilization of these certified EHR systems. Failure to continue to do so could subject us to penalties that may have an adverse effect on our net revenues and results of operations.

Medicaid

Medicaid programs and the corresponding reimbursement methodologies vary from state to state‑to‑state and from year to year‑to‑year. Estimated revenues under various state Medicaid programs, including state-fundedstate‑funded Medicaid managed care Medicaid programs, constituted 18.4%approximately 18.7%, 19.8%17.8% and 20.4%18.4% of the total net patient service revenues less implicit price concessions and provision for doubtful accounts of our acute care hospitals and related outpatient facilities for the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively. We also receive DSH and other supplemental revenues under various state Medicaid programs. For the years ended December 31, 2019, 20182021, 2020 and 2017,2019, our total Medicaid revenues attributable to DSH and other supplemental revenues were $782approximately $915 million, $847$754 million and $864$782 million, respectively. The $782 million of total Medicaid revenues attributable to DSH and other supplemental revenues for the year ended December 31, 2019 was comprised of $2462021 included $223 million related to the California provider fee program, described below, $263$254 million related to the Michigan provider fee program, $137$174 million related to Medicaid DSH programs in multiple states, $118$71 million related to the Texas Section 1115 waiver program, described below, and $18$193 million from a number of other state and local programs.

SeveralEven prior to the COVID-19 pandemic, several states in which we operate continue to facefaced budgetary challenges that have resulted and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs authorized under the Social Security Act.

Continuing pressure on state budgets and other factors, could adversely affect the Medicaid supplemental payments our hospitals receive.


The California Department of Health Care Services’ Hospital Quality Assurance Fee (“HQAF”) program provides funding for supplemental payments to California hospitals that serve Medi-Calincluding legislative and uninsured patients. Our hospitals recognized HQAF revenues, net of provider fees and other expenses, of $246 million, $262 million and $267 million in calendar years 2019, 2018 and 2017, respectively. Because HQAF funding levels are based in part on Medi-Cal utilization,regulatory changes, in coverage of individuals under the Medi-Cal program could affect the net revenues and cash flows of our hospitals under the HQAF program. Also, because funding of the HQAF program is dependent on federal funding, we cannot provide assurances that such funding will continue in future periods.

Certain of our Texas hospitals participate in the Texas 1115 waiver program. The current waiver extension (“Waiver”), which was approved during the three months ended December 31, 2017, covers the period January 1, 2018 through September 30, 2022. In 2019, we recognized $118 million of revenues from the Waiver program. Separately, during the same period, we incurred $70 million of expenses related to funding indigent care services by certain of our Texas hospitals. We are unable to predict the changes to the funding pool amount or the allocation of the funding pool amount, which could result in an increasefuture reductions to Medicaid payments, payment delays or decreasechanges to our net revenues and cash flows. Furthermore, we cannot provide any assurances as to future extensionsMedicaid supplemental payment programs. Federal government denials or delayed approvals of the Texas 1115 waiver program,applications or the ultimate amount of revenues that our hospitals may receive from this program following the expiration of the Waiver.

Because we cannot predict what actions the federal government orextension requests by the states may take under existing or future legislation and/or regulatory changes to address budget gaps, deficits,in which we operate could materially impact our Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation or regulatory action might have on our business; however, the impact on our future financial position, resultsfunding levels.
48

Table of operations or cash flows could be material.Contents

Total Medicaid and Managed Medicaid net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations and other segment from Medicaid-related programs in the states in which our facilities are (or were, as the case may be) located, as well as from Medicaid programs in neighboring states, for the years ended December 31, 2021, 2020 and 2019 2018were $2.760 billion, $2.427 billion, and 2017 are set forth in$2.639 billion, respectively. During the following table. These revenues are presented net of provider assessments, which are reported as an offset reduction to fee-for-service Medicaid revenue.
   Years Ended December 31,
Hospital Location  2019 2018 2017
Alabama  $91
 $91
 $88
Arizona  159
 165
 177
California  855
 875
 862
Florida  222
 231
 232
Georgia  
 
 (3)
Illinois  5
 89
 143
Massachusetts  92
 94
 83
Michigan  714
 749
 710
Missouri  
 
 2
North Carolina  
 
 (1)
Pennsylvania  
 8
 285
South Carolina  55
 53
 46
Tennessee  37
 35
 36
Texas  409
 398
 371
   $2,639
 $2,788
 $3,031

year ended December 31, 2021, Medicaid and Managed Medicaid revenues comprised 45% and 55%, respectively, of our Medicaid-relatedMedicaid‑related net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations and other segment for the years ended December 31, 2019.segment. These revenues are presented net of provider taxes or assessments paid by our hospitals, which are reported as an offset reduction to FFS Medicaid revenue.


Regulatory and Legislative Changes

The Medicare and Medicaid programs are subject toto: statutory and regulatory changes, administrative and judicial rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating reimbursements, among other things; requirements for utilization review,review; and federal and state funding restrictions, all of which could materially increase or decrease payments from these government programs in the future, as well as affect the cost of providing services to our patients and the timing of payments to our facilities. We are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid or services covered by governmental payers are reduced, or if we or one or more of our subsidiaries’ hospitals are excluded from participation in the Medicare or Medicaid program or any other government healthcare program, there could be a material adverse effect on our business, financial condition, results of operations or cash flows. Recent regulatory and legislative updates to the Medicare and Medicaid payment systems, as well as other government programs impacting our business, are provided below.

Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems

Under Medicare law,Section 1886(d) of the Social Security Act requires CMS is required to annually update certain rules governing the inpatient prospectiveFFS payment systems (“IPPS”).rates for hospitals reimbursed under IPPS annually. The updates generally become effective October 1, the beginning of the federal fiscal year. In August 2019,2021, CMS issued the final Changeschanges to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 20202022 Rates (“August 2019Final IPPS Rule”) and, in October 2019, CMS issued a notice (“October 2019 Correction Notice”) correcting minor errors in the August 2019 Rule. The August 2019 Rule and the October 2019 Correction Notice are collectively referred to as the “Final IPPS Rule”. The Final IPPS Rule includes the following payment and policy changes:

A market basket increase of 3.0%2.7% for Medicare severity-adjusted diagnosis-related group (“MS-DRG”)MS‑DRG operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record technology; CMS also finalized certain adjustments toa 0.7% multifactor productivity reduction required by the 3.0% market basketACA and a 0.5% increase required by the Medicare Access and CHIP Reauthorization Act (“MACRA”) that collectively result in a net operating payment update of 3.1% (before2.5% before budget neutrality adjustments), including:adjustments;

A multifactor productivity reduction required by the ACA of 0.4%; and

A 0.5% increase required under the Medicare Access and CHIP Reauthorization Act of 2015;

Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share (“UC-DSH”UC‑DSH”) payments; in addition to adjusting the UC-DSH amounts, CMS will base the distribution of the FFY 2020 UC-DSH amounts on uncompensated care costs reported by hospitals in the 2015 cost reports, which reflects changes to the calculation of a hospital’s share of the UC-DSH amounts by: (1) removing low income days; and (2) using a single year of uncompensated care cost in lieu of the three-year averaging methodology used in recent years;

A 0.64%1.37% net increase in the capital federal MS-DRGMS‑DRG rate;

An increase in the cost outlier threshold from $25,769$29,064 to $26,552; and$30,988;

Changes in the calculationAn extension of the wage index areas that include:

IncreasingNew COVID‑19 Treatments Add‑on Payment for certain eligible products through the wage index for hospitals with a wage index below the 25th percentile and applying a uniform budget neutrality factor to the IPPS base rates to offset the estimated increase in IPPS payments to hospitals with wage index values below the 25th percentile;

A refinement to the calculationend of the “rural floor” wage index;FFY in which the public health emergency as declared by the Secretary of HHS ends; and

A one-year stop-loss transitionThe establishment of new requirements and the revision of existing requirements for a hospital that experiences a decline of greater than 5% in its wage index.the Hospital Value‑Based Purchasing, Hospital Readmissions Reduction and Hospital‑Acquired Condition Reduction programs.

According to CMS, the combined impact of the payment and policy changes in the Final IPPS Rule for operating costs will yield an average 2.8%2.6% increase in Medicare operating MS-DRG fee-for-service (“FFS”)MS‑DRG FFS payments for hospitals in large urban areas (populations over one million), and an average 2.8%2.6% increase in operating MS-DRG FFSsuch payments for proprietary hospitals in FFY 2020.2022. We estimate that all of the final payment and policy changes affecting operating MS-DRGMS‑DRG and UC‑DSH payments including those affecting Medicare UC-DSH amounts, will result in an estimated 1.4% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately $28$27 million. Because of the uncertainty associated with

various factors that may influence our future IPPS payments by individual hospital, including legislative, regulatory or legal actions, admission volumes, length of stay and case mix, we cannot provide any assurances regarding our estimateestimates of the impact of the payment and policy changes.

49

Table of Contents
Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems

OnIn November 1, 2019,2021, CMS releasedissued the final policy changes and payment rates for the Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center (“ASC”) Payment System for calendar year (“CY”) 20202022 (“Final OPPS/ASC Rule”). The Final OPPS/ASC Rule includes the following payment and policy changes:

An estimated net increase of 2.6%2.0% for the OPPS rates based on an estimated market basket increase of 3.0%2.7%, reduced by a multifactor productivity adjustment required by the ACA of 0.4%0.7%;

A continuationContinuation of the reduced paymentcurrent policy of paying an adjusted amount for separately payable drugs acquired with a discount under CMS’ 340B program (“340B Drugs”) equal to a rate of average sales price (“ASP”) minus 22.5%. CMS is also soliciting comments on alternative payment policies for 340B Drugs, as well as the appropriate remedy for CYs 2018 and 2019. CMS recently announced its intent to conduct a 340B hospital survey to collect drug acquisition cost data for CY 2018 and 2019. Such data may be used in setting the future Medicare payment amount for drugs acquired byunder the CMS 340B and may be used to devise a remedy for prior years inprogram (which program is the event that CMS does not prevail on appeal in the pendingsubject of litigation discussed in greater detail below;below);

Cessation of the elimination of the Inpatient Only List (“IPO List”) (which is the list of procedures that must be performed on an inpatient basis); efforts to eliminate the IPO List commenced in CY 2021 and were scheduled to be completed over a transitional period ending in CY 2024; in addition, CMS reinstated substantially all of the services removed from the IPO List in CY 2021 to the IPO List beginning in CY 2022;

Various modifications to the hospital price transparency requirements that took effect on January 1, 2021, including significant increases to the civil monetary penalty for noncompliance, as well as prohibitions to specific barriers to accessing machine‑readable price transparency files;

A prior authorization process for five categories of services; and

A 2.6%2.0% increase to the ASC payment rates.rates; and

InReinstatement of the ASC Covered Procedures List (“ASC CPL”) criteria in effect in CY 2020 Proposed OPPS/ASC Rule, CMSand removal of 255 of the 258 procedures that were proposed a policy that would require hospitals to post negotiated prices for certain services. CMS subsequently separated the proposal from the CY 2020 OPPS rulemaking, and in November 2019 issued a final rule that requires all hospitals to display payer-specific negotiated charges, minimum and maximum negotiated charges, and discounted cash prices for at least 300 “shoppable” services. The final rule is effective on January 1, 2021.removal.

CMS projects that the combined impact of the proposed payment and policy changes in the Final OPPS/ASC Rule will yield an average 1.3% increase in Medicare FFS OPPS payments for all hospitals, an average 1.2%1.6% increase in Medicare FFS OPPS payments for hospitals in large urban areas (populations over one million), and an average 2.1%1.7% increase in Medicare FFS OPPS payments for proprietary hospitals. Based on CMS’ estimates, the projected annual impact of the payment and policy changes in the Final OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately $10$12 million, which represents an increase of approximately 1.6%1.8%. Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the payment and policy changes.

The Medicare Access and CHIP Reauthorization Act of 2015

The Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”) replaced the Medicare Sustainable Growth Rate methodology with a new system for establishing the annual updates to the MPFS beginning in 2019. The new payment system helps to link fee-for-service payments to quality and value with payment incentives and penalties. Additionally, the MACRA reduced the restoration of the 3.2% coding and document adjustment to hospital inpatient rates that was expected to be effective in FFY 2018 to 3.0%; as modified by the 21st Century Cures Act, the adjustment will be applied at the rate of 0.4588% for FFY 2018 and 0.5% for FFYs 2019 through 2023.

Less than 1% of the net operating revenue generated by our Hospital Operations and other segment during the year ended 2019 was related to the MPFS. We are unable to estimate the potential impact of the MACRA; however, the maximum incentive and penalty adjustments could result in an increase or decrease in our annual net revenues of approximately $15 million. Additionally, we cannot predict the effect of the MACRA on our future operations, revenues and cash flows.


Payment and Policy Changes to the Medicare Physician Fee Schedule

OnIn November 1, 2019,2021, CMS issued a final rule that includesreleased the CY 2022 MPFS Final Rule (“MPFS Final Rule”). The MPFS Final Rule updates to payment policies, payment rates quality provisions and other policiesprovisions for services reimbursed under the MPFS for CY 2020. With2022. Under the MPFS Final Rule, the CY 2022 conversion factor, which is the base rate that is used to convert relative units into payment rates, would have been reduced approximately 3.7% due in part to the expiration of the one‑time 3.75% MPFS payment increase provided for in CY 2021 by the Consolidated Appropriations Act, 2021 (the “Consolidated Appropriations Act”), as well as budget neutrality adjustmentrules. However, the Protecting Medicare and American Farmers from Sequester Cuts Act enacted in December 2021 (“December 2021 Legislation”) restored 3% of the expired 3.75% payment increase for CY 2022. The combined effects of the MPFS Final Rule and the December 2021 Legislation will result in an annual reduction of approximately $1 million to account for changes inour FFS MPFS revenues. Because of the relative value units required by law, the finaluncertainty associated with various factors that may influence our future MPFS conversion factor for 2020 will increase by approximately 0.14%. CMS estimates thatpayments, including legislative, regulatory or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the payment and policy changeschanges.

The Coronavirus Aid, Relief, and Economic Security Act of 2020 and Related Legislation
Several pieces of legislation (the “COVID Acts”) have been signed into law in response to the COVID‑19 pandemic. Among the numerous provisions included in the final rulelegislation is funding to mitigate the economic effects of the COVID‑19 pandemic. Below is a brief overview of certain provisions of the COVID Acts that have impacted, and that we expect will result incontinue to impact, our business. This summary is not exhaustive, and additional legislative action and regulatory developments may evolve rapidly. There is no change in aggregate FFS MPFS payments across all specialties.assurance that we will continue to receive or remain eligible for funding or assistance under the COVID Acts or similar measures. Statements regarding the projected impact of COVID‑19 relief programs on our operations and financial condition are forward‑looking statements.

Medicaid DSH Reductions
50

Table of Contents

On September 23, 2019, CMS issued a final rule for calculating the $4The COVID Acts authorized $178 billion in reductionspayments to state Medicaid DSH allotmentsbe distributed to providers through the Provider Relief Fund. Payments from the PRF are not loans and, therefore, they are not subject to repayment. However, as a condition to receiving distributions, providers are required to agree to certain terms and conditions, including, among other things, that the funds are being used for FFY 2020lost revenues and unreimbursed COVID-related costs as defined by HHS, and that the providers will not seek collection of out‑of‑pocket payments from a COVID-19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in-network provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by HHS. In January 2021, HHS released updated reporting requirements that include lost revenues, expenses attributable to COVID-19 and non-financial information. The updated reporting requirements reflect certain provisions of the Consolidated Appropriations Act affecting the calculation of lost revenues, as well as the distribution of PRF funds among subsidiaries in a hospital system. Furthermore, HHS has indicated that it will be closely monitoring and, along with the Office of Inspector General, auditing providers to ensure that recipients comply with the terms and conditions of relief programs and to prevent fraud and abuse. All providers will be subject to civil and criminal penalties for any deliberate omissions, misrepresentations or falsifications of any information given to HHS. Except for certain immaterial PRF payments we returned to HHS, we have formally accepted PRF payments issued to our providers and the $8 billion for each subsequent year through 2025 required under current law. terms and conditions associated with those payments, and we have complied with the reporting requirements.

During the three monthsyears ended December 31, 2019, the President signed the Further Consolidated Appropriations Act, 2020 which delays through May 22, 2020 the FFY 2020 Medicaid DSH reduction that otherwise would have begun on October 1, 2019. If no further legislative action is taken, we expect our Medicaid DSH revenues to decrease by $45 million for FFY 2020 and an incremental $45 million for FFY 2021 and remain at that level2020, our Hospital Operations and Ambulatory Care segments combined recognized approximately $176 million and $868 million, respectively, of PRF grant income associated with lost revenues and COVID‑related costs. We recognized an additional $14 million and $17 million, respectively, of Provider Relief Fund grant income from our unconsolidated affiliates during 2021 and 2020. Our Hospital Operations and Ambulatory Care segments also recognized $15 million and $14 million of grant income from state and local grant programs during the years ended December 31, 2021 and 2020, respectively. Grant income recognized by our Hospital Operations and Ambulatory Care segments is presented in grant income, and grant income recognized through FFY 2025. We are unable to predict what legislative action, if any, Congress will ultimately take with respect to a further delayour unconsolidated affiliates is presented in equity in earnings of unconsolidated affiliates, in each case in the Medicaid DSH reductions and/or DSH allotment policies.

The American Recoveryaccompanying Consolidated Statements of Operations for the years ended December 31, 2021 and Reinvestment Act2020. At December 31, 2021 and 2020, we had remaining deferred grant payment balances of 2009

The American Recovery$5 million and Reinvestment Act of 2009 (“ARRA”) was enacted to stimulate the U.S. economy. One provision of ARRA provided temporary financial incentives to hospitals and physicians to become “meaningful users” of electronic health records (“EHR”). In addition to the expenditures we incur to qualify for these incentive payments, our operating expenses have increased and we anticipate will increase$18 million, respectively, which amounts were recorded in other current liabilities in the future as a resultaccompanying Consolidated Balance Sheets for those periods. We cannot predict whether additional distributions of these information system investments. Eligible hospitals must continue to demonstrate meaningful use of EHR technology every year to avoid payment reductions in subsequent years. These reductions, which are based on the market basket update, continue until a hospital achieves compliance.

The complexity of the changes required to our hospitals’ systemsgrant funds will be authorized, and the time required to complete the changes could result in some or all of our facilities not being fully compliant and subject to the payment penalties permitted under ARRA. Because of the uncertainties regarding the implementation of HIT, including CMS’ future EHR implementation regulations, we cannot provide any assurances regarding the effectamount of such changesgrant income, if any, to be recognized in the future.

Medicare and Medicaid Payment Policy Changes—The COVID Acts have also alleviated some of the financial strain on hospitals, physicians, other healthcare providers and states through a series of Medicare and Medicaid payment policies that temporarily increase Medicare and Medicaid reimbursement and allow for added flexibility, as described below:

The CMS 2% sequestration reduction on Medicare FFS and Medicare Advantage payments to hospitals, physicians and other providers was suspended effective May 1, 2020 through December 31, 2021. The impact of the suspension on our hospital’s continued complianceoperations was an increase of approximately $78 million and $67 million of revenues in the years ended December 31, 2021 and 2020, respectively. The December 2021 Legislation extended the suspension of the 2% sequestration reduction through March 31, 2022, to be followed by a 1% reduction for the period April 1, 2022 through June 30, 2022, after which the full 2% reduction will be restored.

The COVID Acts instituted a 20% increase in the Medicare MS‑DRG payment for COVID-19 hospital admissions for the duration of the public health emergency as declared by the Secretary of HHS.

The COVID Acts initially eliminated the scheduled nationwide reduction of $4 billion in federal Medicaid DSH allotments in FFY 2020 mandated by the Affordable Care Act and decreased the FFY 2021 DSH reduction from $8 billion to $4 billion effective December 1, 2020. Subsequently, the FFY 2021 DSH reduction was eliminated entirely and the remaining DSH reductions were delayed until FFY 2024.

The COVID Acts expanded the Medicare accelerated payment program, which provides prepayment of claims to providers in certain circumstances, such as national emergencies or natural disasters. Under Section 2501 of the Continuing Appropriations Act, 2021, and Other Extensions Act, providers may retain the accelerated payments for one year from the date of receipt before CMS commenced recoupment, which is effectuated by a 25% offset of claims payments for 11 months, followed by a 50% offset for the succeeding six months. At the end of the 29‑month period, interest on the unpaid balance will be assessed at 4% per annum. During the year ended December 31, 2020, our hospitals and other providers applied for and received approximately $1.5 billion of accelerated payments. No additional accelerated payment funds were applied for or received in the year ended December 31, 2021.

51

Table of Contents
A 6.2% increase in the Federal Medical Assistance Percentage (“FMAP”) matching funds was instituted to help states respond to the COVID‑19 pandemic. The additional funds are available to states from January 1, 2020 through the quarter in which the public health emergency period ends, provided that states meet certain conditions. In addition, the COVID Acts established an incentive for states that have not already done so to expand Medicaid by temporarily increasing each such respective state’s FMAP for their base program by five percentage points for two years. An increase in states’ FMAP leverages Medicaid’s existing financing structure, which allows federal funds to be provided to states more quickly and efficiently than establishing a new program or allocating money from a new funding stream. Increased federal matching funds support states in responding to the increased need for services, such as testing and treatment during the COVID19 public health emergency, as well as increased enrollment as more people lose income and qualify for Medicaid due to the effects of the pandemic.

Because of the uncertainty associated with various factors that may influence our future Medicare and Medicaid payments, including future legislative, legal or regulatory actions, or changes in volumes and case mix, there is a risk that actual payments received under, or the ultimate impact of, these programs will differ materially from our expectations.

Funding for Uninsured Individuals—The COVID Acts provide claims reimbursement to healthcare providers generally at Medicare rates for testing uninsured individuals for COVID‑19 and treating uninsured individuals with a COVID‑19 diagnosis. A portion of the funding may also be used to reimburse providers for COVID‑19 vaccine administration to uninsured individuals. We recognized net revenues.operating revenues totaling $91 million and $40 million related to this program in the accompanying Consolidated Statements of Operations for the years ended December 31, 2021 and 2020, respectively.

Tax Changes—Beginning March 27, 2020, all employers were able to elect to defer payment of the 6.2% employer Social Security tax through December 31, 2020. Deferred tax amounts are required to be paid in equal amounts over two years, with payments due in December 2021 and December 2022. During the year ended December 31, 2020, we deferred Social Security tax payments totaling $275 million pursuant to this COVID Acts provision. In December 2021, we repaid half of the outstanding deferred Social Security tax payments.

CMS Innovation Models

The CMS Innovation Center develops newand tests innovative payment and service delivery models in accordance withthat have the requirementspotential to reduce Medicare, Medicaid or CHIP expenditures while preserving or enhancing the quality of Section 1115A of the Social Security Act. Additionally,care for beneficiaries. Congress has defined – both through the Affordable Care Act and previous legislation – a number of specific demonstrations for CMS to be conducted by CMS. The CMS Innovation Center has a growing portfolio testing various payment and service delivery models that aim to achieve better care for patients, better health for communities and lower costs through improvement for our healthcare system. Participation in some of these models is voluntary; however, participation in certainconduct, including bundled payment arrangements is mandatory for providers located in randomly selected geographic locations.models. Generally, the bundled payment models hold hospitals financially accountable for the quality and costs for an entire episode of care for a specific diagnosis or procedure from the date of the hospital admission or inpatient procedure through 90 days post-discharge,post‑discharge, including services not provided by the hospital, such as physician, inpatient rehabilitation, skilled nursing and home health services.care. Provider participation in some of these models is voluntary; for example, 19 hospitals in our Hospital Operations segment and three surgical hospitals in our Ambulatory Care segment participate in the CMS Bundled Payments for Care Improvement Advanced (“BPCIA”) program that became effective October 1, 2018, and USPI also holds the CMS contract for one physician group practices participating in the BPCIA program. Participation in certain other bundled payment arrangements is mandatory for providers located in randomly selected geographic locations. Under the mandatory models, hospitals are eligible to receive incentive payments or will be subject to payment reductions within certain corridors based on their performance against quality and spending criteria. In 2015, CMS finalized a five‑year bundled payment model (that was subsequently extended for an additional three years), called the Comprehensive Care for Joint Replacement (“CJR”) model, which includes hip and knee replacements, as well as other major leg procedures. Eleven hospitals in our Hospital Operations segment and four surgical hospitals in our Ambulatory Care segment currently participate in the CJR model.

Significant Litigation

340B Litigation

The CMS 340B program allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) (“340B Hospitals”) to purchase separately payable drugs at discounted rates from drug manufacturers.manufacturers (“340B Drugs”). In the final rule regarding OPPS payment and policy changes for CY 2018, CMS reduced the payment for 340B Drugs from average sales price (“ASP”)the ASP plus 6% to the ASP minus 22.5% and made a corresponding budget-neutralbudget‑neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS (the “340B Payment Adjustment”). In the final rulerules regarding OPPS payment and policy

changes for CYCYs 2019, (“CY 2019 OPPS Final Rule”),2020 and 2021, CMS continued the 340B Payment Adjustment. Certain hospital associations and hospitals commenced litigation challenging CMS’ authority to impose the 340B Payment Adjustment for CYs 2018, 2019 and 2019. During the three months ended June 30, 2019,2020. Previously, the U.S. District Court for the District of Columbia (the “District Court”) held that the adoption of the 340B Payment Adjustment in the CYCYs 2018 and 2019 OPPS Final RuleRules exceeded CMS’ statutory authority. This holding followed the District Court’s December 2018 conclusion that HHS exceeded its statutory authority inby reducing the CY 2018 OPPSdrug
52

Table of Contents
reimbursement rates for the 340B Payment Adjustment. The District Court did not grant a permanent injunction to the 340B Payment Adjustment, nor did it vacate the 2018 and 2019 rules. Also during the three months ended June 30, 2019, the District Court issued a Memorandum Opinion granting HHS’ motion for entry of final judgment, thus allowing HHS to proceed with a pending appeal of the District Court’s rulings atHospitals. In July 2020, the U.S. Court of Appeals for the District of Columbia Circuit (the “Circuit“Appeals Court”). During reversed the three months ended December 31, 2019,District Court’s holding, finding that HHS’ decision to reduce the payment rate for 340B Drugs was based on a nationwide coalition of hospitals sued HHS to block implementationreasonable interpretation of the Medicare statute. The Appeals Court subsequently denied the 340B rate cuts contained inHospitals’ petition for a rehearing. The 340B Hospitals filed a timely petition asking the CY 2020 Final OPPS/ASC Rule.U.S. Supreme Court (“Supreme Court”) to reverse the Appeals Court’s decision and, on July 2, 2021, the Supreme Court agreed to review the case. We cannot predict what further actions the ultimate outcomeSupreme Court, CMS or Congress might take with respect to the 340B program; however, a reversal of the current payment policy and return to the prior 340B litigation; however, CMS’ remedy and/or an unfavorable outcome of the litigationpayment methodology could have an adverse effect on the Company’sour net operating revenues and cash flows.

Medicare Disproportionate Share Hospital Litigation

Medicare makes additional payments to hospitals that treat a disproportionately high share of low-income patients, Prior to October 1, 2013, DSH payments were based on each hospital’s low income utilization for each payment year (the “Pre-ACA DSH Formula”). In the final rule regarding IPPS payment and policy changes for FFY 2005, CMS revised its policy on the calculation of one of the ratios used in the Pre-ACA DSH Formula. A group of hospitals challenged the policy change claiming that CMS failed to provide adequate notice and a comment period. The District Court vacated the rule. CMS appealed the ruling, and the Circuit Court affirmed the District Court’s decision. Since then, CMS has continued to use the vacated policy and was again met with legal challenges. In 2019, the U.S. Supreme Court (“SCOTUS”) upheld the Circuit Court’s decision that CMS’ continued use of the vacated policy is not legal. Although the SCOTUS decision applies only to the 2012 ratios for the plaintiff hospitals, it establishes a precedent that we believe will result in a favorable outcome in our pending Medicare DSH appeals for years 2005-2013; however, we cannot predict the timing or outcome of our appeals or when and how CMS will implement the SCOTUS decision. A favorable outcome of our DSH appeals could have a material impact on our future revenues and cash flows.

PRIVATE INSURANCE

Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full-servicefull‑service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost-effectivecost‑effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non-contractednon‑contracted healthcare providers for non-emergencynon‑emergency care.

PPOs generally offer limited benefits to members who use non-contractednon‑contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co-pays, co-insuranceco‑pays, co‑insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high-deductiblehigh‑deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the years ended December 31, 2021, 2020 and 2019 2018 and 2017 was $9.516$9.985 billion, $9.213$9.022 billion and $9.583$9.516 billion, respectively. Our top ten10 managed care payers generated 62%61% of our managed care net patient service revenues for the year ended December 31, 2019. National2021. In 2021, national payers generated 43% of our managed care net patient service revenues forrevenues; the year ended December 31, 2019. The remainder comescame from regional or local payers. At December 31, 20192021 and 2018, 65%2020, 67% and 61%66%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from managed care payers.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diemper‑diem rates, discounted fee-for-serviceFFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a

patient-by-patient patient‑by‑patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at December 31, 2019,2021, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $16 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-lossstop‑loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-housein‑house and discharged-not-final-billeddischarged‑not‑final‑billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate-widecorporate‑wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

53

Table of Contents
We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year-over-yearyear‑over‑year aggregate managed care pricing improvements for several years,some time, we have seen these improvements moderate in recent years, and we believe thethis moderation could continue in future years.into the future. In the year ended December 31, 2019,2021, our commercial managed care net inpatient revenue per admission from the hospitals and related outpatient facilities in our Hospital Operations and other segment was approximately 101%82% higher than our aggregate yield on a per admissionper-admission basis from government payers, including managed Medicare and Medicaid insurance plans.

Indemnity

An indemnity-basedindemnity‑based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

Legislative Changes
As more fully described in Item 1, Business — Healthcare Regulation and Licensing, of Part I of this report, the No Surprises Act (“NSA”) and the rules promulgated thereunder went into effect on January 1, 2022. The NSA is intended to address unexpected gaps in insurance coverage that result in “surprise medical bills” when patients unknowingly obtain medical services from physicians and other providers outside their health insurance network, including certain emergency services, anesthesiology services and air ambulance transportation. At this time, we are unable to assess the effect that the NSA or regulations relating to the NSA might have on our business, financial position, results of operations or cash flows.

UNINSURED PATIENTS

Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our uninsured patients are admitted through our hospitals’ emergency departments and often require high-acuityhigh‑acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self-paySelf‑pay accounts receivable, which include amounts due from uninsured patients, as well as co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance, pose significant collectability problems. At both December 31, 20192021 and 2018,2020, approximately 4% and 6%, respectively, of our net accounts receivable for our Hospital Operations and other segment was self-pay.self‑pay. Further, a significant portion of our implicit price concessions relates to self-payself‑pay amounts. We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, of Part I of this report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non-emergencynon‑emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self-payself‑pay accounts, as well as co-pay, co-insuranceco‑pay, co‑insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical-basedstatistical‑based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.


Over the longer term, several other initiatives we have previously announced should also help address this challenge.the challenges associated with serving uninsured patients. For example, our Compact with Uninsured Patients (“Compact”) is designed to offer managed care-stylecare‑style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. Under the Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-payself‑pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for self-payself‑pay accounts and other factors that affect the estimation process.

We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments
54

Table of Contents
are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.

The following table shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our health plan businesses) of caring for our uninsured and charity patients in the years ended December 31, 2019, 2018 and 2017.
  Years Ended December 31,
  2019 2018 2017
Estimated costs for:  
  
  
Uninsured patients $666
 $640
 $648
Charity care patients 156
 124
 121
Total $822
 $764
 $769

The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of states to expand Medicaid coverage and for persons living in the country who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.


The following table shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our now-divested health plan businesses) of caring for our uninsured and charity patients:
 Years Ended December 31,
 202120202019
Estimated costs for:   
Uninsured patients$650 $617 $664 
Charity care patients97 147 156 
Total$747 $764 $820 

RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 20192021 COMPARED TO THE YEAR ENDED DECEMBER 31, 20182020

The following two tables summarize our consolidated net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, for the years ended December 31, 20192021 and 2018.2020. We present metrics as a percentage of net operating revenues because a significant portion of our costs are variable.
 Years Ended December 31,Increase
(Decrease)
 20212020
Net operating revenues:   
Hospital Operations$15,982 $14,790 $1,192 
Ambulatory Care2,718 2,072 646 
Conifer1,267 1,306 (39)
Inter-segment eliminations(482)(528)46 
Net operating revenues $19,485 $17,640 $1,845 
Grant income191 882 (691)
Equity in earnings of unconsolidated affiliates218 169 49 
Operating expenses:   
Salaries, wages and benefits8,878 8,418 460 
Supplies3,328 2,982 346 
Other operating expenses, net4,206 4,125 81 
Depreciation and amortization855 857 (2)
Impairment and restructuring charges, and acquisition-related costs85 290 (205)
Litigation and investigation costs116 44 72 
Net gains on sales, consolidation and deconsolidation of facilities(445)(14)(431)
Operating income$2,871 $1,989 $882 

55

Table of Contents
Years Ended December 31,Increase
(Decrease)
Years Ended December 31, 20212020
2019 2018 
Increase
(Decrease)
Net operating revenues: 
  
  
Hospital Operations and other$15,522
 $15,285
 $237
Ambulatory Care2,158
 2,085
 73
Conifer1,372
 1,533
 (161)
Inter-segment eliminations(573) (590) 17
Net operating revenues 18,479
 18,313
 166
Net operating revenues100.0 %100.0 %— %
Grant incomeGrant income1.0 %5.0 %(4.0)%
Equity in earnings of unconsolidated affiliates175
 150
 25
Equity in earnings of unconsolidated affiliates1.1 %1.0 %0.1 %
Operating expenses: 
  
  
Operating expenses:
Salaries, wages and benefits8,704
 8,634
 70
Salaries, wages and benefits45.6 %47.8 %(2.2)%
Supplies3,057
 3,004
 53
Supplies17.1 %16.9 %0.2 %
Other operating expenses, net4,189
 4,256
 (67)Other operating expenses, net21.6 %23.4 %(1.8)%
Depreciation and amortization850
 802
 48
Depreciation and amortization4.4 %4.9 %(0.5)%
Impairment and restructuring charges, and acquisition-related costs185
 209
 (24)Impairment and restructuring charges, and acquisition-related costs0.4 %1.6 %(1.2)%
Litigation and investigation costs141
 38
 103
Litigation and investigation costs0.6 %0.2 %0.4 %
Net gains on sales, consolidation and deconsolidation of facilities15
 (127) 142
Net gains on sales, consolidation and deconsolidation of facilities(2.3)%(0.1)%(2.2)%
Operating income$1,513
 $1,647
 $(134)Operating income14.7 %11.3 %3.4 %

The following tables present our net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, by reportable segment for the years ended December 31, 2021 and 2020:
Year Ended December 31, 2021
 Hospital OperationsAmbulatory CareConifer
Net operating revenues $15,500 $2,718 $1,267 
Grant income142 49  
Equity in earnings of unconsolidated affiliates25 193  
Operating expenses:   
Salaries, wages and benefits7,511 690 677 
Supplies2,640 684 
Other operating expenses, net3,586 389 231 
Depreciation and amortization722 95 38 
Impairment and restructuring charges, and acquisition-related costs39 27 19 
Litigation and investigation costs100 14 
Net gains on sales, consolidation and deconsolidation of facilities(411)(34)— 
Operating income$1,480 $1,095 $296 

Year Ended December 31, 2021
 Hospital OperationsAmbulatory CareConifer
Net operating revenues 100.0 %100.0 %100.0 %
Grant income0.9 %1.8 %— %
Equity in earnings of unconsolidated affiliates0.2 %7.1 %— %
Operating expenses:
Salaries, wages and benefits48.5 %25.4 %53.4 %
Supplies17.0 %25.2 %0.3 %
Other operating expenses, net23.2 %14.3 %18.2 %
Depreciation and amortization4.7 %3.5 %3.0 %
Impairment and restructuring charges, and acquisition-related costs0.3 %1.0 %1.5 %
Litigation and investigation costs0.6 %0.5 %0.2 %
Net gains on sales, consolidation and deconsolidation of facilities(2.7)%(1.3)%— %
Operating income9.5 %40.3 %23.4 %

56

Table of Contents
Year Ended December 31, 2020
Hospital OperationsAmbulatory CareConifer
Years Ended December 31,
2019 2018 
Increase
(Decrease)
Net operating revenues100.0% 100.0 %  %Net operating revenues$14,262 $2,072 $1,306 
Grant incomeGrant income823 59  
Equity in earnings of unconsolidated affiliates0.9% 0.8 % 0.1 %Equity in earnings of unconsolidated affiliates6 163  
Operating expenses: 
  
  Operating expenses:
Salaries, wages and benefits47.1% 47.1 %  %Salaries, wages and benefits7,136 609 673 
Supplies16.5% 16.4 % 0.1 %Supplies2,511 468 
Other operating expenses, net22.6% 23.3 % (0.7)%Other operating expenses, net3,513 349 263 
Depreciation and amortization4.6% 4.4 % 0.2 %Depreciation and amortization739 81 37 
Impairment and restructuring charges, and acquisition-related costs1.0% 1.1 % (0.1)%Impairment and restructuring charges, and acquisition-related costs187 57 46 
Litigation and investigation costs0.8% 0.2 % 0.6 %Litigation and investigation costs33 
Net gains on sales, consolidation and deconsolidation of facilities0.1% (0.7)% 0.8 %
Net losses (gains) on sales, consolidation and deconsolidation of facilitiesNet losses (gains) on sales, consolidation and deconsolidation of facilities(15)— 
Operating income8.2% 9.0 % (0.8)%Operating income$971 $739 $279 

Year Ended December 31, 2020
Hospital OperationsAmbulatory CareConifer
Net operating revenues100.0 %100.0 %100.0 %
Grant income5.8 %2.8 %— %
Equity in earnings of unconsolidated affiliates— %7.9 %— %
Operating expenses:
Salaries, wages and benefits50.0 %29.4 %51.5 %
Supplies17.6 %22.6 %0.2 %
Other operating expenses, net24.7 %16.7 %20.2 %
Depreciation and amortization5.2 %3.9 %2.8 %
Impairment and restructuring charges, and acquisition-related costs1.3 %2.8 %3.5 %
Litigation and investigation costs0.2 %0.3 %0.4 %
Net losses (gains) on sales, consolidation and deconsolidation of facilities— %(0.7)%— %
Operating income6.8 %35.7 %21.4 %

Total net operating revenues increased by $166$1.845 billion, or 10.5%, for the year ended December 31, 2021 compared to the year ended December 31, 2020. Hospital Operations net operating revenues, net of inter‑segment eliminations, increased by $1.238 billion, or 8.7%, for the year ended December 31, 2021 compared to 2020, primarily due to increased patient volumes, higher patient acuity, a more favorable payer mix and improved terms of our managed care contracts, partially offset by the sale of our former Miami Hospitals in August 2021.

Ambulatory Care net operating revenues increased by $646 million, or 31.2%, for the year ended December 31, 2021 compared to 2020. The change was primarily due to an increase from acquisitions of $476 million and same-facility growth of $307 million, which was attributable to the impact of higher patient volumes and acuity, incremental revenue from new service lines and negotiated commercial rate increases. These impacts were partially offset by a decrease of $137 million due to the sale of the Ambulatory Care segment’s urgent care centers and the transfer of its imaging centers to the Hospital Operations segment.

Conifer net operating revenues decreased by $39 million, or 3.0%, for the year ended December 31, 2021 compared to 2020. Conifer revenues from third-party customers, which revenues are not eliminated in consolidation, increased $7 million, or 0.9%, for the year ended December 31, 20192021 compared to the year ended December 31, 2018. Hospital Operations and other net operating revenues net2020.

57

Table of inter-segment eliminations increased by $254 million, or 1.7%, for the year ended December 31, 2019 compared to the same period in 2018, primarily due to increased acuity and improved managed care pricing. Ambulatory Care net operating revenues increased by $73 million, or 3.5%, for the year ended December 31, 2019 compared to the prior-year period. This growth was driven by an increase in same-facility net operating revenues of $133 million and an increase from acquisitions of $109 million, partially offset by a decrease of $117 million due to the sale of Aspen and a decrease of $52 million due to the deconsolidation of a facility. Conifer net operating revenues decreased by $161 million, or 10.5%, for the year ended December 31, 2019 compared to 2018. Conifer revenues from third-party customers, which are not eliminated in consolidation, decreased $144 million, or 15.3%, for the year ended December 31, 2019 compared to the prior-year period. Conifer revenues from third-party customers were negatively impacted by contract terminations related to the sales of customer hospitals, partially offset by the impact of the divestiture of former Tenet facilities that have now become third-party customers.Contents

The following table shows selected operating expenses of our three reportable businessoperating segments. Information for our Hospital Operations and other segment is presented on a same-hospitalsame‑hospital basis, which includes the results ofwhereas information presented for our same 65 hospitals operated throughout the years ended December 31, 2019Ambulatory Care and 2018. Our same-hospital information excludes the results of two Philadelphia-area hospitals, which we divested effective January 11, 2018, MacNeal Hospital, which we divestedConifer segments is presented on a continuing operations basis.

effective March 1, 2018, Des Peres Hospital, which we divested effective May 1, 2018, and three Chicago-area hospitals, which we divested effective January 28, 2019. We present same-hospital data because we believe it provides investors with useful information regarding the performance of our hospitals and other operations that are comparable for the periods presented.
  Years Ended December 31,
Selected Operating Expenses 2019 2018 
Increase
(Decrease)
Hospital Operations and other — Same-Hospital  
  
  
Salaries, wages and benefits $7,326
 $6,888
 6.4 %
Supplies 2,602
 2,484
 4.8 %
Other operating expenses 3,578
 3,377
 6.0 %
Total $13,506
 $12,749
 5.9 %
Ambulatory Care  
  
  
Salaries, wages and benefits $635
 $644
 (1.4)%
Supplies 448
 430
 4.2 %
Other operating expenses 340
 359
 (5.3)%
Total $1,423
 $1,433
 (0.7)%
Conifer  
  
  
Salaries, wages and benefits $727
 $863
 (15.8)%
Supplies 4
 5
 (20.0)%
Other operating expenses 255
 308
 (17.2)%
Total $986
 $1,176
 (16.2)%
Total  
  
  
Salaries, wages and benefits $8,688
 $8,395
 3.5 %
Supplies 3,054
 2,919
 4.6 %
Other operating expenses 4,173
 4,044
 3.2 %
Total $15,915
 $15,358
 3.6 %
Rent/lease expense(1)
  
  
  
Hospital Operations and other $240
 $222
 8.1 %
Ambulatory Care 86
 80
 7.5 %
Conifer 11
 17
 (35.3)%
Total $337
 $319
 5.6 %
 Years Ended December 31,Increase
(Decrease)
Selected Operating Expenses20212020
Hospital Operations — Same-Hospital:   
Salaries, wages and benefits$7,227 $6,685 8.1 %
Supplies2,532 2,353 7.6 %
Other operating expenses3,375 3,229 4.5 %
Total$13,134 $12,267 7.1 %
Ambulatory Care:   
Salaries, wages and benefits$690 $609 13.3 %
Supplies684 468 46.2 %
Other operating expenses389 349 11.5 %
Total$1,763 $1,426 23.6 %
Conifer:   
Salaries, wages and benefits$677 $673 0.6 %
Supplies33.3 %
Other operating expenses231 263 (12.2)%
Total$912 $939 (2.9)%
Rent/lease expense(1):
   
Hospital Operations$280 $257 8.9 %
Ambulatory Care100 92 8.7 %
Conifer10 12 (16.7)%
Total$390 $361 8.0 %
(1)
(1)
Included in other operating expenses.


RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

Hospital Operations, and other, which is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, urgent care centers, micro-hospitalsmicro‑hospitals and physician practices. As described in Note 5 to the accompanying Consolidated Financial Statements, certain of our facilities were classified as held for sale at December 31, 2019.practices;

Our Ambulatory Care whichsegment is comprised of USPI’s ambulatory surgery centers, urgent care centers, imaging centersASCs and surgical hospitals (and also included nine facilities in the United Kingdom until we divested Aspen effective August 17, 2018).hospitals; and

Conifer, which provides revenue cycle management and value-basedvalue‑based care services to hospitals, healthcarehealth systems, physician practices, employers and other customers.  


clients.

58

Table of Contents
Hospital Operations andOther Segment

The following tables show operating statistics of our continuing operations hospitals and related outpatient facilities on a same-hospitalsame‑hospital basis, unless otherwise indicated, which includes the results of our same 65 hospitals operated throughout the years ended December 31, 2019 and 2018. Our same-hospital information excludes the results of two Philadelphia-area hospitals, which we divested effective January 11, 2018, MacNeal Hospital, which we divested effective March 1, 2018, Des Peres Hospital, which we divested effective May 1, 2018, and three Chicago-area hospitals, which we divested effective January 28, 2019. We present same-hospital data because we believe it provides investors with useful information regarding the performance of our hospitals and other operations that are comparable for the periods presented. We present certain metrics on a per-adjusted-patient-admission and per-adjusted-patient day basis to show trends other than volume. We present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable.indicated:
  
Same-Hospital
Continuing Operations  
  Years Ended December 31,
Admissions, Patient Days and Surgeries 2019 2018 
Increase
(Decrease)
Number of hospitals (at end of period) 65
 65
 
(1)
Total admissions 683,641
 668,120
 2.3 % 
Adjusted patient admissions(2) 
 1,222,856
 1,200,388
 1.9 % 
Paying admissions (excludes charity and uninsured) 642,303
 627,674
 2.3 % 
Charity and uninsured admissions 41,338
 40,446
 2.2 % 
Admissions through emergency department 489,570
 462,921
 5.8 % 
Paying admissions as a percentage of total admissions 94.0% 93.9% 0.1 %(1)
Charity and uninsured admissions as a percentage of total admissions 6.0% 6.1% (0.1)%(1)
Emergency department admissions as a percentage of total admissions 71.6% 69.3% 2.3 %(1)
Surgeries — inpatient 179,940
 180,038
 (0.1)% 
Surgeries — outpatient 240,221
 243,156
 (1.2)% 
Total surgeries 420,161
 423,194
 (0.7)% 
Patient days — total 3,181,793
 3,059,671
 4.0 % 
Adjusted patient days(2) 
 5,572,035
 5,403,457
 3.1 % 
Average length of stay (days) 4.65
 4.58
 1.5 % 
Licensed beds (at end of period) 17,210
 17,237
 (0.2)% 
Average licensed beds 17,215
 17,240
 (0.1)% 
Utilization of licensed beds(3) 
 50.6% 48.6% 2.0 %(1)
 Same-HospitalIncrease
(Decrease)
Years Ended December 31,
Admissions, Patient Days and Surgeries20212020
Number of hospitals (at end of period)60 60 — (1)
Total admissions547,754 548,569 (0.1)%
Adjusted patient admissions(2) 
973,552 950,789 2.4 %
Paying admissions (excludes charity and uninsured)518,515 518,042 0.1 %
Charity and uninsured admissions29,239 30,527 (4.2)%
Admissions through emergency department409,440 398,708 2.7 %
Paying admissions as a percentage of total admissions94.7 %94.4 %0.3 %(1)
Charity and uninsured admissions as a percentage of total admissions5.3 %5.6 %(0.3)%(1)
Emergency department admissions as a percentage of total admissions74.7 %72.7 %2.0 %(1)
Surgeries — inpatient141,469 144,421 (2.0)%
Surgeries — outpatient216,011 192,600 12.2 %
Total surgeries357,480 337,021 6.1 %
Patient days — total2,888,928 2,798,386 3.2 %
Adjusted patient days(2) 
5,016,029 4,707,262 6.6 %
Average length of stay (days)5.27 5.10 3.3 %
Licensed beds (at end of period)15,379 15,403 (0.2)%
Average licensed beds15,396 15,446 (0.3)%
Utilization of licensed beds(3) 
51.4 %49.5 %1.9 %(1)
(1)The change is the difference between 20192021 and 20182020 amounts shown.
(2)Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3)Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.

  
Same-Hospital
Continuing Operations
  Years Ended December 31,
Outpatient Visits 2019 2018 
Increase
(Decrease)
 
Total visits 6,755,166
 6,695,506
 0.9 % 
Paying visits (excludes charity and uninsured) 6,307,907
 6,251,409
 0.9 % 
Charity and uninsured visits 447,259
 444,097
 0.7 % 
Emergency department visits 2,561,805
 2,535,102
 1.1 % 
Surgery visits 240,221
 243,156
 (1.2)% 
Paying visits as a percentage of total visits 93.4% 93.4%  %(1)
Charity and uninsured visits as a percentage of total visits 6.6% 6.6%  %(1)
 Same-Hospital
 Years Ended December 31,Increase
(Decrease)
Outpatient Visits20212020
Total visits5,319,994 4,598,483 15.7 %
Paying visits (excludes charity and uninsured)4,964,084 4,285,043 15.8 %
Charity and uninsured visits355,910 313,440 13.5 %
Emergency department visits2,034,405 1,846,361 10.2 %
Surgery visits216,011 192,600 12.2 %
Paying visits as a percentage of total visits93.3 %93.2 %0.1 %(1)
Charity and uninsured visits as a percentage of total visits6.7 %6.8 %(0.1)%(1)
(1)The change is the difference between the 20192021 and 20182020 amounts shown.


59

Table of Contents
  
Same-Hospital
Continuing Operations
  Years Ended December 31,
Revenues 2019 2018 
Increase
(Decrease)
Total segment net operating revenues(1)
 $14,918
 $14,201
 5.0%
Selected revenue data – hospitals and related outpatient facilities      
Net patient service revenues(1)(2)
 $14,339
 $13,707
 4.6%
Net patient service revenue per adjusted patient admission(1)(2)
 $11,726
 $11,419
 2.7%
Net patient service revenue per adjusted patient day(1)(2)
 $2,573
 $2,537
 1.4%
 Same-Hospital
 Years Ended December 31,Increase
(Decrease)
Revenues20212020
Total segment net operating revenues(1)
$14,768 $13,272 11.3 %
Selected revenue data – hospitals and related outpatient facilities:
Net patient service revenues(1)(2)
$14,043 $12,655 11.0 %
Net patient service revenue per adjusted patient admission(1)(2)
$14,424 $13,310 8.4 %
Net patient service revenue per adjusted patient day(1)(2)
$2,800 $2,688 4.2 %
(1)
(1)Revenues are net of implicit price concessions.
(2)Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.

  
Same-Hospital
Continuing Operations
 
  Years Ended December 31, 
Total Segment Selected Operating Expenses 2019 2018 
Increase
(Decrease)
 
Salaries, wages and benefits as a percentage of net operating revenues 49.1% 48.5% 0.6 %(1)
Supplies as a percentage of net operating revenues 17.4% 17.5% (0.1)%(1)
Other operating expenses as a percentage of net operating revenues 24.0% 23.8% 0.2 %(1)
 Same-Hospital
 Years Ended December 31,Increase
(Decrease)
Total Segment Selected Operating Expenses20212020
Salaries, wages and benefits as a percentage of net operating revenues48.9 %50.4 %(1.5)%(1)
Supplies as a percentage of net operating revenues17.1 %17.7 %(0.6)%(1)
Other operating expenses as a percentage of net operating revenues22.9 %24.3 %(1.4)%(1)
(1)The change is the difference between the 20192021 and 20182020 amounts shown.

Revenues

Same-hospitalSame‑hospital net operating revenues increased $717 million,$1.496 billion, or 5.0%11.3%, during the year ended December 31, 20192021 compared to the year ended December 31, 2018,2020, primarily due to volume growth, increased patient and surgical volumes, higher patient acuity, a more favorable payer mix and improved terms of our managed care contracts. Same-hospitalnegotiated commercial rate increases. Our Hospital Operations segment also recognized grant income from federal, state and local grants totaling $142 million and $823 million in the years ended December 31, 2021 and 2020, respectively, which is not included in net operating revenues. Same‑hospital admissions increased 2.3% induring the year ended December 31, 2019 compared to the prior-year period. Same-hospital outpatient visits increased 0.9% in2021 were consistent with the year ended December 31, 2019 compared to the prior-year period.

2020, while outpatient visits increased 15.7% and same‑hospital adjusted admissions increased 2.4% year‑over‑year.

The following table shows the consolidated net accounts receivable by payer at December 31, 20192021 and 2018:
  December 31, 2019 December 31, 2018
Medicare $189
 $229
Medicaid 69
 74
Net cost report settlements receivable and valuation allowances 12
 18
Managed care 1,618
 1,467
Self-pay uninsured 25
 47
Self-pay balance after insurance 76
 94
Estimated future recoveries 162
 148
Other payers 337
 325
Total Hospital Operations and other 2,488
 2,402
Ambulatory Care 253
 191
Total discontinued operations 2
 2
  $2,743
 $2,595
2020:

December 31,
 20212020
Medicare$155 $152 
Medicaid47 49 
Net cost report settlements receivable and valuation allowances33 34 
Managed care1,602 1,567 
Self-pay uninsured21 32 
Self-pay balance after insurance70 74 
Estimated future recoveries137 156 
Other payers331 318 
Total Hospital Operations2,396 2,382 
Ambulatory Care374 307 
Total discontinued operations— 
Accounts receivable, net$2,770 $2,690 
When we have an unconditional right to payment, subject only to the passage of time, the right is treated as a receivable. Patient accounts receivable, including billed accounts and certain unbilled accounts, as well as estimated amounts due from third-party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. Estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts. Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations and other segment, our contract assets consist primarily of services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations and other segment’s contract assets are included in other current assets in the accompanying Consolidated Balance Sheet at December 31, 2019.

Collection of accounts receivable has been a key area of focus, particularly over the past several years. At December 31, 2019,2021, our Hospital Operations and other segment collection rate on self-payself‑pay accounts was approximately 22.5%26.5%. Our self-payself‑pay collection rate includes payments made by patients, including co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from uninsured patients and co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance at December 31, 2019,2021, a 10% decrease or increase in our self-payself‑pay collection rate, or approximately 2%3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $10$9 million. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and
60

Table of Contents
underinsured patients, the volume of patients through our emergency departments, the increased burden of co-paysco‑pays and deductibles to be made by patients with insurance, and business practices related to collection efforts. These factors, many of which have been affected by the COVID‑19 pandemic, continuously change and can have an impact on collection trends and our estimation process.

Payment pressure from managed care payers also affects the collectability of our accounts receivable. We typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations and other segment collection rate from managed care payers was approximately 98.0%96.6% at December 31, 2019.2021.

We manage our implicit price concessions using hospital-specifichospital‑specific goals and benchmarks such as (1) total cash collections, (2) point-of-servicepoint‑of‑service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations and other segment of $2.476$2.363 billion and $2.384$2.348 billion at December 31, 20192021 and 2018,2020, respectively, excluding cost report settlements receivable and valuation allowances of $12$33 million and $18$34 million, respectively, at December 31, 20192021 and 2018:2020:
MedicareMedicaidManaged
Care
Indemnity,
Self-Pay
and Other
Total
At December 31, 2021:
0-60 days93 %35 %57 %22 %52 %
61-120 days%31 %18 %14 %16 %
121-180 days%14 %10 %%%
Over 180 days%20 %15 %55 %23 %
Total 
100 %100 %100 %100 %100 %
At December 31, 2020:
0-60 days91 %33 %58 %24 %52 %
61-120 days%31 %15 %13 %14 %
121-180 days%14 %%%%
Over 180 days%22 %19 %55 %26 %
Total 
100 %100 %100 %100 %100 %

 December 31, 2019
 Medicare Medicaid 
Managed
Care
 
Indemnity,
Self-Pay
and Other
 Total
0-60 days91% 49% 56% 21% 51%
61-120 days5% 21% 16% 14% 15%
121-180 days2% 10% 10% 10% 9%
Over 180 days2% 20% 18% 55% 25%
Total 
100% 100% 100% 100% 100%
 December 31, 2018
 Medicare Medicaid 
Managed
Care
 
Indemnity,
Self-Pay
and Other
 Total
0-60 days89% 51% 60% 24% 54%
61-120 days6% 24% 14% 15% 14%
121-180 days2% 10% 8% 10% 8%
Over 180 days3% 15% 18% 51% 24%
Total 
100% 100% 100% 100% 100%

Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre-registration,pre‑registration, registration, verification of eligibility and benefits, liability identification and collections at point-of-service,point‑of‑service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

At December 31, 2019,2021, we had a cumulative total of patient account assignments to Conifer of $2.824$1.932 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables or in the allowance for doubtful accounts;receivables; however, an estimate of future recoveries from all the accounts assigned to Conifer is determined based on our historical experience and recorded in accounts receivable.

Patient advocates from Conifer’s Medicaid Eligibility Programand Enrollment Services program (“MEP”EES”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of

applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the MEP, withEES, net of appropriate contractual allowances recorded.implicit price concessions. Based on recent trends, approximately 96%97% of all accounts in the MEPEES are ultimately approved for benefits under a government program, such as Medicaid.

61

Table of Contents
The following table shows the approximate amount of accounts receivable in the MEPEES still awaiting determination of eligibility under a government program at December 31, 20192021 and 20182020 by aging category for the hospitals currently in the program: category:
December 31,
 20212020
0-60 days $87 $91 
61-120 days17 24 
121-180 days
Over 180 days
Total 
$115 $127 
 December 31,
 2019 2018
0-60 days $89
 $72
61-120 days11
 16
121-180 days4
 3
Over 180 days11
 5
Total 
$115
 $96

Salaries, Wages and Benefits

Same-hospitalSame‑hospital salaries, wages and benefits increased $542 million, or 8.1%, in the year ended December 31, 2021 compared to 2020. This increase was primarily attributable to higher patient volumes, increased contract labor costs, increased overtime expense, annual merit increases for certain of our employees and higher incentive compensation. Same‑hospital salaries, wages and benefits as a percentage of net operating revenues increaseddecreased by 60150 basis points to 49.1%48.9% in the year ended December 31, 2019 compared to the prior-year period. Same-hospital net operating revenues increased 5.0% in the year ended December 31, 20192021 compared to the year ended December 31, 2018, and same-hospital salaries, wages and benefits increased by 6.4% in the 2019 period compared to the 2018 period. The change in same-hospital salaries, wages and benefits as a percentage of net operating revenues was2020, primarily due to annual merit increases for certainhigher patient acuity and cost-reduction measures, including the use of our employees, a greater number of employed physicians and increased incentive compensation expense, partially offset by decreased health benefits costs, improved workers’ compensation experience and the impact of previously announced workforce reductionslabor management tools as part of our enterprise-wide cost reduction initiatives.volumes fluctuate. Salaries, wages and benefits expense for the yearsyear ended December 31, 20192021 and 20182020 included stock-basedstock‑based compensation expense of $30$41 million and $25$28 million, respectively.

Supplies

Same-hospitalSame‑hospital supplies expense increased $179 million, or 7.6%, in the year ended December 31, 2021 compared to 2020. The increase was primarily due to higher patient volumes, the increased cost of certain supplies as a result of the COVID‑19 pandemic and growth in our higher‑acuity, supply‑intensive surgical services. Same‑hospital supplies expense as a percentage of net operating revenues decreased by 1060 basis points to 17.4%17.1% in the year ended December 31, 20192021 compared to the 2018 period. Suppliesyear ended December 31, 2020, primarily due to the growth of our higher-margin services and our cost-efficiency measures.

The COVID‑19 pandemic has created supply‑chain disruptions, including shortages and delays, as well as significant price increases in medical supplies, particularly for PPE. We strive to control supplies expense was impacted by the benefitsthrough product standardization, consistent contract terms and end‑to‑end contract management, improved utilization, bulk purchases, focused spending with a smaller number of the group-purchasing strategiesvendors and supplies-management services we utilize to reduce costs, partially offset by increased costs from certain higher acuity supply-intensive surgical services.operational improvements. The items of current cost‑reduction focus include cardiac stents and pacemakers, orthopedics, implants and high‑cost pharmaceuticals.

Other Operating Expenses, Net

Same-hospitalSame‑hospital other operating expenses increased by $146 million, or 4.5%, in the year ended December 31, 2021 compared to 2020. Same‑hospital other operating expenses as a percentage of net operating revenues increaseddecreased by 20140 basis points to 24.0%22.9% in the year ended December 31, 20192021 compared to 23.8%24.3% in the 2018 period. Same-hospital other operating expenses increased by $201 million, or 6.0%, for the year ended December 31, 2019 compared2020, primarily due to higher patient volumes and the year ended December 31, 2018.growth of our net operating revenues. The changes in other operating expenses included:

increased medical fees of $88 million;

increased software costs of $22 million;

increased consulting and legal fees of $23 million;

decreased malpractice expense of $6$60 million;

increased rent and lease expense of $22 million;

increased collection fees of $19 million;

increased software costs of $17 million;

increased repair and maintenance costs of $17 million; and

decreased gainsa gain on asset salessale and leaseback of $21a medical office building of $12 million, compared to the 2018 period primarily related to the salewhich was classified as a reduction of an equity method investment in 2018.other operating expenses, net.

Same-hospital malpractice expense in the 2019 period included an unfavorable adjustment
62

Table of approximately $20 million from a 76 basis point decrease in the interest rate used to estimate the discounted present value of projected future malpractice liabilities compared to a favorable adjustment of approximately $10 million from an 26 basis point increase in the interest rate in the 2018 period.Contents


Ambulatory Care Segment

Our Ambulatory Care segment is comprised of USPI’s ambulatory surgery centers, urgent care centers, imaging centersASCs and surgical hospitals. Our Ambulatory Care segment also included nine facilities in the United Kingdom until we divested Aspen effective August 17, 2018. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a healthcarehealth system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. USPI operates facilities on a day-to-dayday‑to‑day basis through management services contracts. Our sources of earnings from each facility consist of:

management and administrative services revenues, computed as a percentage of each facility’s net revenues (often net of implicit price concessions); and

our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by USPI.

Our role as an owner and day-to-dayday‑to‑day manager provides us with significant influence over the operations of each facility. For many of the facilities our Ambulatory Care segment operates (108(166 of 346423 facilities at December 31, 2019)2021), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls 238 257of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than USPI is classified within “netnet income available to noncontrolling interests.

For unconsolidated affiliates, our consolidated statements of operations reflect our earnings in two line items:

equity in earnings of unconsolidated affiliates—our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by USPI; and

management and administrative services revenues, which is included in our net operating revenues—income we earn in exchange for managing the day‑to‑day operations of each facility, usually quantified as a percentage of each facility’s net revenues less implicit price concessions.

—our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by USPI; and

management and administrative services revenues, which is included in our net operating revenues—income we earn in exchange for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less implicit price concessions.

Our Ambulatory Care segment operating income is driven by the performance of all facilities USPI operates and by USPI’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 69%61% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses, which is why we disclose certain statistical and financial data on a pro forma systemwide basis that includes both consolidated and unconsolidated (equity method) facilities.

Year Ended December 31, 20192021 Compared to the Year Ended December 31, 20182020

The following table summarizes certain consolidated statements of operations items for the periods indicated:
 Years Ended December 31, Years Ended December 31,Increase (Decrease)
Ambulatory Care Results of Operations 2019 2018 Increase (Decrease)Ambulatory Care Results of Operations20212020
Net operating revenues $2,158
 $2,085
 3.5 %Net operating revenues$2,718 $2,072 31.2 %
Grant incomeGrant income$49 $59 (16.9)%
Equity in earnings of unconsolidated affiliates $160
 $140
 14.3 %Equity in earnings of unconsolidated affiliates$193 $163 18.4 %
Salaries, wages and benefits $635
 $644
 (1.4)%Salaries, wages and benefits$690 $609 13.3 %
Supplies $448
 $430
 4.2 %Supplies$684 $468 46.2 %
Other operating expenses, net $340
 $359
 (5.3)%Other operating expenses, net$389 $349 11.5 %

Revenues
Our Ambulatory Care net operating revenues increased by $73$646 million, or 3.5%31.2%, forduring the year ended December 31, 20192021 compared to 2020. The change was driven by an increase from acquisitions of $476 million, as well as an increase in same‑facility net operating revenues of $307 million, which was attributable to the impact of higher patient volumes and acuity, incremental revenue from new service lines and negotiated commercial rate increases. These impacts were partially offset by a decrease of $137 million, due primarily to the sale of USPI’s urgent care centers and the transfer of imaging centers to the Hospital Operations segment. Our Ambulatory Care segment also recognized grant income from federal grants totaling
63

Table of Contents
$49 million and $59 million during the years ended December 31, 2021 and 2020, respectively, which is not included in net operating revenues.

Salaries, Wages and Benefits
Salaries, wages and benefits expense increased by $81 million, or 13.3%, during the year ended December 31, 2018.2021 compared to 2020. Salaries, wages and benefits expense was impacted by an increase from acquisitions of $79 million and an increase in same‑facility salaries, wages and benefits expense of $57 million due primarily to higher surgical patient volumes. These increases were partially offset by a decrease of $55 million due to the sale of USPI’s urgent care centers, the transfer of imaging centers to the Hospital Operations segment and the deconsolidation of a facility. Salaries, wages and benefits expense as a percentage of net operating revenues decreased 400 basis points during the year ended December 31, 2021 compared to 2020. This growthdecrease was primarily attributable to higher surgical patient volumes and acuity, as well as staffing alignment and cost-reduction measures. Salaries, wages and benefits expense for the years ended December 31, 2021 and 2020 included stock‑based compensation expense of $13 million and $14 million, respectively.

Supplies
Supplies expense increased by $216 million, or 46.2%, during the year ended December 31, 2021 compared to 2020. The change was driven by an increase from acquisitions of $143 million, as well as an increase in same‑facility supplies expense of $82 million due primarily to an increase in surgical cases at our consolidated centers, higher costs driven by the higher level of patient acuity, and higher pricing of certain supplies as a result of the COVID‑19 pandemic, partially offset by a decrease of $9 million due to the sale of USPI’s urgent care centers, the transfer of imaging centers to the Hospital Operations segment and the deconsolidation of a facility. Supplies expense as a percentage of net operating revenues increased 260 basis points from 22.6% in the year ended December 31, 2020 to 25.2% in the year ended December 31, 2021. This change was driven by an increase in same-facility nethigher‑acuity, supply‑intensive surgeries and higher pricing of certain supplies as a result of the COVID‑19 pandemic.

Other Operating Expenses, Net
Other operating revenues of $133expenses increased by $40 million, andor 11.5%, during the year ended December 31, 2021 compared to 2020. The change was driven by an increase from acquisitions of $109$52 million, as well as an increase in same‑facility other operating expenses of $27 million, partially offset by a decrease of $117$39 million due to the sale of AspenUSPI’s urgent care centers and a decreasethe transfer of $52 million dueimaging centers to the deconsolidationHospital Operations segment. Other operating expenses, net as a percentage of a facility.


Salaries, wages and benefits expensenet operating revenues decreased by $9 million, or 1.4%, forfrom 16.7% during the year ended December 31, 2019 compared2020 to the year ended December 31, 2018. The change was driven by a decrease of $44 million14.3% for 2021, primarily due to the sale of Aspen and a decrease of $13 million due to the deconsolidation of a facility, partially offset byhigher patient volumes, an increase in same-facility salaries, wagesour net operating revenues and benefits expense of $19 million and an increase from acquisitions of $29 million.our cost-efficiency measures.

Supplies expense increased by $18 million, or 4.2%, for the year ended December 31, 2019 compared to the year ended December 31, 2018. The change was driven by an increase in same-facility supplies expense of $29 million and an increase from acquisitions of $28 million, partially offset by a decrease of $25 million due to the sale of Aspen and a decrease of $14 million due to the deconsolidation of a facility.

Other operating expenses decreased by $19 million, or 5.3%, for the year ended December 31, 2019 compared to the year ended December 31, 2018. The change was driven by a decrease of $32 million due to the sale of Aspen and a decrease of $10 million due to the deconsolidation of a facility, partially offset by an increase in same-facility other operating expenses of $3 million and an increase from acquisitions of $20 million.

Facility Growth

The following table summarizes the changes in our same-facilitysame‑facility revenue year-over-yearyear‑over‑year on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.
Ambulatory Care Facility GrowthYear Ended December 31, 20192021
Net revenues6.1%14.5%
Cases3.7%15.6%
Net revenue per case2.2%(1.0)%

64

Table of Contents
Joint Ventures with HealthcareHealth System Partners

USPI’s business model is to jointly own its facilities with local physicians and, in many of these facilities, a not-for-profit healthcarenot‑for‑profit health system partner. Accordingly, as of December 31, 2019,2021, the majority of facilities in our Ambulatory Care segment are operated in this model.

The table below summarizes the amounts we paid to acquire various ownership interests in ambulatory care facilities in the periods indicated:
 Years Ended December 31,Increase (Decrease)
Type of Ownership Interests Acquired20212020
Controlling interests$1,219 $1,175 $44 
Noncontrolling interests792455
Equity investment in unconsolidated affiliates and consolidated facilities17116
$1,315 $1,200 $115 

The table below provides information about the ownership structure of the facilities our Ambulatory Care segment operated at December 31, 2021:
Ambulatory Care FacilitiesDecember 31, 2021
Ownership Structure:
With a health system partner196 
Without a health system partner227 
Total facilities operated423

The table below reflects changes in the number of facilities operated during the year ended December 31, 2021:
Ambulatory Care FacilitiesYear Ended December 31, 20192021
Facilities:
With a healthcare system partner218
Without a healthcare system partner128
Total facilities operated346

Change from December 31, 20182020:
Acquisitions1091 
De novo7
Dispositions/Mergers(8(68))
Total increase in number of facilities operated279

Through our transaction with SCD in December 2021, we acquired majority ownership interests in six SCD Centers and minority ownership interests in 80 SCD Centers, along with other related ambulatory support services, for a cash payment of $1.048 billion. Since that initial closing, we have separately made offers, and continue to make offers in an ongoing process, to acquire a portion of the equity interests in certain of the SCD Centers from the physician owners for consideration of up to approximately $250 million; before the end of 2021, we had completed purchases of physician equity resulting in the consolidation in our financial statements of an additional 10 SCD Centers for aggregate payments of $77 million. At December 31, 2021, we held controlling interests in 15 SCD Centers and noncontrolling interests in 57 SCD Centers. The remaining 14 SCD Centers were acquired in the development stage and, therefore, are not included in total acquisitions in the table above. We cannot reasonably predict how many additional physician owners will accept our offers to acquire a portion of their equity, nor the timing or amount of any related payments. We will consolidate in our financial statements the results of the centers in which USPI acquires a majority ownership position.

During the year ended December 31, 2019,2021, we also acquired controlling interests in four ASCs in Maryland, two multi-specialty surgery centers in Virginia, multi-specialty surgery centers ineach of Florida, TennesseeGeorgia and Colorado, a surgical hospital in Texas, and a single-specialty endoscopy centerone in Florida.Arizona. We paid cash totaling approximately $15$73 million for these acquisitions. We alsoThe ASC acquired in Arizona and one of the Florida centers are jointly owned with a health system partner and physicians. The remaining nine ASCs are jointly owned with physicians. During 2021, we obtained a controlling interest in three multi-specialty surgery centers locatedsurgical hospitals in California and a single-specialty endoscopy center in Tennessee, as well as a multi-specialty surgery center in PennsylvaniaArizona in which we already had an equity method investment,previously owned a noncontrolling interest for cash totaling $4$13 million. AllWe own one of these acquired facilities are jointly ownedthe hospitals with local physicians, and a healthcarehealth system partner is an ownerand the remaining two hospitals with a health system and physician partners.

In addition to the those acquired through the SCD acquisition, we acquired noncontrolling interests in all of the facilities except thefour ASCs in Florida, two facilitiesASCs in Florida. AlsoNorth Carolina, and one each in New Mexico and Texas during the year ended December 31, 2019, we acquired noncontrolling interests in two multi-specialty surgery centers and a single-specialty endoscopy center, all of which are located in New Jersey.2021. We paid cash totaling approximately $11$79 million for these acquisitions. Following our initial investment, we purchased additional ownership interests. All threeinterests in two of these facilitiesthe ASCs in Florida for $8 million and subsequently consolidated them. We own the ASC
65

Table of Contents
acquired in New Mexico and one of the ASCs acquired in North Carolina jointly with a health system and physician partners, and the remaining six centers are jointly owned with local physicians and a healthcare system partner.physicians.

We also regularly engage in the purchase of equity interests with respect to our investments in unconsolidated affiliates and consolidated facilities that do not result in a change ofin control. These transactions are primarily the acquisitions of equity interests in ambulatory care facilitiesASCs and the investment of additional cash in facilities that need capital for new acquisitions, new

construction or other business growth opportunities. During the year ended December 31, 2019,2021, we invested approximately $14$17 million in such transactions.

During the year ended December 31, 2021, we transferred all 24 imaging centers held in our Ambulatory Care segment to our Hospital Operations segment, divested 40 urgent care centers and sold a portion of our ownership in two ASCs in which we previously had a controlling interest to a health system for approximately $12 million, resulting in the deconsolidation of those facilities.

Conifer Segment

Revenues
Our Conifer segment generated net operating revenues of $1.372$1.267 billion and $1.533$1.306 billion during the years ended December 31, 20192021 and 2018, respectively, a portion2020, respectively. The decline in Conifer’s net operating revenues of which$39 million, or 3.0%, was eliminated in consolidation as described in Note 23primarily due to the Consolidated Financial Statements.revised terms in the Amended RCM Agreement, partially offset by client volume improvement in 2021 compared to 2020, as well as new business expansion. Conifer revenues from third-partythird‑party customers, which revenues are not eliminated in consolidation, decreased $144increased $7 million, or 15.3%0.9%, for the year ended December 31, 20192021 compared to 2020. The increase was primarily driven by the prior-year period. Conifer revenues from third-party customers were negatively impactedtransition of the Miami Hospitals sold in August 2021 to a third‑party customer and new business expansion, partially offset by contract terminationsexpected client attrition.

The Amended RCM Agreement updated certain terms and conditions related to the sales of customer hospitals, partially offset by the impact of the divestiture of former Tenet facilities that have now become third-party customers.

Salaries, wages and benefits expense for Conifer decreased $136 million, or 15.8%, in the year ended December 31, 2019 compared to the year ended December 31, 2018 primarily due to the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives.

Other operating expenses for Conifer decreased $53 million, or 17.2%, in the year ended December 31, 2019 compared to the year ended December 31, 2018 primarily due to the impact of our enterprise-wide cost reduction initiatives.

Agreements document the current terms and conditions of variousrevenue cycle management services Conifer provides to Tenet hospitals, as well as certain administrative services our Hospital Operations and other segment provides to Conifer; however, execution of a restructured services agreement between Conifer and Tenet is a condition to completion of the proposed spin-off.hospitals. Conifer’s contract with Tenet represented 41.8%38.0% of the net operating revenues Conifer recognized in the year ended December 31, 2019.2021.

Salaries, Wages and Benefits
Salaries, wages and benefits expense for Conifer increased $4 million, or 0.6%, in the year ended December 31, 2021 compared to 2020. Salaries, wages and benefits expense included stock‑based compensation expense of $2 million in both 2021 and 2020.

Other Operating Expenses, Net
Other operating expenses for Conifer decreased $32 million, or 12.2%, in the year ended December 31, 2021 compared to 2020. This decrease was attributable to reduced pass-through costs associated with the Amended RCM Agreement and a reduction of legal expenses.

66

Table of Contents
Consolidated

Impairment and Restructuring Charges, and Acquisition-Related Costs

The following table provides information about our impairment and restructuring charges, and acquisition‑related costs:
During
Years Ended December 31,
20212020
Consolidated:  
Impairment charges$$92 
Restructuring charges57 184 
Acquisition-related costs20 14 
Total impairment and restructuring charges, and acquisition-related costs$85 $290 
By segment:
Hospital Operations$39 $187 
Ambulatory Care27 57 
Conifer19 46 
Total impairment and restructuring charges, and acquisition-related costs$85 $290 

Impairment charges for the year ended December 31, 2019, we recorded2021 were comprised of $5 million from our Ambulatory Care segment, primarily related to the impairment of certain management contract intangible assets, and restructuring$3 million from our Conifer segment. Restructuring charges and acquisition-related costs of $185 million, consisting of $42 million of impairment charges, $137 million of restructuring charges and $6 million of acquisition-related costs. Impairment chargesduring the year ended December 31, 2021 consisted of $26 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Memphis-area facilities and $16 million of other impairment charges. Restructuring charges consisted of $57$14 million of employee severance costs, $28$19 million related to the transition of various administrative functions to our Global Business Center in the Republic of the Philippines, $6 million of contractGBC and lease termination fees, and $46$24 million of other restructuring costs. Acquisition-relatedAcquisition‑related costs consisted of $6$20 million of transaction costs. Our impairment and restructuring charges and acquisition-related costs for the year ended December 31, 2019 were comprised of $111 million from our Hospital Operations and other segment, $18 million from our Ambulatory Care segment and $56 million from our Conifer segment.2021.

DuringImpairment charges during the year ended December 31, 2018, we recorded impairment and restructuring charges and acquisition-related costs of $209 million, consisting of $77 million of impairment charges, $115 million of restructuring charges and $17 million of acquisition-related costs. Impairment charges2020 primarily included $40$76 million for the write-downwrite‑down of hospital buildings and other long-lived assets to their estimated fair values at two hospitals.in one of our markets, which assets are part of our Hospital Operations segment. Material adverse trends in our then recent estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals’ long-livedlong‑lived assets was not recoverable from the estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. As a result, we updated the estimate of the fair value of the hospitals’ long-lived assets and compared the fair value estimateit to the aggregate carrying value of the hospitals’ long-livedthose assets. Because the fair value estimates were lower than the aggregate carrying value of the long-lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals’ assets held and used of the hospitals for which impairment charges were recorded was $130$483 million at December 31, 2018 after recording the impairment charges.2020. We also recorded $24 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Chicago-area facilities, $9 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen and $4$16 million of other impairment charges. For additional discussion see Note 6 to the accompanying Consolidated Financial Statements.

Restructuring charges for the year ended December 31, 2020 consisted of $68$65 million of employee severance costs, $17$50 million related to the transitioning of various administrative functions to our GBC, $23 million of charges due to the termination of the USPI management equity plan, $14 million of contract and lease termination fees, and $30$32 million of other restructuring costs. Acquisition-relatedAcquisition‑related costs consisted of $10$14 million of transaction costs and $7 million of acquisition integration charges. Our impairment and restructuring charges and acquisition-related costs for the year ended December 31, 2018 were comprised of $141 million from our Hospital Operations and other segment, $28 million from our Ambulatory Care segment and $40 million from our Conifer segment.2020.


Our impairment tests presume stable, improving or, in some cases, declining operating results in our hospitals,facilities, which are based on programs and initiatives being implemented that are designed to achieve the hospital’seach facility’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, future impairments of long-livedlong‑lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

Litigation and Investigation Costs

Litigation and investigation costs for the years ended December 31, 20192021 and 20182020 were $141$116 million and $38$44 million, respectively, primarily related to costcosts associated with significant legal proceedings and governmental investigations. See Note 17 to the accompanying Consolidated Financial Statements for additional information.

67

Table of Contents
Net Gains(Losses)Gains on Sales, Consolidation and Deconsolidation of Facilities

During the year ended December 31, 2019, we recorded net losses on sales, consolidation and deconsolidation of facilities of $15 million, primarily comprised of a loss on sale of $14 million related to the sale of three of our hospitals in the Chicago area, as well as other operations affiliated with the hospitals.

During the year ended December 31, 2018,2021, we recorded net gains on sales, consolidation and deconsolidation of facilities of $127$445 million, primarily comprised of gainsa gain of $36$406 million fromrelated to the sale of our health planthe Miami Hospitals in California, $90August 2021, a gain of $14 million fromrelated to the sale of MacNeal Hospital and other operations affiliated with the hospital in the Chicago area, $11 million from the salesmajority of our minority interestsurgent care centers in four North Texas hospitalsApril 2021, net gains of $22 million related to consolidation changes of certain USPI businesses due to ownership changes and $12net gains of $3 million fromrelated to other activity.

During the sale of Des Peres Hospital, physician practices and other hospital-affiliated operations in St. Louis, Missouri, as well asyear ended December 31, 2020, we recorded net gains on sales, consolidation and deconsolidation of $8facilities of $14 million, from our Ambulatory Care segment,primarily comprised of aggregate gains of $15 million related to consolidation changes of certain USPI businesses due to ownership changes and a gain of $7 million related to post‑closing adjustments on the 2017 sale of facilities in the Houston area, partially offset by lossesa loss of $21$5 million fromrelated to post‑closing adjustments on the 2019 sale of three of our hospitals physician practices and related assets in Philadelphia, Pennsylvania and the surroundingChicago area and $10a loss of $3 million due to post-closing adjustments related to post‑closing adjustments on the 2018 sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area.MacNeal Hospital.

Interest Expense

Interest expense for the year ended December 31, 20192021 was $985$923 million compared to $1.004$1.003 billion for the year ended December 31, 2018.2020, primarily due to the early redemption of all $1.410 billion aggregate principal amount outstanding of our 5.125% senior secured second lien notes due 2025 (the “2025 Senior Secured Second Lien Notes”) in June 2021 and early retirement of all $478 million aggregate principal amount outstanding of our 7.000% senior unsecured notes due 2025 (“2025 Senior Unsecured Notes”) in March 2021.

Loss from Early Extinguishment of Debt
Loss from early extinguishment of debt was $74 million for the year ended December 31, 2021 and consisted of aggregate losses incurred from the redemption of our 4.625% senior secured first lien notes due 2024 (“2024 Senior Secured First Lien Notes”) in September 2021, the redemption of our 2025 Senior Secured Second Lien Notes in June 2021 and the retirement of our 2025 Senior Unsecured Notes in March 2021, all in advance of their respective maturity dates. See Note 8to the accompanying Consolidated Financial Statements for additional information.

Loss from early extinguishment of debt was $316 million for the year ended December 31, 2020 and consisted of an aggregate loss of $320 million from the redemption and purchase of our 8.125% senior unsecured notes due 2022, partially offset by $4 million of gains on the extinguishment of mortgage notes.

Income Tax Expense

During the year ended December 31, 2019,2021, we recorded income tax expense of $153$411 million in continuing operations on pre-taxpre‑tax income of $296 million$1.888 billion compared to an income tax expensebenefit of $176$97 million in continuing operations on pre-taxpre‑tax income of $639$671 million during the year ended December 31, 2018. 2020.

The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown in the following table:
 Years Ended December 31,
 20212020
Tax expense at statutory federal rate of 21%$396 $141 
State income taxes, net of federal income tax benefit77 33 
Expired state net operating losses, net of federal income tax benefit— 
Tax benefit attributable to noncontrolling interests(114)(75)
Nondeductible goodwill35 — 
Nondeductible executive compensation
Nondeductible litigation costs— 
Expired charitable contribution carryforward— 
Stock-based compensation tax benefits(5)(2)
Changes in valuation allowance(226)
Prior-year provision to return adjustments and other changes in deferred taxes14 
Other items10 
Income tax expense (benefit)$411 $(97)

68

Table of Contents
 Years Ended December 31,
 2019 2018
Tax expense (benefit) at statutory federal rate of 21%$62
 $134
State income taxes, net of federal income tax benefit20
 23
Expired state net operating losses, net of federal income tax benefit2
 9
Tax attributable to noncontrolling interests(79) (70)
Nondeductible goodwill4
 8
Nondeductible executive compensation6
 4
Nondeductible litigation costs7
 
Expired charitable contribution carryforward8
 
Impact of decrease in federal tax rate on deferred taxes
 (1)
Reversal of permanent reinvestment assumption and other adjustments related to divestiture of foreign subsidiary
 (6)
Stock-based compensation tax deficiencies4
 5
Changes in valuation allowance133
 76
Change in tax contingency reserves, including interest(14) (1)
Prior-year provision to return adjustments and other changes in deferred taxes(3) (5)
Other items3
 
Income tax expense$153
 $176
As a result of the change in the business interest expense disallowance rules under the COVID Acts, we recorded an income tax benefit of $88 million during the year ended December 31, 2020 to decrease the valuation allowance for interest expense and carryforwards due to the additional deduction of interest expense. In September 2020, we filed an application with the Internal Revenue Services (“IRS”) to change our method of accounting for certain capitalized costs on our 2019 tax return. This change in tax accounting method resulted in additional interest expense being allowed on our 2019 and 2020 tax returns. We reduced our valuation allowance by an additional $126 million in the year ended December 31, 2020 related to the change in tax accounting method. Charitable contribution carryforward and state valuation allowance changes resulted in an additional $12 million decrease for the year ended December 31, 2020.


Net Income Available to Noncontrolling Interests

Net income available to noncontrolling interests was $386$562 million for the year ended December 31, 20192021 compared to $355$369 million for the year ended December 31, 2018.2020. Net income available (loss attributable) to noncontrolling interests in the 2019 period2021 was comprised of $(21)$448 million related to our Hospital Operations and other segment, $337 millionof income related to our Ambulatory Care segment, and $70$69 million of income related to our Conifer segment and $45 million of income related to our Hospital Operations segment. Of the portion related to our Ambulatory Care segment, $10$21 million of income was related to the minority interests in USPI.

ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

The financial information provided throughout this report, including our Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non-GAAPnon‑GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non-GAAPnon‑GAAP measure defined by the Companywe define as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating expense,non‑operating income (expense), net, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-relatedacquisition‑related costs, (11) depreciation and amortization, and (12) income (loss) from divested and closed businesses (i.e., our health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

The Company believesWe believe the foregoing non-GAAPnon‑GAAP measure is useful to investors and analysts because it presents additional information about the Company’sour financial performance. Investors, analysts, Companycompany management and the Company’sour board of directors utilize this non-GAAPnon‑GAAP measure, in addition to GAAP measures, to track the Company’sour financial and operating performance and compare the Company’sthat performance to peer companies, which utilize similar non-GAAPnon‑GAAP measures in their presentations. The human resources committee of the Company’sour board of directors also uses certain non-GAAPnon‑GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. The Company believesWe believe that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non-GAAPnon‑GAAP measures, as factors in determining the estimated fair value of shares of the Company’sour common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company doesWe do not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non-GAAPnon‑GAAP Adjusted EBITDA measure the Company utilizeswe utilize may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’sour financial performance.


69

Table of Contents
The following table shows the reconciliation of Adjusted EBITDA to net income available (loss attributable) to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the years ended December 31, 20192021 and 2018:
2020:
  Years Ended December 31,
  2019 2018
Net income available (loss attributable) to Tenet Healthcare Corporation
common shareholders
 $(232) $111
Less: Net income available to noncontrolling interests (386) (355)
Income from discontinued operations, net of tax 11
 3
Income from continuing operations 143
 463
Income tax expense (153) (176)
Gain (loss) from early extinguishment of debt (227) 1
Other non-operating expense, net (5) (5)
Interest expense (985) (1,004)
Operating income 1,513
 1,647
Litigation and investigation costs (141) (38)
Net gains (losses) on sales, consolidation and deconsolidation of facilities (15) 127
Impairment and restructuring charges, and acquisition-related costs (185) (209)
Depreciation and amortization (850) (802)
Income (loss) from divested and closed businesses (i.e., the Company’s
health plan businesses)
 (2) 9
Adjusted EBITDA $2,706
 $2,560
     
Net operating revenues $18,479
 $18,313
Less: Net operating revenues from health plans 1
 14
Adjusted net operating revenues $18,478
 $18,299
     
Net income available (loss attributable) to Tenet Healthcare Corporation
common shareholders as a % of net operating revenues
 (1.3)% 0.6%
     
Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin)  14.6 % 14.0%

 Years Ended December 31,
 20212020
Net income available to Tenet Healthcare Corporation common shareholders$914 $399 
Less: Net income available to noncontrolling interests(562)(369)
Loss from discontinued operations, net of tax(1)— 
Income from continuing operations1,477 768 
Income tax benefit (expense)(411)97 
Loss from early extinguishment of debt(74)(316)
Other non-operating income, net14 
Interest expense(923)(1,003)
Operating income2,871 1,989 
Litigation and investigation costs(116)(44)
Net gains on sales, consolidation and deconsolidation of facilities445 14 
Impairment and restructuring charges, and acquisition-related costs(85)(290)
Depreciation and amortization(855)(857)
Income (loss) from divested and closed businesses (i.e. health plan businesses)(1)20 
Adjusted EBITDA$3,483 $3,146 
Net operating revenues$19,485 $17,640 
Less: Net operating revenues from health plans 21 
Adjusted net operating revenues$19,485 $17,619 
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues4.7 %2.3 %
Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin) 17.9 %17.9 %

RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 20182020 COMPARED TO THE YEAR ENDED DECEMBER 31, 2017

2019
A discussion of the results of operations for the year ended December 31, 20182020 compared to the year ended December 31, 20172019 can be found in our Annual Report on Form 10-K10‑K for the year ended December 31, 2018.2020.



70

Table of Contents
LIQUIDITY AND CAPITAL RESOURCES

CASH REQUIREMENTS

Scheduled Contractual Obligations
Our obligations to make future cash payments under contracts such as debt and lease agreements, and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, are summarized in the table below, all as of December 31, 2019:2021. Other than the repayment of long-term debt, we expect to use net cash generated from operating activities, cash on hand or borrowings under our revolving credit facility to satisfy the below obligations. Long‑term debt maturities may be refinanced or repaid using net cash generated from operating activities or from the proceeds from sales of facilities.
 Total Years Ended December 31, Later Years
  2020 2021 2022 2023 2024 
 (In Millions)
Long-term debt(1)
$19,077
 $895
 $898
 $3,579
 $2,480
 $3,000
 $8,225
Capital lease obligations(1)
387
 143
 96
 38
 10
 9
 91
Long-term non-cancelable operating leases(1)
1,264
 159
 180
 160
 140
 121
 504
Standby letters of credit93
 93
 
 
 
 
 
Guarantees(2)
192
 87
 40
 20
 10
 6
 29
Asset retirement obligations159
 
 
 
 
 
 159
Academic affiliation agreements(3)
73
 38
 18
 17
 
 
 
Tax liabilities5
 
 
 
 
 
 5
Defined benefit plan obligations531
 19
 23
 23
 23
 23
 420
Information technology contract services1,172
 278
 291
 241
 213
 139
 10
Purchase orders316
 316
 
 
 
 
 
Total(4)
$23,269
 $2,028
 $1,546
 $4,078
 $2,876
 $3,298
 $9,443
 TotalYears Ended December 31,Later Years
 20222023202420252026
 (In Millions)
Long-term debt(1)
$19,986 $851 $2,698 $2,121 $1,359 $2,664 $10,293 
Finance lease obligations(1)
350 116 76 48 16 11 83 
Long-term non-cancelable operating leases1,368 236 211 185 156 124 456 
Medicare accelerated payment program880 880 — — — — — 
Academic teaching services315 63 63 63 63 63 — 
Defined benefit plan obligations486 25 23 23 23 23 369 
Information technology contract services546 214 203 119 
Purchase orders335 335 — — — — — 
Total$24,266 $2,720 $3,274 $2,559 $1,619 $2,887 $11,207 

(1)Includes interest through maturity date/lease termination.
(2)(1)Includes minimum revenue guarantees, primarily related to physicians under relocation agreementsAmounts include both principal and physician groups that provide services at our hospitals, and operating lease guarantees.interest.
(3)These agreements contain various rights and termination provisions.
(4)Professional liability and workers’ compensation reserves, and our obligations under the Baylor Put/Call Agreement, as defined and described in Note 18 to our Consolidated Financial Statements, have been excluded from the table. At December 31, 2019, the current and long-term professional and general liability reserves included in our Consolidated Balance Sheet were $330 million and $585 million, respectively, and the current and long-term workers’ compensation reserves included in our Consolidated Balance Sheet were $40 million and $124 million, respectively. Redeemable noncontrolling interests in USPI that are subject to the Baylor Put/Call Agreement totaled $214 million at December 31, 2019.


Long-term Debt—We have a senior secured revolving credit facility (as amended to date, the “Credit Agreement”) that provides for revolving loans in an aggregate principal amount of up to $1.900 billion with a $200 million subfacility for standby letters of credit. Any amounts outstanding under the Credit Agreement are due upon the facility’s maturity in September 2024. At December 31, 2021, we had no cash borrowings outstanding under the Credit Agreement and less than $1 million of standby letters of credit outstanding.

At December 31, 2021, we had outstanding senior unsecured and senior secured notes (“Senior Notes”) with an aggregate principal balance of $15.354 billion. The Senior Notes generally require semi‑annual interest payments and have maturity dates ranging from 2023 through 2031. Any outstanding principal and accrued but unpaid interest is due upon maturity.

We consummated the following transactions affecting our long‑term commitments in the year ended December 31, 2021:

In December 2021, we issued $1.450 billion aggregate principal amount of our 2030 Senior Secured First Lien Notes. We will pay interest on these notes semi‑annually in arrears on January 15 and July 15 of each year, commencing in July 2022. We used the net proceeds from the issuance of the 2030 Senior Secured First Lien Notes, after payment of fees and expenses, to finance the acquisition of the SCD Centers in December 2021 and for general corporate purposes.

In September 2021, we redeemed approximately $1.100 billion of the then‑outstanding $1.870 billion aggregate principal amount of our 2024 Senior Secured First Lien Notes in advance of their maturity date. We paid $1.113 billion to redeem the notes, which was primarily funded with the proceeds from the sale of the Miami Hospitals in August 2021. In connection with the redemption, we recorded a loss from early extinguishment of debt of $20 million in the three months ended September 30, 2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

In June 2021, we issued $1.400 billion aggregate principal amount of our 2029 Senior Secured First Lien Notes. We pay interest on the 2029 Senior Secured First Lien Notes semi‑annually in arrears on June 1 and December 1 of each year, which payments commenced in December 2021. The proceeds from the sale of the 2029 Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $1.410 billion aggregate principal amount then outstanding of our 2025 Senior Secured Second Lien Notes in advance of their maturity date for approximately $1.428 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $31 million in the three
71

Table of Contents
months ended June 30, 2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write‑off of associated unamortized issuance costs.

In March 2021, we retired all $478 million aggregate principal amount outstanding of our 2025 Senior Unsecured Notes in advance of their maturity date. We paid approximately $495 million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $23 million in the three months ended March 31, 2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

At December 31, 2021, using the last 12 months of Adjusted EBITDA, our ratio of total long‑term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 3.81x, or 4.07x if adjusted to include outstanding obligations arising from cash advances received from Medicare pursuant to the COVID Acts. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our revolving credit facility as a source of liquidity and acquisitions that involve the assumption of long‑term debt. We seek to manage this ratio and increase the efficiency of our balance sheet by following our business plan and managing our cost structure, including through possible asset divestitures, and through other changes in our capital structure. As part of our long‑term objective to manage our capital structure, we continue to evaluate opportunities to retire, purchase, redeem and refinance outstanding debt subject to prevailing market conditions, our liquidity requirements, operating results, contractual restrictions and other factors. In the year ending December 31, 2023 and beyond, we may also consider share repurchases depending on market conditions and other investment opportunities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward‑Looking Statements and Risk Factors sections in Part I of this report.

Interest payments, net of capitalized interest, were $937 million, $962 million and $946 million in the years ended December 31, 2021, 2020 and 2019, respectively. For the year ending December 31, 2022, we expect annual interest payments to be approximately $850 million to $860 million.

On February 9, 2022, we called for the redemption of all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes. We anticipate redeeming the notes using cash on hand. We expect this transaction will lower our annual cash interest payments by approximately $53 million, which savings are reflected in the expected annual interest payments above.

Future maturities of our long-term debt obligations are summarized in the table above. See Note 8 to the accompanying Consolidated Financial Statements for additional information about our long‑term debt obligations.

Lease Obligations—We have operating lease agreements primarily for real estate, including off‑campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as for medical office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. As of December 31, 2021, we had fixed payment obligations of $1.407 billion under non‑cancellable lease agreements. Future payments due in connection with our operating and finance leases, including imputed interest, are summarized in the table above. Additional information about our lease commitments is provided in Note 7 to the accompanying Consolidated Financial Statements.

Medicare Accelerated Payment Program—As further discussed in Note 1 to the accompanying Consolidated Financial Statements, we received advance payments from the Medicare accelerated payment program following its expansion under the COVID Acts. As of December 31, 2021, we had a liability of $880 million related to advances received under the Medicare accelerated payment program that will be recouped during the year ending December 31, 2022 through reductions of our Medicare claims payments.

Academic Teaching Services—We enter into contracts for academic teaching services with university and physician groups to support graduate medical education. These agreements contain various rights and termination provisions.

Defined Benefit Obligations—We maintain three frozen, non‑qualified defined benefit plans that provide supplemental retirement benefits to certain of our current and former executives. These plans are unfunded, and plan obligations are paid from our working capital. We also maintain a frozen, qualified defined benefit plan that benefits certain of our employees in Detroit. See Note 10 to the accompanying Consolidated Financial Statements for additional information about our defined benefit plans.

72

Table of Contents
Information Technology Contracts—We enter into various non‑cancellable contracts for information technology services and licenses as a normal part of our business. These contracts generally relate to information technology infrastructure support and services, software licenses for certain operational and administrative systems, and cybersecurity‑related software and services.

Purchase Orders—We had outstanding short‑term purchase commitments of $335 million at December 31, 2021, which we expect to pay within 12 months.

Other Contractual Obligations
Asset Retirement Obligations—Asset retirement obligations represent the estimated costs to perform environmental remediation work, which we are legally obligated to complete, at certain of our facilities upon their retirement. This work could include asbestos abatement, the removal of underground storage tanks and other similar activities. At December 31, 2021, the undiscounted aggregate future estimated payments related to these obligations was $185 million. We are unable to predict the timing of these payments due to the uncertainty and long timeframes inherent in these obligations.

Standby Letters of Credit—Standby letters of credit are required principally by our insurers and various states to collateralize our workers’ compensation programs pursuant to statutory requirements and as security to collateralize the deductible and self-insuredself‑insured retentions under certain of our professional and general liability insurance programs. The amount of collateral required is primarily dependent upon the level of claims activity and our creditworthiness. The insurers require the collateral in case we are unable to meet our obligations to claimants within the deductible or self-insuredself‑insured retention layers.

We consummatedhave a letter of credit facility (as amended, the following transactions affecting our long-term commitments in“LC Facility”) that provides for the year ended December 31, 2019:

On August 26, 2019, we sold $600 millionissuance of standby and documentary letters of credit. The aggregate principal amount of 4.625% senior secured first lien notes, whichletters of credit that from time to time may be issued under the LC Facility is $200 million. Drawings under any letter of credit issued under the LC Facility accrue interest if not reimbursed within three business days. At December 31, 2021, we had $139 million of standby letters of credit outstanding under the LC Facility. The timing of reimbursement payments is uncertain, as we cannot foresee when, or if, a standby letter of credit will mature on September 1, 2024 (the “2024 Senior Secured First Lien Notes”), $2.1 billion aggregate principalbe drawn upon.

Guarantees—Our guarantees include minimum revenue guarantees, primarily related to physicians under relocation agreements and physician groups that provide services at our hospitals, as well as operating lease guarantees. At December 31, 2021, the maximum potential amount of 4.875% senior secured first lien notes,future payments under these guarantees was $216 million, of which will mature on January 1, 2026 (the “2026 Senior Secured First Lien Notes”)$116 million were recorded in the accompanying Consolidated Balance Sheet at December 31, 2021. The timing and $1.5 billion aggregate principal amount of 5.125% senior secured first lien notes, which will maturefuture payments under these guarantees is uncertain.

Professional and General Liability Obligations—At December 31, 2021, the current and long‑term professional and general liability reserves included in our Consolidated Balance Sheet were $254 million and $791 million, respectively, and the current and long‑term workers’ compensation reserves included in our Consolidated Balance Sheet were $43 million and $107 million, respectively. The timing of professional and general liability payments is uncertain as such payments depend on Novemberseveral factors, including the nature of claims and when they are received.

Baylor Put/Call Agreement—As further discussed in Note 18 to the accompanying Consolidated Financial Statements, we have a put/call agreement with Baylor with respect to Baylor’s 5% ownership in USPI. Each year starting in 2021, Baylor may put up to one‑third of its total shares in USPI held as of April 1, 20272017 (the “2027 Senior Secured First Lien Notes”“Baylor Shares”). The proceeds from by delivering notice by the salesend of these notes were used, after paymentJanuary of fees and expenses, together with cash on hand and borrowings under our senior secured revolving credit facility, to fundsuch year. In each year that Baylor does not put the redemptionsfull 33.3% of all $500 million aggregate principal amount of our outstanding 4.750% senior secured first lien notes due 2020, all $1.8 billion aggregate principal amount of our outstanding 6.000% senior secured first lien notes due 2020, all $850 million aggregate principal amount of our outstanding 4.500% senior secured first lien notes due 2021 and all $1.05 billion aggregate principal amount of our outstanding 4.375% senior secured first lien notes due 2021. In connection with the redemptions,USPI’s shares allowable, we recorded a loss from early extinguishment of debt of approximately $180 million in the three months ended September 30, 2019, primarily related tomay call the difference between the redemption pricesnumber of shares Baylor put and the par valuesmaximum number of shares it could have put that year. In addition, the Baylor Put/Call Agreement contains a call option pursuant to which we have the ability to acquire all of Baylor’s ownership interest by 2024. We have the ability to choose whether to settle the purchase price for the Baylor put/call, which is mutually agreed‑upon fair market value, in cash or shares of our common stock. The carrying value of the notes, as well asredeemable noncontrolling interests in USPI that are subject to the write-offBaylor Put/Call Agreement was $258 million at December 31, 2021.

Baylor did not deliver a put notice to us in January 2021 or January 2022. In February 2021, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the associated unamortized issuance costs.


OnBaylor Shares. We are continuing to negotiate the terms of that purchase. In addition, in February 5, 2019,2022, we sold $1.5 billion aggregate principal amountnotified Baylor of 6.250% senior secured second lien notes, which will mature on February 1, 2027 (the “2027 Senior Secured Second Lien Notes”). The proceeds from the saleour intention to again exercise our call option to purchase an additional 33.3% of the 2027 Senior Secured Second Lien Notes were used, after paymentBaylor Shares. The amount and timing of fees and expenses, together with cash on hand and borrowings under our senior secured revolving credit facility,the payments related to fund the redemption of all $300 million aggregate principal amountexercise of our outstanding 6.750% senior notes due 2020call options in 2021 and all $750 million aggregate principal amount of our outstanding 7.500% senior secured second lien notes due 2022, as well as payments related to future put or call decisions under the repayment upon maturityBaylor Put/Call Agreement, are currently uncertain.

73

Table of all $468 million aggregate principalContents
SCD Development Agreement—In November 2021, USPI and SCD’s principals entered into a joint venture and development agreement under which USPI will have the exclusive option to partner with affiliates of SCD on the future development of a minimum target of 50 de novo ASCs over a period of five years. The timing and amount of our outstanding 5.500% senior unsecured notes due March 1, 2019. In connection with the redemptions, we recorded a loss from early extinguishment of debt of approximately $47 million in the three months ended March 31, 2019, primarilypayments related to the difference betweendevelopment of these facilities is currently unknown.

Investment in the redemption pricesSCD Centers—Beginning in December 2021, USPI made offers, and the par valuesit continues to make offers in an ongoing process, to acquire a portion of the notes, as well as the write-offequity interests in certain of the associated unamortized issuance costs.SCD Centers from the physician owners for consideration of up to approximately $250 million. Before the end of 2021, we made aggregate payments of $77 million to acquire majority ownership interests in 10 SCD Centers. We cannot reasonably predict how many additional physician owners will accept our offers to acquire a portion of their equity, nor the timing or amount of any remaining payments. We expect to fund these payments using cash on hand.

AtOther than the obligations described above, we had no off‑balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources at December 31, 2019, using the last 12 months of Adjusted EBITDA, our ratio of total long-term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 5.35x. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our revolving credit facility as a source of liquidity and acquisitions that involve the assumption of long-term debt. We seek to manage this ratio and increase the efficiency of our balance sheet by following our business plan and managing our cost structure, including through possible asset divestitures, and through other changes in our capital structure. As part of our long-term objective to manage our capital structure, we may issue equity or convertible securities, and we may seek to retire, purchase, redeem or refinance some of our outstanding debt or equity securities, in each case subject to prevailing market conditions, our liquidity requirements, operating results, contractual restrictions and other factors. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward-Looking Statements and Risk Factors sections in Part I of this report.2021.

Other Cash Requirements
Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements, introduction of new medical technologies, design and construction of new buildings, and various other capital improvements, as well as commitments to make capital expenditures in connection with acquisitions of businesses. Capital expenditures were $670$658 million, $617$540 million and $707$670 million in the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 20202022 will total approximately $700$725 million to $750$775 million, including $136$95 million that was accrued as a liability at December 31, 2019. We have been granted2021.

As previously reported, we are building a certificate of need, which is no longer subject to additional legal challenges or further appeals, to construct100‑bed acute‑care hospital and a 100-bed acute care hospitalmedical office building in Fort Mill, South Carolina. We are in the development and design stage for the new hospital, andCarolina, which we expect to submit our plans for approval toopen in August 2022. We expect construction of the South Carolina Department of Health and Environment Control this year. Once approved, the construction is expected to take up to two years andFort Mill campus will cost approximately $150 million over the construction period.

Interest payments, netperiod, of capitalized interest, were $946which $51 million $976 million and $939 million in the years endedwas expended as of December 31, 2019, 20182021. In San Antonio, we are planning to break ground on a new healthcare campus in Westover Hills in 2022, inclusive of a hospital, ASC and 2017, respectively. Formedical office space. We expect construction of the year ending December 31, 2020, we expect annual interest payments to beWestover Hills facilities will cost approximately $935$260 million to $945 million.over the construction period.

Income tax payments, net of tax refunds, were $92 million in year ended December 31, 2021 and $12 million $25 million and $56 million in both the years ended December 31, 2019, 20182020 and 2017, respectively.2019. At December 31, 2019,2021, our carryforwards available to offset future taxable income consisted of (1) federal net operating loss (“NOL”)NOL carryforwards of approximately $600$194 million pre-tax expiringpre‑tax, $13 million of which expires in 20322026 to 2034,2036 and $181 million of which has no expiration date, (2) general business credit carryforwards of approximately $25$9 million expiring in 20232034 through 2039,2038, (3) charitable contribution carryforwards of approximately $90 million expiring in 2024 through 2025 and (3)(4) state NOL carryforwards of approximately $3.5$3.333 billion expiring in 20202022 through 20392041 for which the associated deferred tax benefit, net of valuation allowance and federal tax impact, is $25$49 million.

Our ability to utilize NOL carryforwards to reduce future taxable income may be limited under Section 382 of the Internal Revenue Code if certain ownership changes in our company occur during a rolling three-yearthree‑year period. These ownership changes include purchases of common stock under share repurchase programs, the offering of stock by us, the purchase or sale of our stock by 5% shareholders, as defined in the Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5% shareholders result in aggregate increases that exceed 50 percentage points during the three-yearthree‑year period, then Section 382 imposes an annual limitation on the amount of our taxable income that may be offset by the NOL carryforwards or tax credit carryforwards at the time of ownership change.

Periodic examinations of our tax returns by the Internal Revenue Service (“IRS”)IRS or other taxing authorities could result in the payment of additional taxes. The IRS has completed audits of our tax returns for all tax years ended on or before December 31, 2007. All disputed issues with respect to these audits have been resolved and all related tax assessments

(including (including interest) have been paid. Our tax returns for years ended after December 31, 2007 and USPI’s tax returns for years ended after December 31, 20152017 remain subject to audit by the IRS.

74

Table of Contents
SOURCES AND USES OF CASH

Our liquidity for the year ended December 31, 20192021 was primarily derived from net cash provided by operating activities and cash on handhand. During 2021, we also received $215 million, including $37 million received by our unconsolidated affiliates, of supplemental funds from federal, state and borrowingslocal grants provided under our revolving credit facility.the COVID Acts. We had $262 million$2.364 billion of cash and cash equivalents on hand at December 31, 20192021 to fund our operations and capital expenditures, and our borrowing availability under our credit facilityCredit Agreement was $1.499$1.797 billion based on our borrowing base calculation as ofat December 31, 2019.2021.

OurWhen operating under normal conditions, our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors. Our revolving credit facility provides additional liquidity to manage fluctuations in operating cash caused by these factors.

Net cash provided by operating activities was $1.233$1.568 billion forin the year ended December 31, 20192021 compared to $1.049$3.407 billion forin the year ended December 31, 2018.2020. Key factors contributing to the change between the 20192021 and 2018 periods2020 include the following:

An increase in operating income of $29$1.031 billion before net losses on sales, consolidation and deconsolidation of facilities; litigation and investigation costs; impairment and restructuring charges and acquisition-related costs; depreciation and amortization; loss (income) from divested and closed businesses; and income recognized from government relief packages;

$512 million of Medicare advances recouped and repaid in the year ended December 31, 2021 compared to $1.393 billion of Medicare advances received in the year ended December 31, 2020;

$178 million of cash received from federal, state and local grants in 2021 compared to $900 million received in 2020;

A $128 million payment in 2021 of payroll taxes deferred pursuant to the COVID Acts compared to the deferral of $260 million of payroll taxes in 2020;

Lower interest payments of $25 million in 2021;

Higher income tax payments of $80 million in 2021;

A decrease of $180 million in payments on reserves for restructuring charges, acquisition-relatedacquisition‑related costs, and litigation costs and settlements;settlements in 2021; and

Decreased cash receipts of $13 million related to supplemental Medicaid programs in California and Texas;

Lower interest payment of $30 million in the 2019 period;

Lower income tax payments of $13 million in the 2019 period;

A $146 million increase in income from continuing operations before income taxes, gain (loss) from early extinguishment of debt, other non-operating expense, net, interest expense, net gains (losses) on sales, consolidation and deconsolidation of facilities, litigation and investigation costs, impairment and restructuring charges, and acquisition-related costs, depreciation and amortization and income (loss) from divested operations and closed businesses (i.e., our health plan businesses) in the year ended December 31, 2019 compared to the year ended December 31, 2018; and

The timing of other working capital items.

Net cash used in investing activities was $619$714 million for the year ended December 31, 20192021 compared to $115 million of net cash used in investing activities$1.608 billion for the year ended December 31, 2018.2020. The primary reason for the change was2021 activity included an increase in proceeds from salesthe sale of facilities and other assets of $63 million in the 2019 period when we completed$1.171 billion compared to 2020, primarily related to the sale of three hospitals and hospital-affiliated operations in the Chicago area compared to proceeds from sales of facilities and other assets of $543 million in the 2018 period when we completed the salemajority of our hospitals, physician practices and related assetsurgent care centers in the Philadelphia area, the sale of MacNeal Hospital and other operations affiliated with the hospital in the Chicago area, the sale of Des Peres Hospital in St. Louis, the sale of nine Aspen facilities in the United Kingdom,April 2021 and the sale of certain assetsthe Miami Hospitals in August 2021. This increase was partially offset by increased capital expenditures of $118 million and the related liabilitiesan increase of our health plan in California. There was also a decrease in proceeds from sales of marketable securities, long-term investments and other assets of $117$64 million in purchases of equity interests in unconsolidated affiliates during the 2019 periodyear ended December 31, 2021 compared to the 2018 period primarily due to the sales of our minority interests in four North Texas hospitals in the 2018 period. Capital expenditures were $670 million and $617 million in the yearsyear ended December 31, 2019 and 2018, respectively.2020. We made aggregate payments of $1.220 billion during the year ended December 31, 2021 to acquire businesses, primarily for the purchase of ownership interests in the SCD Centers. During the year ended December 31, 2020 we paid $1.177 billion to acquire businesses, primarily related to our acquisition of ownership interests in 45 ASCs from affiliates of SCD.

Net cash used in financing activities was $763$936 million for the year ended December 31, 20192021 compared to $1.134 billionnet cash provided by financing activities of $385 million for the year ended December 31, 2018. In 2019,2020. During the year ended December 31, 2021, we sold a total of $5.7issued $2.850 billion aggregate principal amount of notes. Thesenior secured first lien notes and used a portion of the proceeds, together with the proceeds from our sale of the sales of these notes were used, after payment of feesMiami Hospitals and expenses, together with cash on hand, to redeem and borrowings under our senior secured revolving credit facility, to fund the redemptions of a total of $5.7retire $2.988 billion aggregate principal amount of our then‑outstanding senior unsecured and senior secured first lien notes. In connection withFinancing activity in 2021 also included the redemptions,receipt of $37 million of grant funds by our Ambulatory Care segment’s unconsolidated affiliates and their repayment of $104 million of Medicare advances. Additionally, we recorded a loss from early extinguishmentpaid total distributions to noncontrolling interest holders of debt of approximately $227$423 million forduring the year end ended December 31, 2019 primarily related2021.

75

Table of Contents
During the year ended December 31, 2020, we issued $3.800 billion aggregate principal amount of senior unsecured and senior secured first lien notes and paid $3.099 billion to the difference between the redemption pricesredeem and the par valuespurchase $2.800 billion aggregate principal amount then outstanding of the notes, as well as the write-offour senior notes. Additionally, our Ambulatory Care segment’s non-consolidated affiliates received $74 million of the associated unamortized issuance costs. For additional information regarding our long-term debt, see Note 8 to the accompanying Consolidated Financial Statements. The 2019 amount also included $70grant funds and $113 million of cash paid for debt issuance costs related to these debt transactions. The 2018 amount included $647 million related to purchases of noncontrolling interests, primarily our purchase of an additional 15% ownership interest in USPI and to settle the adjustment to the price we paid in 2017 based on actual 2017 financial results of USPI.advances from Medicare.


We have several structured payables arrangements that are a part of our strategy to make our procurement processes more efficient and cost effective. For the year endedAt December 31, 2019,2021, we hadwere paying approximately 2,0506,300 vendors being paid byunder these programs, with an annual charge volume of approximately $675 million.$1.2 billion. We do not expect these programs to result in any significant changes to our liquidity.

We record our equity securities and our debt securities classified as available-for-saleavailable‑for‑sale at fair market value. The majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.

DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

Credit Agreement. Agreement—We amendedAt December 31, 2021, our senior secured revolving credit facility in September 2019 (as amended, the “Credit Agreement”) to provide, subject to borrowing availability,Credit Agreement provided for revolving loans in an aggregate principal amount of up to $1.5$1.900 billion (from a previous limit of $1.0 billion), with a $200 million subfacility for standby letters of credit. In April 2020, we amended our Credit Agreement to, among other things, (i) increase the aggregate revolving credit commitments from $1.500 billion to $1.900 billion (the “Increased Commitments”), subject to borrowing availability, and (ii) increase the advance rate and raise limits on certain eligible accounts receivable in the calculation of the borrowing base, in each case, for an incremental period of 364 days. In April 2021, we further amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April 22, 2022 and reduce the interest rate margins. Obligations under the Credit Agreement, which now has a scheduled maturity date of September 12, 2024, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priorityfirst‑priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments as of the most recent amendment. payments.

At December 31, 2019,2021, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.797 billion was available for borrowing at December 31, 2021. At December 31, 2021, we were in compliance with all covenants and conditions in our Credit Agreement. At December 31, 2019, we had no cash borrowings outstanding underSee Note 8 to the accompanying Consolidated Financial Statements for additional information about our Credit Agreement, and we had $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.499 billion was available for borrowing under the Credit Agreement at December 31, 2019.Agreement.

Letter of Credit Facility. Facility—We have a letter of credit facility (asIn March 2020, we amended our LC Facility to extend the “LC Facility”) that provides forscheduled maturity date from March 7, 2021 to September 12, 2024 and to increase the issuanceaggregate principal amount of standby and documentary letters of credit that from time to time in an aggregate principal amount of up tomay be issued thereunder from $180 million (subject to increase to up to $200 million). The maturity date ofmillion. In July 2020, we further amended the LC Facility isto incrementally increase the maximum secured debt covenant from 4.25 to 1.00 on a quarterly basis up to 6.00 to 1.00 for the quarter ended March 7,31, 2021, at which point the maximum ratio began to step down incrementally on a quarterly basis through the quarter ended December 31, 2021. At December 31, 2021, the effective maximum secured debt covenant was 4.25 to 1.00, where it will remain until maturity. Obligations under the LC Facility are guaranteed and secured by a first-priorityfirst‑priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal equal‑ranking basis with our senior secured first lien notes. At December 31, 2019,2021, we were in compliance with all covenants and conditions in ourthe LC Facility. At December 31, 2019,2021, we had $92$139 million of standby letters of credit outstanding under the LC Facility.

Senior Secured Note Issuances and Senior Unsecured NoteDebt Refinancing Transactions.In 2019,2021, we sold a total of $5.7$2.850 billion aggregate principal amount of notes.senior secured first lien notes – specifically, our 2029 Senior Secured First Lien Notes in June 2021 and our 2030 Senior Secured First Lien Notes in December 2021. The net proceeds from these note issuances was primarily used to redeem our 2025 Senior Secured Second Lien Notes in June 2021 and to finance the acquisition of the SCD Centers in December 2021.

During the year ended December 31, 2021, we paid $3.036 billion to redeem and/or retire $2.988 billion aggregate principal amount then outstanding of senior unsecured and senior secured notes in advance of their respective maturity dates. We used the net proceeds from the salesJune 2021 issuance of these notes were used,our 2029 Senior Secured First Lien Notes, after payment of fees and expenses, together withthe proceeds from the sale of the Miami Hospitals and cash on hand to finance these transactions. We recognized an aggregate loss from early extinguishment of debt of $74 million in the year ended December 31, 2021, primarily related to the difference between the purchase prices and borrowings underthe par values of the notes, as well as the write‑off of associated unamortized issuance costs.
76

Table of Contents

LIQUIDITY
Broad economic factors resulting from the COVID‑19 pandemic, including higher inflation, increased unemployment rates in certain areas in which we operate and reduced consumer spending, continued to impact our service mix, revenue mix and patient volumes in 2021. Business closings and layoffs in the areas we operate have led to increases in the uninsured and underinsured populations; higher uninsured and underinsured populations adversely affect demand for our services, as well as the ability of patients to pay for services as rendered. Any increase in the amount of or deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted.

Throughout the COVID‑19 pandemic, we have taken, and we continue to take, various actions to increase our liquidity and mitigate the impact of reductions in our patient volumes and operating revenues. These actions included the sale and redemption of various senior unsecured and senior secured revolving credit facility,notes, which eliminated any significant debt maturities until June 2023 and reduced our required annual cash interest payments. In April 2021, we further amended our Credit Agreement to fundextend the redemptionsavailability of a totalthe Increased Commitments through April 22, 2022. In addition, we have continued to focus on cost‑reduction measures and corporate efficiencies to substantially offset incremental costs, including temporary staffing and premium pay, as well as higher supply costs for PPE. We have also sought to compensate for the COVID‑19 pandemic’s disruption of $5.7 billion aggregate principal amountour patient volumes and mix by growing our services for which demand has been more resilient, including our higher‑acuity service lines, and we expect demand for these higher‑acuity service lines will continue to grow in the future. We believe all of notes. For additional information regardingthese actions, together with government relief packages, supported our long-term debt, see Note 8continued operation during the initial uncertainty caused by the COVID‑19 pandemic and continue to the accompanying Consolidated Financial Statements.do so.

LIQUIDITY

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day-to-dayday‑to‑day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest payments and income tax payments.payments, as well as cash disbursements required to respond to the COVID‑19 pandemic. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future willmay cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, borrowing availability under our Credit Agreement and anticipated future cash provided by our operating activities and our investments in marketable securities of our captive insurance companies classified as noncurrent investments on our balance sheet should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to joint venture partners, including those related to put and call arrangements, and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and

contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section and other sectionsthe Risk Factors section in Part I of this report, including any costs associated with legal proceedings and government investigations.

We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our consolidated balance sheets.sheet. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest except for any borrowings under our Credit Agreement.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $195 million of standby letters of credit outstanding and guarantees at December 31, 2019.

RECENTLY ISSUED ACCOUNTING STANDARDS

See Note 24 to the accompanying Consolidated Financial Statements for a discussion of recently issued accounting standards.

77

Table of Contents
CRITICAL ACCOUNTING ESTIMATES

In preparing our Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.

Our critical accounting estimates cover the following areas:

Recognition of net operating revenues, including contractual allowances and implicit price concessions;

Accruals for general and professional liability risks;

Impairment of long-livedlong‑lived assets;

Impairment of goodwill; and 

Accounting for income taxes.

REVENUE RECOGNITION

We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third-partythirdparty payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third-partythird‑party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.

We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance

obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when: (1) services are provided;provided and (2) we do not believe the patient requires additional services.

We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments provided to third-partythird‑party payers, discounts provided to uninsured patients in accordance with our Compact, and implicit price concessions provided primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.

Revenues under the traditional fee-for-serviceFFS Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost-basedcost‑based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospitalIME, DGME, DSH and bad debt expense reimbursement, which are based on our hospitals’ cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years untilbefore final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.

We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost
78

Table of Contents
reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diemper‑diem rates, discounted fee-for-serviceFFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patientpatient‑by‑patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at December 31, 2019,2021, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $16 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-lossstop‑loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-housein‑house and discharged-not-final-billeddischarged‑not‑final‑billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate-widecorporate‑wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

Generally, patients who are covered by third-partythird‑party payers are responsible for related co-pays, co-insuranceco‑pays, co‑insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co-pays, co-insuranceco‑pays, co‑insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our Compact and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-payself‑pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price

concessions based on historical collection trends for self-payself‑pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such asas: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients,patients; the volume of patients through our emergency departments,departments; the increased burden of co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles to be made by patients with insurance,insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.

We have provided implicit price concessions, primarily to uninsured patients and patients with co-pays, co-insuranceco‑pays, co‑insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co-pays, co-insuranceco‑pays, co‑insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (“EMTALA”). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non-emergencynon‑emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1) we are unable to obtain verification because the patient’s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3) under physician orders we provide services to patients that require immediate treatment.

79

Table of Contents
Based on our accounts receivable from uninsured patients and co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance at December 31, 2019,2021, a 10% decreaseincrease or increasedecrease in our self-payself‑pay collection rate, or approximately 2%3%, which we believe could be a reasonably likely change, would result in ana favorable or unfavorable or favorable adjustment to patient accounts receivable of approximately $10$9 million.

ACCRUALS FOR GENERAL AND PROFESSIONAL LIABILITY RISKS

We accrue for estimated professional and general liability claims, to the extent not covered by insurance, when they are probable and can be reasonably estimated. We maintain reserves, which are based on modeled estimates for the portion of our professional liability risks, including incurred but not reported claims, to the extent we do not have insurance coverage. Our liability consists of estimates established based upon discounted calculations using several factors, including the number of expected claims, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience and the timing of historical payments, and risk free discount rates used to determine the present value of projected payments. We consider the number of expected claims and average cost per claim and discount rate to be the most significant assumptions in estimating accruals for general and professional liabilities. Our liabilities are adjusted for new claims information in the period such information becomes known. Malpractice expense is recorded within other operating expenses in the accompanying Consolidated Statements of Operations.

Our estimated reserves for professional and general liability claims will change significantly if future trends differ from projected trends. We believe it is reasonably likely for there to be a 500 basis point increase or decrease in our frequency or severity trend. Based on our reserves and other information at December 31, 2019,2021, a 500 basis point increase in our frequency trend would increase the estimated reserves by $42$47 million, and a 500 basis point decrease in our frequency trend would decrease the estimated reserves by $35$37 million. A 500 basis point increase in our severity trend would increase the estimated reserves by $149$190 million, and a 500 basis point decrease in our severity trend would decrease the estimated reserves by $118 million. Because our estimated reserves for future claim payments are discounted to present value, a change in our discount rate assumption could also have a significant impact on our estimated reserves. Our discount rate was 1.83% and 2.59% at December 31, 2019 and 2018, respectively. A 100 basis point increase or decrease in the discount rate would change the estimated reserves by $23$131 million. In addition, because of the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes, our ultimate liability for professional and general liability claims could change materially from our current estimates.


The table below shows the case reserves and incurred but not reported and loss development reserves as of December 31, 20192021 and 2018:
2020:
December 31, December 31,
2019 2018 20212020
Case reserves$212
 $210
Case reserves$387 $273 
Incurred but not reported and loss development reserves753
 742
Incurred but not reported and loss development reserves658 705 
Total undiscounted reserves$965
 $952
Total reservesTotal reserves$1,045 $978 

Several actuarial methods, including the incurred, paid loss development and Bornhuetter-FergusonBornhuetter‑Ferguson methods, are applied to our historical loss data to produce estimates of ultimate expected losses and the resulting incurred but not reported and loss development reserves. These methods use our specific historical claims data related to paid losses and loss adjustment expenses, historical and current case reserves, reported and closed claim counts, and a variety of hospital census information. These analyses are considered in our determination of our estimate of the professional liability claims, including the incurred but not reported and loss development reserve estimates. The determination of our estimates involves subjective judgment and could result in material changes to our estimates in future periods if our actual experience is materially different than our assumptions.

Malpractice claims generally take up to five years to settle from the time of the initial reporting of the occurrence to the settlement payment. Accordingly, the percentage of undiscounted reserves at December 31, 20192021 and 20182020 representing unsettled claims was approximately 97%98% and 93%99%, respectively.

80

Table of Contents
The following table, which includes both our continuing and discontinued operations, presents the amount of our accruals for professional and general liability claims and the corresponding activity therein:
Years Ended December 31, Years Ended December 31,
2019 2018 20212020
Accrual for professional and general liability claims, beginning of the year$882
 $854
Accrual for professional and general liability claims, beginning of the year$978 $965 
Less losses recoverable from re-insurance and excess insurance carriers(31) (24)Less losses recoverable from re-insurance and excess insurance carriers(50)(86)
Expense (income) related to:(1)
 
  
Expense related to:(1)
Expense related to:(1)
  
Current year192
 223
Current year200 195 
Prior years155
 176
Prior years131 120 
Expense (income) from discounting20
 (10)
Total incurred loss and loss expense367
 389
Total incurred loss and loss expense331 315 
Paid claims and expenses related to: 
  
Paid claims and expenses related to:  
Current year(8) (3)Current year(13)(3)
Prior years(381) (365)Prior years(239)(263)
Total paid claims and expenses(389) (368)Total paid claims and expenses(252)(266)
Plus losses recoverable from re-insurance and excess insurance carriers86
 31
Plus losses recoverable from re-insurance and excess insurance carriers38 50 
Accrual for professional and general liability claims, end of year$915
 $882
Accrual for professional and general liability claims, end of year$1,045 $978 
(1)Total malpractice expense for continuing operations, including premiums for insured coverage and recoveries from third parties, was $355 million and $320 million in the years ended December 31, 2021 and 2020, respectively.
(1)Total malpractice expense for continuing operations, including premiums for insured coverage and recoveries from third parties, was $374 million and $388 million in the years ended December 31, 2019 and 2018, respectively.

IMPAIRMENT OF LONG-LIVED ASSETS

We evaluate our long-livedlong‑lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of thean asset or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets,asset group, we calculate the amount of an impairment charge only if the carrying value of the long-lived assetsasset group exceeds the fair valuevalue. For purposes of impairment testing, all asset groups are evaluated at a level below that of the assets.reporting unit, and their carrying values do not include any allocations of goodwill. The fair valuevalues of the assets isare estimated based on appraisals, established market values of comparable assets or internal estimates of future net cash flows expected to result from the use and ultimate disposition of the asset.those assets. The estimates of these future net cash flows are based on assumptions and projections we believe to be reasonable and supportable. TheyEstimates require our subjective judgments and take into account assumptions about revenue and expense growth rates.rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of facilityasset group and presume stable, improving or, in some cases, declining results, at our hospitals, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.


We report long-livedlong‑lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows.

Fair value estimates can change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the following risks:

future financial results, of our hospitals, which can be impacted by volumes of insured patients and declines in commercial managed care patients, terms of managed care payer arrangements, our ability to collect amounts due from uninsured and managed care payers, loss of volumes as a result of competition, physician recruitment and retention, and our ability to manage costs such as labor costs, which can be adversely impacted by union activity and the shortage of experienced nurses;

changes in payments from governmental healthcare programs and in government regulations such as reductions to Medicare and Medicaid payment rates resulting from government legislation or rule-makingrule‑making or from budgetary challenges of states in which we operate;

how the hospitals are operated in the future; and 

the nature of the ultimate disposition of the assets.assets; and

macro-economic conditions such as inflation, GDP growth and unforeseen technological advancements.

81

Table of Contents
During the year ended December 31, 2019,2021, we recorded $42$8 million of impairment charges, primarily related to the write‑down of certain indefinite-lived management contracts within our Ambulatory Care segment to their estimated fair values. Of the total impairment charges recognized for the year ended December 31, 2021, $5 million related to our Ambulatory Care segment and $3 million related to our Conifer segment.

During the year ended December 31, 2020, we recorded $92 million of impairment charges, consisting of $26$76 million to write‑down hospital buildings located in one of charges to write-down assets held for saleour Hospital Operations segment’s markets to their estimated fair value, less estimated costs to sell, for certain of our Memphis-area facilitiesvalues and $16 million of other impairment charges. Of the total impairment charges recognized for the year ended December 31, 2019, $312020, $79 million related to our Hospital Operations and other segment, $6 million related to our Ambulatory Care segment, and $5 million related to our Conifer segment.

During the year ended December 31, 2018, we recorded $77 million of impairment charges, consisting of $40 million for the write-down of buildings and other long-lived assets to their estimated fair values at two hospitals, $24 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Chicago-area facilities, $9 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen and $4 million of other impairment charges. Of the total impairment charges recognized for the year ended December 31, 2018, $67 million related to our Hospital Operations and other segment, $9$12 million related to our Ambulatory Care segment and $1 million related to our Conifer segment.

In our most recent impairment analysis as of December 31, 2019,2021, we had one asset group, including threetwo hospitals and related operations, with an aggregate carrying value of long-lived assets of $159$224 million whose estimated undiscounted future cash flows exceeded the carrying value of long-lived assets by approximately 50%188%. The estimated undiscounted future cash flows of these long-livedlong‑lived asset groups aremay not be considered to be substantially in excess of cash flows necessary to recover the carrying values of their long-lived assets. Future adverse trends that necessitate changes in the estimates of undiscounted future cash flows could result in the estimated undiscounted future cash flows being less than the carrying values of the long-livedlong‑lived assets, which would require a fair value assessment, and if the fair value amount is less than the carrying value of the long-livedlong‑lived assets, material impairment charges could result.

IMPAIRMENT OF GOODWILL

Goodwill represents the excess of costspurchase price over the net estimated fair value of assets of businesses acquired. Goodwill and other intangibleidentifiable assets acquired and liabilities assumed in purchasea business combinations andcombination. Goodwill is determined to have an indefinite useful lives arelife and is not amortized, but is instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level, as defined by applicable accounting standards,annually, or when events occur that require an evaluationwould more likely than not reduce the fair value of the reporting unit below its carrying amount. For goodwill, we assess qualitative factors to be performed or at least annually.determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Further testing is required only if we determine, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying value. Otherwise no further impairment testing is required. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, then we reduce the carrying value, including any allocated goodwill, to fair value. Estimatesvalue, with any impairment not to exceed the carrying amount of fairgoodwill. Any impairment would be recognized as a charge to income from operations and a reduction in the carrying value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals or outpatient facilities, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.goodwill.

At December 31, 2019,2021, our continuing operations consisted ofbusiness included three reportable segments Hospital Operations, and other, Ambulatory Care and Conifer. Our reportable segments are reporting units used to perform our goodwill impairment analysis.analysis, and goodwill is accordingly assigned to these reporting segments. We completed our annual impairment tests for goodwill as of October 1, 2019.2021.


The allocated goodwill balance related to our Hospital Operations and other segment totals $2.908$2.808 billion. In our latest impairmentFor the Hospital Operations segment, we performed a qualitative analysis forand concluded that it was more likely than not that the year ended December 31, 2019, the estimated fair value of our Hospital Operations and other segmentthe reporting unit exceeded theits carrying value of long-lived assets, including goodwill, by approximately 35%.value.

The allocated goodwill balance related to our Ambulatory Care segment totals $3.739$5.848 billion. For the Ambulatory Care segment, we performed a qualitative analysis and concluded that it was more likely than not that the fair value of the reporting unit exceeded its carrying value. Factors considered in the analysis included recent and estimated future operating trends.

The allocated goodwill balance related to our Conifer segment totals $605 million. For the Conifer segment, we performed a qualitative analysis and concluded that it was more likely than not that the fair value of the reporting unit exceeded its carrying value.

Factors considered in the analysisabove analyses included recent and estimated future operating trends.trends derived from macro-economic conditions, industry conditions and other factors specific to each reporting segment.

ACCOUNTING FOR INCOME TAXES

We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.

82

Table of Contents
Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.

We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:

Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;

Income/losses expected in future years;

Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;

The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and

The carryforward period associated with the deferred tax assets and liabilities.


During the year ended December 31, 2019,2021, the valuation allowance increased by $133$2 million, including an increase of $130$2 million due to limitations on the tax deductibility of interest expense, a decrease of $2 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $5$2 million due to changes in expected realizability of deferred tax assets. The balance in the valuation allowance as of December 31, 20192021 was $281$57 million. During the year ended December 31, 2018,2020, the valuation allowance increaseddecreased by $76$226 million, including an increasea decrease of $89$211 million due to limitations on deductionsthe tax deductibility of interest expense, a decrease of $9$1 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and a decrease of $4$14 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December 31, 20182020 was $148$55 million. Federal and state deferredDeferred tax assets relating to interest expense limitations under Internal Revenue Code Section 163(j) have a full valuation allowance because the interest expense carryovers are not expected to be utilized in the foreseeable future.

We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more likely than not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.


While we believe we have adequately provided for our income tax receivables or liabilities and our deferred tax assets or liabilities, adverse determinations by taxing authorities or changes in tax laws and regulations could have a material adverse effect on our consolidated financial position, results of operations or cash flows.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The following table presents information about certain of our market-sensitivemarket‑sensitive financial instruments at December 31, 2019.2021. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting date.period. The effects of unamortized premiumsdiscounts and discountsissue costs are excluded from the table.
Maturity Date, Years Ending December 31,  Maturity Date, Years Ending December 31,
20202021202220232024ThereafterTotalFair Value 20222023202420252026ThereafterTotalFair Value
(Dollars in Millions) (Dollars in Millions)
Fixed-rate long-term debt$171
$112
$2,851
$1,903
$2,486
$7,414
$14,937
$15,893
Fixed-rate long-term debt$135 $1,983 $1,446 $742 $2,120 $9,371 $15,797 $16,323 
Average effective interest rates5.5%5.6%8.6%7.3%4.9%5.7%6.3% 
Average effective interest rates4.3 %6.6 %4.6 %7.4 %4.9 %5.4 %5.5 % 

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose”“special‑purpose” or “variable-interest”“variable‑interest” entities) whose purpose is to facilitate off-balanceoff‑balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities.

We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

83


Table of Contents
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
MANAGEMENT REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

To Our Shareholders:

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Management assessed the effectiveness of Tenet’s internal control over financial reporting as of December 31, 2019.2021. This assessment was performed under the supervision of and with the participation of management, including the chief executive officer and chief financial officer.

In making this assessment, management used criteria based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on the assessment using the COSO framework, management concluded that Tenet’s internal control over financial reporting was effective as of December 31, 2019.2021.

Tenet’s internal control over financial reporting as of December 31, 20192021 has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report, which is included herein. Deloitte & Touche LLP has also audited Tenet’s Consolidated Financial Statements as of and for the year ended December 31, 2019,2021, and that firm’s audit report on such Consolidated Financial Statements is also included herein.

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

/s/ RONALD A. RITTENMEYERSAUMYA SUTARIA/s/ DANIEL J. CANCELMI
Ronald A. RittenmeyerSaumya Sutaria, M.D.Daniel J. Cancelmi
Executive Chairman and Chief Executive OfficerExecutive Vice President and Chief Financial Officer
February 24, 202018, 2022February 24, 202018, 2022

84

Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Tenet Healthcare Corporation

Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Tenet Healthcare Corporation and subsidiaries (the “Company”) as of December 31, 2019,2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019,2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statement schedule as of and for the year ended December 31, 2019,2021 of the Company and our report dated February 24, 2020,18, 2022, expressed an unqualified opinion on those financial statements.

Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



/s/ DELOITTE & TOUCHE LLP
Dallas, Texas
February 24, 202018, 2022


85

Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Tenet Healthcare Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Tenet Healthcare Corporation and subsidiaries (the “Company”) as of December 31, 20192021, and 2018,2020, the related consolidated statements of operations, other comprehensive income (loss), changes in equity, and cash flows for each of the three years in the period ended December 31, 2019,2021, and the related notes and the consolidated financial statement schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 20192021, and 2018,2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019,2021, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019,2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 24, 2020,18, 2022, expressed an unqualified opinion on the Company’s internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters
The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Net Operating Revenues and Accounts Receivable and Net Operating Revenues—- Refer to Notes 1, 3 and 15 to the financial statements
Critical Audit Matter Description
Management reports net patient service revenues and accounts receivable at the amounts that reflect the consideration to which they expect to be entitled for providing patient care. ThisAs of and for the year ended December 31, 2021, the balances for net operating revenues, of which approximately 93% is net patient service revenues, and accounts receivable were $19.485 billion and $2.770 billion, respectively. The transaction price is based on gross charges for services provided, reduced by contractual adjustments provided to third-party payers, discounts provided to uninsured patients in accordance with the Company’s Compact with Uninsured Patients, and implicit price concessions provided primarily to uninsured patients. The implicit price concessions are estimates developed by management based on their historical collection experience with these classes of patients using a portfolio approach.

86

Table of Contents
Given the judgments necessary to estimate the implicit price concessions to determine the amount of net revenues recognized and the value of patient accounts receivable as a result of inherent subjectivity in collection trends from changes in the economy, patient volumes, amounts to be paid by patients with insurance and other factors, auditing such estimates involved especially subjective judgments.


How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to management’s estimates of the implicit price concessions used to determine the value of net patient service revenues and accounts receivable included the following, among others:
We tested the effectiveness of controls over net patient service revenues and the valuation of accounts receivable, including those over the historical collections data and management’s analysis of their historical collection experience and judgments applied to develop their assumptions for implicit price concessions.
We evaluated the methods and assumptions used by management to estimate the implicit price concessions by:
oTesting the underlying data that served as the basis for the implicit price concession rates developed by management, including the historical collections data within the classes of patients, to evaluate whether the inputs to management’s estimate were reasonable.
oComparing management’s prior-year recorded balance to actual write-offs during the current year, and reviewing trends in implicit price concessions over time.
Testing the underlying data that served as the basis for the implicit price concession rates developed by management, including the historical collections data within the classes of patients, to evaluate whether the inputs to management’s estimate were reasonable.
Comparing management’s prior-year expectation to actual amounts recorded during the current year.
We developed an independent estimate using historical collection data for each class of patients. We then compared the result to the implicit price concession estimate developed by management to evaluate the reasonableness of accounts receivable and revenues.
Property and
Professional and General Liability Insurance – Professional and General Liability Reserves —Reserves- Refer to Notes 1 and 16 to the financial statements
Critical Audit Matter Description
Management records an accrual for the portion of their professional and general liability risks, including incurred but not reported claims, for which they do not have insurance coverageare self-insured and that are probable and can be reasonably estimated. As of December 31, 2021, the accrual for professional and general liability reserves was $1.045 billion. This accrual is estimated based on internal and third-party modeled estimates of projected payments using case-specific facts and circumstances and the Company’s historical claim loss reporting, claim development and settlement patterns, reported and closed claim counts, and a variety of hospital census information.

Given the subjectivity of estimating the projected liability of reported and unreported claims, auditing the professional and general liability reserves involved especially subjective judgment.judgments.

How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the professional and general liability reserves included the following, among others:
We tested the effectiveness of controls related to the professional and general liability reserves, including those over the estimation of the projected liability of reported and unreported claims.
We evaluated the methods and assumptionsdata used by management to estimate the professional and general liability reserves by:
oTesting the underlying data that served as the basis for the internal and third-party actuarial analyses, including historical claims, to evaluate that the inputs to the actuarial estimates were reasonable.
oComparing management’s prior-year recorded balance to actual losses incurred during the current year.
Testing the underlying data that served as the basis for the internal and third-party actuarial analyses, including historical claims, to evaluate that the inputs to the actuarial estimates were reasonable.
Comparing management’s prior-year recorded balance to actual losses incurred during the current year.
With the assistance of our internal actuarial specialists, we developed an independent range of estimates of the professional and general liability reserves, using loss data, historical and industry claim development factors, among other factors, to derive a range of projections of ultimate losses, and compared our estimates to management’s estimates.


/s/ DELOITTE & TOUCHE LLP
Dallas, Texas
February 24, 202018, 2022

We have served as the Company’s auditor since 2007.

87

Table of Contents

CONSOLIDATED BALANCE SHEETS
Dollars in Millions
 December 31,December 31,
20212020
ASSETS  
Current assets:  
Cash and cash equivalents$2,364 $2,446 
Accounts receivable2,770 2,690 
Inventories of supplies, at cost384 368 
Assets held for sale— 140 
Other current assets1,557 1,503 
Total current assets 7,075 7,147 
Investments and other assets3,254 2,534 
Deferred income taxes65 325 
Property and equipment, at cost, less accumulated depreciation and amortization
($5,960 at December 31, 2021 and $6,043 at December 31, 2020)
6,427 6,692 
Goodwill9,261 8,808 
Other intangible assets, at cost, less accumulated amortization
($1,374 at December 31, 2021 and $1,284 at December 31, 2020)
1,497 1,600 
Total assets $27,579 $27,106 
LIABILITIES AND EQUITY  
Current liabilities:  
Current portion of long-term debt$135 $145 
Accounts payable1,300 1,207 
Accrued compensation and benefits896 942 
Professional and general liability reserves254 243 
Accrued interest payable203 248 
Liabilities held for sale— 70 
Contract liabilities959 659 
Other current liabilities1,362 1,333 
Total current liabilities 5,109 4,847 
Long-term debt, net of current portion15,511 15,574 
Professional and general liability reserves791 735 
Defined benefit plan obligations421 497 
Deferred income taxes36 29 
Contract liabilities – long-term15 918 
Other long-term liabilities1,439 1,617 
Total liabilities 23,322 24,217 
Commitments and contingencies00
Redeemable noncontrolling interests in equity of consolidated subsidiaries2,203 1,952 
Equity:  
Shareholders’ equity:  
Common stock, $0.05 par value; authorized 262,500,000 shares; 155,520,691 shares
issued at December 31, 2021 and 154,407,524 shares issued at December 31, 2020
Additional paid-in capital4,877 4,844 
Accumulated other comprehensive loss(233)(281)
Accumulated deficit(1,214)(2,128)
Common stock in treasury, at cost, 48,331,649 shares at December 31, 2021 and
48,337,947 shares at December 31, 2020
(2,410)(2,414)
Total shareholders’ equity1,028 28 
Noncontrolling interests 1,026 909 
Total equity 2,054 937 
Total liabilities and equity $27,579 $27,106 
 December 31, December 31,
 2019 2018
ASSETS 
  
Current assets: 
  
Cash and cash equivalents$262
 $411
Accounts receivable2,743
 2,595
Inventories of supplies, at cost310
 305
Income tax receivable10
 21
Assets held for sale387
 107
Other current assets1,369
 1,197
Total current assets 5,081
 4,636
Investments and other assets2,369
 1,456
Deferred income taxes169
 312
Property and equipment, at cost, less accumulated depreciation and amortization
($5,498 at December 31, 2019 and $5,221 at December 31, 2018)
6,878
 6,993
Goodwill7,252
 7,281
Other intangible assets, at cost, less accumulated amortization
($1,092 at December 31, 2019 and $1,013 at December 31, 2018)
1,602
 1,731
Total assets $23,351
 $22,409
LIABILITIES AND EQUITY 
  
Current liabilities: 
  
Current portion of long-term debt$171
 $182
Accounts payable1,204
 1,207
Accrued compensation and benefits877
 838
Professional and general liability reserves330
 216
Accrued interest payable245
 240
Liabilities held for sale44
 43
Other current liabilities1,334
 1,131
Total current liabilities 4,205
 3,857
Long-term debt, net of current portion14,580
 14,644
Professional and general liability reserves585
 666
Defined benefit plan obligations560
 521
Deferred income taxes27
 36
Other long-term liabilities1,405
 578
Total liabilities 21,362
 20,302
Commitments and contingencies


 


Redeemable noncontrolling interests in equity of consolidated subsidiaries1,506
 1,420
Equity: 
  
Shareholders’ equity: 
  
Common stock, $0.05 par value; authorized 262,500,000 shares; 152,540,815 shares issued at December 31, 2019 and 150,897,143 shares issued at December 31, 20187
 7
Additional paid-in capital4,760
 4,747
Accumulated other comprehensive loss(257) (223)
Accumulated deficit(2,467) (2,236)
Common stock in treasury, at cost, 48,344,195 shares at December 31, 2019 and 48,359,705 shares at December 31, 2018(2,414) (2,414)
Total shareholders’ deficit(371) (119)
Noncontrolling interests 854
 806
Total equity 483
 687
Total liabilities and equity $23,351
 $22,409

See accompanying Notes to Consolidated Financial Statements.

88

Table of Contents
CONSOLIDATED STATEMENTS OF OPERATIONS
Dollars in Millions, Except Per-Share Amounts
 Years Ended December 31,
 202120202019
Net operating revenues $19,485 $17,640 $18,479 
Grant income191 882  
Equity in earnings of unconsolidated affiliates218 169 175 
Operating expenses:   
Salaries, wages and benefits8,878 8,418 8,698 
Supplies3,328 2,982 3,057 
Other operating expenses, net4,206 4,125 4,171 
Depreciation and amortization855 857 850 
Impairment and restructuring charges, and acquisition-related costs85 290 185 
Litigation and investigation costs116 44 141 
Net losses (gains) on sales, consolidation and deconsolidation of facilities(445)(14)15 
Operating income2,871 1,989 1,537 
Interest expense(923)(1,003)(985)
Other non-operating income (expense), net14 (5)
Loss from early extinguishment of debt(74)(316)(227)
Income from continuing operations, before income taxes1,888 671 320 
Income tax benefit (expense)(411)97 (160)
Income from continuing operations, before discontinued operations1,477 768 160 
Discontinued operations:   
Income (loss) from operations(1)— 15 
Income tax expense— — (4)
Income (loss) from discontinued operations(1) 11 
Net income1,476 768 171 
Less: Net income available to noncontrolling interests562 369 386 
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders$914 $399 $(215)
Amounts available (attributable) to Tenet Healthcare Corporation common shareholders   
Income (loss) from continuing operations, net of tax$915 $399 $(226)
Income (loss) from discontinued operations, net of tax(1)— 11 
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders$914 $399 $(215)
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders:   
Basic   
Continuing operations$8.56 $3.80 $(2.19)
Discontinued operations$(0.01)$— $0.11 
 $8.55 $3.80 $(2.08)
Diluted   
Continuing operations$8.43 $3.75 $(2.19)
Discontinued operations$(0.01)$— $0.11 
 $8.42 $3.75 $(2.08)
Weighted average shares and dilutive securities outstanding (in thousands):   
Basic106,833 105,010 103,398 
Diluted108,571 106,263 103,398 
 Years Ended December 31,
 2019 2018 2017
Net operating revenues: 
  
  
Net operating revenues before provision for doubtful accounts

 

 $20,613
Less: Provision for doubtful accounts

 

 1,434
Net operating revenues $18,479
 $18,313
 19,179
Equity in earnings of unconsolidated affiliates175
 150
 144
Operating expenses: 
  
  
Salaries, wages and benefits8,704
 8,634
 9,274
Supplies3,057
 3,004
 3,085
Other operating expenses, net4,189
 4,256
 4,561
Depreciation and amortization850
 802
 870
Impairment and restructuring charges, and acquisition-related costs185
 209
 541
Litigation and investigation costs141
 38
 23
Net losses (gains) on sales, consolidation and deconsolidation of facilities15
 (127) (144)
Operating income 1,513
 1,647
 1,113
Interest expense(985) (1,004) (1,028)
Other non-operating expense, net(5) (5) (22)
Gain (loss) from early extinguishment of debt(227) 1
 (164)
Income (loss) from continuing operations, before income taxes 296
 639
 (101)
Income tax expense(153) (176) (219)
Income (loss) from continuing operations, before discontinued operations 143
 463
 (320)
Discontinued operations: 
  
  
Income from operations15
 4
 
Income tax expense(4) (1) 
Income from discontinued operations 11
 3
 
Net income (loss)154
 466
 (320)
Less: Net income available to noncontrolling interests386
 355
 384
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders $(232) $111
 $(704)
Amounts available (attributable) to Tenet Healthcare Corporation common shareholders 
  
  
Income (loss) from continuing operations, net of tax$(243) $108
 $(704)
Income from discontinued operations, net of tax11
 3
 
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders$(232) $111
 $(704)
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders: 
  
  
Basic 
  
  
Continuing operations$(2.35) $1.06
 $(7.00)
Discontinued operations0.11
 0.03
 
 $(2.24) $1.09
 $(7.00)
Diluted 
  
  
Continuing operations$(2.35) $1.04
 $(7.00)
Discontinued operations0.11
 0.03
 
 $(2.24) $1.07
 $(7.00)
Weighted average shares and dilutive securities outstanding
(in thousands):
 
  
  
Basic103,398
 102,110
 100,592
Diluted103,398
 103,881
 100,592

See accompanying Notes to Consolidated Financial Statements.

89

Table of Contents
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Dollars in Millions
 Years Ended December 31,
 202120202019
Net income$1,476 $768 $171 
Other comprehensive income (loss):   
Adjustments for defined benefit plans50 (41)(52)
Amortization of net actuarial loss included in other non-operating income (expense), net11 10 
Unrealized gain on debt securities held as available-for-sale— — 
Foreign currency translation adjustments and other— — 
Other comprehensive income (loss) before income taxes62 (31)(42)
Income tax benefit (expense) related to items of other comprehensive income (loss)(14)
Total other comprehensive income (loss), net of tax48 (24)(34)
Comprehensive net income1,524 744 137 
Less: Comprehensive income to noncontrolling interests562 369 386 
Comprehensive income available (loss attributable) to Tenet Healthcare Corporation common shareholders$962 $375 $(249)
 Years Ended December 31,
 2019 2018 2017
Net income (loss)$154
 $466
 $(320)
Other comprehensive income (loss): 
  
  
Adjustments for defined benefit plans(52) (29) 42
Amortization of net actuarial loss included in other non-operating expense, net10
 14
 14
Unrealized gains (losses) on debt securities held as available-for-sale
 
 6
Sale of foreign subsidiary
 37
 
Foreign currency translation adjustments
 (4) 15
Other comprehensive income (loss) before income taxes(42) 18
 77
Income tax benefit (expense) related to items of other comprehensive income (loss)8
 6
 (23)
Total other comprehensive income (loss), net of tax(34) 24
 54
Comprehensive net income (loss)120
 490
 (266)
Less: Comprehensive income attributable to noncontrolling interests386
 355
 384
Comprehensive income available (loss attributable) to Tenet Healthcare Corporation common shareholders$(266) $135
 $(650)

See accompanying Notes to Consolidated Financial Statements.

90

Table of Contents
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Dollars in Millions,
Share Amounts in Thousands
 Tenet Healthcare Corporation Shareholders’ Equity  
 Common StockAdditional
Paid-in
Capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit
Treasury
Stock
Noncontrolling
Interests
Total Equity
 Shares
Outstanding
Issued Par
Amount
Balances at December 31, 2018102,537 $7 $4,747 $(223)$(2,299)$(2,414)$806 $624 
Net income (loss)— — — — (215)— 194 (21)
Distributions paid to noncontrolling interests— — — — — — (162)(162)
Other comprehensive loss— — — (34)— — — (34)
Accretion of redeemable noncontrolling interests— — (18)— — — — (18)
Purchases (sales) of businesses and noncontrolling interests, net— — (7)— — — 16 
Cumulative effect of accounting change— — — — — — 
Stock-based compensation expense, tax benefit and issuance of common stock1,660 — 38 — — — — 38 
Balances at December 31, 2019104,197 7 4,760 (257)(2,513)(2,414)854 437 
Net income— — — — 399 — 183 582 
Distributions paid to noncontrolling interests— — — — — — (152)(152)
Other comprehensive loss— — — (24)— — — (24)
Accretion of redeemable noncontrolling interests— — (4)— — — — (4)
Purchases of businesses and noncontrolling interests, net— — 27 — — — 24 51 
Cumulative effect of accounting change— — — — (14)— — (14)
Stock-based compensation expense, tax benefit and issuance of common stock1,873 — 61 — — — — 61 
Balances at December 31, 2020106,070 7 4,844 (281)(2,128)(2,414)909 937 
Net income— — — — 914 — 226 1,140 
Distributions paid to noncontrolling interests— — — — — — (206)(206)
Other comprehensive income— — — 48 — — — 48 
Accretion of redeemable noncontrolling interests— — (11)— — — — (11)
Purchases of businesses and noncontrolling interests, net— — — — — — 97 97 
Stock-based compensation expense, tax benefit and issuance of common stock1,119 44 — — — 49 
Balances at December 31, 2021107,189 $8 $4,877 $(233)$(1,214)$(2,410)$1,026 $2,054 
 Tenet Healthcare Corporation Shareholders’ Equity    
 Common Stock 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Treasury
Stock
 
Noncontrolling
Interests
 Total Equity
 
Shares
Outstanding
 
Issued Par
Amount
      
Balances at December 31, 201699,686
 $7
 $4,827
 $(258) $(1,742) $(2,417) $665
 $1,082
Net income (loss)
 
 
 
 (704) 
 145
 (559)
Distributions paid to noncontrolling interests
 
 
 
 
 
 (123) (123)
Other comprehensive income
 
 
 54
 
 
 
 54
Accretion of redeemable noncontrolling interests
 
 (33) 
 
 
 
 (33)
Purchases (sales) of businesses and noncontrolling interests
 
 4
 
 
 
 (1) 3
Cumulative effect of accounting change
 
 
 
 56
 
 
 56
Stock-based compensation expense, tax benefit and issuance of common stock1,286
 
 61
 
 
 (2) 
 59
Balances at December 31, 2017100,972
 7
 4,859
 (204) (2,390) (2,419) 686
 539
Net income
 
 
 
 111
 
 165
 276
Distributions paid to noncontrolling interests
 
 
 
 
 
 (148) (148)
Other comprehensive income
 
 
 24
 
 
 
 24
Accretion of redeemable noncontrolling interests
 
 (173) 
 
 
 
 (173)
Purchases of businesses and noncontrolling interests
 
 3
 
 
 
 103
 106
Cumulative effect of accounting change
 
 
 (43) 43
 
 
 
Stock-based compensation expense, tax benefit and issuance of common stock1,565
 
 58
 
 
 5
 
 63
Balances at December 31, 2018102,537
 7
 4,747
 (223) (2,236) (2,414) 806
 687
Net income (loss)
 
 
 
 (232) 
 194
 (38)
Distributions paid to noncontrolling interests
 
 
 
 
 
 (162) (162)
Other comprehensive loss
 
 
 (34) 
 
 
 (34)
Accretion of redeemable noncontrolling interests
 
 (18) 
 
 
 
 (18)
Purchases (sales) of businesses and noncontrolling interests
 
 (7) 
 
 
 16
 9
Cumulative effect of accounting change
 
 
 
 1
 
 
 1
Stock-based compensation expense, tax benefit and issuance of common stock1,660
 
 38
 
 
 
 
 38
Balances at December 31, 2019104,197
 $7
 $4,760
 $(257) $(2,467) $(2,414) $854
 $483

See accompanying Notes to Consolidated Financial Statements.

91

Table of Contents
CONSOLIDATED STATEMENTS OF CASH FLOWS
Dollars in Millions
 Years Ended December 31,
 202120202019
Net income$1,476 $768 $171 
Adjustments to reconcile net income to net cash provided by operating activities:   
Depreciation and amortization855 857 850 
Deferred income tax expense (benefit)250 (128)144 
Stock-based compensation expense56 44 42 
Impairment and restructuring charges, and acquisition-related costs85 290 185 
Litigation and investigation costs116 44 141 
Net losses (gains) on sales, consolidation and deconsolidation of facilities(445)(14)15 
Loss from early extinguishment of debt74 316 227 
Equity in earnings of unconsolidated affiliates, net of distributions received(10)(37)(32)
Amortization of debt discount and debt issuance costs33 38 35 
Pre-tax loss (income) from discontinued operations— (15)
Other items, net(33)(29)(15)
Changes in cash from operating assets and liabilities:   
Accounts receivable(197)195 (247)
Inventories and other current assets(52)(145)(94)
Income taxes68 19 
Accounts payable, accrued expenses, contract liabilities and other current liabilities(584)1,302 12 
Other long-term liabilities28 221 
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements(153)(333)(192)
Net cash used in operating activities from discontinued operations, excluding income taxes (1)(5)
Net cash provided by operating activities1,568 3,407 1,233 
Cash flows from investing activities:   
Purchases of property and equipment(658)(540)(670)
Purchases of businesses or joint venture interests, net of cash acquired(1,220)(1,177)(25)
Proceeds from sales of facilities and other assets — continuing operations1,248 77 63 
Proceeds from sales of facilities and other assets — discontinued operations— — 17 
Proceeds from sales of marketable securities, long-term investments and other assets31 59 82 
Purchases of marketable securities and equity investments(108)(44)(62)
Other items, net(7)17 (24)
Net cash used in investing activities(714)(1,608)(619)
Cash flows from financing activities:   
Repayments of borrowings under credit facility— (740)(2,640)
Proceeds from borrowings under credit facility— 740 2,640 
Repayments of other borrowings(3,221)(3,293)(6,131)
Proceeds from other borrowings2,872 3,818 5,719 
Debt issuance costs(31)(48)(70)
Distributions paid to noncontrolling interests(423)(287)(307)
Proceeds from sale of noncontrolling interests25 14 21 
Purchases of noncontrolling interests(27)(39)(11)
 Medicare advances and grants received by unconsolidated affiliates, net of recoupment(67)187 — 
Other items, net(64)33 16 
Net cash provided by (used in) financing activities(936)385 (763)
Net increase (decrease) in cash and cash equivalents(82)2,184 (149)
Cash and cash equivalents at beginning of period2,446 262 411 
Cash and cash equivalents at end of period$2,364 $2,446 $262 
Supplemental disclosures:   
Interest paid, net of capitalized interest$(937)$(962)$(946)
Income tax payments, net$(92)$(12)$(12)
 Years Ended December 31,
 2019 2018 2017
Net income (loss)$154
 $466
 $(320)
Adjustments to reconcile net income (loss) to net cash provided by operating activities: 
  
  
Depreciation and amortization850
 802
 870
Provision for doubtful accounts
 
 1,434
Deferred income tax expense137
 150
 200
Stock-based compensation expense42
 46
 59
Impairment and restructuring charges, and acquisition-related costs185
 209
 541
Litigation and investigation costs141
 38
 23
Net losses (gains) on sales, consolidation and deconsolidation of facilities15
 (127) (144)
Loss (gain) from early extinguishment of debt227
 (1) 164
Equity in earnings of unconsolidated affiliates, net of distributions received(32) (12) (18)
Amortization of debt discount and debt issuance costs35
 45
 44
Pre-tax income from discontinued operations(15) (4) 
Other items, net(15) (21) (18)
Changes in cash from operating assets and liabilities: 
  
  
Accounts receivable(247) (134) (1,448)
Inventories and other current assets(94) 17
 (35)
Income taxes8
 (3) (38)
Accounts payable, accrued expenses and other current liabilities36
 (152) (10)
Other long-term liabilities3
 (102) 26
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements(192) (163) (125)
Net cash used in operating activities from discontinued operations, excluding income taxes(5) (5) (5)
Net cash provided by operating activities1,233
 1,049
 1,200
Cash flows from investing activities: 
  
  
Purchases of property and equipment — continuing operations(670) (617) (707)
Purchases of businesses or joint venture interests, net of cash acquired(25) (113) (50)
Proceeds from sales of facilities and other assets — continuing operations63
 543
 827
Proceeds from sales of facilities and other assets — discontinued operations17
 
 
Proceeds from sales of marketable securities, long-term investments and other assets82
 199
 36
Purchases of marketable securities and equity investments(62) (148) (81)
Other long-term assets(24) 15
 (10)
Other items, net
 6
 6
Net cash provided by (used in) investing activities(619) (115) 21
Cash flows from financing activities: 
  
  
Repayments of borrowings under credit facility(2,640) (950) (970)
Proceeds from borrowings under credit facility2,640
 950
 970
Repayments of other borrowings(6,131) (312) (4,139)
Proceeds from other borrowings5,719
 23
 3,795
Debt issuance costs(70) 
 (62)
Distributions paid to noncontrolling interests(307) (288) (258)
Proceeds from sale of noncontrolling interests21
 20
 31
Purchases of noncontrolling interests(11) (647) (729)
Proceeds from exercise of stock options and employee stock purchase plan12
 16
 7
Other items, net4
 54
 29
Net cash used in financing activities(763) (1,134) (1,326)
Net decrease in cash and cash equivalents(149) (200) (105)
Cash and cash equivalents at beginning of period411
 611
 716
Cash and cash equivalents at end of period$262
 $411
 $611
Supplemental disclosures: 
  
  
Interest paid, net of capitalized interest$(946) $(976) $(939)
Income tax payments, net$(12) $(25) $(56)

See accompanying Notes to Consolidated Financial Statements.

92

Table of Contents
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company headquartered in Dallas, Texas. Through an expansive care network that includes our subsidiary USPI Holding Company, Inc. (“USPI”), at December 31, 2019,2021, we operated 6560 hospitals and over 500535 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and other care sites and clinics.facilities. We hold noncontrolling interests in 109167 of these facilities, which are recorded using the equity method of accounting. At December 31, 2021, we held an ownership interest in USPI of approximately 95%. We also operate Conifer Health Solutions, LLC through our Conifer Holdings, Inc. subsidiary (“Conifer”) subsidiary,. We owned an interest of approximately 76% in Conifer Health Solutions, LLC at December 31, 2021.

Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of USPI, which holds ownership interests in ambulatory surgery centers and surgical hospitals. Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other customers.clients.

Effective June 16, 2015, we completed a transaction that combined our freestanding ambulatory surgery and imaging center assets with the surgical facility assets of United Surgical Partners International, Inc. into our joint venture, USPI. In April 2016, we paid $127 million to purchase additional shares, which increased our ownership interest in USPI from 50.1% to approximately 56.3%. In July 2017, we paid $716 million for the purchase of additional shares and the final adjustment to the 2016 purchase price, which increased our ownership interest in USPI to 80.0%. In April 2018, we paid approximately $630 million for the purchase of an additional 15% ownership interest in USPI and the final adjustment to the 2017 purchase price, which increased our ownership interest in USPI to 95%.

Basis of Presentation

Our Consolidated Financial Statements include the accounts of Tenet and its wholly owned and majority-ownedmajority‑owned subsidiaries. We eliminate intercompany accounts and transactions in consolidation, and we include the results of operations of businesses that are newly acquired in purchase transactions from their dates of acquisition. We account for significant investments in other affiliated companies using the equity method. We also utilize the equity method when we have the ability to exercise significant influence over the affiliated company, despite not holding a significant percentage of its ownership interest. Unless otherwise indicated, all financial and statistical data included in these notes to our Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-shareper‑share amounts).


Effective January 1, 2019,2020, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02,2016‑13, “Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” (“ASU 2016‑13”) using the modified retrospective transition approach as of the period of adoption. The amendments in this ASU required a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Upon adoption of ASU 2016‑13 on January 1, 2020, we recorded a cumulative effect adjustment to increase accumulated deficit by $14 million.

Effective January 1, 2019, we adopted ASU 2016‑02, “Leases (Topic 842)” (“ASU 2016-02”2016‑02”) using the modified retrospective transition approach as of the period of adoption. Our financial statements for periods prior to January 1, 2019 were not modified for the application of the new lease accounting standard. The main difference between the guidance in ASU 2016-022016‑02 and previous accounting principles generally accepted in the United States of America (“GAAP”) is the recognition of lease assets and lease liabilities on the balance sheet by lessees for those leases classified as operating leases under previous GAAP. Upon adoption of ASU 2016-02,2016‑02, we recorded $822 million of right-of-useright‑of‑use assets, net of deferred rent, associated with operating leases in investments and other assets in our consolidated balance sheet, $147 million of current liabilities associated with operating leases in other current liabilities in our consolidated balance sheet and $715 million of long-termlong‑term liabilities associated with operating leases in other long-termlong‑term liabilities in our consolidated balance sheet. We also recognized $1 million of cumulative effect adjustment that decreased accumulated deficit at January 1, 2019.


Effective January 1, 2018, we adopted the FASB ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”) using a modified retrospective method of application to all contracts existing on January 1, 2018. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. For our Hospital Operations and other and Ambulatory Care segments, the adoption of ASU 2014-09 resulted in changes to our presentation and disclosure of revenue primarily related to uninsured or underinsured patients. Prior to the adoption of ASU 2014-09, a significant portion of our provision for doubtful accounts related to uninsured patients, as well as co-pays, co-insurance amounts and deductibles owed to us by patients with insurance. Under ASU 2014-09, the estimated uncollectable amounts due from these patients are generally considered implicit price concessions that are a direct reduction to net operating revenues, with a corresponding material reduction in the amounts presented separately as provision for doubtful accounts. For the year ended December 31, 2018, we recorded approximately $1.422 billion of implicit price concessions as a direct reduction of net operating revenues that would have been recorded as provision for doubtful accounts prior to the adoption of ASU 2014-09. At January 1, 2018, we reclassified $171 million of revenues related to patients who were still receiving inpatient care in our facilities at that date from accounts receivable, less allowance for doubtful accounts, to contract assets, which are included in other current assets in the accompanying

Consolidated Balance Sheet at December 31, 2018. The adoption of ASU 2014-09 also resulted in changes to our presentation and disclosure of customer contract assets and liabilities and the assessment of variable consideration under customer contracts, which are further discussed in Note 4.

Also effective January 1, 2018, we early adopted ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220)” (“ASU 2018-02”), which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded income tax effects resulting from the Tax Cuts and Jobs Act (the “Tax Act”) and requires certain disclosures about stranded income tax effects. We applied the amendments in ASU 2018-02 in the period of adoption, resulting in a reclassification that decreased accumulated deficit and increased accumulated other comprehensive loss by $36 million of stranded income tax effects in the year ended December 31, 2018.

In addition, we adopted ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”) effective January 1, 2018, which supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. Upon adoption of ASU 2016-01 on January 1, 2018, we recorded a cumulative effect adjustment to decrease accumulated deficit by $7 million for unrealized gains on equity securities.

Certain prior-yearprior‑year amounts have been reclassified to conform to the current year presentation. In our accompanying Consolidated Statements of Operations, electronic health record incentives haveconsolidated balance sheets, income tax receivable has been reclassified to other operating expenses, net,current assets, as they areit is no longer significant enough to present separately. In our accompanying Consolidated Statementsconsolidated statements of Cash Flows, purchases of marketable securities havecash flows, long‑term assets has been reclassified fromcombined with other items, net, as it is no longer significant enough to present separately, but it remains located within cash flows from investing activitiesactivities. In addition, within the financing section of our statement of cash flows, proceeds from shares issued under stockbased compensation plans, net of taxes paid related to purchasesnet share settlement has been combined with other items, net.

93

Table of marketable securities and equity investments.Contents

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”),GAAP requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

TranslationCOVID-19 Pandemic
During 2020 and 2021, COVID-19 impacted all three segments of Foreign Currenciesour business, as well as our patients, communities and employees. Federal, state and local authorities undertook several actions in 2020 and 2021 designed to assist healthcare providers in providing care to COVID‑19 and other patients and to mitigate the adverse economic impact of the COVID‑19 pandemic. Among other things, the legislative actions taken by the federal government to respond to the COVID‑19 pandemic (collectively, the “COVID Acts”) authorized aggregate grant payments of $178 billion to be distributed through the Public Health and Social Services Emergency Fund (“PRF”) to health care providers who experienced lost revenues and increased expenses during the pandemic. The COVID Acts also revised the Medicare accelerated payment program to disburse payments to hospitals and other care providers more quickly and permitted employers to defer payment of the 6.2% employer Social Security tax beginning March 27, 2020 through December 31, 2020. Our participation in these programs and the related accounting policies are summarized below.

Grant Income—During the years ended December 31, 2021 and 2020, we received cash payments of $215 million and $974 million, including cash received by our unconsolidated affiliates, from the PRF and state and local grant programs. As a condition to receiving distributions, providers must agree to certain terms and conditions, including, among other things, that the funds are being used for lost revenues and unreimbursed COVIDrelated costs as defined by the U.S. Department of Health and Human Services (“HHS”), and that the providers will not seek collection of outofpocket payments from a COVID19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an innetwork provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by the Secretary of HHS. In June 2021, HHS established new deadlines for when recipients of PRF grants must use the funding received, generally 12 to 18 months after receipt of the grant funds. HHS will recoup PRF grant funds not utilized by the established deadlines.

The table below summarizes grant funds received by our Hospital Operations and Ambulatory Care segments and by our unconsolidated affiliates for which we provide cash management services during the years ended December 31, 2021 and 2020, and their location in the accompanying Consolidated Statements of Cash Flows. There was no grant fund activity during the year ended December 31, 2019.
Years Ended December 31,
20212020
Grant payments received from COVID-19 relief programs:
Included in cash flows from operating activities:
Hospital Operations$142 $824 
Ambulatory Care36 76 
$178 $900 
Included in cash flows from financing activities:
Unconsolidated affiliates for which we provide cash management services$37 $74 

We recognize grant payments as income when there is reasonable assurance that we have complied with the conditions associated with the grant. Our estimates could change materially in the future based on our operating performance or COVID‑19 activities, as well as the government’s grant compliance guidance. Grant income recognized by our Hospital Operations and Ambulatory Care segments is presented in grant income and grant income recognized through our unconsolidated affiliates is presented in equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations.

94

Table of Contents
The table below summarizes grant income recognized by our Hospital Operations and Ambulatory Care segments during the years ended December 31, 2021 and 2020. In addition, the table presents grant income recognized by our unconsolidated affiliates during 2021 and 2020, which is included in equity in earnings of unconsolidated affiliates in our consolidated statement of operations. No grant income was recognized during the year ended December 31, 2019.
Years Ended December 31,
20212020
Grant income recognized from COVID-19 relief programs:
Included in grant income:
Hospital Operations$142 $823 
Ambulatory Care49 59 
$191 $882 
 Included in equity in earnings of unconsolidated affiliates:
Unconsolidated affiliates$14 $17 

At December 31, 2021 and 2020, we had remaining deferred grant payment balances of $5 million and $18 million, respectively, which amounts were recorded in other current liabilities in the accompanying Consolidated Balance Sheets for those periods.

Medicare Accelerated Payment Program—In certain circumstances, when a hospital is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the Medicare accelerated payment program. The COVID Acts revised the Medicare accelerated payment program to disburse payments to healthcare providers more quickly. Recipients may retain the accelerated payments for one year from the date of receipt before recoupment commences, which is effectuated by a 25% offset of claims payments for 11 months, followed by a 50% offset for the succeeding six months. At the end of the 29‑month period, interest on the unrecouped balance will be assessed at 4.00% per annum. The initial 11‑month recoupment period began in April 2021.

Our Hospital Operations and Ambulatory Care segments both received advance payments from the Medicare accelerated payment program during 2020. No additional advances were received in the year ended December 31, 2021. During the year ended December 31, 2019,2021, $457 million of advances received by our Hospital Operations segment and $36 million of advances received by our Ambulatory Care segment were recouped through a reduction of our Medicare claims payments. Also in 2021, $40 million of advances received by our unconsolidated affiliates for which we provide cash management services were recouped through a reduction of those affiliates’ Medicare claims payments. In addition to the amounts recouped during the year ended December 31, 2021, our Ambulatory Care segment repaid $83 million of advances, including $64 million for advances received by our unconsolidated affiliates for which we provide cash management services. In the accompanying Consolidated Balance Sheets, advances totaling $880 million and $603 million were included in contract liabilities at December 31, 2021 and December 31, 2020, respectively, and advances totaling $902 million were included in contract liabilities – long term at December 31, 2020.

Deferral of Employment Tax Payments—The COVID Acts permitted employers to defer payment of the 6.2% employer Social Security tax beginning March 27, 2020 through December 31, 2020. Deferred tax amounts are required to be paid in equal amounts over two years, with payments due in December 2021 and December 2022. We remitted the first portion of the deferred Social Security tax payments in December 2021. At December 31, 2021, deferred Social Security tax payments totaling $128 million were included in accrued compensation and benefits in the accompanying Consolidated Balance Sheets.

Translation of Foreign Currencies
We formed our Global Business Center (“GBC”) in the Republic ofPhilippines during the Philippines.year ended December 31, 2019. The GBC’s accounts are measured in its local currency (the Philippine peso) and then translated into U.S. dollars. We divested European Surgical Partners Limited (“Aspen”) in August 2018; prior to that time, Aspen’s accounts were measured in its local currency (the pound sterling) and then translated into U.S. dollars. All assets and liabilities denominated in foreign currency are translated using the current rate of exchange at the balance sheet date. Results of operations denominated in foreign currency are translated using the average rates prevailing throughout the period of operations. Translation gains or losses resulting from changes in exchange rates are accumulated in shareholders’ equity.

95

Table of Contents
Net Operating Revenues

ASU 2014-09 was issued to clarify the principles for recognizing revenue, to remove inconsistencies and weaknesses in revenue recognition requirements, and to provide a more robust framework for addressing revenue issues. Our adoption of ASU 2014-09 was accomplished using a modified retrospective method of application, and our accounting policies related to revenues were revised accordingly effective January 1, 2018, as discussed below.

We recognize net operating revenues in the period in which we satisfy our performance obligations under contracts by transferring services to our customers. Net operating revenues are recognized in the amounts we expect to be entitled to, which are the transaction prices allocated for the distinct services. Net operating revenues for our Hospital Operations and other and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare,

Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients (“Compact”) and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to healthcarehealth systems, as well as individual hospitals and physician practices, self-insured organizations, health plans and other entities.practices.

Net Patient Service Revenues—We report net patient service revenues at the amounts that reflect the consideration we expect to be entitled to in exchange for providing patient care. These amounts are due from patients, third-partythirdparty payers (including managed care payers and government programs) and others, and they include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, we bill our patients and third-partythird‑party payers several days after the services are performed or shortly after discharge. Revenues are recognized as performance obligations are satisfied.

We determine performance obligations based on the nature of the services we provide. We recognize revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. We believe that this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. We measure performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. We recognize revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when: (1) services are provided;provided and (2) we do not believe the patient requires additional services.

Because our patient service performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in ASC 606-10-50-14(a)FASB Accounting Standards Codification (“FASB ASC”) 606‑10‑50‑14(a) and, therefore, we are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

We determine the transaction price based on gross charges for services provided, reduced by contractual adjustments provided to third-partythird‑party payers, discounts provided to uninsured patients in accordance with our Compact, and implicit price concessions provided primarily to uninsured patients. We determine our estimates of contractual adjustments and discounts based on contractual agreements, our discount policies and historical experience. We determine our estimate of implicit price concessions based on our historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The financial statement effects of using this practical expedient are not materially different from an individual contract approach.

Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-lossstop‑loss payments). Because Medicare requires that a hospital’s gross charges be the same for all patients (regardless of payer category), gross charges are what hospitals charge all patients prior to the application of discounts and allowances.


Revenues under the traditional fee-for-servicefee‑for‑service (“FFS”) Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost-basedcost‑based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense reimbursement, which are based on our hospitals’ cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates we record could change by material amounts.
96

Table of Contents

We have a system and estimation process for recording Medicare net patient service revenue and estimated cost report settlements. As a result, we record accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as

previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted.

Settlements with third-partythird‑party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and our historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diemper‑diem rates, discounted fee-for-serviceFFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patientpatient‑by‑patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate-widecorporate‑wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

We know of no claims, disputes or unsettled matters with any payer that would materially affect our revenues for which we have not adequately provided in the accompanying Consolidated Financial Statements.

Generally, patients who are covered by third-partythird‑party payers are responsible for related co-pays, co-insuranceco‑pays, co‑insurance and deductibles, which vary in amount. We also provide services to uninsured patients and offer uninsured patients a discount from standard charges. We estimate the transaction price for patients with co-pays, co-insuranceco‑pays, co‑insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under our Compact and other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-payself‑pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self-payself‑pay accounts and other factors that affect the estimation process. There are various factors that can impact collection trends, such asas: changes in the economy, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients,patients; the volume of patients through our emergency departments,departments; the increased burden of co-pays, co-insuranceco‑pays, co‑insurance amounts and deductibles to be made by patients with insurance,insurance; and business practices related to collection efforts. These factors continuously change and can have an impact on collection trends and our estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.

We have provided implicit price concessions, primarily to uninsured patients and patients with co-pays, co-insuranceco‑pays, co‑insurance and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts we expect to collect based on our collection history with similar patients. Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co-pays, co-insuranceco‑pays, co‑insurance and deductibles due from patients with insurance, at the time of service while complying with all federal and state statutes and regulations, including, but not limited to, the Emergency Medical Treatment and Active Labor Act (“EMTALA”). Generally, as required by EMTALA, patients may not be denied emergency treatment due to inability to pay. Therefore, services, including the legally
97

Table of Contents
required medical screening examination and stabilization of the patient, are performed without delaying to obtain insurance information. In non-emergencynon‑emergency circumstances or for elective procedures and services, it is our policy to verify insurance prior to a patient being treated; however, there are various exceptions that can occur. Such exceptions can include, for example, instances where (1) we are unable to obtain verification because the patient’s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as

Medicaid or Victims of Crime, and it takes several days or weeks before qualification for such benefits is confirmed or denied, and (3) under physician orders we provide services to patients that require immediate treatment.

We also provide charity care to patients who are financially unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diemper‑diem amount for services received, subject to a cap. Except for the per-diemper‑diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Patient advocates from Conifer’s Medical Eligibility Programand Enrollment Services program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.

Conifer Revenues—Our Conifer segment recognizes revenue from its contracts when Conifer’s performance obligations are satisfied, which is generally as services are rendered. Revenue is recognized in an amount that reflects the consideration to which Conifer expects to be entitled.

At contract inception, Conifer assesses the services specified in its contracts with customers and identifies a performance obligation for each distinct contracted service. Conifer identifies the performance obligations and considers all the services provided under the contract. Conifer generally considers the following distinct services as separate performance obligations:

revenue cycle management services;

value-basedvalue‑based care services;

patient communication and engagement services;

consulting services; and

other client-definedclient‑defined projects.

Conifer’s contracts generally consist of fixed-price, volume-basedfixed‑price, volume‑based or contingency-basedcontingency‑based fees. Conifer’s long-termlong‑term contracts typically provide for Conifer to deliver recurring monthly services over a multi-yearmulti‑year period. The contracts are typically priced such that Conifer’s monthly fee to its customer represents the value obtained by the customer in the month for those services. Such multi-yearmulti‑year service contracts may have upfront fees related to transition or integration work performed by Conifer to set up the delivery for the ongoing services. Such transition or integration work typically does not result in a separately identifiable obligation; thus, the fees and expenses related to such work are deferred and recognized over the life of the related contractual service period. For contracts in which the amortization period of the asset is one year or less, we have elected to apply the practical expedient provided by FASB ASC 340‑40‑25‑4 and expense these costs as incurred.

Revenue for fixed-pricedfixed‑priced contracts is typically recognized at the time of billing unless evidence suggests that the revenue is earned or Conifer’s obligations are fulfilled in a different pattern. Revenue for volume-basedvolume‑based contracts is typically recognized as the services are being performed at the contractually billable rate, which is generally a percentage of collections or a percentage of client net patient revenue.

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $262 million$2.364 billion and $411 million$2.446 billion at December 31, 20192021 and 2018,2020, respectively. At December 31, 20192021 and 2018,2020, our book overdrafts were $246$226 million and $288$154 million, respectively, which were classified as accounts payable.

At December 31, 20192021 and 2018, $1762020, $188 million and $177$166 million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries, and $2 million and $8 million, respectively, of total cash and cash equivalents in the accompanying Consolidated Balance Sheets were intended for the operations of our health plan-related businesses.

insurance‑related subsidiaries.

At December 31, 2019, 20182021, 2020 and 2017,2019, we had $136$95 million, $135$93 million and $117$136 million,, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $119$88 million, $114$85 million and $79$119 million,, respectively, were included in accounts payable.
98

Table of Contents

During the years ended December 31, 2019, 2018 and 2017, we recorded non-cancellable capital (finance) leases of $141 million, $149 million and
$162 million, respectively, primarily for equipment.


Investments in Debt and Equity Securities

Prior to the adoption of ASU 2016-01 on January 1, 2018, we classifiedWe classify investments in debt and equity securities as either available-for-sale, held-to-maturityavailable‑for‑sale, held‑to‑maturity or as part of a trading portfolio. We carried securities classified as available-for-sale at fair value. We reported their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss) unless we determined that a loss was other-than-temporary, at which point we would record a loss in our consolidated statements of operations. We included realized gains or losses in our consolidated statements of operations based on the specific identification method.

SubsequentOur policy is to the adoption of ASU 2016-01 on January 1, 2018, we classify investments in debt securities that may be needed for cash requirements as either available-for-sale, held-to-maturity or as part of a trading portfolio, but these classifications are no longer applicable to equity securities.“available‑for‑sale.” At December 31, 2019,2021, we had no significant investments in debt securities classified as either held-to-maturityheld‑to‑maturity or trading. We carry debt securities classified as available-for-saleavailable‑for‑sale at fair value. We report their unrealized gains and losses, net of taxes, as accumulated other comprehensive income (loss) unless we determine that a loss is other-than-temporary,other‑than‑temporary, at which point we would record a loss in our consolidated statements of operations.

We carry equity securities at fair value, and we report their unrealized gains and losses in other non-operatingnon‑operating expense, net, in our consolidated statements of operations. If the equity security does not have a readily determinable fair value, the carrying value of the security is adjusted only when there is a price change that is observable from a transaction of an identical or similar investment. We include realized gains or losses in our consolidated statements of operations based on the specific identification method.

Investments in Unconsolidated Affiliates

We control 238257 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment operates (108(166 of 346423 at December 31, 2019)2021), as well as additional companies in which our Hospital Operations and other segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in the accompanying Consolidated Statements of Operations. In the years ended December 31, 2021 and 2020, equity in earnings of unconsolidated affiliates included $14 million and $17 million, respectively, from PRF grants recognized by our Ambulatory Care segment’s unconsolidated affiliates.

Summarized financial information for these equity method investees is included in the following table; among the equity method investees are 4 North Texas hospitals in which we held minority interests and that were operated by our Hospital Operations and other segment through the divestiture of these investments effective March 1, 2018. We recorded a gain of $11 million in the year ended December 31, 2018 due to the sales of our minority interest in these hospitals.table. For investments acquired during the reported periods, amounts reflect 100% of the investee’s results beginning on the date of our acquisition of the investment.
December 31,
 202120202019
Current assets$1,176 $1,309 $1,180 
Noncurrent assets$1,390 $1,262 $1,042 
Current liabilities$(495)$(516)$(372)
Noncurrent liabilities$(855)$(866)$(739)
Noncontrolling interests$(659)$(621)$(579)
 Years Ended December 31,
 202120202019
Net operating revenues$3,030 $2,665 $2,680 
Net income$836 $702 $765 
Net income attributable to the investees$499 $437 $499 
 December 31, 2019 December 31, 2018 December 31, 2017
Current assets$1,180
 $842
 $805
Noncurrent assets$1,042
 $662
 $1,223
Current liabilities$(372) $(313) $(354)
Noncurrent liabilities$(739) $(430) $(389)
Noncontrolling interests$(579) $(530) $(490)
      
 Years Ended December 31,
 2019 2018 2017
Net operating revenues$2,680
 $2,469
 $2,907
Net income$765
 $599
 $558
Net income attributable to the investees$499
 $372
 $363

Our equity method investment that contributes the most to our equity in earnings of unconsolidated affiliates is Texas Health Ventures Group, LLC (“THVG”), which is operated by USPI. THVG represented $107 million, $85 million and $79 million of the total $175 million equity in earnings of unconsolidated affiliates we recognized forof $218 million, $169 million and $175 million in the yearyears ended December 31, 2021, 2020 and 2019, $70 million of the total $150 million equity in earnings of unconsolidated affiliates we recognized for the year ended December 31, 2018 and $69 million of the total $144 million equity in earnings of unconsolidated affiliates we recognized for the year ended December 31, 2017.respectively.

Property and Equipment

Additions and improvements to property and equipment exceeding established minimum amounts with a useful life greater than one year are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. We use the straight-linestraight‑line method of depreciation for buildings, building improvements and equipment. The estimated useful life for buildings and improvements is primarily 15 to 40 years, and for equipment three to 15 years. Newly constructed hospitals are usually depreciated over 50 years. Interest costs related to construction projects are capitalized. In the years ended December 31, 2019, 20182021, 2020 and 2017,2019, capitalized interest was $4 million, $5 million and $11 million, $7 million and $15 million, respectively.


99

We evaluate our long-livedlong‑lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows. If the estimated future undiscounted cash flows are less than the carrying value of the assets, we calculate the amount of an impairment charge only if the carrying value of the long-livedlong‑lived assets exceeds thetheir fair value of the assets.value. The fair value of the assetsasset is estimated based on appraisals, established market values of comparable assets or internal estimates of future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. TheyEstimates require our subjective judgments and take into account assumptions about revenue and expense growth rates.rates, operating margins and recoverable disposition values, based on industry and operating factors. These assumptions may vary by type of facilityasset and presume stable, improving or, in some cases, declining results, at our hospitals or outpatient facilities, depending on their circumstances. If the presumed level of performance does not occur as expected, impairment may result.

We report long-livedlong‑lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows.

Leases

ASU 2016-02 was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Our adoption of ASU 2016-02 was accomplished using a modified retrospective method of application, and our accounting policies related to leases were revised accordingly effective January 1, 2019, as discussed below.

We determine if an arrangement is a lease at inception of the contract. Our right-of-useright‑of‑use assets represent our right to use the underlying assets for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-useRight‑of‑use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. We use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. For our Hospital Operations and other and Conifer segments, we estimate our incremental borrowing rates for our portfolio of leases using documented rates included in our recent equipment finance leases or, if applicable, recent secured debt issuances that correspond to various lease terms. We also give consideration to information obtained from our bankers, our secured debt fair value and publicly available data for instruments with similar characteristics. For our Ambulatory Care segment, we estimate an incremental borrowing rate for each center by utilizing historical and projected financial data, estimating a hypothetical credit rating using publicly available market data and adjusting the market data to reflect the effects of collateralization.

Our operating leases are primarily for real estate, including off-campusoff‑campus outpatient facilities, medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Our finance leases are primarily for medical equipment and information technology and telecommunications assets. Our real estate lease agreements typically have initial terms of five to 10 years, and our equipment lease agreements typically have initial terms of three years. We do not record leases with an initial term of 12 months or less (“short-termshort‑term leases”) in our consolidated balance sheets.

Our real estate leases may include one1 or more options to renew, with renewals that can extend the lease term from five to 10 years. The exercise of lease renewal options is at our sole discretion. In general, we do not consider renewal options to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of our right-of-useright‑of‑use assets and lease liabilities. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of our medical equipment leases have terms of three years with a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life, typically ranging from five to seven years. Similarly, some of our leases of information technology and telecommunications assets include a transfer of title and, therefore, have useful lives of 15 years.

Certain of our lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the right-of-useright‑of‑use asset or liability balances. Our lease agreements do not contain any material residual value guarantees, restrictions or covenants.

100

We have elected the practical expedient that allows lessees to choose to not separate lease and non-leasenon‑lease components by class of underlying asset and are applying this expedient to all relevant asset classes. We have also elected the practical

expedient package to not reassess at adoption (i) expired or existing contracts for whether they are or contain a lease, (ii) the lease classification of any existing leases or (iii) initial indirect costs for existing leases.

Goodwill and Other Intangible Assets

Goodwill represents the excess of costs over the fair value of assets of businesses acquired. Goodwill and other intangible assets acquired in purchase business combinations and determined to have indefinite useful lives are not amortized, but instead are subject to impairment tests performed at least annually. For goodwill, we perform the test at the reporting unit level when events occur that require an evaluation to be performed or at least annually. If we determine the carrying value of goodwill is impaired, or if the carrying value of a business that is to be sold or otherwise disposed of exceeds its fair value, we reduce the carrying value, including any allocated goodwill, to fair value. Estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows and presume stable, improving or, in some cases, declining results at our hospitals, depending on their circumstances.

Other intangible assets consist of capitalized software costs, which are amortized on a straight-linestraight‑line basis over the estimated useful life of the software, which ranges from three to 15 years, costs of acquired management and other contract service rights, most of which have indefinite lives, and miscellaneous intangible assets.

Accruals for General and Professional Liability Risks

We accrue for estimated professional and general liability claims, when they are probable and can be reasonably estimated. The accrual, which includes an estimate forof incurred but not reported claims, is updated each quarter based on a model of projected payments using case-specificcase‑specific facts and circumstances and our historical loss reporting, development and settlement patterns and is discounted to its net present value using a risk-free discount rate of 1.83% at December 31, 2019 and 2.59% at December 31, 2018.patterns. To the extent that subsequent claims information varies from our estimates, the liability is adjusted in the period such information becomes available. Malpractice expense is presented within other operating expenses in the accompanying Consolidated Statements of Operations.

Income Taxes

We account for income taxes using the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Income tax receivables and liabilities and deferred tax assets and liabilities are recognized based on the amounts that more likely than not will be sustained upon ultimate settlement with taxing authorities.


Developing our provision for income taxes and analysis of uncertain tax positions requires significant judgment and knowledge of federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets.


We assess the realization of our deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we determine whether it is more likely than not that all or a portion of the deferred tax assets will be realized. The main factors that we consider include:

Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;

Cumulative profits/losses in recent years, adjusted for certain nonrecurring items;
Income/losses expected in future years;

Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels;

The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and

The carryforward period associated with the deferred tax assets and liabilities.


Income/losses expected in future years; 

Unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels; 

The availability, or lack thereof, of taxable income in prior carryback periods that would limit realization of tax benefits; and 

The carryforward period associated with the deferred tax assets and liabilities.

We consider many factors when evaluating our uncertain tax positions, and such judgments are subject to periodic review. Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more likely than not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position

101

has expired. Tax benefits associated with an uncertain tax position are derecognized in the period in which the more likely than not recognition threshold is no longer satisfied.

Segment Reporting

We primarily operate acute care hospitals and related healthcare facilities. Our Hospital Operations and other segment generated 81%, 80% and 82% of our net operating revenues netin the year ended December 31, 2021 and 81% during both of implicit price concessions and provision for doubtful accounts in the years ended December 31, 2019, 20182020 and 2017, respectively.2019. At December 31, 2019,2021, each of our markets related to our general hospitals reported directly to our president and chief operatingexecutive officer. Major decisions, including capital resource allocations, are made at the consolidated level, not at the market or hospital level.

Our Hospital Operations and other segment is comprised of our acute care and specialty hospitals, ancillary outpatient facilities, urgent care centers, micro-hospitals and physician practices. As described in Note 5, certain of our facilities were classified as held for sale in the accompanying Consolidated Balance Sheet at December 31, 2019. Our Ambulatory Care segment is comprised of the operations of USPI and included 9 Aspen facilities in the United Kingdom until their divestiture effective August 17, 2018. Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other customers. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Costs Associated With Exit or Disposal Activities

We recognize costs associated with exit (including restructuring) or disposal activities when they are incurred and can be measured at fair value, rather than at the date of a commitment to an exit or disposal plan.

NOTE 2. EQUITY
Noncontrolling Interests

NONCONTROLLING INTERESTS
Our noncontrolling interests balances at December 31, 20192021 and 20182020 in the accompanying Consolidated Statements of Changes in Equity were comprised of $114$128 million and $112$116 million, respectively, from our Hospital Operations and other segment, and $740$898 million and $694$793 million, respectively, from our Ambulatory Care segment. Our net income attributable to noncontrolling interests for the years ended December 31, 2019, 20182021, 2020 and 20172019 were comprised of $16$21 million, $8$14 million and $11$16 million, respectively, from our Hospital Operations and other segment, and $178$205 million, $157$169 million and $134$178 million, respectively, from our Ambulatory Care segment.

NOTE 3. ACCOUNTS RECEIVABLE

The principal components of accounts receivable are shown in the table below:
December 31,
 20212020
Continuing operations:  
Patient accounts receivable$2,600 $2,499 
Estimated future recoveries137 156 
Net cost reports and settlements receivable and valuation allowances33 34 
 2,770 2,689 
Discontinued operations— 
Accounts receivable, net 
$2,770 $2,690 
 December 31, 2019 December 31, 2018
Continuing operations: 
  
Patient accounts receivable$2,567
 $2,427
Estimated future recoveries162
 148
Net cost reports and settlements receivable and valuation allowances12
 18
 2,741
 2,593
Discontinued operations2
 2
Accounts receivable, net 
$2,743
 $2,595


Accounts that are pursued for collection through Conifer’s business offices are maintained on our hospitals’ books and reflected in patient accounts receivable. Patient accounts receivable, including billed accounts and certain unbilled accounts, as well as estimated amounts due from third-partythird‑party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. Estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts.

We had $316 million and $213 million of receivables recorded in other current assets and investments and other assets, respectively, and $115 million and $57 million of payables recorded in other current liabilities and other long-term liabilities, respectively, in the accompanying Consolidated Balance Sheet at December 31, 2019 related to California’s provider

fee program. We had $278 million and $231 million of receivables recorded in other current assets and investments and other assets, respectively, and $100 million and $42 million of payables recorded in other current liabilities and other long-term liabilities, respectively, in the accompanying Consolidated Balance Sheet at December 31, 2018 related to California’s provider fee program.    

We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid disproportionate share hospital (“DSH”) payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.

102

Table of Contents
We participate in various provider fee programs, which help reduce the amount of uncompensated care from indigent patients and those paying with Medicaid. The following table summarizes the amount and classification of assets and liabilities in the accompanying Consolidated Balance Sheets related to California’s provider fee program:
December 31,
 20212020
Assets:
Other current assets$370 $378 
Investments and other assets$213 $206 
Liabilities:
Other current liabilities$123 $110 
Other long-term liabilities$60 $56 

The following table shows our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses and which exclude the costs of our now-divested health plan businesses) of caring for our uninsured and charity patients in the years ended December 31, 2019, 2018 and 2017.patients:
 Years Ended December 31,
 202120202019
Estimated costs for:   
Uninsured patients$650 $617 $664 
Charity care patients97 147 156 
Total$747 $764 $820 
 Years Ended December 31,
 2019 2018 2017
Estimated costs for: 
  
  
Uninsured patients$666
 $640
 $648
Charity care patients156
 124
 121
Total$822
 $764
 $769


NOTE 4. CONTRACT BALANCES

Hospital Operations and Other Segment
Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations and other segment, our contract assets consist primarily ofinclude services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations and other segment’s contract assets arewere included in other current assets in the accompanying Consolidated Balance SheetSheets at December 31, 2019. The opening2021 and closing balances of contract assets for our Hospital Operations and other segment are as follows:
December 31, 2018 $169
December 31, 2019 170
Increase/(decrease) $1
   
January 1, 2018 $171
December 31, 2018 169
Increase/(decrease) $(2)


2020. Approximately 85%91% of our Hospital Operations and other segment’s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days.

In certain circumstances, when a hospital is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the Medicare accelerated payment program. As discussed in Note 1, the COVID Acts revised the Medicare accelerated payment program to disburse payments more quickly. During the year ended December 31, 2020, our Hospital Operations segment received advance payments from the Medicare accelerated payment program following its expansion under the COVID Acts. No additional advances were received during the year ended December 31, 2021. The advance payments received were recorded as contract liabilities in the accompanying Consolidated Balance Sheets at December 31, 2021 and 2020.

The opening and closing balances of contract assets and contract liabilities for our Hospital Operations segment were as follows:
Contract Liability –Contract Liability –
CurrentLong-term
Contract AssetsAdvances from MedicareAdvances from Medicare
December 31, 2020$208 $510 $819 
December 31, 2021181 876 — 
Increase (decrease)$(27)$366 $(819)
December 31, 2019$170 $— $— 
December 31, 2020208 510 819 
Increase$38 $510 $819 
103

Table of Contents

Ambulatory Care Segment
During the year ended December 31, 2020, our Ambulatory Care segment also received advance payments from the Medicare accelerated payment program. In addition to the advances received by our Ambulatory Care segment, contract liabilities and contract liabilities – long‑term in the accompanying Consolidated Balance Sheet included $51 million and $62 million, respectively, of Medicare advance payments received by our unconsolidated affiliates for which we provide cash management services at December 31, 2020.

The opening and closing balances of contract liabilities for our Ambulatory Care segment were as follows:
Contract Liability –Contract Liability –
CurrentLong-term
Advances from MedicareAdvances from Medicare
December 31, 2020$93 $83 
December 31, 2021— 
Decrease$(89)$(83)
December 31, 2019$— $— 
December 31, 202093 83 
Increase$93 $83 

Conifer Segment

Conifer enters into contracts with customers to sell revenue cycle management and other services, such as value-based care, consulting and project services. The payment terms and conditions in our customer contracts vary. In some cases, customers are invoiced in advance and (for other than fixed-price fee arrangements) a true-up to the actual fee is included on a subsequent invoice. In other cases, payment is due in arrears. In addition, some contracts contain performance incentives, penalties and other forms of variable consideration. When the timing of Conifer’s delivery of services is different from the timing of payments made by the customers, Conifer recognizes either unbilled revenue (performance precedes contractual right to invoice the customer) or deferred revenue (customer payment precedes Conifer service performance). In the following table, customers that prepay prior to obtaining control/benefit of the service are represented by deferred contract revenue until the performance obligations are satisfied. Unbilled revenue represents arrangements in which Conifer has provided services to and the customer has obtained control/benefit of services prior to the contractual invoice date. Contracts with payment in arrears are recognized as receivables in the month the service is performed.

The opening and closing balances of Conifer’s receivables, contract asset, and current and long-termlong‑term contract liabilities arewere as follows:
Contract Liability –Contract Liability –
Contract Asset –CurrentLong-Term
ReceivablesUnbilled RevenueDeferred RevenueDeferred Revenue
December 31, 2020$56 $20 $56 $16 
December 31, 202128 18 79 15 
Increase (decrease)$(28)$(2)$23 $(1)
December 31, 2019$26 $11 $61 $18 
December 31, 202056 20 56 16 
Increase (decrease)$30 $9 $(5)$(2)
      Contract Liability- Contract Liability-
    Contract Asset- Current Long-Term
  Receivables Unbilled Revenue Deferred Revenue Deferred Revenue
December 31, 2018 $42
 $11
 $61
 $20
December 31, 2019 26
 11
 61
 18
Increase/(decrease) $(16) $
 $
 $(2)
         
January 1, 2018 $89
 $10
 $80
 $21
December 31, 2018 42
 11
 61
 20
Increase/(decrease) $(47) $1
 $(19) $(1)

The differencedifferences between the opening and closing balances of Conifer’s contract assets and contract liabilities are primarily related to prepayments for those customers who are billed in advance, changes in estimates related to metric-basedmetric‑based services, and up-frontup‑front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment’s receivables and contract assets arewere reported as part of other current assets in ourthe accompanying Consolidated Balance Sheets, and our Conifer segment’sits current and long-termlong‑term contract liabilities arewere reported as part of other currentcontract liabilities and other long-termcontract liabilities – long‑term, respectively, in ourthe accompanying Consolidated Balance Sheets.

The amount of revenue Conifer recognized inIn the years ended December 31, 20192021 and 20182020, Conifer recognized $56 million and $61 million, respectively, of revenue that was included in the opening current deferred revenue liability was $61 million and $72 million, respectively.liability. This revenue consists primarily of prepayments for those customers who are billed in advance, changes in estimates related to metric-basedmetric‑based services, and up-frontup‑front integration services that are recognized over the services period.

Contract Costs

We have electedrecognized amortization expense related to apply the practical expedient provided by FASB Accounting Standards Codification 340-40-25-4 and expense as incurred the incremental customer contract acquisition costs for contracts in which the amortization period of the asset is one year or less. However, incremental costs incurred to obtain and fulfill customer contracts for which the amortization period of the asset is longer than one year, which consist primarily of Conifer deferred contract setup costs are capitalized and amortized on a straight-line basis over the lesser of their estimated useful lives or the term$4 million in both of the related contract. During the years ended December 31, 2019, 20182021 and 2017, we recognized amortization expense of2020, and $5 million $11 million and 10 million, respectively.in the year ended December 31, 2019. At December 31, 20192021 and 2018,2020, the unamortized customer contract costs were $25$23 million and $28$24 million, respectively, and arewere presented as part of investments and other assets in the accompanying Consolidated Balance Sheets.


104

Table of Contents
NOTE 5. ASSETS AND LIABILITIES HELD FOR SALE
In August 2021, we completed the sale of 5 Miami‑area hospitals and certain related operations (the “Miami Hospitals”) held by our Hospital Operations segment. We recognized a pre‑tax gain on sale of $406 million during the year ended December 31, 2021, which was included in net losses (gains) on sales, consolidation and deconsolidation of facilities in the accompanying Consolidated Statement of Operations.

In the three months ended June 30, 2021, we completed the sale of the majority of our urgent care centers operated under the MedPost and CareSpot brands by our Hospital Operations and Ambulatory Care segments. During the same period, we also completed the sale of a building we owned in the Philadelphia area that was held by our Hospital Operations segment. The assets and liabilities related to the urgent care centers and the building were classified as held for sale at December 31, 2020 in the accompanying Consolidated Balance Sheet. We recorded pre‑tax gains of $14 million and $2 million related to the sale of the urgent care centers and the sale of the building in Philadelphia, respectively, in the year ended December 31, 2021.

In the fourth quarter of 2019, we reached a definitive agreement to sell 2 of our hospitals and other operations in the Memphis area metand we classified the criteria to be classifiedrelated assets and liabilities as held for sale. As a result, we have classified these assets totaling $387 million as “assets held for sale”sale in current assets and the related liabilities of $44 million as “liabilities held for sale” in current liabilities in the accompanying Consolidated Balance Sheetour consolidated balance sheet at December 31, 2019. We recorded impairment charges of $26 millionFollowing action by the U.S. Federal Trade Commission to challenge the proposed transaction, we determined in December 2020 that we no longer intend to pursue the year ended December 31, 2019 for the write-downsale of the hospitals and related operations. These assets and liabilities were removed from assets and liabilities held for sale to their estimated fair value, less estimated costs to sell, as a result of the planned divestiture of these assets.


Assetsin December 2020 and liabilities classifiedreclassified as held for sale at December 31, 2019 were comprised of the following:and used in our consolidated balance sheet.
Accounts receivable $108
Other current assets 24
Investments and other long-term assets 6
Property and equipment 184
Other intangible assets 23
Goodwill 42
Current liabilities (35)
Long-term liabilities (9)
Net assets held for sale $343


In the three months ended March 31,first quarter of 2019, we completed the sale of 3 of our hospitals in the Chicago area, as well as other operations affiliated with the hospitals; these assets and liabilities were classified as held for sale beginning in the three months ended December 31,fourth quarter of 2017. Related to this transaction, we recorded a loss on sale of $14 million in the year ended December 31, 2019, and impairment charges of $24$5 million and $73$14 million in the years ended December 31, 20182020 and December 31, 2017, respectively,2019, respectively.

Gains and losses related to the sales described above were included in net losses (gains) on sales, consolidation and deconsolidation of facilities in the accompanying Consolidated Statements of Operations in the respective years in which they were realized.

During the year ended December 31, 2019, we recognized an impairment charge of $26 million for the write-downwrite‑down of the assets held for sale to their estimated fair value, less estimated costs to sell.

sell, as a result of planned divestitures. No impairment charge was incurred during the years ended December 31, 2021 and 2020 related to planned divestitures.

The following table provides information on significant components of our business that have beenwere recently disposed of or are classified as held for sale at December 31, 2019:of:
 Years Ended December 31,
 2019 2018 2017
Significant disposals:   
  
Loss from continuing operations, before income taxes      
Chicago area (includes a $14 million loss on sale in the 2019 period, $24 million of impairment charges in the 2018 period and $73 million of impairment charges in the 2017 period)$(19) $(41) $(82)
Total$(19) $(41) $(82)
      
Significant planned divestitures classified as held for sale:     
Income from continuing operations, before income taxes     
Memphis area (includes $26 million of impairment charges in the 2019 period)$8
 $23
 $33
Total$8
 $23
 $33
 Years Ended December 31,
 202120202019
Significant disposals:  
Income (loss) from continuing operations, before income taxes:
Chicago-area hospitals (includes a $5 million loss on sale in the 2020 period and a $14 million loss on sale in the 2019 period)$(2)$$(19)
Miami Hospitals (includes a $406 million gain on sale in 2021)455 67 44 
Total$453 $70 $25 


NOTE 6. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS

We recognized impairment charges on long-livedlong‑lived assets in 2019, 20182021, 2020 and 20172019 because the fair values of those assets or groups of assets indicated that the carrying amount was not recoverable. The fair value estimates were derived from appraisals, established market values of comparable assets, or internal estimates of future net cash flows. These fair value estimates can change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the future financial results of the hospitals, how the hospitals are operated in the future, changes in healthcare industry trends and regulations, and the nature of the ultimate disposition of the assets. In certain cases, these fair value estimates assume the highest and best use of hospital assets in the future to a market placemarketplace participant is other than as a hospital. In these cases, the estimates are based on the fair value of the real property and equipment if utilized other than as a hospital. The impairment recognized does not include the costs of closing the hospitals or other future operating costs, which could be substantial. Accordingly, the ultimate net cash realized from the hospitals, should we choose to sell them, could be significantly less than their impaired value.

105

Table of Contents
Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve theeach facility’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, future impairments of long-livedlong‑lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

At December 31, 2019,2021, our continuing operations consisted of 3 reportable segments Hospital Operations, and other, Ambulatory Care and Conifer. Our segments are reporting units used to perform our goodwill impairment analysis. We completed our annual impairment tests for goodwill as of October 1, 2019.2021.


We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effectivecost‑effective structure, such as the establishment of offshore support operations at our GBC in the Republic of the Philippines that we began in the year ended December 31, 2019.GBC. Certain restructuring and acquisition-relatedacquisition‑related costs are based on estimates. Changes in estimates are recognized as they occur.

Year Ended December 31, 20192021

During the year ended December 31, 2019,2021, we recorded impairment and restructuring charges and acquisition-relatedacquisition‑related costs of $185$85 million, consisting of $42$57 million of restructuring charges, $8 million of impairment charges $137and $20 million of restructuring charges and $6 million of acquisition-relatedacquisition‑related costs. ImpairmentRestructuring charges consisted of $26$14 million of employee severance costs, $19 million related to the transition of various administrative functions to our GBC and $24 million of other restructuring costs. Impairments primarily consisted of charges to write-downreduce the carrying value of certain management contract intangible assets held for saleby our Ambulatory Care segment to their estimated fair value, less estimated costs to sell, for certain of our Memphis-area facilities and $16 million of othervalue. Our impairment charges. Of the total impairment charges recognized for the year ended December 31, 2019, $312021 were comprised of $5 million related to our Hospital Operations and other segment, $6 million related tofrom our Ambulatory Care segment and $5$3 million related tofrom our Conifer segment. Restructuring charges consisted of $57 million of employee severance costs, $28 million Acquisition‑related to our GBC in the Republic of the Philippines, $6 million of contract and lease termination fees, and $46 million of other restructuring costs. Acquisition-related costs consisted of $6$20 million of transaction costs.

Year Ended December 31, 2018

2020
During the year ended December 31, 2018,2020, we recorded impairment and restructuring charges and acquisition-relatedacquisition‑related costs of $209$290 million, consisting of $77$92 million of impairment charges, $115$184 million of restructuring charges and $17$14 million of acquisition-relatedacquisition‑related costs. Impairment charges included $40$76 million for the write-downwrite‑down of hospital buildings and other long-lived assets to their estimated fair values, at 2 hospitals.which assets are part of our Hospital Operations segment. Material adverse trends in our then recent estimates of future undiscounted cash flows of the hospitals indicated the aggregate carrying value of the hospitals’ long-livedlong‑lived assets was not recoverable from the estimated future cash flows. We believe the most significant factors contributing to the adverse financial trends included reductions in volumes of insured patients, shifts in payer mix from commercial to governmental payers combined with reductions in reimbursement rates from governmental payers, and high levels of uninsured patients. As a result, we updated the estimate of the fair value of the hospitals’ long-livedlong‑lived assets and compared the fair value estimateit to the aggregate carrying value of the hospitals’ long-livedthose assets. Because the fair value estimates were lower than the aggregate carrying value of the long-livedlong‑lived assets, an impairment charge was recorded for the difference in the amounts. The aggregate carrying value of the hospitals’ assets held and used of the hospitals for which impairment charges were recorded was $130$483 million at December 31, 2018 after recording the impairment charges.2020. We also recorded $24$16 million of other impairment charges. Restructuring charges consisted of $65 million of employee severance costs, $50 million related to the transitioning of various administrative functions to our GBC, $23 million of charges due to the termination of the USPI management equity plan, $14 million of contract and lease termination fees, and $32 million of other restructuring costs. Acquisition‑related costs consisted of $14 million of transaction costs. Our impairment charges for the year ended December 31, 2020 were comprised of $79 million from our Hospital Operations segment, $12 million from our Ambulatory Care segment and $1 million from our Conifer segment.

Year Ended December 31, 2019
During the year ended December 31, 2019, we recorded impairment and restructuring charges and acquisition‑related costs of $185 million, consisting of $42 million of impairment charges, $137 million of restructuring charges and $6 million of acquisition‑related costs. Impairment charges consisted of $26 million of charges to write-downwrite‑down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Chicago-areaMemphis-area facilities $9 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen and $4$16 million of other impairment charges. Of the total impairment charges recognized for the year ended December 31, 2018, $672019, $31 million related to our Hospital Operations and other segment, $9$6 million related to our Ambulatory Care segment, and $1$5 million related to our Conifer segment. Restructuring charges consisted of $68$57 million of employee severance costs, $17$28 million related to the transitioning of various administrative functions to our GBC, $6 million of contract and lease termination fees, and $30$46 million of other restructuring costs. Acquisition-related costs consisted of $10 million of transaction costs and $7 million of acquisition integration charges.

Year Ended December 31, 2017

During the year ended December 31, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $541 million, consisting of $402 million of impairment charges, $117 million of restructuring charges and $22 million of acquisition-related costs. Impairment charges consisted of $364 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen, our Philadelphia-area facilities and certain of our Chicago-area facilities, $31 million for the impairment of 2 equity method investments and $7 million to write-down intangible assets. Of the total impairment charges recognized for the year ended December 31, 2017, $337 million Acquisition‑related to our Hospital Operations and other segment, $63 million related to our Ambulatory Care segment, and $2 million related to our Conifer segment. Restructuring charges consisted of $82 million of employee severance costs, $15 million of contract and lease termination fees, and $20 million of other restructuring costs. Acquisition-related costs consisted of $6 million of transaction costs and $16 millioncosts.

106

Table of acquisition integration charges.Contents


NOTE 7. LEASES

The following table presents the components of our right-of-useright‑of‑use assets and liabilities related to leases and their classification in our Consolidated Balance Sheet at December 31, 2019:Sheets at:
December 31,
Component of Lease BalancesClassification in Consolidated Balance Sheet20212020
Assets:  
Operating lease assetsInvestments and other assets$1,002 $1,062 
Finance lease assets
Property and equipment, at cost, less
accumulated depreciation and amortization
333 345 
Total leased assets$1,335 $1,407 
Liabilities:
Operating lease liabilities:
CurrentOther current liabilities$201 $188 
Long-termOther long-term liabilities924 999 
Total operating lease liabilities1,125 1,187 
Finance lease liabilities:
CurrentCurrent portion of long-term debt106 122 
Long-termLong-term debt, net of current portion176 151 
Total finance lease liabilities282 273 
Total lease liabilities$1,407 $1,460 
Component of Lease Balances Classification in Consolidated Balance Sheet December 31, 2019
Assets:    
Operating lease assets Investments and other assets $912
Finance lease assets Property and equipment, at cost, less
accumulated depreciation and amortization
 407
Total leased assets   $1,319
     
Liabilities:    
Operating lease liabilities:    
Current Other current liabilities $159
Long-term Other long-term liabilities 858
Total operating lease liabilities   1,017
Finance lease liabilities:    
Current Current portion of long-term debt 143
Long-term Long-term debt, net of current portion 182
Total finance lease liabilities   325
Total lease liabilities   $1,342


The following table presents the components of our lease expense and their classification in our Consolidated StatementStatements of Operations for the year ended December 31, 2019:Operations:
Component of Lease ExpenseClassification in Consolidated Statements of OperationsYears Ended December 31,
202120202019
Operating lease expenseOther operating expenses, net$241 $247 $211 
Finance lease expense:
Amortization of leased assetsDepreciation and amortization71 86 85 
Interest on lease liabilitiesInterest expense11 15 
Total finance lease expense80 97 100 
Variable and short term-lease expenseOther operating expenses, net171 156 133 
Total lease expense$492 $500 $444 
    Year Ended
Component of Lease Expense Classification on Consolidated Statements of Operations December 31, 2019
Operating lease expense Other operating expenses, net $211
Finance lease expense:    
Amortization of leased assets Depreciation and amortization 85
Interest on lease liabilities Interest expense 15
Total finance lease expense   100
Variable and short term-lease expense Other operating expenses, net 133
Total lease expense   $444

The weighted-averageweighted‑average lease terms and discount rates for operating and finance leases are presented in the following table:
Years Ended December 31,
202120202019
Weighted-average remaining lease term (years):
Operating leases7.57.97.8
Finance leases5.75.75.4
Weighted-average discount rate:
Operating leases5.1 %5.5 %5.6 %
Finance leases5.4 %5.6 %5.5 %

107

December 31, 2019
Weighted-average remaining lease term (years)
Operating leases7.8
Finance leases5.4
Weighted-average discount rate
Operating leases5.6%
Finance leases5.5%
Table of Contents

Cash flow and other information related to leases is included in the following table:
Years Ended December 31,
202120202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases$237 $239 $197 
Operating cash outflows from finance leases$12 $15 $18 
Financing cash outflows from finance leases$140 $154 $151 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$176 $304 $249 
Finance leases$136 $98 $141 
  Year Ended
  December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:  
Operating cash outflows from operating leases $197
Operating cash outflows from finance leases $18
Financing cash outflows from finance leases $151
   
Right-of-use assets obtained in exchange for lease obligations:  
Operating leases $249
Finance leases $141


Future maturities of lease liabilities at December 31, 20192021 are presented in the following table:
Operating LeasesFinance LeasesTotal
2022$236 $116 $352 
2023211 76 287 
2024185 48 233 
2025156 16 172 
2026124 11 135 
Later years456 83 539 
Total lease payments1,368 350 1,718 
Less: Imputed interest243 68 311 
Total lease obligations1,125 282 1,407 
Less: Current obligations201 106 307 
Long-term lease obligations$924 $176 $1,100 
  Operating Leases Finance Leases Total
2020 $159
 $143
 $302
2021 180
 96
 276
2022 160
 38
 198
2023 140
 10
 150
2024 121
 9
 130
Later years 504
 91
 595
Total lease payments 1,264
 387
 1,651
Less: Imputed interest 247
 62
 309
Total lease obligations 1,017
 325
 1,342
Less: Current obligations 159
 143
 302
Long-term lease obligations $858
 $182
 $1,040


Future maturities of lease liabilities at December 31, 2018, prior to our adoption of ASU 2016-02, are presented in the following table:
   Years Ending December 31, Later Years
 Total 2019 2020 2021 2022 2023 
Capital lease obligations$425
 $140
 $95
 $57
 $37
 $21
 $75
Long-term non-cancelable operating leases$932
 $171
 $151
 $133
 $113
 $92
 $272


Rental expense under operating leases, including short-term leases, was $326 million and $340 million in the years ended December 31, 2018 and 2017, respectively. Included in rental expense for each of these periods was sublease income of $11 million and $14 million, respectively, which was recorded as a reduction of rental expense.

NOTE 8. LONG-TERM DEBT

The table below shows our long-termlong‑term debt as of December 31, 2019 and 2018:included in the accompanying Consolidated Balance Sheets:
December 31,
 20212020
Senior unsecured notes:  
6.750% due 2023$1,872 $1,872 
7.000% due 2025— 478 
6.125% due 20282,500 2,500 
6.875% due 2031362 362 
Senior secured first lien notes:  
4.625% due 2024770 1,870 
4.625% due 2024600 600 
7.500% due 2025700 700 
4.875% due 20262,100 2,100 
5.125% due 20271,500 1,500 
4.625% due 2028600 600 
4.250% due 20291,400 — 
4.375% due 20301,450 — 
Senior secured second lien notes:
5.125% due 2025— 1,410 
6.250% due 20271,500 1,500 
Finance leases, mortgage and other notes443 403 
Unamortized issue costs and note discounts(151)(176)
Total long-term debt15,646 15,719 
Less current portion135 145 
Long-term debt, net of current portion$15,511 $15,574 
 December 31, 2019 December 31, 2018
Senior unsecured notes:   
  
5.500% due 2019$
 $468
6.750% due 2020
 300
8.125% due 20222,800
 2,800
6.750% due 20231,872
 1,872
7.000% due 2025478
 478
6.875% due 2031362
 362
Senior secured first lien notes: 
  
4.750% due 2020
 500
6.000% due 2020
 1,800
4.500% due 2021
 850
4.375% due 2021
 1,050
4.625% due 20241,870
 1,870
4.625% due 2024600
 
4.875% due 20262,100
 
5.125% due 20271,500
 
Senior secured second lien notes:   
7.500% due 2022
 750
5.125% due 20251,410
 1,410
6.250% due 20271,500
 
Finance leases and mortgage notes445
 500
Unamortized issue costs and note discounts(186) (184)
Total long-term debt14,751
 14,826
Less current portion171
 182
Long-term debt, net of current portion$14,580
 $14,644


108


Table of Contents
Credit Agreement

We amended ourhave a senior secured revolving credit facility in September 2019 (as amended, the “Credit Agreement”) to provide, subject to borrowing availability,that provides for revolving loans in an aggregate principal amount of up to $1.5$1.900 billion (from a previous limit of $1.0 billion), with a $200 million subfacility for standby letters of credit. ObligationsWe amended our credit agreement (as amended to date, the “Credit Agreement”) in April 2020 to, among other things, (i) increase the aggregate revolving credit commitments from the previous limit of $1.500 billion to $1.900 billion (the “Increased Commitments”), subject to borrowing availability, and (ii) increase the advance rate and raise limits on certain eligible accounts receivable in the calculation of the borrowing base, in each case, for an incremental period of 364 days. In April 2021, we further amended the Credit Agreement to, among other things, extend the availability of the Increased Commitments through April 22, 2022 and reduce the interest rate margins. At December 31, 2021, we had no cash borrowings outstanding under the Credit Agreement, which now hasand we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.797 billion was available for borrowing at December 31, 2021.

The Credit Agreement continues to have a scheduled maturity date of September 12, 2024, areand obligations under the Credit Agreement continue to be guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priorityfirst‑priority lien on the eligible inventory and accounts receivable owned by us and the subsidiary guarantors, including receivables for Medicaid supplemental payments as of the most recent amendment. payments.

Outstanding revolving loans accrue interest depending on the type of loan at either (i) a base rate plus a margin ranging from 0.25% to 0.75% per annum, or (ii) the LondonEuro Interbank Offered Rate (“LIBOR”) plus a margin ranging from 1.25% to 1.75% per annum, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible inventory and accounts receivable, including self-payself‑pay accounts. At December 31, 2019, we were in compliance with all covenants and conditions in our Credit Agreement. At December 31, 2019, we had 0 cash borrowings outstanding under the Credit Agreement, and we had $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.499 billion was available for borrowing under the Credit Agreement at December 31, 2019.

Letter of Credit Facility

We have a letter of credit facility (as amended, the “LC Facility”) that provides for the issuance of standby and documentary letters of credit. In March 2020, we amended our letter of credit from timefacility (as amended, the “LC Facility”) to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). Theextend the scheduled maturity date of the LC Facility isfrom March 7, 2021 to September 12, 2024 and to increase the aggregate principal amount of standby and documentary letters of credit that from time to time may be issued thereunder from $180 million to $200 million. In July 2020, we further amended the LC Facility to incrementally increase the maximum secured debt covenant from 4.25 to 1.00 on a quarterly basis up to 6.00 to 1.00 for the quarter ended March 31, 2021, at which point the maximum ratio began to step down incrementally on a quarterly basis through the quarter ended December 31, 2021. At December 31, 2021, the effective maximum secured debt covenant was 4.25 to 1.00, where it will remain until maturity. Obligations under the LC Facility are guaranteed and secured by a first-priorityfirst‑priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal equal‑ranking basis with our senior secured first lien notes.

Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within three3 business days after notice thereof accrue interest at a base rate plus a margin equal toof 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured debt-to-EBITDAdebt‑to‑EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit accrues at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. At December 31, 2019, we were in compliance with all covenants and conditions in our LC Facility. At December 31, 2019,2021, we had $92$139 million of standby letters of credit outstanding under the LC Facility.Facility and were in compliance with all applicable covenants and conditions.

Senior Secured Notes and Senior Unsecured Notes

On December 1, 2021, we issued $1.450 billion aggregate principal amount of 4.375% senior secured first lien notes, which will mature on January 15, 2030 (the “2030 Senior Secured First Lien Notes”). We will pay interest on the 2030 Senior Secured First Lien Notes semi‑annually in arrears on January 15 and July 15 of each year, commencing on July 15, 2022. We used the net proceeds from the issuance of the 2030 Senior Secured First Lien Notes, after payment of fees and expenses, to finance the acquisition of the SCD Centers in December 2021 and for general corporate purposes.

On September 10, 2021, we redeemed approximately $1.100 billion of the then‑outstanding $1.870 billion aggregate principal amount of our 4.625% senior secured first lien notes due 2024 in advance of their maturity date. We paid $1.113 billion to redeem the notes, which was primarily funded with the proceeds from the sale of the Miami Hospitals in August 26, 2019,2021. In connection with the redemption, we recorded a loss from early extinguishment of debt of $20 million in the three months ended September 30, 2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.
109

Table of Contents

On June 2, 2021, we issued $1.400 billion aggregate principal amount of 4.250% senior secured first lien notes, which will mature on June 1, 2029 (the “2029 Senior Secured First Lien Notes”). We pay interest on the 2029 Senior Secured First Lien Notes semi‑annually in arrears on June 1 and December 1 of each year, which payments commenced on December 1, 2021. The proceeds from the sale of the 2029 Senior Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $1.410 billion aggregate principal amount then outstanding of our 5.125% senior secured second lien notes due 2025 (the “2025 Senior Secured Second Lien Notes”) in advance of their maturity date for approximately $1.428 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $31 million in the three months ended June 30, 2021, primarily related to the difference between the purchase price and the par value of the 2025 Senior Secured Second Lien Notes, as well as the write‑off of associated unamortized issuance costs.

In March 2021, we retired all $478 million aggregate principal amount outstanding of our 7.000% senior unsecured notes due 2025 in advance of their maturity date. We paid approximately $495 million from cash on hand to retire the notes. In connection with the retirement, we recorded a loss from early extinguishment of debt of $23 million in the three months ended March 31, 2021, primarily related to the difference between the purchase price and the par value of the notes, as well as the write‑off of associated unamortized issuance costs.

In September 2020, we sold $2.500 billion aggregate principal amount of 6.125% senior notes, which will mature on October 1, 2028 (the “2028 Senior Notes”). We pay interest on the 2028 Senior Notes semi‑annually in arrears on April 1 and October 1 of each year, which payments commenced on April 1, 2021. The proceeds from the sale of the 2028 Senior Notes were used, after payment of fees and expenses, together with cash on hand, to finance the redemption of all $2.556 billion aggregate principal amount then outstanding of our 8.125% senior unsecured notes due 2022 (the “2022 Senior Notes”) for approximately $2.843 billion. In connection with the redemption, we recorded a loss from early extinguishment of debt of approximately $305 million in the three months ended September 30, 2020, primarily related to the difference between the purchase price and the par value of the 2022 Senior Notes, as well as the write‑off of associated unamortized issuance costs.

Through a series of transactions during June, July and August 2020, we purchased approximately $244 million aggregate principal amount of our 2022 Senior Notes for approximately $256 million. In connection with the purchases, we recorded a loss from early extinguishment of debt totaling $15 million in the year ended December 31, 2020, primarily related to the differences between the purchase prices and the par values of the 2022 Senior Notes, as well as the write‑off of associated unamortized issuance costs.

In June 2020, we sold $600 million aggregate principal amount of 4.625% senior secured first lien notes, which will mature on September 1, 2024June 15, 2028 (the “2024“2028 Senior Secured First Lien Notes”), $2.1 billion. We pay interest on the 2028 Senior Secured First Lien Notes semi‑annually in arrears on June 15 and December 15 of each year, which payments commenced on December 15, 2020.

In April 2020, we sold $700 million aggregate principal amount of 4.875%7.500% senior secured first lien notes, which will mature on JanuaryApril 1, 20262025 (the “2026 Senior Secured First Lien Notes”) and $1.5 billion aggregate principal amount of 5.125% senior secured first lien notes, which will mature on November 1, 2027 (the “2027“2025 Senior Secured First Lien Notes”). We will pay interest on the 20242025 Senior Secured First Lien Notes semi-annuallysemi‑annually in arrears on MarchApril 1 and September 1 of each year, which payments will commence on March 1, 2020. We will pay interest on the 2026 Senior Secured First Lien Notes semi-annually in arrears on January 1 and July 1 of each year, which payments will commence on January 1, 2020. We will pay interest on the 2027 Senior Secured First Lien Notes semi-annually in arrears on May 1 and November 1 of each year, which payments will commence on May 1, 2020. The proceeds from the sales of these notes were used, after payment of fees and expenses, together with cash on hand and borrowings under our senior secured revolving credit facility, to fund the redemptions of all $500 million aggregate principal amount of our outstanding 4.750% senior secured first lien notes due 2020, all $1.8 billion aggregate principal amount of our outstanding 6.000% senior secured first lien notes due 2020, all $850 million aggregate principal amount of our outstanding 4.500% senior secured first lien notes due 2021 and all $1.05 billion aggregate principal amount of our outstanding 4.375% senior secured first lien notes due 2021. In connection with the redemptions, we recorded a loss from early extinguishment of debt of approximately $180 million in the three months ended September 30, 2019, primarily related to the difference between the redemption prices and the par values of the notes, as well as the write-off of the associated unamortized issuance costs.
On February 5, 2019, we sold $1.5 billion aggregate principal amount of 6.250% senior secured second lien notes, which will mature on February 1, 2027 (the “2027 Senior Secured Second Lien Notes”). We will pay interest on the 2027 Senior Secured Second Lien Notes semi-annually in arrears on February 1 and AugustOctober 1 of each year, which payments commenced on AugustOctober 1, 2019. The2020. A portion of the proceeds from the sale of the 20272025 Senior Secured Second Lien Notes were used, after payment of fees and expenses, together with cash on hand and borrowings under our senior secured revolving credit facility, to

fund the redemption of all $300 million aggregate principal amount of our outstanding 6.750% senior notes due 2020 and all $750 million aggregate principal amount of our outstanding 7.500% senior secured second lien notes due 2022, as well as the repayment upon maturity of all $468 million aggregate principal amount of our outstanding 5.500% senior unsecured notes due March 1, 2019. In connection with the redemptions, we recorded a loss from early extinguishment of debt of approximately $47 million in the three months ended March 31, 2019, primarily related to the difference between the redemption prices and the par values of the notes, as well as the write-off of the associated unamortized issuance costs.

In December 2018 and November 2018, we purchased $22 million and $10 million, respectively, of aggregate principal amount of our 5.500% senior unsecured notes due 2019 for $22 million and $10 million, respectively.

In August 2018, we purchased $38 million aggregate principal amount of our 6.875% senior unsecured notes due 2031 for $36 million, including $1 million in accrued and unpaid interest through the dates of purchase.

In May 2018, we purchased $30 million aggregate principal amount of our 6.875% senior unsecured notes due 2031 for $28 million. In connection with the purchase, we recorded a loss from early extinguishment of debt of $1 million in the three months ended June 30, 2018, primarily related to the write-off of associated unamortized note discount and issuance costs, partially offset by the difference between the purchase price and the par value of the notes.

In March 2018, we purchased $28 million aggregate principal amount of our 6.750% senior unsecured notes due 2023 and $22 million aggregate principal amount of our 7.000% senior unsecured notes due 2025 for $51 million, including $1 million in accrued and unpaid interest through the dates of purchase. In connection with these purchases, we recorded a loss from early extinguishment of debt of $1 million in the three months ended March 31, 2018, primarily related to the write-off of associated unamortized issuance costs.

On June 14, 2017, we sold $830 million aggregate principal amount of our 4.625% senior secured first lien notes, which will mature on July 15, 2024 (the “2024 Secured First Lien Notes”). The proceeds from the sale of the 2024 Secured First Lien Notes were used, after payment of fees and expenses, together with cash on hand, to deposit with the trustee an amount sufficient to fund the redemption of all $900 million in aggregate principal amount of our outstanding floating rate senior secured notes due 2020 (the “2020 Floating Rate Notes”) on July 14, 2017, thereby fully discharging the 2020 Floating Rate Notes as of June 14, 2017. In connection with the redemption, we recorded a loss from early extinguishment of debt of $26 million in the three months ended June 30, 2017, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.
Also on June 14, 2017, THC Escrow Corporation III (“Escrow Corp.”), a Delaware corporation established for the purpose of issuing the securities referred to in this paragraph, issued $1.040 billion in aggregate principal amount of 4.625% senior secured first lien notes due 2024 (the “Escrow Secured First Lien Notes”), $1.410 billion in aggregate principal amount of 5.125% senior secured second lien notes due 2025 (the “Escrow Secured Second Lien Notes”) and $500 million in aggregate principal amount of 7.000% senior unsecured notes due 2025 (the “Escrow Unsecured Notes”).

On July 14, 2017, we (i) assumed Escrow Corp.’s obligations with respect to the Escrow Secured Second Lien Notes and (ii) effected a mandatory exchange of all outstanding Escrow Secured First Lien Notes for a like principal amount of our newly issued 2024 Secured First Lien Notes. The proceeds from the sale of the Escrow Secured Second Lien Notes and Escrow Secured First Lien Notes were released from escrow on July 14, 2017 and werewas used, after payment of fees and expenses, to finance our redemption on July 14, 2017 of $1.041 billion aggregate principal amount of our outstanding 6.250% senior secured notes due 2018 and $1.100 billion aggregate principal amount of our outstanding 5.000% senior unsecured notes due 2019.

On August 1, 2017, we assumed Escrow Corp.’s obligations with respect torepay the Escrow Unsecured Notes. The proceeds from the sale of the Escrow Unsecured Notes were released from escrow on August 1, 2017 and were used, after payment of fees and expenses, to finance our redemption on August 1, 2017 of $500 million aggregate principal amount of borrowings outstanding under our outstanding 8.000% senior unsecured notes dueCredit Agreement as of March 31, 2020.

On September 11, 2017, we redeemed the remaining $250 million aggregate principal amount of our outstanding 8.000% senior unsecured notes due 2020 using cash on hand.

As a result of the redemption activities in the three months ended September 30, 2017 discussed above, we recorded a loss from early extinguishment of debt of $138 million in the period, primarily related to the difference between the redemption price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

All of our senior secured notes are guaranteed by certain of our wholly owned domestic hospital company subsidiaries and secured by a pledge of the capital stock and other ownership interests of those subsidiaries on either a first lien or second lien basis, as indicated in the table above. All of our senior secured notes and the related subsidiary guarantees are our and the subsidiary guarantors’ senior secured obligations. All of our senior secured notes rank equally in right of payment with all of our other senior secured indebtedness. Our senior secured notes rank senior to any subordinated indebtedness that we or such subsidiary guarantors may incur; they are effectively senior to our and such subsidiary guarantors’ existing and future unsecured indebtedness and other liabilities to the extent of the value of the collateral securing the notes and the subsidiary guarantees; they are effectively subordinated to our and such subsidiary guarantors’ obligations under our Credit Agreement to the extent of the value of the collateral securing borrowings thereunder; and they are structurally subordinated to all obligations of our non-guarantornon‑guarantor subsidiaries.

The indentures setting forth the terms of our senior secured notes contain provisions governing our ability to redeem the notes and the terms by which we may do so. At our option, we may redeem our senior secured notes, in whole or in part, at any time at a redemption price equal to 100% of the principal amount of the notes redeemed plus the make-wholemake‑whole premium set forth in the related indenture, together with accrued and unpaid interest thereon, if any, to the redemption date. Certain series of
110

Table of Contents
the senior secured notes may also be redeemed, in whole or in part, at certain redemption prices set forth in the applicable indentures, together with accrued and unpaid interest. In addition, we may be required to purchase for cash all or any part of each series of our senior secured notes upon the occurrence of a change of control (as defined in the applicable indentures) for a cash purchase price of 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest.

All of our senior unsecured notes are general unsecured senior debt obligations that rank equally in right of payment with all of our other unsecured senior indebtedness, but are effectively subordinated to our senior secured notes described above, the obligations of our subsidiaries and any obligations under our Credit Agreement to the extent of the value of the collateral. We may redeem any series of our senior unsecured notes, in whole or in part, at any time at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a make-wholemake‑whole premium specified in the applicable indenture, if any, together with accrued and unpaid interest to the redemption date.

Covenants

Credit Agreement. Our Credit Agreement contains customary covenants for an asset-backedasset‑backed facility, including a minimum fixed charge coverage ratio to be met if the designated excess availability under the revolving credit facility falls below $150 million, as well as limits on debt, asset sales and prepayments of certain other debt. The Credit Agreement also includes a provision, which we believe is customary in receivables-backedreceivables‑backed credit facilities, that gives our lenders the right to require that proceeds of collections of substantially all of our consolidated accounts receivable be applied directly to repay outstanding loans and other amounts that are due and payable under the Credit Agreement at any time that unused borrowing availability under the revolving credit facility is less than $150 million for three3 consecutive business days or if an event of default has occurred and is continuing thereunder. In that event, we would seek to re-borrowre‑borrow under the Credit Agreement to satisfy our operating cash requirements. Our ability to borrow under the Credit Agreement is subject to conditions that we believe are customary in revolving credit facilities, including that no events of default then exist.

Senior Secured Notes. The indentures governing our senior secured notes contain covenants that, among other things, restrict our ability and the ability of our subsidiaries to incur liens, consummate asset sales, enter into sale and lease-backlease‑back transactions or consolidate, merge or sell all or substantially all of our or their assets, other than in certain transactions between one or more of our wholly owned subsidiaries. These restrictions, however, are subject to a number of exceptions and qualifications. In particular, there are no restrictions on our ability or the ability of our subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities). In addition, the indentures governing our senior secured notes contain a covenant that neither we nor any of our subsidiaries will incur secured debt, unless at the time of and after giving effect to the incurrence of such debt, the aggregate amount of all such secured debt (including the aggregate principal amount of senior secured notes outstanding and any outstanding borrowings under our Credit Agreement at such time) does not exceed the amount that would cause the secured debt ratio (as defined in the indentures) to exceed 4.0 to 1.0.

Senior Unsecured Notes. The indentures governing our senior unsecured notes contain covenants and conditions that have, among other requirements, limitations on (1) liens on “principal properties” and (2) sale and lease-backlease‑back transactions with respect to principal properties. A principal property is defined in the senior unsecured notes indentures as a hospital that has an asset value on our books in excess of 5% of our consolidated net tangible assets, as defined in such indentures. The above limitations do not apply, however, to (1) debt that is not secured by principal properties or (2) debt that is secured by principal

properties if the aggregate of such secured debt does not exceed 15% of our consolidated net tangible assets, as further described in the indentures. The senior unsecured notes indentures also prohibit the consolidation, merger or sale of all or substantially all assets unless no event of default would result after giving effect to such transaction.

Future Maturities

Future long-termlong‑term debt maturities, including finance lease obligations were as follows as of December 31, 2019 are as follows: 2021:
   Years Ending December 31, Later Years
 Total 2020 2021 2022 2023 2024 
Long-term debt, including finance lease obligations$14,937
 $171
 $112
 $2,851
 $1,903
 $2,486
 $7,414
  Years Ending December 31,Later Years
 Total20222023202420252026
Long-term debt, including finance lease obligations$15,797 $135 $1,983 $1,446 $742 $2,120 $9,371 


As discussed in Note 25, in February 2022, we announced the redemption of all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes. These notes are included in the table above based on their stated maturity date.

111

Table of Contents
NOTE 9. GUARANTEES

Consistent with our policy on physician relocation and recruitment, we provide income guarantee agreements to certain physicians who agree to relocate to fill a community need in the service area of one of our hospitals and commit to remain in practice in the area for a specified period of time. Under such agreements, we are required to make payments to the physicians in excess of the amounts they earn in their practices up to the amount of the income guarantee. The income guarantee periods are typically 12 months. If a physician does not fulfill his or her commitment period to the community, which is typically three years subsequent to the guarantee period, we seek recovery of the income guarantee payments from the physician on a prorated basis. We also provide revenue collection guarantees to hospital-basedhospital‑based physician groups providing certain services at our hospitals with terms generally ranging from one to three years.

At December 31, 2019,2021, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-basedhospital‑based physician groups providing certain services at our hospitals was $133$122 million. We had a total liability of $107$104 million recorded for these guarantees included in other current liabilities in the accompanying Consolidated Balance Sheet at December 31, 2019.2021.

At December 31, 2019,2021, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $25$94 million. Of the total, $8$12 million relates to the obligations of consolidated subsidiaries, which obligations arewere recorded in the accompanying Consolidated Balance Sheet at December 31, 2019.2021.

NOTE 10. EMPLOYEE BENEFIT PLANS

Share-Based Compensation Plans

In recent years, weWe have granted stock options and restricted stock units (“RSUs”) to certain of our employees and directors pursuant to our stock incentive plans. OptionsStock options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years from the date of grant. A restricted stock unitAn RSU is a contractual right to receive 1 share of our common stock in the future, and the fair value of the restricted stock unitRSU is based on our share price on the grant date. Typically, stock options and time-based restricted stock unitstime‑based RSUs vest one-thirdone‑third on each of the first three anniversary dates of the grant; however, certain special retention awards may have different vesting terms. In addition, wegrants of RSUs to our non‑employee directors as part of their annual compensation vest immediately and are settled on the third anniversary of the date of grant, performance-basedwhile initial grants to directors vest immediately but settle upon separation from the board.

We also grant performance‑based stock options and performance-based restricted stock unitsperformance‑based RSUs that vest subject to the achievement of specified performance goals within a specified time frame. At December 31, 2019, assuming outstanding performance-based restricted stock units andThe performance‑based RSUs may contain provisions that increase or decrease the number of RSUs that ultimately vest, depending upon the level of achievement. For certain of our performance‑based awards, the number of options for which performance has not yet been determined will achieve target performance, approximately 8.2 million sharesor RSUs that ultimately vest is also subject to adjustment based on the achievement of common stock were available under our 2019 Stock Incentive Plan for future stock option grants and other equity incentive awards, including restricted stock units.

a market‑based condition. These adjustments generally range from 0% to 200% of the number of RSUs initially granted. The accompanying Consolidated Statementsfair value of Operations for the years ended December 31, 2019, 2018 and 2017 include $42 million, $46 million and $59 million, respectively, of pre-tax compensation costs related to our stock-based compensation arrangements. The table below shows certain stock option and restricted stock unit grants and other awards that comprise the stock-based compensation expense recorded in the year ended December 31, 2019. Compensation costcontain a market‑based condition is measured byestimated using a discrete model to analyze the fair value of the awards on their grant dates and is recognized oversubject shares. The discrete model utilizes multiple stock paths, through the requisite service perioduse of a Monte Carlo simulation, which paths are then analyzed to determine the fair value of the awards, whether or not the awards had any intrinsic value during the period.subject shares.

Grant Date Awards 
Exercise Price
Per Share
 
Fair Value
Per Share at
Grant Date
 
Stock-Based
Compensation Expense for Year Ended December 31, 2019
  (In Thousands)     (In Millions)
Stock Options:        
February 27, 2019 210
 $28.26
 $12.49
 $1
February 28, 2018 442
 $20.60
 $8.83
 1
March 1, 2017 821
 $18.99
 $8.52
 1
Restricted Stock Units:  
  
  
  
July 9, 2019 94
   $18.55
 1
May 3, 2019 100
   $16.18
 2
February 27, 2019 800
   $28.26
 9
January 31, 2019 318
   $21.99
 2
June 28, 2018 51
   $34.61
 1
March 29, 2018 293
   $24.25
 4
February 28, 2018 204
   $20.60
 2
March 1, 2017 383
  
 $18.99
 2
August 25, 2014 456
  
 $59.90
 3
Other grants       2
USPI Management Equity Plan  
  
  
 11
   
  
  
 $42


Pursuant to the terms of our stock-basedstock‑based compensation plans, awards granted under the plan vest and may be exercised as determined by the human resources committee of our board of directors. In the event of a change in control, the human resources committee of our board of directors may, at its sole discretion without obtaining shareholder approval, accelerate the vesting or performance periods of the awards.

At December 31, 2021, assuming outstanding performance‑based stock options and RSUs for which performance has not yet been determined will achieve target performance, approximately 5.3 million shares of common stock were available under our 2019 Stock Incentive Plan for future stock option grants and other equity incentive awards, including RSUs. The accompanying Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019 include $56 million, $44 million and $42 million, respectively, of pre‑tax compensation costs related to our stock‑based compensation arrangements.

112

Table of Contents
The table below shows certain stock option and RSU grants and other awards, net of forfeitures, that comprise the stock‑based compensation expense recorded in the year ended December 31, 2021. Compensation cost is measured by the fair value of the awards on their grant dates and is recognized over the requisite service period of the awards, whether or not the awards had any intrinsic value during the period.
Grant DateAwardsExercise Price
Per Share
Fair Value
Per Share at
Grant Date
Stock-Based
Compensation Expense for Year Ended December 31, 2021
 (In Thousands)  (In Millions)
Stock options:
February 27, 2019188 $28.26 $12.49 $
Restricted stock units:    
May 7, 202137 $47.99 
February 24, 2021585 $52.85 12 
February 26, 20201,221 $27.80 15 
February 27, 2019790 $28.26 
January 31, 2019318 $21.99 
Other grants(1)
661 $30.73 
Other stock-based compensation plans:
USPI management equity plan1,883  $34.13 13 
    $56 
(1)Per-share value presented is the weighted-average grant date fair value of the grants included. Grant dates range from June 2016 to September 2021 with per‑share grant date fair values ranging from $18.11 to $74.99.

Stock Options

The following table summarizes stock option activity during the years ended December 31, 2019, 20182021, 2020 and 2017:2019:
OptionsWtd. Avg.
Exercise Price
Per Share
Aggregate
Intrinsic Value
Wtd. Avg
Remaining Life
 Options 
Weighted Average
Exercise Price
Per Share
 
Aggregate
Intrinsic Value
 
Weighted Average
Remaining Life
  (In Millions) 
     (In Millions)  
Outstanding at December 31, 2016 1,435,921
 $22.87
  
  
Granted 1,396,307
 18.24
  
  
Exercised (20,400) 4.56
  
  
Forfeited/Expired (247,006) 24.37
  
  
Outstanding at December 31, 2017 2,564,822
 $20.35
  
  
Granted 635,196
 21.33
  
  
Exercised (619,849) 18.19
  
  
Forfeited/Expired (317,426) 35.30
  
  
Outstanding at December 31, 2018 2,262,743
 $19.12
  
  Outstanding at December 31, 20182,262,743 $19.12   
Granted 230,713
 28.28
  
  Granted230,713 $28.28   
Exercised (306,427) 18.05
  
  Exercised(306,427)$18.05   
Forfeited/Expired (226,037) 20.21
  
  Forfeited/Expired(226,037)$20.21   
Outstanding at December 31, 2019 1,960,992
 $20.24
 $35
 6.1 yearsOutstanding at December 31, 20191,960,992 $20.24   
Vested and expected to vest at December 31, 2019 1,960,992
 $20.24
 $35
 6.1 years
Exercisable at December 31, 2019 454,360
 $17.26
 $9
 2.7 years
ExercisedExercised(987,471)$17.96   
Forfeited/ExpiredForfeited/Expired(60,990)$23.28   
Outstanding at December 31, 2020Outstanding at December 31, 2020912,531 $22.51   
ExercisedExercised(391,533)$20.66   
Outstanding at December 31, 2021Outstanding at December 31, 2021520,998 $23.90 $30 6.2 years
Vested and expected to vest at December 31, 2021Vested and expected to vest at December 31, 2021520,998 $23.90 $30 6.2 years
Exercisable at December 31, 2021Exercisable at December 31, 2021324,980 $21.25 $20 5.7 years


No stock options were granted during the years ended December 31, 2021 and 2020. There were 306,427391,533 stock options exercised during the year ended December 31, 20192021 with an aggregated intrinsic value of approximately $3$15 million, and 619,849987,471 stock options exercised in 20182020 with an aggregate intrinsic value of approximately $4$15 million. There were 230,713 performance-based stock options granted in the year ended December 31, 2019, and 635,196 performance-based stock options granted in the year ended 2018. On March 29, 2019, we granted an aggregate of 7,862 performance-based stock options to a senior officer. The options will all vest on the third anniversary of the grant date, subject to the achievement of a closing stock price of at least $36.05 (a 25% premium above the March 29, 2019 grant-date closing stock price of $28.84) for at least 20 consecutive trading days within three years of the grant date, and will expire on the tenth anniversary of the grant date. On February 27, 2019, we granted to certain of our senior officers an aggregate of 222,851

performance-based stock options. The options will all vest on the third anniversary of the grant date, subject to the achievement of a closing stock price of at least $35.33 (a 25% premium above the February 27, 2019 grant-date closing stock price of $28.26) for at least 20 consecutive trading days within three years of the grant date, and will expire on the tenth anniversary of the grant date.

On May 31, 2018, we granted new senior officers 31,184 performance-based stock options. The options will all vest on the third anniversary of the grant date, subject to achieving a closing stock price of at least $44.29 (a 25% premium above the May 31, 2018 grant-date closing stock price of $35.43) for at least 20 consecutive trading days within three years of the grant date, and will expire on the tenth anniversary of the grant date. On February 28, 2018, we granted to certain of our senior officers an aggregate of 604,012 performance-based stock options. The stock options will all vest on the third anniversary of the grant date because, in the three months ended June 30, 2018, the requirement that our stock close at a price of at least $25.75 (a 25% premium above the February 28, 2018 grant-date closing stock price of $20.60) for at least 20 consecutive trading days within three years of the grant date was met; these options will expire on the tenth anniversary of the grant date.

At December 31, 2019, there were $4 million of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 1.6 years.

The weighted average estimated fair value of stock options we granted during the years ended December 31, 2019 and 2018 was $12.50 and $9.16 per share, respectively. These fair values were calculated based on each grant date, using a Monte Carlo simulation with the following assumptions:
  February 27, February 28,
  2019 2018
Expected volatility 48% 46%
Expected dividend yield 0% 0%
Expected life 6.2 years 6.2 years
Expected forfeiture rate 0% 0%
Risk-free interest rate 2.53% 2.72%


113

Table of Contents
The expected volatility used for the 2019 and 2018 Monte Carlo simulations incorporates historical volatility based on an analysis of historical prices of our stock. The expected volatility reflects the historical volatility for a duration consistent with the expected life of the options; it does not consider the implied volatility from open-market exchanged options due to the limited trading activity and the transient nature of factors impacting our stock price volatility. The historical share-price volatility for 2019 and 2018 excludes the movements in our stock price for the period from August 15, 2017 through November 30, 2017 due to impact that the announcement of the departure of certain board members and officers, as well as reports that we were exploring a potential sale of the company, had on our stock price during that time. The risk-free interest rates are based on zero-coupon United States Treasury yields in effect at the date of grant consistent with the expected exercise time frames.

The following table summarizes information about our outstanding stock options at December 31, 2019:2021:
  Options Outstanding Options Exercisable
Range of Exercise Prices  
Number of
Options
 
Weighted Average
Remaining
Contractual Life
 
Weighted Average
Exercise Price
 
Number of
Options
 
Weighted Average
Exercise Price
$16.43 to $19.759 1,224,289
 5.2 years $18.14
 408,526
 $16.43
$19.76 to $35.430 736,703
 7.5 years 23.74
 45,834
 24.63
  1,960,992
 6.1 years $20.24
 454,360
 $17.26
 Options OutstandingOptions Exercisable
Range of Exercise Prices Number of
Options
Wtd. Avg.
Remaining
Contractual Life
Wtd. Avg.
Exercise Price
Number of
Options
Wtd. Avg.
Exercise Price
$18.99 to $20.609293,796 5.6 years$19.75 293,796 $19.75 
$20.61 to $35.430227,202 6.9 years29.26 31,184 35.43 
 520,998 6.2 years$23.90 324,980 $21.25 


As of December 31, 2019, 61.2%2021, 57.0% of all our outstanding options were held by current employees and 38.8%43.0% were held by former employees. Of our outstanding options, 100% were in-the-money,in‑the‑money, that is, they had exercise price less than the $38.03$81.69 market price of our common stock on December 31, 2019. There were no options out-of-the-money.2021.
 In-the-Money Options Out-of-the-Money Options All Options In-the-Money OptionsOut-of-the-Money OptionsAll Options
 Outstanding % of Total Outstanding % of Total Outstanding % of Total Outstanding% of TotalOutstanding% of TotalOutstanding% of Total
Current employees 1,199,274
 61.2% 
 % 1,199,274
 61.2%Current employees296,916 57.0 %— — %296,916 57.0 %
Former employees 761,718
 38.8% 
 % 761,718
 38.8%Former employees224,082 43.0 %— — %224,082 43.0 %
Totals 1,960,992
 100.0% 
 % 1,960,992
 100.0%Totals520,998 100.0 %  520,998 100.0 %
% of all outstanding options 100.0%  
 %  
 100.0%  
% of all outstanding options100.0 %  % 100.0 % 



Restricted Stock Units

The following table summarizes restricted stock unitRSU activity during the years ended December 31, 2019, 20182021, 2020 and 2017:2019:
Restricted Stock UnitsWtd. Avg. Grant Date Fair Value Per Unit
 Restricted Stock Units Weighted Average Grant Date Fair Value Per Unit
Unvested at December 31, 2016 3,174,533
 $38.75
Granted 714,018
 18.25
Vested (1,397,953) 35.50
Forfeited (236,610) 32.13
Unvested at December 31, 2017 2,253,988
 $35.20
Granted 765,184
 24.74
Vested (995,331) 32.63
Forfeited (139,711) 36.01
Unvested at December 31, 2018 1,884,130
 $32.25
Unvested at December 31, 20181,884,130 $32.25 
Granted 1,481,021
 27.87
Granted1,481,021 $27.87 
Vested (1,562,191) 36.45
Vested(1,562,191)$36.45 
Forfeited (339,461) 24.74
Forfeited(339,461)$24.74 
Unvested at December 31, 2019 1,463,499
 $25.08
Unvested at December 31, 20191,463,499 $25.08 
GrantedGranted1,767,730 $27.72 
VestedVested(825,727)$25.66 
ForfeitedForfeited(310,296)$32.09 
Unvested at December 31, 2020Unvested at December 31, 20202,095,206 $25.87 
GrantedGranted900,018 $58.61 
VestedVested(765,814)$30.51 
ForfeitedForfeited(58,208)$37.60 
Unvested at December 31, 2021Unvested at December 31, 20212,171,202 $40.51 


InDuring the year ended December 31, 2019,2021 we granted an aggregate561,788 RSUs that vest based on the passage of 1,481,021 restricted stock units. Of these, 337,848 willtime. The granted RSUs vest as follows:

263,180 RSUs vest and be settledsettle ratably over a three-yearthree‑year period from the grant date, 566,172 willdate;

189,215 RSUs vest and be settledsettle ratably over 98 quarterly periods from the grant date, and 353,354 willdate;

53,341 RSUs vest and be settledsettle on the fourth anniversary of the grant date;

33,351 RSUs vest and settle on the third anniversary of the grant date;

14,192 RSUs vested on December 31, 2021 and settled in January 2022; and

8,509 RSUs, one-third of which vest and settle on the second anniversary of the grant date and the remainder of which vest and settle on the fourth anniversary.

114

Table of Contents
During the year ended December 31, 2021 we granted 298,492 performance-based RSUs which vest as follows:

244,259 RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2023;

53,341 RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2021 to 2025; and

892 RSUs vested and settled immediately as a result of our level of achievement with respect to performance‑based RSUs granted in 2018.

The actual number of performance‑based RSUs that could vest will range from 0% to 200% of the 297,600 unvested RSUs granted, depending upon our level of achievement with respect to the performance goals.

During the year ended December 31, 2021, we also granted 39,738 RSUs to our non‑employee directors. These consisted of 36,681 RSUs for the 2021‑2022 board service year, 1,372 for an initial grant to a new member of our board of directors and 1,685 for a pro‑rata annual grant to the same new member. While RSUs granted to our board of directors vest immediately, annual grants settle on the third anniversary of the grant date and initial grants settle upon separation from the board.

During the year ended December 31, 2020 we granted 1,084,883 RSUs that vest based on the passage of time. The granted RSUs vest as follows:

607,198 RSUs vest and settle ratably over a three‑year period from the grant date;

359,713 RSUs vest and settle ratably over 11 quarterly periods from the grant date;

104,167 RSUs vest and settle ratably over a four-year period from the grant date; and

13,805 RSUs vest and settle on the third anniversary of the grant date.

During the year ended December 31, 2020 we granted 579,413 performance-based RSUs which vest as follows:

499,285 RSUs vest and settle on the third anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2022 and

80,128 RSUs vest and settle on the fourth anniversary of the grant date, contingent upon the achievement of performance goals for the years 2020 to 2023, all of which were subsequently forfeited.

The actual number of performance‑based RSUs that could vest will range from 0% to 200% of the 499,285 remaining RSUs granted, depending upon our level of achievement with respect to the performance goals.

In addition, in May 2019,2020, we made an annual grant of 100,444 restricted stock units103,434 RSUs to our non-employeenon‑employee directors for the 2019-20202020-2021 board service year, which units vested immediately and will settle in shares of our common stock on the third anniversary of the date of the grant. The board of directors appointed 2 new members, 1 in August 2019 and 1 in October 2019. We made initial grants totaling 5,569 restricted stock units to these directors, as well as prorated annual grants totaling 13,257 restricted stock units. Both the initial grants and the annual grants vested immediately, however, the initial grants settle upon separation from the board, while the annual grants settle on the third anniversary of the grant date. We also granted 7,427 additional restricted stock units that vested and settled immediately as a result of our level of achievement with respect to a performance goal on a 2013 grant and 96,950 additional restricted stock units as a result of our level of achievement with respect to a performance goal on 2014 grants.

In the year ended December 31, 2018, we granted 765,184 restricted stock units, of which 288,325 will vest and be settled ratably over a three-year period from the grant date, 339,806 will vest and be settled ratably over two-year period from the grant date, and 60,963 will vest and be settled on the third anniversary of the grant date. In addition, in May 2018, we made an annual grant of 54,198 restricted stock units to our non-employee directors for the 2018-2019 board service year, which units vested immediately and will settle in shares of our common stock on the third anniversary of the date of the grant. Because the board of directors appointed 2 new members in May 2018, we made initial grants totaling 3,670 restricted stock units to these directors, as well as prorated annual grants totaling 12,154 restricted stock units. Both the initial grants and the annual grants vested immediately, however, the initial grants will not settle until the directors’ separation from the board, while the annual grants settle on the third anniversary of the grant date. In addition, we granted 6,068 performance-based restricted stock units to certain of our senior officers; the vesting of these restricted stock units is contingent on our achievement of specified three-year performance goals for the years 2018 to 2020. Provided the goals are achieved, the performance-based restricted stock units will vest and settle on the third anniversary of the grant date. The actual number of performance-based restricted stock units that could vest will range from 0% to 200% of the 6,068 units granted, depending on our level of achievement with respect to the performance goals.

As of December 31, 2019,2021, there were $25$47 million of total unrecognized compensation costs related to restricted stock units.RSUs. These costs are expected to be recognized over a weighted average period of 1.61.7 years.

For certain of the performance-based RSU grants, the number of units that will ultimately vest is subject to adjustment based on the achievement of a market-based condition. The fair value of these RSUs is estimated through the use of a Monte Carlo simulation. Significant inputs used in our valuation of these RSUs included the following:
Years Ended December 31,
20212020
Expected volatility65.2% - 79.3%54.7 %
Risk-free interest rate0.1% - 0.6%1.2 %

115

Table of Contents
USPI Management Equity Plan

2015 USPI Management Equity Plan
As described in Note 25, USPI’s prior equity compensation plan was terminated in February 2020, and in accordance withIn 2015, USPI adopted the terms of that plan, all vested options or shares of USPI stock acquired upon exercise of an option will be repurchased byHolding Company, Inc. 2015 Stock Incentive Plan (“2015 USPI at their estimated fair value. At December 31, 2019, USPI maintained a separate management equity plan wherebyManagement Equity Plan”) under which it had granted non-qualified options to purchase nonvoting shares of USPI’s outstanding common stock to eligible plan participants, allowing the recipient to participate in incremental growth in the value of USPI from the applicable grant date.

Under this plan, the 2015 USPI Management Equity Plan, the total pool of options consisted of approximately 10% of USPI’s fully diluted outstanding common stock. Options had an exercise price equal to the estimated fair market value of USPI’s common stock on the date of grant. The option awards were structured such that they had a three or four year vesting period in which half of the award vested in equal pro-rata amounts over the applicable vesting period and the remaining half vested at the end of the applicable three or four year period. Any unvested awards were forfeited upon the participant’s termination of service with USPI, and vested options were required to have been exercised within 90 days of termination. Once an award was exercised and the requisite holding period met, the participant was eligible to sell the underlying shares to USPI at their estimated fair market value. Payment for USPI’s purchase of any eligible nonvoting common shares could be made in cash or in shares of Tenet’s common stock.

In February 2020, the 2015 USPI Management Equity Plan and all unvested options granted under the plan were terminated in accordance with the terms of the plan. USPI repurchased all vested options and all shares of USPI stock acquired upon exercise of an option for approximately $35 million.

2020 USPI Management Equity Plan
In February 2020, USPI adopted the USPI Holding Company, Inc. Restricted Stock Plan (“2020 USPI Management Equity Plan”) to replace the terminated 2015 USPI Management Equity Plan. Under the 2020 USPI Management Equity Plan, USPI grants RSUs representing a contractual right to receive 1 share of USPI’s non‑voting common stock in the future. The vesting of RSUs granted under the plan varies based on the terms of the underlying award agreement. Once the requisite holding period is met, during specified times, the participant can sell the underlying shares to USPI at their estimated fair market value. At our sole discretion, the purchase of any non‑voting common shares can be made in cash or in shares of Tenet’s common stock.

The following table summarizes RSU activity under USPI’s management equity plan during the year ended December 31, 2021 and 2020:
Number of
Restricted Stock Units
Wtd. Avg. Grant
Date Fair Value Per Unit
Inception of Plan
Granted2,556,353 $34.13 
Forfeited(531,297)$34.13 
Unvested at December 31, 20202,025,056 $34.13 
Granted76,990 $34.13 
Vested(388,588)$34.13 
Forfeited(218,576)$34.13 
Unvested at December 31, 20211,494,882 $34.13 

During the year ended December 31, 2021, USPI granted 76,990 RSUs under its management equity plan. NaN percent of these RSUs vests on each of the first and second anniversaries of the grant date, and the remaining 60% vests on the third anniversary of the grant date. In 2020, USPI granted 2,556,333 RSUs, 20% of which vest in each of the first three years on the anniversary of the grant date with the remaining 40% vesting on the fourth anniversary of the grant date.

During the year ended December 31, 2021, USPI paid $9.0 million to repurchase a portion of the non‑voting common stock issued under the USPI management equity plan. No shares were repurchased through the issuance of Tenet common stock during the year ended December 31, 2021.

At December 31, 2021, 1,494,882 RSUs were outstanding under USPI’s management equity plan, all of which are expected to vest. The accompanying Consolidated StatementStatements of Operations for the years ended December 31, 2021, 2020 and 2019 2018 and 2017 includes $11included $13 million, $18$12 million and $13$11 million, respectively, of pre-tax compensation costs related to USPI’s management equity plan.plans.


116

Table of Contents
Employee Stock Purchase Plan

We have an employee stock purchase plan under which we are currently authorized to issue up to 5,062,5004,070,363 shares of common stock to our eligible employees. As of December 31, 2019,2021, there were approximately 3.02.7 million shares available for issuance under our employee stock purchase plan. Under the terms of the plan, eligible employees may elect to have between 1% and 10% of their base earnings withheld each quarter to purchase shares of our common stock. Shares are purchased at a price equal to 95% of the closing price on the last day of the quarter. The plan requires a one-yearone‑year holding period for all shares issued. The holding period does not apply upon termination of employment. Under the plan, no individual may purchase, in any year, shares with a fair market value in excess of $25,000. The plan is currently not considered to be compensatory.

We soldissued the following numbers of shares under our employee stock purchase plan in the years ended December 31, 2019, 2018 and 2017:plan:
 Years Ended December 31,  Years Ended December 31, 
 2019 2018 2017 202120202019
Number of shares 215,422
 228,045
 395,957
Number of shares89,865 254,767 215,422 
Weighted average price $24.44
 $22.96
 $17.28
Weighted average price$63.01 $19.97 $24.44 


Employee Retirement Plans

Substantially all of our employees, upon qualification, are eligible to participate in 1 of our defined contribution 401(k) plans. Under the plans, employees may contribute a portion of their eligible compensation, andwhich we may match suchwith employer contributions annually up to a maximum percentage for participants actively employed, as defined by the plan documents.at our discretion. Employer matching contributions will vary by plan. Plan expenses, primarily related to our contributions to the plans, were $127$98 million, $99$119 million and $128$127 million for the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively. Such amounts are reflected in salaries, wages and benefits in the accompanying Consolidated Statements of Operations.

We maintain 3 frozen non-qualifiednon‑qualified defined benefit pension plans (“SERPs”) that provide supplemental retirement benefits to certain of our current and former executives. These plans are not funded, and plan obligations for these plans are paid from our working capital. Pension benefits are generally based on years of service and compensation. Upon completing the acquisition of Vanguard Health Systems, Inc. on October 1, 2013, we assumed a frozen qualified defined benefit plan (“DMC Pension Plan”) covering substantially all of the employees of our Detroit market that were hired prior to June 1, 2003. The benefits paid under the DMC Pension Plan are primarily based on years of service and final average earnings. During the year ended December 31, 2019, the Society of Actuaries issued a new mortality base table (Pri-2012)(Pri‑2012), which we incorporated into the estimates of our defined benefit plan obligations atbeginning December 31, 2019. During the years ended December 31, 20192021 and 2018,2020, the Society of Actuaries issued new mortality improvement scales (MP-2019(MP‑2021 and MP‑2018,2020, respectively), which we incorporated into the estimates of our defined benefit plan obligations at December 31, 20192021 and 2018.2020. These changes to our mortality assumptions increased our projected benefit obligations as of December 31, 2021 by approximately $5 million and decreased our projected benefit obligations as of December 31, 2019 and 20182020 by approximately $14 million and $4 million, respectively. $39 million.

117

Table of Contents
The following tables summarize the balance sheet impact, as well as the benefit obligations, funded status and rate assumptions associated with the SERPs and the DMC Pension Plan based on actuarial valuations prepared as of December 31, 2019 and 2018:prepared:

  December 31,
  2019 2018
Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:  
  
Projected benefit obligations(1)
  
  
Beginning obligations $(1,301) $(1,455)
Service cost 
 (2)
Interest cost (58) (56)
Actuarial gain (loss) (132) 90
Benefits paid 123
 122
Special termination benefit costs (1) 
Ending obligations (1,369) (1,301)
Fair value of plans assets  
  
Beginning plan assets 731
 850
Gain (loss) on plan assets 128
 (65)
Employer contribution 33
 47
Benefits paid (102) (101)
Ending plan assets 790
 731
Funded status of plans $(579) $(570)
Amounts recognized in the Consolidated Balance Sheets consist of:  
  
Other current liability $(19) $(49)
Other long-term liability $(560) $(521)
Accumulated other comprehensive loss $323
 $281
SERP Assumptions:  
  
Discount rate 3.50% 4.50%
Compensation increase rate 3.00% 3.00%
Measurement date December 31, 2019
 December 31, 2018
DMC Pension Plan Assumptions:  
  
Discount rate 3.60% 4.62%
Compensation increase rate Frozen
 Frozen
Measurement date December 31, 2019
 December 31, 2018
 December 31,
 20212020
Reconciliation of funded status of plans and the amounts included in the Consolidated Balance Sheets:  
Projected benefit obligations(1)
  
Beginning obligations$(1,429)$(1,369)
Interest cost(36)(47)
Actuarial gain (loss)42 (92)
Benefits paid110 79 
Ending obligations(1,313)(1,429)
Fair value of plans assets  
Beginning plan assets869 790 
Gain on plan assets62 98 
Employer contribution22 38 
Benefits paid(86)(57)
Ending plan assets867 869 
Funded status of plans$(446)$(560)
(1)The accumulated benefit obligation at December 31, 2021 and 2020 was approximately $1.311 billion and $1.426 billion, respectively.
(1)The accumulated benefit obligation at December 31, 2019 and 2018 was approximately $1.367 billion and $1.299 billion, respectively.

 December 31,
 20212020
Amounts recognized in the Consolidated Balance Sheets consist of:  
Other current liability$(25)$(63)
Other long-term liability$(421)$(497)
Accumulated other comprehensive loss$294 $355 
SERP Assumptions:  
Discount rate3.00 %2.75 %
Compensation increase rate3.00 %3.00 %
Measurement dateDecember 31, 2021December 31, 2020
DMC Pension Plan Assumptions:  
Discount rate2.89 %2.53 %
Compensation increase rateFrozenFrozen
Measurement dateDecember 31, 2021December 31, 2020

118

Table of Contents
The components of net periodic benefit costs and related assumptions are as follows:
 Years Ended December 31,
 202120202019
Interest costs$36 $47 $58 
Expected return on plan assets(53)(48)(46)
Amortization of net actuarial loss11 10 
Special termination benefit costs— — 
Net periodic benefit cost (income)$(6)$$23 
SERP Assumptions:   
Discount rate2.75 %3.50 %4.50 %
Compensation increase rate3.00 %3.00 %3.00 %
Measurement dateJanuary 1, 2021January 1, 2020January 1, 2019
Census dateJanuary 1, 2021January 1, 2020January 1, 2019
DMC Pension Plan Assumptions:   
Discount rate2.53 %3.60 %4.62 %
Long-term rate of return on assets6.25 %6.25 %6.50 %
Compensation increase rateFrozenFrozenFrozen
Measurement dateJanuary 1, 2021January 1, 2020January 1, 2019
Census dateJanuary 1, 2021January 1, 2020January 1, 2019
  Years Ended December 31,
  2019 2018 2017
Service costs $
 $2
 $2
Interest costs 58
 56
 62
Expected return on plan assets (46) (54) (50)
Amortization of net actuarial loss 10
 14
 14
Special termination benefit costs 1
 
 
Net periodic benefit cost $23
 $18
 $28
SERP Assumptions:  
  
  
Discount rate 4.50% 3.75% 4.25%
Long-term rate of return on assets n/a
 n/a
 n/a
Compensation increase rate 3.00% 3.00% 3.00%
Measurement date January 1, 2019
 January 1, 2018
 January 1, 2017
Census date January 1, 2019
 January 1, 2018
 January 1, 2017
DMC Pension Plan Assumptions:  
  
  
Discount rate 4.62% 4.00% 4.42%
Long-term rate of return on assets 6.50% 6.50% 6.50%
Compensation increase rate Frozen
 Frozen
 Frozen
Measurement date January 1, 2019
 January 1, 2018
 January 1, 2017
Census date January 1, 2019
 January 1, 2018
 January 1, 2017


Net periodic benefit costs for the current year are based on assumptions determined at the valuation date of the prior year for the SERPs and the DMC Pension Plan. As a result of the adoption of ASU 2017-07 discussed in Note 1, we

recognized service costs in salaries, wages and benefits expense, and recognized other components of net periodic benefit cost in other non-operating expense, net, in the accompanying Consolidated Statements of Operations.

We recorded gain (loss) adjustments of $(42)$61 million, $(15)$(32) million and $56$(42) million in other comprehensive income (loss) in the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively, to recognize changes in the funded status of our SERPs and the DMC Pension Plan. Changes in the funded status are recorded as a direct increase or decrease to shareholders’ equity through accumulated other comprehensive loss. Net actuarial gains (losses) of $(52)$50 million, $(29)$(41) million and $42$(52) million were recognized during the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively, and the amortization of net actuarial loss of $10$11 million, $14$9 million and $14$10 million for the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively, were recognized in other comprehensive incomeincome. Actuarial gain (loss). affecting the benefit obligation during the years ended December 31, 2021, 2020 and 2019 are primarily attributable to changes in the discount rate utilized for the SERP and DMC Pension Plan. Cumulative net actuarial losses of $323$294 million, $281$355 million and $266$323 million as of December 31, 2021, 2020 and 2019, 2018respectively. There were no unrecognized prior service costs at December 31, 2021 and 2017, respectively,2020, and unrecognized prior service costs of less than $1 million as of each of the years endedat December 31, 2019 2018 and 2017 havethat had not yet been recognized as components of net periodic benefit cost.

To develop the expected long-termlong‑term rate of return on plan assets assumption, the DMC Pension Plan considers the current level of expected returns on risk-freerisk‑free investments (primarily government bonds), the historical level of risk premium associated with the other asset classes in which the portfolio is invested and the expectations for future returns on each asset class. The expected return for each asset class is then weighted based on the target asset allocation to develop the expected long-termlong‑term rate of return on assets assumption for the portfolio. The weighted-averageweighted‑average asset allocations by asset category as of December 31, 2019,2021, were as follows:
Asset Category Target ActualAsset CategoryTargetActual
Cash and cash equivalents 2% 2%Cash and cash equivalents— %%
U.S. government obligations % 2%
Equity securities 65% 64%Equity securities32 %28 %
Debt securities 33% 32%Debt securities58 %59 %
Alternative investments % %Alternative investments11 %11 %


The DMC Pension Plan assets are invested in public commingled vehicles, segregated separately managed portfolios usingaccounts, and private commingled vehicles, all of which are managed by professional investment management firms. The objective for all asset categories is to maximize total return without assuming undue risk exposure. The DMC Pension Plan maintains a well-diversifiedwell‑diversified asset allocation that best meets these objectives. The DMC Pension Plan assets are largely comprised of cash and cash equivalents, including but not limited to money market funds and repurchase agreements secured by U.S. Treasury or federal agency obligations, equity securities, which includeincluding but not limited to the publicly traded shares of U.S. companies with
119

Table of Contents
various market capitalization sizescapitalizations in addition to international and convertible securities. Cash and cash equivalents are comprised of money market funds. Debt securities, includedebt securities including, but not limited to, domestic and foreign government obligations, corporate bonds, and mortgage-backed securities. Undermortgage‑backed securities, and alternative investments. Alternative investments is a broadly defined asset category with the investment policyobjective of diversifying the overall portfolio, complementing traditional equity and fixed‑income securities and improving the overall performance consistency of the DMC Pension Plan,portfolio. Alternative investments may include, but are not limited to, diversified hedge funds in the form of professionally managed pooled limited partnership investments and investments in derivative securities are not permitted for the sole purpose of speculating on the direction of market interest rates. Included in this prohibition are leveraging, shorting, swaps, futures, options, forwards and similar strategies.private markets via professionally managed pooled limited partnership interests.

In each investment account, the DMC Pension Plan investment managers are responsible for monitoring and reacting to economic indicators, such as gross domestic product, consumer price index and U.S. monetary policy that may affect the performance of their account. The performance of all managers and the aggregate asset allocation are formally reviewed on a quarterly basis, with a rebalancing of the asset allocation occurring at least once per year.basis. The current asset allocation objective is to maintain a certain percentage withwithin each asset class allowing for a 10% deviation fromwithin the target.established range for each asset class. The portfolio is rebalanced on an as‑needed basis to keep these allocations within the accepted ranges.

The following tables summarize the DMC Pension Plan assets measured at fair value on a recurring basis as of December 31, 20192021 and 2018,2020, aggregated by the level in the fair value hierarchy within which those measurements are determined. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices for similar assets, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

 December 31, 2021Level 1Level 2Level 3
Cash and cash equivalents$11 $11 $— $— 
Equity securities242 242 — — 
Debt Securities:
U.S. government obligations67 67 — — 
Corporate debt securities448 448 — — 
Alternative investments:
Private equity securities57 — — 57 
Real estate securities16 16 — — 
Hedge funds26 — — 26 
 $867 $784 $— $83 

  December 31, 2019 Level 1 Level 2 Level 3
Cash and cash equivalents $37
 $37
 $
 $
U.S. government obligations 9
 9
 
 
Equity securities 461
 461
 
 
Fixed income funds 283
 283
 
 
Futures contracts 
 
 
 
  $790
 $790
 $
 $
  December 31, 2018 Level 1 Level 2 Level 3
Cash and cash equivalents $33
 $33
 $
 $
U.S. government obligations 9
 9
 
 
Equity securities 423
 423
 
 
Fixed income funds
 262
 262
 
 
Futures contracts $4
 $4
    
  $731
 $731
 $
 $

 December 31, 2020Level 1Level 2Level 3
Cash and cash equivalents$44 $44 $— $— 
Equity securities484 484 — — 
Debt Securities:
U.S. government obligations76 76 — — 
Corporate debt securities240 240 — — 
Alternative investments:
Private equity securities— — 
Hedge funds17 — 17 — 
 $869 $844 $17 $

The following table presents the estimated future benefit payments to be made from the SERPs and the DMC Pension Plan, a portion of which will be funded from plan assets, for the next five years and in the aggregate for the five years thereafter:
  Years Ending December 31, Five Years Thereafter
 Total20222023202420252026
Estimated benefit payments$828 $83 $84 $85 $85 $85 $406 
    Years Ending December 31,  Five Years
  Total 2020 2021 2022 2023 2024 Thereafter
Estimated benefit payments $876
 $85
 $87
 $89
 $89
 $90
 $436


120

Table of Contents
The SERP and DMC Pension Plan obligations of $579$446 million at December 31, 20192021 are classified in the accompanying Consolidated Balance Sheet as an other current liability ($19 million)of $25 million and defined benefit plan obligations ($560 million)of $421 million based on an estimate of the expected payment patterns. We expect to make total contributions to the plans of approximately $19$25 million for the year ending December 31, 2020.2022.

NOTE 11. PROPERTY AND EQUIPMENT

The principal components of property and equipment are shown in the following table. Prior to the adoption of ASU 2016-02 effective January 1, 2019, assets under capital leases were included with buildings and improvements and with equipment in the following table.table below:
December 31, December 31,
2019 2018 20212020
Land$602
 $613
Land$635 $612 
Buildings and improvements6,856
 6,920
Buildings and improvements6,652 6,985 
Construction in progress184
 199
Construction in progress166 33 
Equipment4,173
 4,482
Equipment4,455 4,593 
Finance lease assets561
 
Finance lease assets479 512 
12,376
 12,214
12,387 12,735 
Accumulated depreciation and amortization(5,498) (5,221)Accumulated depreciation and amortization(5,960)(6,043)
Net property and equipment$6,878
 $6,993
Net property and equipment$6,427 $6,692 


Property and equipment is stated at cost, less accumulated depreciation and amortization and impairment write-downswrite‑downs related to assets held and used.


NOTE 12. GOODWILL AND OTHER INTANGIBLE ASSETS

The following table provides information on changes in the carrying amount of goodwill, which iswas included in the accompanying Consolidated Balance Sheets as of 2019 and 2018:
 2019
2018
Hospital Operations and other 
  
As of January 1: 
  
Goodwill$5,410
 $5,406
Accumulated impairment losses(2,430) (2,430)
Total2,980
 2,976
Goodwill acquired during the year and purchase price allocation adjustments
 1
Goodwill related to assets held for sale and disposed or deconsolidated facilities(72) 3
Total$2,908
 $2,980
As of December 31: 
  
Goodwill$5,338
 $5,410
Accumulated impairment losses(2,430) (2,430)
Total$2,908
 $2,980

Sheets:

December 31,
 20212020
Hospital Operations  
Goodwill at beginning of period:  
Goodwill$5,375 $5,338 
Accumulated impairment losses(2,430)(2,430)
2,945 2,908 
Goodwill transferred from Ambulatory Care segment41 — 
Goodwill related to assets held for sale and disposed(178)37 
Goodwill at end of period$2,808 $2,945 
Goodwill at end of period:  
Goodwill$5,238 $5,375 
Accumulated impairment losses(2,430)(2,430)
Goodwill at end of period$2,808 $2,945 
Ambulatory Care
Goodwill at beginning of period$5,258 $3,739 
Goodwill acquired during the year and purchase price allocation adjustments664 1,581 
Goodwill transferred to Hospital Operations segment(41)— 
Goodwill related to assets held for sale and disposed or deconsolidated facilities(33)(62)
Goodwill at end of period$5,848 $5,258 
Conifer
Goodwill at beginning of period$605 $605 
Goodwill acquired during the year and purchase price allocation adjustments— — 
Goodwill related to assets held for sale and disposed or deconsolidated facilities— — 
Goodwill at end of period$605 $605 
 2019 2018
Ambulatory Care   
As of January 1: 
  
Goodwill$3,696
 $3,437
Accumulated impairment losses
 
Total3,696
 3,437
Goodwill acquired during the year and purchase price allocation adjustments43
 219
Goodwill related to assets held for sale and disposed or deconsolidated facilities
 40
Total$3,739
 $3,696
As of December 31: 
  
Goodwill$3,739
 $3,696
Accumulated impairment losses
 
Total$3,739
 $3,696

 2019 2018
Conifer 
  
As of January 1: 
  
Goodwill$605
 $605
Accumulated impairment losses
 
Total605
 605
Goodwill acquired during the year and purchase price allocation adjustments
 
Total$605
 $605
As of December 31: 
  
Goodwill$605
 $605
Accumulated impairment losses
 
Total$605
 $605
121

Table of Contents
There were no accumulated impairment losses related to the goodwill in our Ambulatory Care and Conifer segments at December 31, 2021 and 2020.



The following table provides information regarding other intangible assets, which arewere included in the accompanying Consolidated Balance Sheets as of 2019December 31, 2021 and 2018:2020:
 Gross
Carrying
Amount
Accumulated
Amortization
Net Book
Value
At December 31, 2021:   
Capitalized software costs$1,770 $(1,165)$605 
Trade names102 — 102 
Contracts897 (128)769 
Other102 (81)21 
Total$2,871 $(1,374)$1,497 
At December 31, 2020:   
Capitalized software costs$1,800 $(1,084)$716 
Trade names102 — 102 
Contracts872 (111)761 
Other110 (89)21 
Total$2,884 $(1,284)$1,600 
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net Book
Value
At December 31, 2019: 
  
  
Capitalized software costs$1,616
 $(912) $704
Trade names102
 
 102
Contracts869
 (94) 775
Other107
 (86) 21
Total$2,694
 $(1,092) $1,602
At December 31, 2018: 
  
  
Capitalized software costs$1,667
 $(858) $809
Trade Names102
 
 102
Contracts871
 (76) 795
Other104
 (79) 25
Total$2,744
 $(1,013) $1,731


Estimated future amortization of intangibles with finite useful lives as of December 31, 2019 is2021 was as follows:
 Total Years Ending December 31, Later Years
  2020 2021 2022 2023 2024 
Amortization of intangible assets$1,037
 $156
 $142
 $130
 $122
 $104
 $383
 TotalYears Ending December 31,Later Years
 20222023202420252026
Amortization of intangible assets$786 $147 $119 $108 $94 $73 $245 


We recognized amortization expense of $188 million, $185$172 million and $172$188 million in the accompanying Consolidated Statements of Operations for the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively.

NOTE 13. INVESTMENTS AND OTHER ASSETS

The principal components of investments and other assets in the accompanying Consolidated Balance Sheets are as follows:
December 31, December 31,
2019 2018 20212020
Marketable securities$2
 $40
Marketable securities$$
Equity investments in unconsolidated healthcare entities978
 956
Equity investments in unconsolidated healthcare entities1,806 1,024 
Total investments980
 996
Total investments1,815 1,027 
Cash surrender value of life insurance policies36
 30
Cash surrender value of life insurance policies47 42 
Long-term deposits59
 44
Long-term deposits57 67 
California provider fee program receivables213
 231
California provider fee program receivables213 206 
Operating lease assets912
 
Operating lease assets1,002 1,062 
Land held for expansion, other long-term receivables and other assets169
 155
Land held for expansion, other long-term receivables and other assets120 130 
Investments and other assets$2,369
 $1,456
Investments and other assets$3,254 $2,534 


Our policy is to classify investments in debt securities that may be needed for cash requirements as “available-for-sale.” In doing so, the carrying values of debt instruments are adjusted at the end of each accounting period to their market values through a credit or charge to other comprehensive income (loss), net of taxes.

NOTE 14. ACCUMULATED OTHER COMPREHENSIVE LOSS

Our accumulated other comprehensive loss is comprised of the following:
December 31, December 31,
2019 2018 20212020
Adjustments for defined benefit plans$(257) $(223)Adjustments for defined benefit plans$(232)$(281)
Foreign currency translation adjustments and otherForeign currency translation adjustments and other(1)— 
Accumulated other comprehensive loss$(257) $(223)Accumulated other comprehensive loss$(233)$(281)


122

Table of Contents
The income tax benefits (expense) allocated to the adjustments for our defined benefit plans was approximately $8 million for the year ended December 31, 2019, and the tax benefits allocated to the adjustments for our defined benefit plans and foreign currency translation adjustments were approximately $3 million and $3 million, respectively, for the year ended December 31, 2018. As

discussed in Note 1, we recorded cumulative effect adjustments of $36$(14) million and $7 million uponfor the adoptions of ASU 2018-02years ended December 31, 2021 and ASU 2016-01, respectively, effective January 1, 2018.2020, respectively.

NOTE 15. NET OPERATING REVENUES

Net operating revenues for our Hospital Operations and other and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to healthcarehealth systems, as well as individual hospitals and physician practices, self-insured organizations, health plans and other entities.practices.

The table below shows our sources of net operating revenues less provision for doubtful accounts and implicit price concessions from continuing operations:
  Years Ended December 31,
  2019 2018 2017
Hospital Operations and other:      
Net patient service revenues from hospitals and related
outpatient facilities
      
Medicare $2,888
 $2,882
 $3,243
Medicaid 1,193
 1,294
 1,304
Managed care 9,516
 9,213
 9,583
Uninsured 92
 96
 91
Indemnity and other 679
 596
 608
Total 14,368
 14,081
 14,829
Other revenues(1)
 1,154
 1,204
 1,431
Hospital Operations and other total prior to
inter-segment eliminations
 15,522
 15,285
 16,260
Ambulatory Care 2,158
 2,085
 1,940
Conifer 1,372
 1,533
 1,597
Inter-segment eliminations (573) (590) (618)
Net operating revenues $18,479
 $18,313
 $19,179

Years Ended December 31,
202120202019
Hospital Operations:
Net patient service revenues from hospitals and related outpatient facilities:
Medicare$2,615 $2,695 $2,888 
Medicaid1,254 1,081 1,193 
Managed care9,985 9,022 9,516 
Uninsured199 162 92 
Indemnity and other706 658 679 
Total14,759 13,618 14,368 
Other revenues(1)
1,223 1,172 1,154 
Hospital Operations total prior to inter-segment eliminations15,982 14,790 15,522 
Ambulatory Care2,718 2,072 2,158 
Conifer1,267 1,306 1,372 
Inter-segment eliminations(482)(528)(573)
Net operating revenues$19,485 $17,640 $18,479 
(1)
(1) Primarily physician practices revenues.

Adjustments for prior-yearprior‑year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December 31, 2021, 2020 and 2019 2018 and 2017 by $27$26 million, $24$6 million and $35$27 million, respectively. Estimated cost report settlements and valuation allowances arewere included in accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.

The table below shows the composition of net operating revenues for our Ambulatory Care segment:
Years Ended December 31,
202120202019
Net patient service revenues$2,604 $1,960 $2,040 
Management fees86 86 95 
Revenue from other sources28 26 23 
Net operating revenues$2,718 $2,072 $2,158 
  Years Ended December 31,
  2019 2018 2017
Net patient service revenues $2,040
 $1,965
 $1,816
Management fees 95
 92
 93
Revenue from other sources 23
 28
 31
Net operating revenues $2,158
 $2,085
 $1,940


123


Table of Contents
The table below shows the composition of net operating revenues for our Conifer segment:
Years Ended December 31,
202120202019
Revenue cycle services – Tenet$467 $514 $556 
Revenue cycle services – other customers705 700 713 
Other services – Tenet15 14 17 
Other services – other customers80 78 86 
Net operating revenues$1,267 $1,306 $1,372 
  Years Ended December 31,
  2019 2018 2017
Revenue cycle services – Tenet $556
 $568
 $583
Revenue cycle services – other customers 713
 855
 891
Other services – Tenet 17
 22
 35
Other services – other customers 86
 88
 88
Net operating revenues $1,372
 $1,533
 $1,597


Other services representrepresented approximately 8%7% of Conifer’s revenue for the year ended December 31, 2021 and include value-basedincluded value‑based care services, consulting services and other client-definedclient‑defined projects.

Performance Obligations

The following table includes Conifer’s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period. The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volumevolume‑ or contingency contingency‑based contracts, performance incentives, penalties or other variable consideration that is considered constrained. Conifer’s contract with Catholic Health Initiatives (“CHI”), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed-feefixed‑fee revenue related to remaining performance obligations. Conifer’s contract term with CHI ends December 31, 2032.
  Years Ending December 31,Later Years
 Total20222023202420252026
Performance obligations$6,181 $606 $606 $552 $552 $552 $3,313 
    Years Ending December 31, Later Years
  Total 2020 2021 2022 2023 2024 
Performance obligations $7,347
 $601
 $598
 $598
 $597
 $550
 $4,403


NOTE 16. PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE

Property Insurance

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis. For the policy period April 1, 20192021 through March 31, 2020,2022, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub-limitssub‑limits of $100 million for floods, $200 million for earthquakes and a per-occurrence sub-limitper‑occurrence sub‑limit of $200 million for named windstorms with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values up to a maximum of $40$25 million for California earthquakes, $25 million for floods and named windstorms, and 2% of insured values for New Madrid fault earthquakes, with a maximum per per‑claim deductible of $25 million. Floods and certain other covered losses, including fires and other perils, have a minimum deductible of $1 million.

Professional and General Liability Reserves

We are self-insuredself‑insured for the majority of our professional and general liability claims, and we purchase insurance from third-partiesthird‑parties to cover catastrophic claims. At December 31, 20192021 and 2018,2020, the aggregate current and long-termlong‑term professional and general liability reserves in the accompanying Consolidated Balance Sheets were $915 million$1.045 billion and $882$978 million, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self-insuredself‑insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. We estimated

All commercial insurance we purchase is subject to per‑claim and policy period aggregate limits. If the reserves for losses and related expenses using expected loss-reporting patterns discounted to their present value under a risk-free rate approach using a Federal Reserve seven-year maturity rate of 1.83%,  2.59% and 2.33% at December 31, 2019, 2018 and 2017, respectively.

If thepolicy period aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.

IncludedMalpractice expense of $355 million, $320 million and $356 million was included in other operating expenses, net, in the accompanying Consolidated Statements of Operations is malpractice expense of $374 million, $388 million and $303 million for the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively, of which $155$131 million, $176$120 million and $61$155 million, respectively, related to adverse claims development for prior years.


124

Table of Contents
NOTE 17. CLAIMS AND LAWSUITS

We operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment-relatedemployment‑related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us.

We are also subject to a non-prosecution agreement (“NPA”). If we fail to comply with this agreement, we could be subject to criminal prosecution, substantial penalties and exclusion from participation in federal healthcare programs, any of which could adversely impact our business, financial condition, results of operations or cash flows.
We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties involved inassociated with these matters, especially those involving governmental agencies, and the indeterminate damages sought in some of these matters,cases, there is significant uncertainty as to the ultimate liability we may incur from these matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period.

Shareholder Derivative Litigation

In January 2017, the Dallas County District Court consolidated 2 previously disclosed shareholder derivative lawsuits filed on behalf of the Company by purported shareholders of the Company’s common stock against current and former officers and directors into a single matter captioned In re Tenet Healthcare Corporation Shareholder Derivative Litigation. The plaintiffs filed a consolidated shareholder derivative petition in February 2017. The consolidated shareholder derivative petition alleged that false or misleading statements or omissions concerning the Company’s financial performance and compliance policies, specifically with respect to the previously disclosed civil qui tam litigation and parallel criminal investigation of the Company and certain of its subsidiaries (together, the “Clinica de la Mama matters”), caused the price of the Company’s common stock to be artificially inflated. In addition, the plaintiffs alleged that the defendants violated GAAP by failing to disclose an estimate of the possible loss or a range of loss related to the Clinica de la Mama matters. The plaintiffs claimed that they did not make demand on the Company’s board of directors to bring the lawsuit because such a demand would have been futile. In May 2018, the judge in the consolidated shareholder derivative litigation entered an order lifting the previous year-long stay of the matter and, in July 2018, the defendants filed pleadings seeking dismissal of the lawsuit. In October 2018, the judge granted defendants’ motion to dismiss, but also agreed to give the plaintiffs 30 days to replead their complaint. In January 2019, the court issued a final judgment and order of dismissal after the plaintiffs elected not to replead. In February 2019, the plaintiffs filed an appeal of the court’s ruling that dismissal was appropriate because the plaintiffs failed to adequately plead that a pre-suit demand on the Company’s board of directors, a precondition to their action, should be excused as futile. The parties’ appellate briefs have been filed, and oral arguments were held on February 5, 2020. The parties are awaiting the court’s ruling. The defendants intend to continue to vigorously contest the plaintiffs’ allegations in this matter.

Antitrust Class Action Lawsuit Filed by Registered Nurses in San Antonio

In Maderazo, et al. v. VHS San Antonio Partners, L.P. d/b/a Baptist Health Systems, et al., filed in June 2006 in the U.S. District Court for the Western District of Texas, a purported class of registered nurses employed by 3 unaffiliated San Antonio-area hospital systems alleged those hospital systems, including our Baptist Health System, and other unidentified San Antonio regional hospitals violated Section §1 of the federal Sherman Act by conspiring to depress nurses’ compensation and exchanging compensation-related information among themselves in a manner that reduced competition and suppressed the wages paid to such nurses. The suit sought unspecified damages (subject to trebling under federal law), interest, costs and attorneys’ fees. In January 2019, the district court issued an opinion denying the plaintiffs’ motion for class certification. The

plaintiffs’ subsequent appeal of the district court’s decision to the U.S. Court of Appeals for the Fifth Circuit was denied in March 2019. In April 2019, the appellate court denied the plaintiffs’ request for additional review of the district court’s ruling, and we learned in August 2019 that the plaintiffs did not request further review by the U.S. Supreme Court. The plaintiffs advised the court that they were proceeding on behalf of the 3 named individuals. On November 20, 2019, at court-ordered mediation, the parties entered into a confidential settlement to resolve the 3 plaintiffs’ individual claims for an immaterial amount. In January 2020, the parties executed a settlement agreement, which the court approved, and the case was dismissed.

Government Investigation of Detroit Medical Center

Detroit Medical Center (“DMC”) is subject to an ongoing investigation commenced in October 2017 by the U.S. Attorney’s Office for the Eastern District of Michigan and the Civil Division of the U.S. Department of Justice (“DOJ”) for potential violations of the Stark law, the Medicare and Medicaid anti-kickbackanti‑kickback and anti-fraudanti‑fraud and abuse amendments codified under Section 1128B(b) of the Social Security Act, (the “Anti-kickback Statute”), and the federal False Claims Act (“FCA”) related to DMC’s employment of nurse practitioners and physician assistants (“Mid-LevelMid‑Level Practitioners”) from 2006 through 2017. As previously disclosed, a media report was published in August 2017 alleging that 14 Mid-LevelMid‑Level Practitioners were terminated by DMC earlier in 2017 due to compliance concerns. On September 28, 2021, the DOJ issued a civil investigative demand to DMC for documents and interrogatories. We are cooperating with the investigation and continue to produce documents on a schedule agreed upon with the DOJ. Because the government’s review is in its preliminary stages,investigation; however, we are unable to determine the potential exposure, if any, at this time.

Oklahoma Surgical Hospital Qui Tam Action

In May 2016, a relator filed a qui tam lawsuit under seal in the Western District of Oklahoma against, among other parties, (i) Oklahoma Center for Orthopaedic & Multispecialty Surgery (“OCOM”), a surgical hospital jointly owned by USPI, a healthcare system partner and physicians, (ii) Southwest Orthopaedic Specialists, an independent physician practice group, (iii) Tenet, and (iv) other related entities and individuals. The complaint alleges various violations of the FCA, the Anti-kickback Statute, the Stark law and the Oklahoma Medicaid False Claims Act. In May 2018, Tenet and its affiliates learned that they were parties to the suit when the court unsealed the complaint and the DOJ declined to intervene with respect to the issues involving Tenet, USPI, OCOM and individually named employees. In June 2018, the relator filed an amended complaint more fully describing the claims and adding additional defendants. Tenet, USPI, OCOM and individually named employees filed motions to dismiss the case in October 2018, but the court has not yet ruled on the motions. The litigation is currently stayed while the parties work to finalize the resolution described below.

Pursuant to the obligations under our NPA, we reported the unsealed qui tam action to the DOJ and began investigating the claims contained in the amended complaint and cooperating fully with the DOJ. We began discussing potential resolution of these matters with the DOJ and the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) during the three months ended September 30, 2019.

In October 2019, we reached an agreement in principle with the DOJ to resolve the qui tam lawsuit and related investigations for approximately $66 million, subject to further approvals by the DOJ and other government agencies. In the three months ended September 30, 2019, we established a reserve of $68 million for this matter, which includes an estimate of the relator’s attorney’s fees and certain other costs to be paid by us. In the three months ended December 31, 2019, we increased the reserve for this matter by an additional $1 million to reflect updated information on the other costs to be paid by us. Any final resolution remains subject to negotiation and final approval of a settlement agreement with the DOJ and any other definitive documentation required by OIG or other government agencies. We believe this could be completed as early as the second quarter of 2020, at which time the monetary component of the resolution would be paid.

Other Matters

OnIn July 1, 2019, certain of the entities that purchased the operations of Hahnemann University Hospital and St. Christopher’s Hospital for Children in Philadelphia from us commenced Chapter 11 bankruptcy proceedings. As previously disclosed in our Form 8-K filed September 1, 2017,In the purchasers assumed our fundingthree months ended December 31, 2021, we established a reserve of $23 million for certain obligations under the Pension Fund for Hospital and Health Care Employees of Philadelphia and Vicinity (the “Fund”), a pension plan related to the operations at Hahnemann University Hospitalsale of the hospitals and pursuant to rules under the Employee Retirement Income Security Actsubsequent bankruptcy proceedings of 1974, as amended, under certain circumstances we could become liable for withdrawal liability in the event a withdrawal is triggered with respect to the Fund. In July 2019, the Fund notified us of a withdrawal liability assessment of approximately $63 million. We dispute and are contesting this assessment in accordance with applicable law.buyers.

We are also subject to claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various

federal and state labor laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time.time, including lawsuits from patients, employees and others exposed to COVID‑19 at our facilities. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business.

125

Table of Contents
The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded in continuing operations during the years ended December 31, 2019, 20182021, 2020 and 2017. No amounts were recorded in discontinued operations2019:
 Balances at
Beginning
of Period
Litigation and
Investigation
Costs
Cash
Payments
OtherBalances at
End of
Period
Year Ended December 31, 2021$26 $116 $(59)$(5)$78 
Year Ended December 31, 2020$86 $44 $(108)$$26 
Year Ended December 31, 2019$$141 $(55)$(8)$86 

During 2021, we also established estimated reserves of $39 million for various employment matters and made settlement payments of $11 million, which are included in the 2019, 2018 and 2017 periods.table above.
 
Balances at
Beginning
of Period
 
Litigation and
Investigation
Costs
 
Cash
Payments
 Other 
Balances at
End of
Period
  
  
  
  
  
Year Ended December 31, 2019$8
 $141
 $(55) $(8) $86
Year Ended December 31, 2018$12
 $38
 $(41) $(1) $8
Year Ended December 31, 2017$12
 $23
 $(23) $
 $12


For the years ended December 31, 2019, 2018 and 2017, we recorded net costs of $141 million, $38 million and $23 million, respectively, in connection with significant legal proceedings and governmental investigations.

NOTE 18. REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES

As part of the acquisition of United Surgical Partners International, Inc., we entered intoWe have a put/call agreement (the “Put/Call Agreement”) with respect to the equity interests in USPI held by our joint venture partners. In April 2016, we paid $127 million to purchase shares put to us according to the Put/Call Agreement, which increased our ownership interest in USPI to approximately 56.3%. On May 1, 2017, we amended and restated the Put/Call Agreement to provide for, among other things, the acceleration of our acquisition of certain shares of USPI. Under the terms of the amendment, we paid Welsh Carson, on July 3, 2017, $716 million for the purchase of these shares, which increased our ownership interest in USPI to 80.0%, as well as the final adjustment to the 2016 purchase price. In April 2018, we paid $630 million for the purchase of an additional 15% ownership interest in USPI and the final adjustment to the 2017 purchase price, which increased our ownership interest in USPI to 95%.

In addition, we entered into a separate put call agreement (the “Baylor Put/Call Agreement”) with Baylor University Medical Center (“Baylor”) that contains put and call options with respect to the 5% ownership interest Baylor holds in USPI held by Baylor.USPI. Each year starting in 2021, Baylor may put up to one-thirdone‑third of theirits total shares in USPI held as of April 1, 2017.2017 (the “Baylor Shares”) by delivering notice by the end of January of such year. In each year that Baylor does not put the full 33.3% of USPI’s shares allowable, we may call the difference between the number of shares Baylor put and the maximum number of shares theyit could have put that year. In addition, the Baylor Put/Call Agreement contains a call option pursuant to which we have the ability to acquire all of Baylor’s ownership interest by 2024. We have the ability to choose whether to settle the purchase price for the Baylor put/call, which is mutually agreed‑upon fair market value, in cash or shares of our common stock.

Based on the nature of these put/call structures, the Baylor Put/Call Agreement, Baylor’s minority shareholders’ interestsinterest in USPI arewas classified as a redeemable noncontrolling interestsinterest in the accompanying Consolidated Balance Sheets at December 31, 20192021 and 2018. 2020.

Baylor did not deliver a put notice to us in January 2021 or January 2022. In February 2021, we notified Baylor of our intention to exercise our call option to purchase 33.3% of the Baylor Shares. We are continuing to negotiate the terms of that purchase. In addition, in February 2022, we notified Baylor of our intention to again exercise our call option to purchase an additional 33.3% of the Baylor Shares.

The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the years ended 2019 and 2018:subsidiaries:
 December 31,
 20212020
Balances at beginning of period 
$1,952 $1,506 
Net income336 186 
Distributions paid to noncontrolling interests(217)(135)
Accretion of redeemable noncontrolling interests11 
Purchases and sales of businesses and noncontrolling interests, net121 391 
Balances at end of period 
$2,203 $1,952 
 December 31,
 2019 2018
Balances at beginning of period 
$1,420
 $1,866
Net income192
 190
Distributions paid to noncontrolling interests(145) (142)
Accretion of redeemable noncontrolling interests18
 173
Purchases and sales of businesses and noncontrolling interests, net21
 (667)
Balances at end of period 
$1,506
 $1,420


OurThe following tables show the composition by segment of our redeemable noncontrolling interests balances, at December 31, 2019 and 2018 in the table above were comprised of $383 million and $431 million, respectively, fromas well as our Hospital Operations and other segment, $777 million and $713 million, respectively, from our Ambulatory Care segment, and $346 million and $276 million, respectively, from our Conifer segment. Our net income (loss) attributableavailable to redeemable noncontrolling interests for the years ended December 31, 2019 and 2018 respectively, in the accompanying Consolidated Statementsinterests:
December 31,
 20212020
Hospital Operations$297 $267 
Ambulatory Care1,425 1,273 
Conifer481 412 
Redeemable noncontrolling interests$2,203 $1,952 
 Years Ended December 31,
 202120202019
Hospital Operations$24 $(33)$(37)
Ambulatory Care243 153 159 
Conifer69 66 70 
Net income available to redeemable noncontrolling interests$336 $186 $192 

126

Table of Operations were comprised of $(37) million and $(25) million, respectively, from our Hospital Operations and other segment, $159 million and $151 million, respectively, from our Ambulatory Care segment, and $70 million and $64 million, respectively, from our Conifer segment.Contents

NOTE 19. INCOME TAXES

The provision for income taxes for continuing operations for the years ended December 31, 2021, 2020 and 2019 2018 and 2017 consistsconsisted of the following:
Years Ended December 31, Years Ended December 31,
2019 2018 2017 202120202019
Current tax expense (benefit): 
  
  
Current tax expense (benefit):   
Federal$(6) $(6) $(4)Federal$50 $— $(6)
State26
 33
 23
State111 30 26 
20
 27
 19
161 30 20 
Deferred tax expense (benefit): 
  
  
Deferred tax expense (benefit):   
Federal134
 159
 202
Federal267 (131)140 
State(1) (10) (2)State(17)— 
133
 149
 200
250 (127)140 
$153
 $176
 $219
$411 $(97)$160 


A reconciliation between the amount of reported income tax expense (benefit) and the amount computed by multiplying income (loss) from continuing operations before income taxes by the statutory federal income tax rate is shown below. State income tax expense for the year ended December 31, 20192021 includes $2 million of expense related to the write-offwrite‑off of expired or worthless unutilized state net operating loss carryforwards and other deferred tax assets for which a full valuation allowance had been provided in prior years. A corresponding tax benefit of $2 million is included for the year ended December 31, 20192021 to reflect the reduction in the valuation allowance. Foreign pre-tax loss was $5 million for the yearsyear ended December 31, 20192021, $13 million for the year ended December 31, 2020, and 2018 was $6 million.million for the year ended December 31, 2019.
Years Ended December 31,
Years Ended December 31, 202120202019
2019 2018 2017
Tax expense (benefit) at statutory federal rate of 21% in 2019 and 2018
(35% in 2017)
$62
 $134
 $(35)
Tax expense at statutory federal rate of 21%Tax expense at statutory federal rate of 21%$396 $141 $67 
State income taxes, net of federal income tax benefit20
 23
 4
State income taxes, net of federal income tax benefit77 33 21 
Expired state net operating losses, net of federal income tax benefit2
 9
 28
Expired state net operating losses, net of federal income tax benefit— 
Tax attributable to noncontrolling interests(79) (70) (113)
Tax benefit attributable to noncontrolling interestsTax benefit attributable to noncontrolling interests(114)(75)(79)
Nondeductible goodwill4
 8
 109
Nondeductible goodwill35 — 
Nondeductible executive compensation6
 4
 
Nondeductible executive compensation
Nondeductible litigation costs7
 
 
Nondeductible litigation costs— 
Expired charitable contribution carryforward8
 
 
Expired charitable contribution carryforward— 
Impact of decrease in federal tax rate on deferred taxes
 (1) 246
Reversal of permanent reinvestment assumption and other adjustments related to divestiture of foreign subsidiary
 (6) (30)
Stock-based compensation tax deficiencies4
 5
 15
Changes in valuation allowance (including impact of decrease in federal tax rate)133
 76
 
Stock-based compensation tax deficiencies (benefits)Stock-based compensation tax deficiencies (benefits)(5)(2)
Changes in valuation allowanceChanges in valuation allowance(226)133 
Change in tax contingency reserves, including interest(14) (1) (6)Change in tax contingency reserves, including interest— — (14)
Prior-year provision to return adjustments and other changes in deferred taxes(3) (5) 4
Prior-year provision to return adjustments and other changes in deferred taxes14 (3)
Other items3
 
 (3)Other items10 
Income tax expense$153
 $176
 $219
Income tax expense (benefit)Income tax expense (benefit)$411 $(97)$160 


In December 2017, the President signed into law the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act amended the Internal Revenue CodeCOVID Acts included a significant number of tax provisions applicable to reduce tax rates and modify policies, credits and deductions for individuals and businesses. For businesses, the Tax ActCOVID Acts made broad and complex changes to the U.S. tax code including but not limitedrelating to, among other things: (1) reducing the corporate federal tax rate from a maximumbusiness interest expense disallowance rules for 2019 and 2020; (2) net operating loss rules; (3) charitable contribution limitations; and (4) the realization of 35% to a flat 21% rate effective January 1, 2018, (2) repealing the corporate alternative minimum tax (“AMT”) and changing how existing AMT credits may be realized, (3) creating a new limitation on the deductibility of interest expense, (4) allowing full expensing of certain capital expenditures, and (5) denying deductions for

performance-based compensation paid to certain key executives. International provisions in the Tax Act have not had, and are not expected to have, a material impact on the Company’s taxes.

credits. As a result of the reductionchange in the corporatebusiness interest expense disallowance rules, we recorded an income tax rate from 35% to 21% under the Tax Act, we revalued our net deferred tax assets at December 31, 2017, resulting in a reduction in the valuebenefit of our net deferred tax assets by approximately$251 million. For$88 million during the year ended December 31, 2017,2020 to decrease the valuation allowance for interest expense carryforwards due to the additional deduction of interest expense.

In September 2020, we recorded $252 million as a provisional estimatefiled an application with the Internal Revenue Service (“IRS”) to change our method of the impact of the Tax Act, including the decrease in the corporate incomeaccounting for certain capitalized costs on our 2019 tax rate from 35% to 21%. Approximately $6 million of the total $252 million increase in income tax expense is included in the netreturn. This change in tax accounting method resulted in additional interest expense being allowed on the 2019 and 2020 tax returns. We reduced our valuation allowance with the remaining $246by an additional $126 million shown in the table above. During the year ended December 31, 2018, we recorded $1 million2020 related to the change in accounting method.

127

Table of tax benefit upon finalizing our accounting for the income tax effects of the Tax Act based on actual 2017 federal and state income tax filings.Contents

Deferred income taxes reflect the tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. The following table discloses those significant components of our deferred tax assets and liabilities, including any valuation allowance:
December 31, 2019 December 31, 2018 December 31, 2021December 31, 2020
Assets Liabilities Assets Liabilities AssetsLiabilitiesAssetsLiabilities
Depreciation and fixed-asset differences$
 $282
 $
 $297
Depreciation and fixed-asset differences$— $532 $— $621 
Reserves related to discontinued operations and restructuring charges14
 
 24
 
Reserves related to discontinued operations and restructuring charges— — 
Receivables (doubtful accounts and adjustments)165
 
 155
 
Receivables (doubtful accounts and adjustments)215 — 173 — 
Medicare advance paymentsMedicare advance payments209 — — — 
Accruals for retained insurance risks195
 
 205
 
Accruals for retained insurance risks234 — 223 — 
Intangible assets
 356
 
 341
Intangible assets— 396 — 385 
Other long-term liabilities35
 
 39
 
Other long-term liabilities23 — 55 — 
Benefit plans274
 
 255
 
Benefit plans242 — 265 — 
Other accrued liabilities45
 
 32
 
Other accrued liabilities56 — 74 — 
Investments and other assets
 95
 
 83
Investments and other assets— 92 — 73 
Interest expense limitation219
 
 89
 
Interest expense limitation10 — — 
Net operating loss carryforwards179
 
 266
 
Net operating loss carryforwards99 — 566 — 
Stock-based compensation19
 
 24
 
Stock-based compensation12 — 11 — 
Right-of-use lease assets and obligationsRight-of-use lease assets and obligations208 208 224 224 
Other items45
 34
 88
 32
Other items48 44 86 39 
1,190
 767
 1,177
 753
1,358 1,272 1,693 1,342 
Valuation allowance(281) 
 (148) 
Valuation allowance(57)— (55)— 
$909
 $767
 $1,029
 $753
$1,301 $1,272 $1,638 $1,342 


Below is a reconciliation of the deferred tax assets and liabilities and the corresponding amounts reported in the accompanying Consolidated Balance Sheets.
December 31, December 31,
2019 2018 20212020
Deferred income tax assets$169
 $312
Deferred income tax assets$65 $325 
Deferred tax liabilities(27) (36)Deferred tax liabilities(36)(29)
Net deferred tax asset$142
 $276
Net deferred tax asset$29 $296 


During the year ended December 31, 2021, the valuation allowance increased by $2 million, including an increase of $2 million due to limitations on the tax deductibility of interest expense, a decrease of $2 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $2 million due to changes in expected realizability of deferred tax assets. The balance in the valuation allowance as of December 31, 2021 was $57 million. During the year ended December 31, 2020, the valuation allowance decreased by $226 million, including a decrease of $211 million due to limitations on the tax deductibility of interest expense, a decrease of $1 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and a decrease of $14 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December 31, 2020 was $55 million. During the year ended December 31, 2019, the valuation allowance increased by $133 million, including an increase of $130 million due to limitations on the tax deductibility of interest expense, a decrease of $2 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and an increase of $5 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance as of December 31, 2019 was $281 million. During the year ended December 31, 2018, the valuation allowance increased by $76 million, including an increase of $89 million due to limitations on deductions of interest expense, a decrease of $9 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, and a decrease of $4 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance at December 31, 2018 was $148 million. During the year ended December 31, 2017, we had no net change in the valuation allowance, but there was a decrease of $28 million due to the expiration or worthlessness of unutilized state net operating loss carryovers, an increase of $6 million due to the decrease in the federal tax rate, and an increase of $22 million due to changes in expected realizability of deferred tax assets. The remaining balance in the valuation allowance as of December 31, 2017 was $72 million. Federal and state deferredDeferred tax assets relating to interest expense limitations under Internal Revenue Code Section 163(j) have a full valuation allowance because the interest expense carryovers are not expected to be utilized in the foreseeable future.

We account for uncertain tax positions in accordance with FASB ASC 740-10-25, which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected

to be taken in income tax returns. The following table summarizes the total changes in unrecognized tax benefits in continuing operations during the years ended December 31, 2019, 20182021, 2020 and 2017.2019. There were no such changes in discontinued operations. The additions and reductions for tax positions include the impact of items for which the ultimate deductibility is
128

Table of Contents
highly certain, but for which there is uncertainty about the timing of such deductions. Such amounts include unrecognized tax benefits that have impacted deferred tax assets and liabilities at December 31, 2019, 20182021, 2020 and 2017.2019.
Continuing
Operations
Balance At December 31, 2018$45
Reductions due to a lapse of statute of limitations(14)
Balance At December 31, 2019$31
Reductions due to a lapse of statute of limitations— 
Balance At December 31, 2020$31
Increases due to tax positions taken in prior periods
Balance At December 31, 2021$34
 
Continuing
Operations
Balance At December 31, 2016$35
Additions for prior-year tax positions31
Reductions for tax positions of prior years(15)
Reductions due to a lapse of statute of limitations(5)
Balance At December 31, 2017$46
Reductions due to a lapse of statute of limitations(1)
Balance At December 31, 2018$45
Reductions due to a lapse of statute of limitations(14)
Balance At December 31, 2019$31


The total amount of unrecognized tax benefits as of December 31, 2021 was $34 million, of which $32 million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. Income tax expense in the year ended December 31, 2021 included expense of $3 million in continuing operations attributable to an increase in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December 31, 2020 was $31 million, of which $29 million, if recognized, would affect our effective tax rate and income tax benefit from continuing operations. In the year ended December 31, 2020, there was no change in our estimated liabilities for uncertain tax positions.The total amount of unrecognized tax benefits as of December 31, 2019 was $31 million, of which $29 million, if recognized, would affect our effective tax rate and income tax expense (benefit) from continuing operations. Income tax expense in the year ended December 31, 2019 includesincluded a benefit of $11 million in continuing operations attributable to a decrease in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December 31, 2018 was $45 million, of which $43 million, if recognized, would affect our effective tax rate and income tax expense (benefit) from continuing operations. Income tax expense in the year ended December 31, 2018 includes a benefit of $1 million in continuing operations attributable to a decrease in our estimated liabilities for uncertain tax positions, net of related deferred tax effects. The total amount of unrecognized tax benefits as of December 31, 2017 was $46 million, of which $44 million, if recognized, would affect our effective tax rate and income tax expense (benefit) from continuing operations. Income tax expense in the year ended December 31, 2017 includes a benefit of $5 million in continuing operations attributable to a decrease in our estimated liabilities for uncertain tax positions, net of related deferred tax effects.

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Total accruedWe did not have any interest andor penalties on unrecognized tax benefits as ofaccrued at December 31, 2019 were 0.

2021.

The Internal Revenue Service (“IRS”)IRS has completed audits of our tax returns for all tax years ended on or before December 31, 2007. All disputed issues with respect to these audits have been resolved and all related tax assessments (including interest) have been paid. Our tax returns for years ended after December 31, 2007 and USPI’s tax returns for years ended after December 31, 20152017 remain subject to audit by the IRS.

As of December 31, 2019, 02021, no significant changes in unrecognized federal and state tax benefits are expected in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

At December 31, 2019,2021, our carryforwards available to offset future taxable income consisted of (1) federal net operating loss (“NOL”) carryforwards of approximately $600$194 million pre-tax expiringpre‑tax, $13 million of which expires in 20322026 to 2034,2036 and $181 million of which has no expiration date, (2) general business credit carryforwards of approximately $25$9 million expiring in 20232034 through 2039,2038, (3) charitable contribution carryforwards of approximately $90 million expiring in 2024 through 2025 and (3)(4) state NOL carryforwards of approximately $3.5$3.333 billion expiring in 20202022 through 20392041 for which the associated deferred tax benefit, net of valuation allowance and federal tax impact, is $25$49 million. Our ability to utilize NOL carryforwards to reduce future taxable income may be limited under Section 382 of the Internal Revenue Code if certain ownership changes in our company occur during a rolling three-yearthree‑year period. These ownership changes include purchases of common stock under share repurchase programs, the offering of stock by us, the purchase or sale of our stock by 5% shareholders, as defined in the Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5% shareholders result in aggregate increases that exceed 50 percentage points during the three-yearthree‑year period, then Section 382 imposes an annual limitation on the amount of our taxable income that may be offset by the NOL carryforwards or tax credit carryforwards at the time of ownership change.


129


Table of Contents
NOTE 20. EARNINGS (LOSS) PER COMMON SHARE

The following table is a reconciliation of the numerators and denominators of our basic and diluted earnings (loss) per common share calculations for our continuing operations for the years ended December 31, 2019, 20182021, 2020 and 2017.2019. Net income available (loss attributable) to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.
 Net Income Available (Loss Attributable) to Common Shareholders (Numerator)Weighted
Average Shares
(Denominator)
Per-Share
Amount
Year Ended December 31, 2021   
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$915 106,833 $8.56 
Effect of dilutive stock options, restricted stock units and deferred compensation units— 1,738 (0.13)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$915 108,571 $8.43 
Year Ended December 31, 2020   
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$399 105,010 $3.80 
Effect of dilutive stock options, restricted stock units and deferred compensation units— 1,253 (0.05)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$399 106,263 $3.75 
Year Ended December 31, 2019   
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic loss per share$(226)103,398 $(2.19)
Effect of dilutive stock options, restricted stock units and deferred compensation units— — — 
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share$(226)103,398 $(2.19)
 
Net Income Available (Loss Attributable)
to Common
Shareholders
(Numerator)
 
Weighted
Average Shares
(Denominator)
 
Per-Share
Amount
Year Ended December 31, 2019 
  
  
Net loss attributable to Tenet Healthcare Corporation common
   shareholders for basic loss per share
$(243) 103,398
 $(2.35)
Effect of dilutive stock options, restricted stock units and deferred compensation units
 
 
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share$(243) 103,398
 $(2.35)
Year Ended December 31, 2018 
  
  
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$108
 102,110
 $1.06
Effect of dilutive stock options, restricted stock units and deferred compensation units
 1,771
 (0.02)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$108
 103,881
 $1.04
Year Ended December 31, 2017 
  
  
Net loss attributable to Tenet Healthcare Corporation common
   shareholders for basic loss per share
$(704) 100,592
 $(7.00)
Effect of dilutive stock options, restricted stock units and deferred compensation units
 
 
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted loss per share$(704) 100,592
 $(7.00)


All potentially dilutive securities were excluded from the calculation of diluted loss per share for the yearsyear ended December 31, 2019 and 2017 because we did not report income from continuing operations available to common shareholders in those periods.that period. In circumstances where we do not have income from continuing operations available to common shareholders, the effect of stock options and other potentially dilutive securities is anti-dilutive,anti‑dilutive, that is, a loss from continuing operations attributable to common shareholders has the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to common shareholders in the yearsyear ended December 31, 2019, and 2017, the effect (in thousands) of employee stock options, restricted stock unitsRSUs and deferred compensation units on the diluted shares calculation would have been an increase in shares of 1,457 and 788 for the yearsyear ended December 31, 2019 and 2017, respectively.2019.

NOTE 21. FAIR VALUE MEASUREMENTS

Fair Value Measurements
Our non-financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long-lived assets held and used, long-lived assets held for sale and goodwill. We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value on a non-recurring basis. The following tables present this information and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values.value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non-financialnon‑financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.

  December 31, 2019 
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Long-lived assets held for sale $387
 $
 $387
 $
  December 31, 2018 
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Long-lived assets held for sale $39
 $
 $39
 $
Long-lived assets held and used $130
 $
 $130
 $

130

Table of Contents
Our non‑financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long‑lived assets held and used, long‑lived assets held for sale and goodwill. The following table presents this information about assets measured at fair value at December 31, 2020 and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values:
 December 31, 2020Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Long-lived assets held for sale$140 $— $140 $— 
Long-lived assets held and used483 — 483 — 
$623 $— $623 $— 

As describeddiscussed in Note 6, we recognized an impairment charge of $76 million to write down buildings in one of our Hospital Operations segment’s markets to their estimated fair value during the year ended December 31, 2019, we recorded impairment charges in continuing operations of $26 million to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Memphis-area facilities and $16 million of other impairment charges. In the year ended December 31, 2018, we recorded impairment charges in continuing operations of $40 million for the write-down of buildings and other long-lived assets to their estimated fair values at 2 hospitals. We also recorded $24 million to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Chicago-area facilities, as well as $9 million of impairment charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen and $4 million related to other impairment charges.2020.

Financial Instruments
The fair value of our long-termlong‑term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs, which include inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. At December 31, 20192021 and 2018,2020, the estimated fair value of our long-termlong‑term debt was approximately 106.4%103.3% and 97.3%104.5%, respectively, of the carrying value of the debt.

NOTE 22. ACQUISITIONS
In December 2021, subsidiaries of USPI acquired ownership interests in 86 ambulatory surgery centers and related ambulatory support services (collectively, the “2021 SCD Centers”) from Surgical Center Development #3, LLC and Surgical Center Development #4, LLC (“SCD”). Of these, we acquired controlling interests in 15 ambulatory surgery centers, noncontrolling interests in 57 centers and interests in 14 centers still in the development stage. The newly acquired facilities augmented our Ambulatory Care segment’s existing musculoskeletal service line and expanded the number of markets it serves. We made a cash payment of $1.125 billion, net of cash acquired, to acquire these facilities. The 2021 SCD Centers are included in our Ambulatory Care segment.

In addition to the 2021 SCD Centers, we paid an aggregate purchase price of $74 million to acquire controlling interests in 11 outpatient businesses and various physician practices during the year ended December 31, 2021. During 2021, we also acquired a controlling interests in 3 surgical hospitals and 2 ambulatory surgery centers in which we previously owned a noncontrolling interest for $21 million. All of these facilities are included in our Ambulatory Care segment.

In December 2020, USPI acquired controlling interests in 45 ambulatory surgery centers (collectively, the “2020 SCD Centers”) from SurgCenter Development and physician owners. The fair value of the consideration conveyed for the 2020 SCD Centers was $1.115 billion, consisting of a cash payment of $1.097 billion, fully funded using cash on hand, and the assumption of $18 million of center‑level debt.

In addition to the 2020 SCD Centers, we acquired ownership interests in 10 outpatient businesses (all of which are in our Ambulatory Care segment), and various physician practices during the year ended December 31, 2020. The aggregate purchase price for these acquisitions was $80 million.

During the year ended December 31, 2019, we acquired ownership interests in 10 outpatient businesses (all of which are owned by USPI), and various physician practices. The fair value of the consideration conveyed in the acquisitions (the “purchase price”) was $25 million.

During the year ended December 31, 2018, we acquired 10 outpatient businesses (all of which are owned by USPI)our Ambulatory Care segment), 3 off-campusoff‑campus emergency departments and various physician practices. The fair value of the consideration conveyed inaggregate purchase price for the acquisitions (the “purchase price”) was $113$25 million.

During the year ended December 31, 2017, we acquired 8 outpatient businesses (all of which are owned by USPI) and various physician practices. The fair value of the consideration conveyed in the acquisitions (the “purchase price”) was $50 million.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2019 is2021, including the 2021 SCD Centers, are preliminary. We are in process of finalizing the purchase price allocations, includingassessing working capital balances as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling interests for some of our 2019 acquisitions; therefore,interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying consolidated financial statements are subject to adjustment once the valuationsassessments and valuation work are completed. completed and evaluated. Such adjustments will be recorded as soon as practical and within the measurement period as defined by the accounting literature.

131


Table of Contents

Preliminary or final purchase price allocations for all the acquisitions made during the years ended December 31, 2019, 20182021, 2020 and 20172019 are as follows:
Years Ended December 31,
2019 2018 2017 202120202019
Current assets$16
 $6
 $7
Current assets$59 $67 $16 
Property and equipment20
 19
 9
Property and equipment88 63 20 
Other intangible assets4
 9
 8
Other intangible assets14 
Goodwill43
 220
 91
Goodwill664 1,581 43 
Other long-term assets, including previously held equity method investments24
 (18) (3)Other long-term assets, including previously held equity method investments753 38 24 
Current liabilities(16) 
 (8)Current liabilities(25)(45)(16)
Long-term liabilities(35) (15) (2)Long-term liabilities(70)(43)(35)
Redeemable noncontrolling interests in equity of consolidated subsidiaries(18) (21) (29)Redeemable noncontrolling interests in equity of consolidated subsidiaries(139)(478)(18)
Noncontrolling interests(7) (85) (18)Noncontrolling interests(95)(20)(7)
Cash paid, net of cash acquired(25) (113) (50)Cash paid, net of cash acquired(1,220)(1,177)(25)
Gains on consolidations$6
 $2
 $5
Gains on consolidations$23 $ $6 


The goodwill generated from these transactions, the majority of which will not be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. The goodwill total of $43$664 million from acquisitions completed during the year ended December 31, 20192021 was recorded in our Ambulatory Care segment. Approximately $6$20 million, $10$14 million and $6 million in transaction costs related to prospective and closed acquisitions were expensed during the years ended December 31, 2019, 20182021, 2020 and 2017,2019, respectively, and are included in impairment and restructuring charges, and acquisition-relatedacquisition‑related costs in the accompanying Consolidated Statements of Operations.

During the years ended December 31, 2019, 20182021 and 2017,2019, we recognized gains totaling $6 million, $2$23 million, and $5$6 million, respectively, associated with stepping up our ownership interests in previously held equity investments, which we began consolidating after we acquired controlling interests. No such gains or losses were recognized in the year ended December 31, 2020.

Pro Forma Information - Unaudited
The following table provides certain pro forma information for Tenet as if the 2021 SCD Centers acquisition had occurred at the beginning of the year ended December 31, 2020:
 Year Ended December 31,
 20212020
Net operating revenues$19,627 $17,752 
Equity in earnings of unconsolidated affiliates$258 $192 
Net income available to Tenet Healthcare Corporation common shareholders$941 $416 
Diluted earnings per share available to Tenet Healthcare Corporation
common shareholders
$8.66 $3.92 

NOTE 23. SEGMENT INFORMATION

Our business consists of our Hospital Operations and other segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities.

Our Hospital Operations and other segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, urgent care centers, micro-hospitalsmicro‑hospitals and physician practices. As described in Note 5, certain of our facilities were classified as held for sale in the accompanying Consolidated Balance Sheet at December 31, 2019. At December 31, 2019,2021, our subsidiaries operated 6560 hospitals serving primarily urban and suburban communities in 9 states. On April 1, 2021, we transferred 24 imaging centers from our Ambulatory Care segment to our Hospital Operations segment. The total assets associated with the imaging centers transferred to our Hospital Operations segment constituted less than 1% of our consolidated total assets at March 31, 2021. In April 2021, we also completed the sale of the majority of the urgent care centers held by our Hospital Operations segment to an unaffiliated urgent care provider. In addition, we completed the sale of the Miami Hospitals in August 2021.

132

Table of Contents
Our Ambulatory Care segment is comprised of the operations of USPI, in which we held an ownership interest of approximately 95% at December 31, 2021 and included 9 Aspen facilities in the United Kingdom until their divestiture effective August 17, 2018.2020. At December 31, 2019,2021, USPI had interests in 260399 ambulatory surgery centers 39 urgent care centers operated under the CareSpot brand, 23 imaging centers(249 consolidated) and 24 surgical hospitals (8 consolidated) in 2734 states. At December 31, 2019, we owned 95%We completed the divestiture of USPI.40 urgent care centers held by our Ambulatory Care segment on April 1, 2021.

Our Conifer segment provides revenue cycle management and value-based care services to hospitals, healthcarehealth systems, physician practices, employers and other customers.clients. At December 31, 2019,2021, Conifer provided services to approximately 660650 Tenet and non-Tenetnon‑Tenet hospitals and other clients nationwide. In 2012, we entered into agreementsan agreement documenting the terms and conditions of various services Conifer provides to Tenet hospitals (“RCM Agreement”), as well as an agreement documenting certain administrative services our Hospital Operations and other segment provides to Conifer. TheIn March 2021, we entered into a month‑to‑month agreement amending the RCM Agreement effective January 1, 2021 (“Amended RCM Agreement”) to update certain terms and conditions related to the revenue cycle management services Conifer provides to Tenet hospitals. We believe the pricing terms for the services provided by each under the Amended RCM Agreement are commercially reasonable and consistent with estimated third‑party to the other under these contracts were based on estimated third-party pricing terms in effect at the time the agreements were signed.terms. At December 31, 2019,2021, we owned 76.2%approximately 76% of Conifer Health Solutions, LLC, which is theConifer’s principal subsidiary of Conifer Holdings, Inc.


subsidiary.

The following table includes amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Consolidated Balance Sheets and Consolidated Statements of Operations:
December 31,
 202120202019
Assets:  
Hospital Operations$17,173 $18,048 $16,196 
Ambulatory Care9,473 8,048 6,195 
Conifer933 1,010 974 
Total 
$27,579 $27,106 $23,365 

Years Ended December 31,
December 31,
2019
 December 31,
2018
 December 31,
2017
202120202019
Assets: 
  
  
Hospital Operations and other$16,182
 $15,684
 $16,466
Capital expenditures:Capital expenditures:   
Hospital OperationsHospital Operations$578 $467 $572 
Ambulatory Care6,195
 5,711
 5,822
Ambulatory Care66 51 75 
Conifer974
 1,014
 1,097
Conifer14 22 23 
Total
$23,351
 $22,409
 $23,385
Total
$658 $540 $670 
Net operating revenues:Net operating revenues:   
Hospital Operations total prior to inter-segment eliminationsHospital Operations total prior to inter-segment eliminations$15,982 $14,790 $15,522 
Ambulatory CareAmbulatory Care2,718 2,072 2,158 
ConiferConifer   
TenetTenet482 528 573 
Other clientsOther clients785 778 799 
Total Conifer revenuesTotal Conifer revenues1,267 1,306 1,372 
Inter-segment eliminationsInter-segment eliminations(482)(528)(573)
Total
Total
$19,485 $17,640 $18,479 
Equity in earnings of unconsolidated affiliates:Equity in earnings of unconsolidated affiliates:   
Hospital OperationsHospital Operations$25 $$15 
Ambulatory CareAmbulatory Care193 163 160 
Total
Total
$218 $169 $175 
Adjusted EBITDA:Adjusted EBITDA:   
Hospital OperationsHospital Operations$1,931 $1,911 $1,449 
Ambulatory CareAmbulatory Care1,197 868 895 
ConiferConifer355 367 386 
Total
Total
$3,483 $3,146 $2,730 

 Years Ended December 31,
 2019 2018 2017
Capital expenditures: 
  
  
Hospital Operations and other$572
 $527
 $625
Ambulatory Care75
 68
 60
Conifer23
 22
 22
Total 
$670
 $617
 $707
      
Net operating revenues: 
  
  
Hospital Operations and other total prior to inter-segment eliminations$15,522
 $15,285
 $16,260
Ambulatory Care2,158
 2,085
 1,940
Conifer 
  
  
Tenet573
 590
 618
Other clients799
 943
 979
Total Conifer revenues1,372
 1,533
 1,597
Inter-segment eliminations(573) (590) (618)
Total 
$18,479
 $18,313
 $19,179
      
Equity in earnings of unconsolidated affiliates: 
  
  
Hospital Operations and other$15
 $10
 $4
Ambulatory Care160
 140
 140
Total 
$175
 $150
 $144
      
Adjusted EBITDA: 
  
  
Hospital Operations and other$1,425
 $1,411
 $1,462
Ambulatory Care895
 792
 699
Conifer386
 357
��283
Total 
$2,706
 $2,560
 $2,444
      
Depreciation and amortization: 
  
  
Hospital Operations and other$733
 $685
 $736
Ambulatory Care72
 68
 84
Conifer45
 49
 50
Total 
$850
 $802
 $870
      
Adjusted EBITDA 
$2,706
 $2,560
 $2,444
Income (loss) from divested and closed businesses
(i.e., the Company’s health plan businesses)
(2) 9
 (41)
Depreciation and amortization(850) (802) (870)
Impairment and restructuring charges, and acquisition-related costs(185) (209) (541)
Litigation and investigation costs(141) (38) (23)
Interest expense(985) (1,004) (1,028)
Gain (loss) from early extinguishment of debt(227) 1
 (164)
Other non-operating expense, net(5) (5) (22)
Net gains (losses) on sales, consolidation and deconsolidation of facilities(15) 127
 144
Income (loss) from continuing operations, before income taxes$296
 $639
 $(101)
133

Table of Contents
Years Ended December 31,
202120202019
Depreciation and amortization:
Hospital Operations$722 $739 $733 
Ambulatory Care95 81 72 
Conifer38 37 45 
Total $855 $857 $850 
Adjusted EBITDA $3,483 $3,146 $2,730 
Income (loss) from divested and closed businesses(1)20 (2)
Depreciation and amortization(855)(857)(850)
Impairment and restructuring charges, and acquisition-related costs(85)(290)(185)
Litigation and investigation costs(116)(44)(141)
Interest expense(923)(1,003)(985)
Loss from early extinguishment of debt(74)(316)(227)
Other non-operating income (expense), net14 (5)
Net gains (losses) on sales, consolidation and deconsolidation of facilities445 14 (15)
Income from continuing operations, before income taxes$1,888 $671 $320 



NOTE 24. RECENT ACCOUNTING STANDARDS

Recently Issued Accounting Standards

In August 2018,October 2021, the FASB issued ASU 2018-13, “Fair Value Measurement2021-08, “Business Combinations (Topic 820)805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). The standard addresses diversity in practice related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 – Revenue from Contracts with Customers as if the acquirer had originated the contracts, as opposed to at their fair value on the acquisition date. ASU 2021-08 is effective for us beginning in 2023, with early adoption permitted. We are currently evaluating the impact of this standard to our financial statements.

The FASB issued ASU 2021-10, “Government Assistance (Topic 832)” (“ASU 2021-10”) in November 2021. The amendments in this update require additional disclosures regarding government grants and money contributions, including information on the nature of transactions and related accounting policies used to account for transactions, detail on the line items on the balance sheet and income statement affected by these transactions, and significant terms and conditions of the transactions. ASU 2021-10 is effective for us beginning in 2022, with early adoption permitted. The adoption of this guidance will not impact our financial position, results of operations or cash flows.

In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (ASU 2020-06”). Among other amendments, ASU 2020-06 changes the accounting for diluted earnings-per-share for convertible instruments and contracts that may be settled in cash or stock. Under current GAAP, entities can overcome the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer’s election. If successfully rebutted, entities can use the treasury stock method to determine the dilutive effect of these instruments and, under certain conditions, exclude them from diluted weighted average shares outstanding. ASU 2020-06 requires that the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments and eliminates an entity’s ability to assume cash settlement for an instrument that may be share-settled. This standard is effective for the Company in the first quarter of fiscal 2022 and may be applied on a modified or fully retrospective basis. Although the adoption of this guidance will not impact our financial position or cash flows, it may result in an increase in the number of diluted weighted average shares outstanding utilized in our diluted earnings per share calculation.

Recently Adopted Accounting Standards
Effective January 1, 2021, we adopted ASU 2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans –General (Subtopic 715-20) Disclosure Framework—Framework – Changes to the Disclosure Requirements for Fair Value Measurement”Defined Benefit Plans” (“ASU 2018-13”2018-14”), which appliesapplied to all entitiesemployers that are required to make disclosures about recurringsponsor defined benefit pension or nonrecurring fair value measurements.other postretirement plans. The amendments in ASU 2018-13, which remove, modify2018-14, removed, modified or addadded certain disclosure requirements as part of the FASB’s disclosure framework project to improve the effectiveness of the notes to the financial statements, are effective for us beginning in 2020.statements. The adoption of this guidance willASU did not impact our financial position, results of operations or cash flows.

134

Table of Contents

Effective January 1, 2020, as further discussed in Note 1, we adopted ASU 2016-13 using the modified retrospective transition approach as of the period of adoption. Also in August 2018, the FASB issuedeffective January 1, 2020, we adopted ASU 2018-14, “Compensation2018-13, “Fair Value Measurement (Topic 820) Disclosure FrameworkRetirement Benefits – Defined Benefit Plans –General (Subtopic 715-20) Disclosure Framework—Changes to the Disclosure Framework Requirements for Defined Benefit Plans”Fair Value Measurement” (“ASU 2018-14”2018-13”), which applies to all employers that sponsor defined benefit pension or other postretirement plans. The amendments in ASU 2018-14, which remove, modify or add certain disclosure requirements as part of using the FASB’s disclosure framework project to improve the effectiveness of the notes to the financial statements, are effective for us beginning in 2021. The adoption of this guidance will not impact our financial position, results of operations or cash flows.

Additionally, the FASB issuedprescribed transition method and ASU 2018-15, “Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Isis a Service Contract” (“ASU 2018-14”2018-15”), which applies to all entities that are a customer in a hosting arrangement that is a service contract. The amendments in ASU 2018-14, which align using the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software, are effective for us beginning in 2020. We do not expectprospective transition method. The adoption of this guidance toASU 2018-13 and ASU 2018-15 did not have a material effect on our financial position, results of operations or cash flows.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which applies to entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. We will adopt ASU 2016-13 effective January 1, 2020 using the modified retrospective transition approach as of the period of adoption by recording a cumulative effect adjustment to increase accumulated deficit by $15 million to $20 million. We do not expect the adoption to have a material effect on our financial position, results of operations or cash flow.

Recently Adopted Accounting Standards

Effective January 1, 2019, as further discussed in Note 1, we adopted ASU 2016-02 using the modified retrospective transition approach as of the period of adoption.

Effective January 1, 2018, as further discussed in Note 1, we adopted ASU 2014-09 and ASU 2016-01, and we early adopted ASU 2018-02. Also effective January 1, 2018, we adopted ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” and ASU 2016-18, “Statement of Cash Flows (Topic 230) Restricted Cash,” both of which were applied using a retrospective transition method to each period presented and did not have any effect on our statements of cash flows.

Effective January 1, 2017, as further discussed in Note 1, we adopted ASU 2016-09 and early adopted ASU 2017-07. We also early adopted ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350)” (“ASU 2017‑04”) for our annual goodwill impairment tests for the year ended December 31, 2017. The amendments in ASU 2017-04 modified the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer determines goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. Our adoption of ASU 2017-04 did not affect our financial position, results of operations or cash flows.


NOTE 25. SUBSEQUENT EVENT

Termination of USPI Management Equity Plan and Adoption of USPI Restricted Stock Plan
As described in Note 10, USPI previously maintained a management equity plan whereby it had granted non-qualified options to purchase nonvoting shares of USPI’s outstanding common stock to eligible plan participants. InOn February 2020, the plan and all unvested options granted under the plan were terminated in accordance with the terms of the plan. In the first quarter of 2020, USPI will repurchase all vested options and all shares of USPI stock acquired upon exercise of an option. All participants in the plan will receive fair market value for any such vested options or shares; all unvested options under the plan were canceled. USPI will pay approximately $35 million to eligible plan participants in connection with the repurchase of eligible securities. Also in February 2020, USPI adopted a new restricted stock plan whereby USPI will grant shares of restricted non-voting common stock to eligible plan participants.

SUPPLEMENTAL FINANCIAL INFORMATION

SELECTED QUARTERLY FINANCIAL DATA
(UNAUDITED)
 Year Ended December 31, 2019
 First Second Third Fourth
Net operating revenues$4,545
 $4,560
 $4,568
 $4,806
Net income (loss)$65
 $112
 $(152) $129
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders$(19) $17
 $(232) $2
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders: 
  
  
  
Basic$(0.18) $0.17
 $(2.24) $0.02
Diluted$(0.18) $0.16
 $(2.24) $0.02
 Year Ended December 31, 2018
 First Second Third Fourth
Net operating revenues$4,699
 $4,506
 $4,489
 $4,619
Net income$191
 $108
 $65
 $102
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders$99
 $26
 $(9) $(5)
Earnings (loss) per share available (attributable) to Tenet Healthcare Corporation common shareholders: 
  
  
  
Basic$0.98
 $0.25
 $(0.09) $(0.04)
Diluted$0.96
 $0.25
 $(0.09) $(0.04)


Quarterly operating results are not necessarily indicative of the results that may be expected9, 2022, we called for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularlyredemption of all $700 million aggregate principal amount outstanding of our 2025 Senior Secured First Lien Notes. We expect to redeem the timing and magnitudenotes on February 23, 2022 using cash on hand.
135

Table of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; trends in patient accounts receivable collectability and associated implicit price concessions; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters and other weather-related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains (losses) from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect service mix, revenue mix, patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: changes in federal and state healthcare regulations; the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; hospital performance data on quality measures and patient satisfaction, as well as standard charges for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures. These considerations apply to year-to-year comparisons as well.Contents

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e)13a‑15(e) and 15d-15(e)15d‑15(e) under the Exchange Act, as of the end of the period covered by this report. The

evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

Management’s report on internal control over financial reporting is set forth on page 7984 and is incorporated herein by reference. The independent registered public accounting firm that audited the financial statements included in this report has issued an attestation report on our internal control over financial reporting as set forth on page 8085 herein.

There were no changes in our internal control over financial reporting during the quarter ended December 31, 20192021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION 

None.


ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.

136

Table of Contents
PART III.
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information required by this Item is hereby incorporated by reference to our definitive proxy statement in accordance with General Instruction G(3) to Form 10-K.10‑K. Information concerning our StandardsCode of Conduct, by which all of our employees and officers, including our chief executive officer, chief financial officer and principal accounting officer, are required to abide appears under Item 1, Business – Compliance and Ethics, of Part I of this report.

ITEM 11. EXECUTIVE COMPENSATION

Information required by this Item is hereby incorporated by reference to our definitive proxy statement in accordance with General Instruction G(3) to Form 10-K.10‑K.

ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Information required by this Item is hereby incorporated by reference to our definitive proxy statement in accordance with General Instruction G(3) to Form 10-K.10‑K.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information required by this Item is hereby incorporated by reference to our definitive proxy statement in accordance with General Instruction G(3) to Form 10-K.10‑K.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Information required by this Item is hereby incorporated by reference to our definitive proxy statement in accordance with General Instruction G(3) to Form 10-K.10‑K.


137

Table of Contents
PART IV.

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

FINANCIAL STATEMENTS

The Consolidated Financial Statements and notes thereto can be found on pages 8388 through 129.135.

FINANCIAL STATEMENT SCHEDULES

Schedule II—Valuation and Qualifying Accounts (included on page 141)146).

All other schedules and financial statements of the Registrant are omitted because they are not applicable or not required or because the required information is included in the Consolidated Financial Statements or notes thereto.

138
FINANCIAL STATEMENTS REQUIRED BY RULE 3-09 OF REGULATION S-X


The consolidated financial statementsTable of Texas Health Ventures Group, L.L.C. and subsidiaries (“THVG”), which are included due to the significance of the equity in earnings of unconsolidated affiliates we recognized from our investment in THVG for the years ended December 31, 2019, 2018 and 2017 can be found on pages F-1 through F-20.Contents

All other schedules and financial statements of THVG are omitted because they are not applicable or not required or because the required information is included in the Consolidated Financial Statements or notes thereto.


EXHIBITS

Unless otherwise indicated, the following exhibits are filed with this report:
(3)Articles of Incorporation and Bylaws
(3)Articles of Incorporation and Bylaws
(a)
(b)
(c)
(4)Instruments Defining the Rights of Security Holders, Including Indentures
(a)
(b)
(c)

(d)
(e)
(f)(d)

(g)(e)

(h)(f)

(i)(g)

(j)

(k)


139

(10)Material Contracts
(a)(l)


(b)(m)
(n)
(o)
(p)

(10)(c)Material Contracts
(a)

(d)

(e)(b)
(f)


(g)(c)

(h)(d)
(i)(e)
(f)
(g)

(j)(h)
140

Table of Contents

(k)(i)
First Amendment to Stock Pledge Agreement, dated as of May 8, 2009, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit 10(h) to Registrant’s Annual Report on Form 10-K for the year ended December 31, 2015, filed February 22, 2016)

(l)(j)
Second Amendment to Stock Pledge Agreement, dated as of June 15, 2009, by and among the Registrant, as pledgor, The Bank of New York Mellon Trust Company, N.A., as collateral trustee, and the other pledgors party thereto (Incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K filed June 16, 2009)

(m)(k)

(n)(l)

(o)(m)
(p)(n)
(q)(o)
(r)(p)

(s)

(t)(q)
(u)
(v)
(w)

(x)
(y)

(z)

(aa)
(bb)

(cc)(r)

(dd)(s)
(t)

(ee)(u)
(v)
(ff)(w)
(x)
141

(gg)(y)
(z)
(hh)


(ii)(aa)
(jj)(bb)

(kk)(cc)

(ll)(dd)

(mm)(ee)
(ff)
(gg)
(nn)
(oo)(hh)
(pp)

(qq)(ii)
(rr)
(ss)
(tt)(jj)
(uu)(kk)
(ll)
(mm)
(nn)
142

(oo)
(pp)
(vv)(qq)
(ww)(rr)
(xx)(ss)
(21)
(23)
Consents
(a)

(31)(b)

(31)
Rule 13a-14(a)/15d-14(a) Certifications
(a)
(b)
(32)
(101 SCH)
Inline XBRL Taxonomy Extension Schema Document
(101 CAL)
Inline XBRL Taxonomy Extension Calculation Linkbase Document
(101 DEF)
Inline XBRL Taxonomy Extension Definition Linkbase Document
(101 LAB)
Inline XBRL Taxonomy Extension Label Linkbase Document
(101 PRE)
Inline XBRL Taxonomy Extension Presentation Linkbase Document
(101 INS)
Inline XBRL Taxonomy Extension Instance Document – the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document
(104(104))Cover Page Interactive Data File -page from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021 formatted in Inline XBRL (included in Exhibit 101)
* Management contract or compensatory plan or arrangement.arrangement

ITEM 16. FORM 10-K SUMMARY

Not applicable.



143

Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TENET HEALTHCARE CORPORATION

(Registrant)
Date: February 24, 202018, 2022By:/s/ R. SCOTT RAMSEY
R. Scott Ramsey
Senior Vice President, Controller
 (Principal Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
144

Table of Contents
Date: February 24, 202018, 2022By:/s/ RONALD A. RITTENMEYERSAUMYA SUTARIA
Ronald A. RittenmeyerSaumya Sutaria, M.D.
Executive Chairman and Chief Executive Officer and Director
(Principal Executive Officer)
Date: February 24, 202018, 2022By:/s/ DANIEL J. CANCELMI
Daniel J. Cancelmi
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
Date: February 24, 202018, 2022By:/s/ R. SCOTT RAMSEY
R. Scott Ramsey
Senior Vice President, Controller
(Principal Accounting Officer)
Date: February 24, 202018, 2022By:/s/ LLOYD J. AUSTIN, IIIRONALD A. RITTENMEYER
Lloyd J. Austin, III
Ronald A. Rittenmeyer
Executive Chairman and
Director
Date: February 24, 202018, 2022By:/s/ JAMES L. BIERMAN
James L. Bierman

Director
Date: February 24, 202018, 2022By:/s/ RICHARD FISHER
Richard Fisher

Director
Date: February 24, 202018, 2022By:/s/ MEGHAN M. FITZGERALD
Meghan M. FitzGerald, DrPH
Director
Date: February 24, 202018, 2022By:/s/ CECIL D. HANEY
Cecil D. Haney
Director
Date: February 18, 2022By:/s/ J. ROBERT KERREY
J. Robert Kerrey

Director
Date: February 24, 202018, 2022By:/s/ CHRIS LYNCH
Chris Lynch

Director
Date: February 24, 202018, 2022By:/s/ RICHARD MARK
Richard Mark

Director
Date: February 24, 202018, 2022By:/s/ TAMMY ROMO
Tammy Romo

Director
Date: February 24, 202018, 2022By:/s/ NADJA WEST M.D.
Nadja West, M.D.

Director
145


Table of Contents
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
(In Millions)
 
Balance at
Beginning
of Period
 

Costs and
Expenses(1)(2)
 
Deductions(3)
 
Other
Items(4)(5)
 
Balance at
End of
Period
Allowance for doubtful accounts: 
  
  
  
  
Year ended December 31, 2019$
 $
 $
 $
 $
Year ended December 31, 2018$898
 $
 $
 $(898) $
Year ended December 31, 2017$1,031
 $1,434
 $(1,445) $(122) $898
Valuation allowance for deferred tax assets: 
  
  
  
  
Year ended December 31, 2019$148
 $133
 $
 $
 $281
Year ended December 31, 2018$72
 $76
 $
 $
 $148
Year ended December 31, 2017$72
 $
 $
 $
 $72
 Balance at
Beginning
of Period

Costs and
Expenses(1)
DeductionsOther
Items
Balance at
End of
Period
Valuation allowance for deferred tax assets:     
Year ended December 31, 2021$55 $$— $— $57 
Year ended December 31, 2020$281 $(226)$— $— $55 
Year ended December 31, 2019$148 $133 $— $— $281 
(1)
(1)Includes amounts recorded in discontinued operations.
(2)Before considering recoveries on accounts or notes previously written off.
(3)Accounts written off.
(4)Acquisition and divestiture activity in 2017.
(5)Allowance for doubtful accounts eliminated in 2018 upon adoption of new accounting standard ASC 606.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
CONTENTS
Audited Financial Statements

Report of Independent Auditors
To the Board of Trustees of Baylor Scott & White Holdings
We have audited the accompanying consolidated financial statements of Texas Health Ventures Group, L.L.C. and its subsidiaries, which comprise the consolidated balance sheets as of June 30, 2019 and 2018, and the related consolidated statements of income, changes in equity and cash flows for each of the three years in the period ended June 30, 2019.
Management's Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
Auditors’ Responsibility
Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Texas Health Ventures Group, L.L.C. and its subsidiaries as of June 30, 2019 and 2018, and the results of their operations and their cash flows for each of the three years in the period ended June 30, 2019 in accordance with accounting principles generally accepted in the United States of America.

/s/ PricewaterhouseCoopers LLP

Dallas, Texas
November 1, 2019


TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS – AS OF JUNE 30, 2019 AND 2018
(in thousands)
 2019 2018
ASSETS   
CURRENT ASSETS:   
Cash$23,703
 $29,041
Funds due from USPI101,282
 114,408
Patient receivables, net of allowance for doubtful accounts of $60,631 at June 30, 2018111,579
 107,426
Supplies27,017
 26,070
Prepaid and other current assets13,951
 8,533
Total current assets277,532
 285,478
    
NON-CURRENT ASSETS:   
Property and equipment, net (Note 2)234,423
 238,054
Restricted cash1,300
 4,439
Investments in unconsolidated affiliates (Note 3)6,837
 6,987
Goodwill and intangible assets, net (Note 5)432,000
 431,828
Other279
 505
    
Total assets$952,371
 $967,291
    
LIABILITIES AND EQUITY   
    
CURRENT LIABILITIES:   
Accounts payable, including funds due to USPI of $10,747 and $16,014 at June 30, 2019 and
   2018, respectively
$78,658
 $87,153
Accrued expenses and other47,092
 43,163
Current portion of long-term obligations (Note 6)23,249
 19,789
Total current liabilities148,999
 150,105
    
NON-CURRENT LIABILITIES:   
Long-term obligations, net of current portion (Note 6)161,930
 174,228
Other liabilities18,080
 17,159
    
Total liabilities329,009
 341,492
    
COMMITMENTS AND CONTINGENCIES (Notes 6, 7, 8 and 9)  
   
    
NONCONTROLLING INTERESTS - REDEEMABLE170,640
 172,416
    
EQUITY:  
   
Members’ equity419,847
 419,870
Noncontrolling interests – nonredeemable32,875
 33,513
Total equity452,722
 453,383
Total liabilities and equity$952,371
 $967,291

See accompanying notes to consolidated financial statements.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEARS ENDED JUNE 30, 2019, 2018 AND 2017
(in thousands)
 2019 2018 2017
REVENUES:     
Net patient service revenue$1,216,601
 $1,204,516
 $1,073,887
Less provision for doubtful accounts
 34,636
 27,135
Net patient service revenue less provision for doubtful accounts1,216,601
 1,169,880
 1,046,752
Other revenue3,268
 3,653
 3,038
Total revenues1,219,869
 1,173,533
 1,049,790
      
Equity in earnings of unconsolidated affiliates (Note 3)4,458
 5,065
 3,965
      
OPERATING EXPENSES:     
Salaries, benefits, and other employee costs302,202
 277,721
 244,798
Medical services and supplies307,784
 284,386
 249,158
Management and royalty fees (Note 8)46,362
 41,973
 38,530
Professional fees7,700
 8,679
 7,785
Purchased services64,169
 56,829
 47,549
Other operating expenses146,303
 137,252
 121,832
Provision for doubtful accounts
 25,244
 22,503
Depreciation and amortization39,962
 31,829
 28,605
Total operating expenses914,482
 863,913
 760,760
Operating income309,845
 314,685
 292,995
      
NONOPERATING INCOME (EXPENSES):     
Interest expense(15,698) (14,091) (15,586)
Interest income (Note 8)1,032
 711
 492
Other (expenses)/income, net(32) 1,059
 (1,825)
Net income before income taxes295,147
 302,364
 276,076
      
Income taxes(5,698) (5,099) (5,036)
Net income289,449
 297,265
 271,040
      
Net income attributable to noncontrolling interests - redeemable(141,348) (143,580) (134,905)
      
Net income attributable to noncontrolling interests - nonredeemable(5,280) (8,648) (8,229)
Net income attributable to THVG$142,821
 $145,037
 $127,906

See accompanying notes to consolidated financial statements.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED JUNE 30, 2019, 2018 AND 2017
(in thousands)
   Members’ Equity  
 Total Equity USP BUMC 
Total Members’
Equity
 
Noncontrolling
Interests -
Nonredeemable
Balance at June 30, 2016$313,308
 $138,185
 $138,746
 $276,931
 $36,377
Net income136,135
 63,825
 64,081
 127,906
 8,229
Distributions to members(129,002) (60,778) (61,022) (121,800) (7,202)
Contributions from members13,571
 6,772
 6,799
 13,571
 
Purchase of noncontrolling interests(1,160) (718) (720) (1,438) 278
Sale of noncontrolling interests2,406
 451
 453
 904
 1,502
Balance at June 30, 2017335,258
 147,737
 148,337
 296,074
 39,184
Net income153,685
 72,373
 72,664
 145,037
 8,648
Distributions to members(132,424) (63,076) (63,329) (126,405) (6,019)
Contributions from members102,545
 51,169
 51,376
 102,545
 
Purchase of noncontrolling interests(5,456) 674
 676
 1,350
 (6,806)
Sale of noncontrolling interests(225) 633
 636
 1,269
 (1,494)
Balance at June 30, 2018453,383
 209,510
 210,360
 419,870
 33,513
Net income148,101
 71,268
 71,553
 142,821
 5,280
Distributions to members(145,615) (69,990) (70,270) (140,260) (5,355)
Purchase of noncontrolling interests(5,526) (2,270) (2,280) (4,550) (976)
Sale of noncontrolling interests2,379
 981
 985
 1,966
 413
Balance at June 30, 2019$452,722
 $209,499
 $210,348
 $419,847
 $32,875

See accompanying notes to consolidated financial statements.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2019, 2018 AND 2017
(in thousands)
 2019 2018 2017
CASH FLOWS FROM OPERATING ACTIVITIES:     
Net income$289,449
 $297,265
 $271,040
Adjustments to reconcile net income to net cash provided by operating activities:     
Provision for doubtful accounts
 59,880
 49,638
Depreciation and amortization39,962
 31,829
 28,605
Amortization of debt issue costs12
 5
 5
Equity in earnings of unconsolidated affiliates, net of distributions received150
 156
 645
Loss/(gain) on sale of assets251
 (2) 405
Changes in operating assets and liabilities, net of effects from purchases of
   new businesses:
     
Increase in patient receivables(4,153) (62,006) (47,022)
(Increase)/Decrease in supplies, prepaid, and other assets(6,363) (4,639) 3,362
Increase in accounts payable, accrued expenses, and other liabilities7,657
 7,980
 11,890
Net cash provided by operating activities326,965
 330,468
 318,568
      
CASH FLOWS FROM INVESTING ACTIVITIES:     
Purchases of new businesses and equity interests, net of cash received of $0, $925, and $0 for 2019, 2018 and 2017, respectively
 925
 (3,853)
Purchases of property and equipment(46,465) (47,693) (16,950)
Sale of property and equipment170
 206
 1,233
Change in deposits and notes receivables35
 (44) (5)
Other investing activities(284) 13
 751
Change in funds due from United Surgical Partners, Inc.13,126
 (21,158) (10,416)
Net cash used in investing activities(33,418) (67,751) (29,240)
      
CASH FLOWS FROM FINANCING ACTIVITIES:     
Proceeds from debt obligations$11,500
 $26,078
 $10,183
Payments on debt obligations(21,829) (49,029) (19,364)
Distributions to noncontrolling interest owners(145,796) (144,265) (144,576)
Purchases of noncontrolling interests(12,792) (8,215) (5,447)
Sales of noncontrolling interests7,153
 9,609
 18,445
Contribution from members
 20,925
 
Distributions to members(140,260) (126,405) (121,800)
Net cash used in financing activities(302,024) (271,302) (262,559)
      
(Decrease)/increase in cash and restricted cash(8,477) (8,585) 26,769
Cash and restricted cash, beginning of period33,480
 42,065
 15,296
Cash and restricted cash, end of period$25,003
 $33,480
 $42,065
      
SUPPLEMENTAL INFORMATION:     
Cash paid for interest$15,776
 $13,991
 $15,642
Cash paid for income taxes$5,222
 $5,076
 $4,525
      
NONCASH TRANSACTIONS:     
Assets acquired under capital leases$1,472
 $32,033
 $4,791
(Decrease)/Increase in accounts payable due to property and equipment received but not paid(10,764) 12,322
 44
Tyler acquisition
 81,620
 
Centennial acquisition
 
 13,571
      
RECONCILIATION OF CASH AND RESTRICTED CASH:2019 2018 2017
      
Cash at beginning of period$29,041
 $32,105
 $15,296
Restricted cash at beginning of period4,439
 9,960
 
Cash and restricted cash at beginning of period$33,480
 $42,065
 $15,296
      
Cash at end of period$23,703
 $29,041
 $32,105
Restricted cash at end of period1,300
 4,439
 9,960
Cash and restricted cash at end of period$25,003
 $33,480
 $42,065
See accompanying notes to consolidated financial statements.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Texas Health Ventures Group, L.L.C. and subsidiaries (THVG or the Company), a Texas limited liability company, was formed on January 21, 1997, for the primary purpose of developing, acquiring, and operating ambulatory surgery centers and related entities. THVG is a joint venture between Baylor University Medical Center (BUMC), an affiliate of Baylor Scott & White Holdings (BSW Holdings), who owns 50.1% of THVG, and USP North Texas, Inc. (USP), a Texas corporation and consolidated subsidiary of United Surgical Partners International, Inc. (USPI), who owns 49.9% of THVG. USPI is a subsidiary of Tenet Healthcare Corporation (Tenet). BSW Holdings and its controlled affiliates are referred collectively herein as “BSWH”. THVG’s fiscal year ends June 30. Fiscal years of THVG’s subsidiaries end December 31; however, the financial information of these subsidiaries included in these consolidated financial statements is as of June 30, 2019 and 2018, and for the years ended, June 30, 2019, 2018, and 2017.
THVG owns equity interests in and operates ambulatory surgery centers, surgical hospitals, and related businesses in Texas. At June 30, 2019, THVG operated thirty-three facilities (the Facilities) under management contracts, thirty-two of which are consolidated for financial reporting purposes and one of which is accounted for under the equity method. THVG also has one consolidated facility and one equity method investment in a facility that does not fall under a management contract. In addition, THVG holds an equity method investment in one partnership that owns the real estate used by one of the Facilities.
THVG has been funded by capital contributions from its members and by cash distributions from the Facilities. The board of managers, which is controlled by BSWH, initiates requests for capital contributions. The Facilities’ operating agreements provide that cash flows available for distribution will be distributed, at least quarterly, to THVG and other owners of the Facilities.
THVG’s operating agreement provides that the board of managers determine, on at least a quarterly basis, if THVG should make a cash distribution based on a comparison of THVG’s excess cash on hand versus current and anticipated needs, including, without limitation, needs for operating expenses, debt service, acquisitions, and a reasonable contingency reserve. The terms of THVG’s operating agreement provide that any distributions, whether driven by operating cash flows or by other sources, such as the distribution of noncash assets or distributions in the event THVG liquidates, are to be shared according to each member’s overall ownership level in THVG.
Change in Reporting Entity
From January 1, 2016 to March 1, 2018, a consolidated BUMC subsidiary, BT East Dallas JV, LLP, a separate partnership with Tenet, had a 60% controlling interest in Texas Regional Medical Center, LLC (Sunnyvale). On March 1, 2018, that partnership was restructured and Sunnyvale was combined with THVG upon contribution by the Company’s members. On March 1, 2018, USP paid BUMC and Tenet approximately $4,100,000 each for its interest in Sunnyvale resulting in THVG owning a controlling 62% interest.
The transfer of ownership interests in Sunnyvale qualified as a common control transaction as defined by Accounting Standards Codification (ASC) 250-10-45-21 as BSWH held a controlling interest in the hospital before the transaction and continued to hold a controlling interest subsequent to the transaction. As a result, the commonly controlled entities, inclusive of Sunnyvale, which historically were not presented together were considered to be a different reporting entity. This change in reporting entity, which took place in prior year financial statements, required retrospective combination of the entities for all periods presented as if the combination had been in effect since inception of common control. For the period prior to Sunnyvale’s contribution into THVG, net income attributable to non-controlling interest was calculated at the percentage used for the previous joint venture, 40%. The Company’s historical consolidated balance sheets and related statements of income, changes in equity, and of cash flows and related disclosures, included Sunnyvale starting with BUMC’s acquisition of Sunnyvale on January 1, 2016. The effect of the change to Net income attributable to THVG for the years ended 2018 and 2017 was approximately $2,900,000 and $1,800,000, respectively.
Basis of Accounting
THVG maintains its books and records on the accrual basis of accounting, and the consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Principles of Consolidation
The consolidated financial statements include the financial statements of THVG and its wholly owned subsidiaries and other entities that THVG controls. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management of THVG to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Cash Equivalents
THVG considers all highly liquid instruments with original maturities when purchased of three months or less to be cash equivalents. There were no cash equivalents at June 30, 2019 or 2018. Under the Company’s cash management system, checks issued but not presented to the bank may result in book cash overdraft balances for accounting purposes. The Company reclassifies book overdrafts to accounts payable reflecting the reinstatement of liabilities cleared in the bookkeeping process. Changes in accounts payable, including those caused by book overdrafts, are reflected as an adjustment to reconcile net income to net cash provided by operating activities in the consolidated statements of cash flows. Book overdrafts included in accounts payable were approximately $22,212,000 and $24,118,000, as of June 30, 2019 and 2018, respectively.
Restricted Cash
THVG holds cash that is restricted as collateral for use in servicing certain of its outstanding debt agreements and ongoing construction projects. Restricted cash balances were approximately $1,300,000 and $4,439,000 as of June 30, 2019 and 2018, respectively, and are classified as non-current, consistent with the nature of their intended use based on the restrictions.
Concentration of Credit Risk
Government-related programs (i.e. Medicare and Medicaid) represent the only concentrated groups of payors from which THVG has significant outstanding receivables, and management does not believe there is any significant or unusual level of credit risk associated with these receivables. Commercial and managed care receivables consist of receivables from various payors involved in diverse activities and subject to differing economic conditions, and do not represent a significant concentrated credit risk to THVG.
Supplies
Supplies, consisting primarily of pharmaceuticals and medical supplies inventories, are stated at the lower of cost or net realizable value, which approximates market value, and are expensed as used.
Property and Equipment
Property and equipment are initially recorded at cost or, when acquired as part of a business combination, at fair value at the date of acquisition. Depreciation is calculated on the straight line method over the estimated useful lives of the assets. Upon retirement or disposal of assets, the asset and accumulated depreciation accounts are adjusted accordingly, and any gain or loss is reflected in earnings or losses of the respective period. Maintenance costs and repairs are expensed as incurred; significant renewals and betterments are capitalized.
Assets held under capital leases are classified as property and equipment and amortized using the straight line method over the shorter of the useful lives or the lease terms, and the related obligations are recorded as debt. Amortization of property and equipment held under capital leases and leasehold improvements is included in depreciation and amortization expense in the consolidated statements of income.
THVG records operating lease expense on a straight-line basis unless another systematic and rational allocation is more representative of the time pattern in which the leased property is physically employed. THVG amortizes leasehold improvements, including amounts funded by landlord incentives or allowances, for which the related deferred rent is amortized as a reduction of lease expense, over the shorter of their economic lives or the lease term.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Investments in Unconsolidated Affiliates
Investments in unconsolidated affiliates in which THVG exerts significant influence, but has less than a controlling ownership are accounted for under the equity method. THVG exerts significant influence in the operations of its unconsolidated affiliates through representation on the governing bodies of the investees and additionally, with respect to the Facilities, through contracts to manage the operations of the investees.
Equity in earnings of unconsolidated affiliates consists of THVG’s share of the profits and losses generated from its noncontrolling equity investments. Because these operations are central to THVG’s business strategy, equity in earnings of unconsolidated affiliates is classified as a component of operating income in the accompanying consolidated statements of income.
Goodwill
Goodwill represents the excess purchase price over the estimated fair value of net identifiable
assets acquired and liabilities assumed from purchased businesses. Goodwill is not amortized but is instead tested for impairment annually, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. The qualitative assessment includes a determination by management based on qualitative factors as to whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If management determines that based on these factors it is more likely than not that the fair value of the reporting unit is less than its carrying value, the Company assesses its goodwill based on the two-step fair value approach.
To measure the amount of an impairment loss, a two-step method is used. In the first step, THVG compares the fair value of each reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that unit, goodwill is not impaired and THVG is not required to perform further testing. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then THVG must perform the second step of the impairment test in order to determine the implied fair value of the reporting unit’s goodwill. If the carrying value of a reporting unit’s goodwill exceeds its implied fair value, then THVG records an impairment loss equal to the difference. Any impairment would be recognized as a charge to income from operations and a reduction in the carrying value of goodwill.
We estimate the fair value of the reporting unit using the market and income approaches. Goodwill is required to be reported at the reporting unit level and we have concluded that THVG represents a single reporting unit. To determine the fair value of the reporting unit, we use the income approach (present value of discounted cash flows) with further corroboration from the market approach (evaluation of market multiples and/or data from third-party valuation specialists). We apply judgment in determining the fair value of our reporting unit which is dependent on significant assumptions and estimates regarding expected future cash flows, terminal value, changes in working capital requirements, and discount rates. The factor most sensitive to change with respect to THVG’s discounted cash flow analyses is the estimated future cash flows of the reporting unit which is, in turn, sensitive to THVG’s estimates of future revenue growth and margins for these businesses. If actual revenue growth and/or margins are lower than estimated, the impairment test results could differ. Although we believe that our estimates are reasonable and consistent with market participant assumptions, actual results could differ from these estimates.
A qualitative analysis of the goodwill balance was performed in March of 2019 and 2018 and no such impairments were identified. A quantitative analysis was performed in March 2017 and no such impairment was identified.
Impairment of Long-Lived Assets
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset, or related groups of assets, may not be fully recoverable from estimated future cash flows. In the event of impairment, measurement of the amount of impairment may be based on appraisal, fair values of similar assets, or estimates of future undiscounted cash flows resulting from use and ultimate disposition of the asset. No such impairment was identified in 2019, 2018, or 2017.
Fair Value of Financial Instruments
The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2) or unobservable inputs (Level 3), depending on the nature of the item being valued.The Company does not have financial assets or liabilities measured at fair value on a recurring basis at June 30, 2019 and 2018. The carrying amounts of cash, restricted cash, funds due from United

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Surgical Partners, Inc., accounts receivable, and accounts payable approximate fair value because of the short maturity of these instruments.
The fair value of the Company’s long-term debt is determined by Level 2 inputs which are an estimation of the discounted future cash flows of the debt at rates currently quoted or offered to a comparable company for similar debt instruments of comparable maturities by its lenders. At June 30, 2019, the aggregate carrying amount and estimated fair value of notes payable to financial institutions are approximately $52,438,000 and $46,424,000, respectively. At June 30, 2018, the aggregate carrying amount and estimated fair value of long-term debt were approximately $54,482,000 and $47,865,000, respectively.
Revenue Recognition
Effective July 1, 2018, THVG adopted the Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers (Topic 606)” and related clarifying standards (“ASC 606”) using a modified retrospective method of application to all contracts which were not completed as of July 1, 2018. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption of ASU 2014-09 resulted in changes to the presentation and disclosure of amounts the Company previously classified as a provision for doubtful accounts in line with the guidance set forth by ASC 605, “Revenue Recognition”. A significant portion of amounts previously recorded within the provision for doubtful accounts relate to self-pay patients, co-pays, co-insurance amounts, and deductibles owed to it by patients with insurance. Under ASU 2014-09, the estimated uncollectible amounts due from these patients are generally considered implicit price concessions that are a direct reduction to net patient service revenues. For the year ended June 30, 2019, THVG recorded $66,277,000 of implicit price concessions as a direct reduction of net patient service revenues that would have been recorded within the Company’s provision for doubtful accounts prior to the adoption of ASU 2014-09. THVG’s accounting policies related to revenues were revised to reflect the adoption of ASC 2014-09 effective July 1, 2018. There was no impact to net accounts receivable on the balance sheet for the year ended June 30, 2019 related to the adoptions of ASC 2014-09.
All subsidiaries of THVG, except for Sunnyvale, assessed the ability of each patient to pay prior to providing service; therefore the estimate of uncollectible amounts related to these entities was presented within the provision for doubtful accounts in the operating expenses section of the consolidated statements of income prior to the adoption of ASU 2014-09. Sunnyvale does not assess the ability to pay prior to providing service, and as such, the related estimate of uncollectible amounts for this entity was presented within the provision for doubtful accounts as a component of total revenues prior to the adoption of ASU 2014-09. Under ASU 2014-09, all estimated uncollectible amounts whether ability to pay is assessed prior to providing service or not, are accounted for as a direct reduction to net patient service revenues.
THVG has agreements with third-party payors that provide for payments to THVG at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Net patient service revenue is reported at the estimated net realizable amount from patients and third-party payors (including managed care payors and government programs) for services rendered. Amounts recorded as net patient service revenue include estimated contractual adjustments under reimbursement agreements with third party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and implicit price concessions. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Company bases its estimate of implicit price concessions on historical collection experience using a portfolio approach, as a practical expedient, rather than arriving at an individualized estimate for each patient service encounter.  The financial statement effects of using this practical expedient are not material as compared to estimating implicit price concessions on an individual basis. Contractual adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined.
Net patient service revenue is reported at the amount that reflects consideration to which THVG expects to be entitled in exchange for providing patient care. These amounts are due from patients, third party payors (including managed care payors and government programs) and others. Generally, THVG collects co-payments from patients at the time of service. After the service is complete, THVG prepares a final bill for the patient and third-party payor. Revenue is recognized as performance obligations are satisfied.
Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time generally relates to inpatient acute care services and is recognized based on actual charges incurred in relation to total expected (or actual) charges. Revenue for performance obligations satisfied at a point in time generally relate to patients receiving outpatient services, when: (1) services are provided; and (2) we do not believe the patient requires additional services.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Any unsatisfied or partially unsatisfied performance obligations primarily relate to in-house patients receiving inpatient acute care services as of the end of the reporting period. Based on the average length of stays, the performance obligations for these contracts have a duration of less than one year and are completed when patients are discharged, which generally occurs within days or weeks of the end of the reporting period. Because all of its performance obligations relate to contracts with a duration of less than one year, THVG has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.
The composition of net patient service revenue by primary payor for the year ended June 30, 2019 is as follows:
Managed care$896,828
Medicare230,274
Medicaid14,342
Indemnity, self-pay, and other75,157
 $1,216,601
For facilities licensed as hospitals, federal regulations require the submission of annual cost reports covering medical costs and expenses associated with services provided to program beneficiaries. Medicare and Medicaid cost report settlements are estimated in the period services are provided to beneficiaries. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is a reasonable possibility that recorded estimates with respect to the ten THVG facilities licensed as hospitals may change as interpretations are clarified. These initial estimates are revised as needed until final cost reports are settled.
The Company provides charity care to patients who are financially unable to pay for the health care services they receive. The determination of charity care is generally made at the time of admission, or shortly thereafter. However, events after discharge could change the ability of patients to pay. The discount amount is generally based on household income compared to the Federal Poverty Limit for the year. The Company’s charity policy is intended to satisfy the requirements in Section 501(r) of the Internal Revenue Code of 1986, as amended, regarding financial assistance and emergency medical care policies, limitations on charges to persons eligible for financial assistance, and reasonable billing and collection efforts. The Company’s policy is not to pursue collection of amounts determined to qualify as charity care; therefore, the Company does not report these amounts in net patient care revenues.
The Company’s estimated costs (based on the selected operating expenses, which include allocated personnel costs, supplies, other operating expenses, and management fee) of caring for charity care patients for the years ended June 30, 2019, 2018, and 2017, was approximately $15,000,000, $7,800,000, and $6,100,000, respectively.
Income Taxes
No amounts for federal income taxes have been reflected in the accompanying consolidated financial statements because the federal tax effects of THVG’s activities accrue to the individual members.
The Texas franchise tax applies to all THVG entities and is reflected in the accompanying consolidated statements of income. The tax is calculated on a margin base and is therefore reflected in THVG’s consolidated statements of income for the years ended June 30, 2019, 2018, and 2017 as income tax.
THVG follows the provisions of ASC 740 “Income Taxes” which prescribes a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements.
As of June 30, 2019 and 2018, THVG had no gross unrecognized tax benefits. THVG files a partnership income tax return in the U.S. federal jurisdiction and a franchise tax return in the state of Texas. THVG is no longer subject to U.S. federal income tax examination for years prior to 2015 and no longer subject to state and local income tax examination for years prior to 2014.THVG has identified Texas as a “major” state taxing jurisdiction. THVG does not expect or anticipate a significant change over the next twelve months in the unrecognized tax benefits.
THVG’s policy for recording interest and penalties associated with income tax matters is to record such items to income tax expense in the consolidated statements of income. There are no interest and penalties for the years ended June 30, 2019, 2018, and 2017.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Commitments and Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Other Comprehensive Income
THVG does not have any items that qualify for treatment as other comprehensive income, therefore THVG’s net income equals other comprehensive income.
Recently Adopted Accounting Pronouncements
In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230), Restricted Cash,” to clarify how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. The new guidance requires amounts generally described as restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The new guidance requires retrospective application and is effective for THVG’s annual reporting period beginning July 1, 2018. The adoption of this guidance resulted in an increase of approximately $5,500,000 in 2018 to previously reported net cash used in investing activities and a decrease of approximately $10,000,000 in 2017 to previously reported net cash used in financing activities and a corresponding decrease and increase, respectively, to previously reported Increase in cash (which is now captioned Increase in cash and restricted cash, pursuant to the adoption of this guidance). In addition, as noted above, we added a reconciliation of cash, cash equivalents, and restricted cash to the consolidated statements of cash flows.
In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments,” to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. In addition, the standard clarifies when cash receipts and cash payments have aspects of more than one class of cash flows and cannot be separated, classification will depend on the predominant source or use. The new guidance requires retrospective application and was effective for our annual reporting period beginning July 1, 2018. The adoption of this accounting standard did not have a material impact on the cash flow statements.
As further described within the “Revenue Recognition” section above, we adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) and related clarifying standards (“ASC 606”), on revenue recognition using the modified retrospective method.
Recently Issued Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Topic 220)”. The ASU is intended to improve the recognition and measurement of financial instruments. The new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of this ASU.
In June 2016, November 2018, April 2019, and May 2019, FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)”; ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments - Credit Losses”; ASU 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments”; and ASU 2019-05, “Financial Instruments-Credit Losses (Topic 326)”, respectively. The current standard delays the recognition of a credit loss on a financial asset until the loss is probable of occurring. These ASU’s remove the requirement that a credit loss be probable of occurring for it to be recognized. Instead these ASU’s require entities to use historical experience, current conditions, and reasonable and supportable forecasts to estimate their future expected credit losses. The provisions of these ASU’s are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of these ASU’s.
In January 2017, FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” This ASU eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. The provisions of ASU 2017-04 are effective for fiscal years beginning after December 15, 2019, and interim periods within those years for public business entities. The adoption of ASU 2017-01 is not expected to have a material impact on the Company.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), and has subsequently issued supplemental and/or clarifying ASU’s (collectively “ASC 842”), which affects any entity that enters into a lease (as that term is defined in ASC 842), with some specified scope exceptions. The main difference between the guidance in ASC 842 and current GAAP is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current GAAP. Recognition of these assets and liabilities will have a material impact to our consolidated balance sheet upon adoption. In transition, the lease standard is required to be applied to leases in existence as of the date of initial application using a modified retrospective transition approach, which includes a number of optional practical expedients. This guidance is effective for the Company on July 1, 2019, and the Company will elect to use the modified retrospective method as of the period of adoption rather than the earliest period presented meaning that its consolidated financial statements for periods prior to July 1, 2019 will not be modified for the application of the new lease accounting standard. The Company will elect the three packaged transitional practical expedients under ASC 842-10-65-1(f) and the practical expedient that allows lessees to choose to not separate lease and non-lease components by class of underlying asset. At July 1, 2019, the Company is expecting to increase its consolidated assets by approximately $260,000,000 to $275,000,000 and the liabilities by approximately $275,000,000 to $290,000,000 related to on-balance sheet recognition of operating lease assets and liabilities.

2.    PROPERTY AND EQUIPMENT
At June 30, 2019 and 2018, property and equipment and related accumulated depreciation and amortization consisted of the following (in thousands):
 
Estimated
Useful Lives
 2019 2018
Land
 $1,697
 $1,719
Buildings and leasehold improvements5-25 years
 272,270
 258,161
Equipment3-15 years
 226,032
 203,672
Furniture and fixtures5-15 years
 10,455
 10,547
Construction in progress 
 1,250
 6,397
  
 511,704
 480,496
Less accumulated depreciation 
 (277,281) (242,442)
Net property and equipment 
 $234,423
 $238,054

At June 30, 2019 and 2018, assets recorded under capital lease arrangements included in property and equipment consisted of the following (in thousands):
 2019 2018
Buildings$142,519
 $143,139
Equipment and furniture3,367
 2,060
 145,886
 145,199
Less accumulated depreciation(65,786) (56,162)
Net property and equipment under capital leases$80,100
 $89,037

3.    INVESTMENTS IN SUBSIDIARIES AND UNCONSOLIDATED AFFILIATES
THVG’s investments in consolidated subsidiaries and unconsolidated affiliates consisted of the following:
Legal NameFacilityCityPercentage Owned
June 30,
2019
June 30,
2018
June 30,
2017
Consolidated subsidiaries (1):
       
DeSoto Surgicare, Ltd.North Texas Surgery CenterDesoto55.2%52.1%52.1%
Metroplex Surgicare Partners, Ltd.Baylor Surgicare at BedfordBedford65.8
65.8
65.8
Baylor Surgicare at North Dallas, LLCBaylor Surgicare at North DallasDallas56.9
56.9
56.6

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Legal NameFacilityCityPercentage Owned
June 30,
2019
June 30,
2018
June 30,
2017
Fort Worth Surgicare Partners, Ltd.Baylor Surgical Hospital of Fort WorthFort Worth51.7
50.7
50.1
Denton Surgicare Partners, Ltd.Baylor Surgicare at DentonDenton50.5
50.5
50.5
Garland Surgicare Partners, Ltd.Baylor Surgicare at GarlandGarland50.1
50.1
50.1
University Surgical Partners of Dallas, L.L.P.(2)
N/ADallas68.6
68.1
66.5
Dallas Surgical Partners, L.L.C.Baylor SurgicareDallas50.4
54.6
58.9
MSH Partners, L.L.C.Baylor Medical Center at UptownDallas34.9
34.9
33.5
North Central Surgical Center, L.L.P.North Central Surgery CenterDallas35.2
34.4
33.4
Grapevine Surgicare Partners, Ltd.Baylor Surgicare at GrapevineGrapevine53.9
53.5
55.2
Frisco Medical Center, L.L.P.Baylor Scott & White Medical Center - FriscoFrisco51.9
50.5
50.4
Physicians Center of Fort Worth, L.L.P.Baylor Surgicare at Fort Worth I & IIFort Worth53.3
54.0
54.1
Bellaire Outpatient Surgery Center, L.L.P.Baylor Surgicare at OakmontFort Worth26.4
25.8
26.1
Park Cities Surgery Center, L.L.C.Park Cities Surgery CenterDallas50.1
50.1
50.1
Trophy Club Medical Center, L.P.Baylor Medical Center at Trophy ClubFort Worth50.8
50.7
50.3
Rockwall/Heath Surgery Center, L.L.P.Baylor Surgicare at HeathHeath

61.9
North Garland Surgery Center, L.L.P.Baylor Surgicare at North GarlandGarland54.5
54.3
52.1
Rockwall Ambulatory Surgery Center, L.L.P.Rockwall Surgery CenterRockwall54.7
54.7
53.3
Baylor Surgicare at Plano, L.L.C.Baylor Surgicare at PlanoPlano50.1
50.1
50.1
Arlington Orthopedic and Spine Hospitals, LLCBaylor Orthopedic and Spine Hospital at ArlingtonArlington50.1
50.1
50.1
Baylor Surgicare at Granbury, LLCBaylor Surgicare at GranburyGranbury51.2
51.2
51.2
Metrocrest Surgery Center, L.L.C.Baylor Surgicare at CarrolltonCarrollton51.0
53.5
53.5
Baylor Surgicare at Mansfield, L.L.C.Baylor Surgicare at MansfieldMansfield50.4
50.1
50.1
Tuscan Surgery Center, L.L.C.Tuscan Surgery Center at Las ColinasLas Colinas53.7
55.5
57.3
Lone Star Endoscopy Center, L.L.C.Lone Star EndoscopyKeller51.0
51.0
51.0
Baylor Surgicare at Plano Parkway, L.L.C.Baylor Surgicare at Plano ParkwayPlano51.0
51.0
51.0
Texas Endoscopy Centers, LLCTexas EndoscopyPlano/Allen51.0
51.0
51.0
Heritage Park Surgical Hospital, LLCBaylor Scott & White Surgical Hospital - ShermanSherman52.6
52.5
52.5
Centennial ASC, LLCFrisco Centennial Surgery CenterFrisco50.2
50.2
50.4
Baylor Surgicare at Baylor Plano, LLCBaylor Plano CampusPlano26.5
25.3
25.3
Texas Spine and Joint Hospital, LLCTexas Spine and JointTyler54.6
54.5

Baylor Surgicare at Blue Star, LLCFrisco StarFrisco26.5
25.8

Texas Regional Medical Center, LLCSunnyvale HospitalSunnyvale62.8
62.1
60.3
SPC at the Star, LLCSPC at the StarFrisco51.9
50.5
50.4

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Legal NameFacilityCityPercentage Owned
June 30,
2019
June 30,
2018
June 30,
2017
Unconsolidated affiliates:      
Denton Surgicare Real Estate, Ltd. (3)
 n/a49.0
49.0
49.0
Irving-Coppell Surgical Hospital, L.L.P.Irving-Coppell Surgical HospitalIrving19.4
19.3
19.6
MCSH Real Estate Investors, Ltd. (3)
  n/a2.0
2.0
2.0
Fusionetics, LLCFusioneticsFrisco15.0
15.8
15.8
1.List excludes holding companies, which are wholly-owned by the Company and hold the Company’s investments in the Facilities.
2.Partnership that has investment in North Central Surgical Center, Baylor Surgicare, and Baylor Medical Center at Uptown.
3.These entities are not surgical facilities and do not have ownership in any surgical facilities.
On August 2, 2017, Texas Health Venture Texas Spine, LLC, a wholly-owned subsidiary of THVG, completed its acquisition of Texas Spine and Joint Hospital, LLC (Tyler), resulting in a 50.25% controlling interest. The consideration of $40,900,000 and $40,700,000 was paid to the sellers by BSWH and USP, respectively. From the date of contribution to June 30, 2018, THVG recognized approximately $98,600,000 of total revenues and approximately $5,800,000 of net income from Tyler. For the twelve months ended June 30, 2019, THVG recognized approximately $117,600,000 of total revenues and approximately $12,000,000 of net income from Tyler.
On February 1, 2017, BSWH and USP contributed their respective ownership interests in Centennial ASC, LLC (Centennial) to THVG, resulting in THVG owning a 50.42% controlling interest. The value of the contributions from BSWH and USP was approximately $6,799,000 and $6,772,000, respectively. From the date of contribution to June 30, 2017, THVG recognized approximately $4,400,000 of total revenues and approximately $1,000,000 of net income from Centennial. For the twelve months ended June 30, 2018, THVG recognized approximately $10,300,000 of total revenues and approximately $2,300,000 of net income from Centennial. For the twelve months ended June 30, 2019, THVG recognized approximately $11,600,000 of total revenues and approximately $2,900,000 of net income from Centennial.
The following table summarizes the recorded values of the assets and liabilities as of the respective contribution date (in thousands):
 Tyler Centennial
Cash and cash equivalents$925
 $
Current assets15,703
 3,690
Long-term assets18,276
 1,079
Goodwill111,831
 19,290
Total assets acquired146,735
 24,059
    
Current liabilities10,127
 585
Long-term liabilities4,378
 
Total liabilities assumed14,505
 585
Noncontrolling interests50,610
 9,903
Net assets acquired$81,620
 $13,571

The assets and liabilities were accounted for at their respective fair values at the date of acquisition. Noncontrolling interests (NCI) are valued upon acquisition with a discount to reflect lack of control and marketability by the NCI holders. These fair value measurements are determined by Level 2 inputs. The resulting goodwill is attributed to expected synergies from combining operations. The results of these contributed facilities are included in THVG’s consolidated financial statements from the respective dates of contribution.
The following table presents the unaudited pro forma results as if THVG had acquired Tyler and Centennial on July 1, 2016 (in thousands). The pro forma results are not necessarily indicative of the results of operations that would have occurred if the acquisitions were completed on the date indicated, nor is indicative of the future operating results of THVG.

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

 Year Ended June 30,
 2019 2018 2017
Total revenues$1,219,869
 $1,178,160
 $1,158,708
Net income attributable to THVG$142,821
 $143,420
 $133,111

4.    NONCONTROLLING INTERESTS
The Company controls and therefore consolidates the results of 33 of its 35 facilities at June 30, 2019. Similar to its investments in unconsolidated affiliates, the Company regularly engages in the purchase and sale of equity interests with respect to its consolidated subsidiaries that do not result in a change of control. These transactions are accounted for as equity transactions, as they are undertaken among the Company, its consolidated subsidiaries, and noncontrolling interests, and their cash flow effects are classified within financing activities.
During the fiscal year ended June 30, 2019, the Company purchased and sold equity interests in various consolidated subsidiaries in the amounts of approximately $12,792,000 and $7,153,000, respectively. During the fiscal year ended June 30, 2018, the Company purchased and sold equity interests in various consolidated subsidiaries in the amounts of approximately $8,215,000 and $9,609,000, respectively. During the fiscal year ended June 30, 2017, the Company purchased and sold equity interests in various consolidated subsidiaries in the amounts of approximately $5,447,000 and $18,445,000, respectively. The basis difference between the Company’s carrying amount and the proceeds received or paid in each transaction is recorded as an adjustment to the Company’s equity. The impact of these transactions is summarized as follows (in thousands):
 Year Ended June 30,
 2019 2018 2017
Net income attributable to the Company$142,821
 $145,037
 $127,906
Net transfers to the noncontrolling interests:     
(Decrease)/increase in the Company’s equity for (losses)/gains related to purchase of subsidiaries’ equity interests(4,550) 1,350
 (1,438)
Increase in the Company’s equity for gains related to sales of subsidiaries’ equity interests1,966
 1,269
 904
Net transfers to noncontrolling interests(2,584) 2,619
 (534)
Change in equity from net income attributable to the Company and net transfers to noncontrolling interests$140,237
 $147,656
 $127,372

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

Upon the occurrence of various fundamental regulatory changes, the Company could be obligated, under the terms of its investees’ partnership and operating agreements, to purchase some or all of the noncontrolling interests related to the Company’s consolidated subsidiaries. As a result, these noncontrolling interests are not included as part of the Company’s equity and are carried as noncontrolling interests-redeemable on the Company’s consolidated balance sheets. The activity in noncontrolling interests-redeemable for the years ended June 30, 2019, 2018, and 2017 is summarized below (in thousands):
Balance, June 30, 2016$89,927
Net income attributable to noncontrolling interests134,905
Distributions to noncontrolling interests(137,373)
Purchases of noncontrolling interests(3,631)
Sales of noncontrolling interests15,415
Noncontrolling interests attributable to business acquisition9,904
Balance, June 30, 2017109,147
Net income attributable to noncontrolling interests143,580
Distributions to noncontrolling interests(138,245)
Purchases of noncontrolling interests(2,512)
Sales of noncontrolling interests9,836
Noncontrolling interests attributable to business acquisition50,610
Balance, June 30, 2018$172,416
Net income attributable to noncontrolling interests141,348
Distributions to noncontrolling interests(140,441)
Purchases of noncontrolling interests(7,457)
Sales of noncontrolling interests4,774
Balance, June 30, 2019$170,640

5.    GOODWILL AND INTANGIBLES
The following is a summary of changes in the carrying amount of goodwill for the years ended June 30, 2019 and 2018 (in thousands):
Balance, June 30, 2017$319,777
Additions:  
Tyler Spine and Joint111,831
Balance, June 30, 2018431,608
Additions:
Balance, June 30, 2019$431,608
Goodwill additions resulting from business combinations are recorded and assigned to the parent and noncontrolling interests. There were no transactions in 2019 resulting in a change in goodwill.

6.    LONG-TERM OBLIGATIONS
At June 30, 2019 and 2018, long-term obligations consisted of the following (in thousands):
 2019 2018
Capital lease obligations (Note 7)$132,741
 $139,535
Notes payable to financial institutions52,438
 54,482
Total long-term obligations185,179
 194,017
Less current portion(23,249) (19,789)
Long-term obligations, less current portion$161,930
 $174,228

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

The aggregate maturities of notes payable for each of the five years subsequent to June 30, 2019 and thereafter are as follows (in thousands):
2020$14,822
202111,200
202210,443
20237,994
20244,561
Thereafter3,418
Total long-term obligations$52,438
The Facilities have notes payable to financial institutions which mature at various dates through 2025 and accrue interest at fixed and variable rates ranging from 2% to 8%. The weighted average interest rate of the notes as of June 30, 2019 was 4%. The payment terms of the notes payable generally require monthly payments, with some agreements having quarterly payments. Each note is collateralized by certain assets of the respective facility. Many of the notes contain various restrictive covenants, including financial covenants that limit THVG’s ability and the ability of the Facilities to borrow money or guarantee other indebtedness, grant liens, make investments, sell assets, and pay dividends. The Company believes it is in accordance with all of the covenants as of June 30, 2019.
Capital lease obligations are collateralized by underlying real estate or equipment and have interest rates ranging from 1% to 13%.

7.    LEASES
The Facilities lease various office equipment, medical equipment, and office space under a number of operating lease agreements, which expire at various times through the year 2032. Such leases do not involve contingent rentals, nor do they contain significant renewal or escalation clauses. Office leases generally require the Facilities to pay all executory costs (such as property taxes, maintenance, and insurance).
Minimum future payments under noncancelable leases with remaining terms in excess of one year as of June 30, 2019 are as follows (in thousands):
 
Capital
Leases
 
Operating
Leases
Year ending June 30:  
   
2020$20,565
 $39,576
202120,858
 37,875
202219,994
 36,542
202319,432
 34,991
202420,073
 33,399
Thereafter106,914
 163,108
Total minimum lease payments207,836
 $345,491
Amount representing interest(75,095)   
Total principal payments$132,741
   

Total rent expense under operating leases was approximately $51,417,000, $48,190,000, and $39,445,000 for the years ended June 30, 2019, 2018, and 2017, respectively, and is included in other operating expenses in the accompanying consolidated statements of income.

8.    RELATED-PARTY TRANSACTIONS
THVG operates the Facilities under management and royalty contracts, and THVG in turn is managed by BSWH and USP, resulting in THVG incurring management and royalty fee expense payable to BSWH and USP in amounts equal to the management and royalty fee income THVG receives from the Facilities. THVG’s management and royalty fee income from the facilities it consolidates for financial reporting purposes eliminates in consolidation with the facilities’ expense and therefore is not included

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

in THVG’s consolidated revenues. THVG’s management and royalty fee income from facilities which are not consolidated was $600,000 for years ended June 30, 2019, 2018, and 2017, and is included in other revenue in the accompanying consolidated statements of income.
The management and royalty fee expense to BSWH and USP was approximately $46,362,000, $41,973,000, and $38,530,000 for the years ended June 30, 2019, 2018, and 2017, respectively, and is reflected in operating expenses in THVG’s consolidated statements of income. Of the total, 64.3% and 1.7% represent management fees paid to USP and BSWH, respectively, and 34% represents royalty fees paid to BSWH.
Under the management and royalty agreements, the Facilities pay THVG an amount ranging from 5.0% to 7.0% of their net patient service revenue annually, subject, in some cases, to an annual cap.
In addition, a subsidiary of USPI pays certain expenses, primarily related to insurance premiums, data warehousing, and accounts payables processing, on behalf of THVG which are recorded within the operating expenses section of the accompanying consolidated statements of income. These expenses amounted to $45,940,000, $57,553,000, and $44,004,000 for the years ended June 30, 2019, 2018, and 2017, respectively.
USPI holds funds through an arrangement with THVG by which cash on hand at certain of THVG’s bank accounts is swept to USPI on a daily basis. USPI pays THVG interest income at the Federal Reserve Prime rate less 2.5% of the average daily balance and the Facilities 0.25% of the average daily balance. Amounts held by USPI on behalf of THVG and the Facilities, shown in Funds due from United Surgical Partners, Inc. on the accompanying consolidated balance sheets, totaled approximately $101,282,000 and $114,408,000 at June 30, 2019 and 2018, respectively. Accrued expenses that USPI paid on behalf of THVG, shown in Accounts payable on the accompanying consolidated balance sheets, totaled approximately $10,747,000 and $16,014,000 at June 30, 2019 and 2018, respectively. The interest income associated with this arrangement amounted to approximately $1,032,000, $711,000, and $492,000 for the years ended June 30, 2019, 2018, and 2017, respectively.

9.    COMMITMENTS AND CONTINGENCIES
Financial Guarantees
THVG guarantees portions of the indebtedness of its investees to third-parties, which could potentially require THVG to make maximum aggregate payments totaling approximately $3,482,000. Of the total, approximately $2,168,000 relates to the obligations of two consolidated subsidiaries whose capital lease obligations are included in THVG’s consolidated balance sheets and related disclosures, and approximately $1,312,000 relates to obligations of two consolidated subsidiaries whose operating lease obligations are not included in THVG’s consolidated balance sheets.
These arrangements (a) consist of guarantees of real estate and equipment financing and lease obligations, (b) are collateralized by all, or a portion of, the investees’ assets, (c) require payments by THVG in the event of a default by the investee primarily obligated under the financing, (d) expire as the underlying debt matures at various dates through 2025, or earlier if certain performance targets are met, and (e) provide no recourse for THVG to recover any amounts from third-parties. The aggregate fair value of the guarantee liabilities was not material to the consolidated financial statements and, therefore, no amounts were recorded at June 30, 2019 related to these guarantees. When THVG incurs guarantee obligations that are disproportionately greater than the guarantees provided by the investee’s other owners, THVG charges the investee a fair market value fee based on the value of the contingent liability THVG is assuming.
Litigation and Professional Liability Claims
In their normal course of business, the Facilities are subject to claims and lawsuits relating to patient treatment. THVG believes that its liability for damages resulting from such claims and lawsuits is adequately covered by insurance or is adequately provided for in its consolidated financial statements. USPI, on behalf of THVG and each of the Facilities, maintains professional liability insurance that provides coverage on a claims-made basis of $1,000,000 per incident and $15,000,000 in annual aggregate amount with retroactive provisions upon policy renewal. Certain of THVG’s insurance policies have deductibles and contingent premium arrangements. Based on historical claims activity associated with litigation and professional liability matters, the Company believes its insurance coverage is appropriate and existing exposure related to known and incurred but not reported claims is negligible. Additionally, from time to time, THVG may be named as a party to other legal claims and proceedings in the ordinary course of business. THVG is not aware of any such claims or proceedings that have more than a remote chance of having a material adverse impact on THVG.


TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- continued

10.    SUBSEQUENT EVENTS
THVG regularly engages in exploratory discussions or enters into letters of intent with various entities regarding possible joint ventures, development, or other transactions. These possible joint ventures, developments of new facilities, or other transactions are in various stages of negotiation.
THVG has performed an evaluation of subsequent events through November 1, 2019, which is the date the consolidated financial statements were available to be issued. There have been no material subsequent events requiring financial statement disclosure after the balance sheet date.



F-20146